











This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
• This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
• A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
• This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
• The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
• When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given. 
 






This thesis is presented for the degree of Doctor of 









I declare that this thesis has been composed entirely by the candidate, Katherine 
Staines. This work has not previously been submitted for a Doctor of Philosophy, a 
degree or any professional qualification. I have done all the work, unless 
























I would firstly like to thank my supervisors Colin Farquharson, and Vicky MacRae. 
I have received outstanding supervision, support and advice throughout the course 
of my PhD and I am certain that my subsequent career in science will be shaped by 
their guidance.  
 
Thanks must also be paid to everyone in the Bone Biology group who have helped 
me when in need of support and advice throughout my years at the Roslin Institute. 
In particular I would like to give thanks to Neil Mackenzie, Matt Prideaux and 
Phillip Newton for their assistance with the collaborative experiments we have 
conducted. I would also like to acknowledge the collaborators I have been fortunate 
to work with during this project: Claire Clarkin, Graham Williams, Adele Boskey, 
Lynda Bonewald, Steve Mitchell and Peter Rowe. I would also like to give gratitude 
to the BBSRC for funding this project, as well as the European Calcified Tissue 
Society for providing the funding for a laboratory exchange visit and Eli-Lilly for 
the antibodies used in this project.  
 
I would also like to pay special thanks to my wonderful friends, especially those I 
have made here in Edinburgh. I am very fortunate to have you in my life and cannot 
thank you enough. Finally I would not be here without my family. I would like to 
thank my parents and my brother for their continuous and unconditional love, 








Matrix Extracellular Phosphoglycoprotein (MEPE) is a member of a family of 
proteins called small integrin-binding ligand, N-linked glycoproteins (SIBLINGs) 
which play key roles in biomineralisation. Altered MEPE expression is associated 
with several phosphate and bone-mineral metabolic disorders such as oncogenic 
osteomalacia and hypophosphatemic rickets. Despite this, it remains undetermined 
what impact MEPE has on the growth plate; the cartilage anlagen from which 
endochondral ossification, the process responsible for linear bone growth, occurs.  
 
The work of this thesis has characterised the ATDC5 cell line and the metatarsal 
organ culture as useful in vitro models of endochondral ossification. These will 
prove vital in the pursuit of underpinning the molecular mechanisms involved in 
endochondral bone growth. These models form the basis of the further studies in 
this thesis examining the role of MEPE within this highly orchestrated process.  
 
Before such role can be defined, this thesis details the spatial and temporal 
localisation patterns of MEPE in 10-day- and 4-week-old murine growth plates. 
More specifically, MEPE protein and mRNA were preferentially expressed by the 
hypertrophic chondrocytes as shown by immunohistochemistry and in situ 
hybridisation respectively. Microdissection of the murine growth plate confirmed 
this. Localisation of the cleavage product of MEPE, a 2.2kDa acidic serine- and 
aspirate-rich motif (ASARM) peptide, followed a similar pattern of expression. 
 
The localisation of MEPE to sites of mineralisation serves to strengthen its potential 
role in chondrocyte matrix mineralisation. This thesis identified this role in both 
mineralising ATDC5 cells and the metatarsal organ culture. The ASARM peptide 
was found to be the functional component of MEPE and this function was 
dependent upon its post-translational phosphorylation. Phosphorylated (p)ASARM 
peptides significantly inhibited chondrocyte matrix mineralisation without altering 
the proliferation or differentiation of the chondrocyte cells, or their ability to 
produce an extracellular matrix. mRNA analysis by qPCR indicted a feedback 
system by which the pASARM peptide functions to allow the release of further 
ASARM peptides. Moreover, the pASARM peptide inhibited mRNA expression of 
markers of vascular angiogenesis highlighting a novel mechanism by which they 
may inhibit chondrocyte matrix mineralisation.  
  
This thesis also determines the regulatory cross-talk between the chondrocytes of 
the murine growth plate, with the most abundant bone cell type, the osteocyte. This 
cross-talk inhibits chondrocyte matrix mineralisation and is attributed to sclerostin, 
an osteocyte-specific secretory protein. Furthermore, it is shown that sclerostin acts 
through the MEPE-ASARM axis to regulate chondrocyte matrix mineralisation and 
thus endochondral ossification.  
 
The work described herein has characterised and validated in vitro models of 
growth plate chondrocyte matrix mineralisation and has used these to identify the 
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Preface 
The skeleton is a highly intricate and complex organ that has a range of functions 
spanning from locomotion to ion homeostasis. Its growth and development, by a 
process termed endochondral ossification, is integral to effective functioning with 
disruption giving rise to a multitude of growth abnormalities. This thesis will 
investigate the process of endochondral ossification, in particular, the hypothesis 
that matrix extracellular phosphoglycoprotein (MEPE) is a novel regulator of 
chondrocyte matrix mineralisation. It is vital that we better understand the 
mechanisms involved in these processes to aid the development of therapeutics for 
bone growth disorders such as hypophosphatemic rickets.  It should be noted that 
many sections of this introduction are based on the published reviews by Staines et 
al., on the effects of the small integrin-binding ligand N-linked glycoprotein 
(SIBLING) family of proteins on skeletal mineralisation and the role of the Wnt 
signalling pathway on cartilage development and degeneration (Staines et al. 2012a; 
Staines et al. 2012b). 
1.1 The structure and function of bone 
Bone is often thought of as dead and inert, however it has been known for centuries 
that bone is in fact a highly dynamic tissue composed of numerous cell types that 
interact to successfully perform its many functions; to act as a supportive 
framework, to protect the vital organs and to provide a source of calcium and 
phosphorus. It has recently come to light that bone also acts as an endocrine organ 
(Lee et al. 2007; Lee & Karsenty 2008).  
 
The structure of bone is adapted to its function. It consists of an organic and an 
inorganic component which combine to allow the skeleton to be strong and stiff to 
withstand loading, and yet light for movement and flexible to prevent fracture. Two 
types of bone structure exist; cortical (compact) and cancellous (trabecular) bone 
(Fig. 1.1). Cortical bone constitutes 80% of the total skeletal mass and
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Figure 1.1 The structure of bone 
Bone consists of both cancellous and cortical bone (A) Low power scanning 
electron microscopy shows normal cancellous bone architecture. Clearly 
visible are the strong struts of trabecular bone organised so as to withstand 
compressive forces (B) The structure of cortical bone found in the shaft of 
the bone. Centrally is the Haversian canal in which nerves and blood vessels 
reside. Surrounding this are concentric layers of bone matrix and osteocytes. 
Images provided from the Bone Research Society, by kind permission of (A) 
Alan Boyde (B) Tim Arnett. 
 
Chapter 1                                                                                                                            Introduction 
~ 4 ~ 
 
anatomically, is primarily present in the shaft of the bone (the diaphysis) (Sambrook 
et al. 1993). Intrinsically, cortical bone is arranged into concentric lamaellae in 
Haversian systems, with a central canal in which blood vessels and nerves reside. 
This compact arrangement is advantageous as cortical bone is placed under acute 
mechanical demands and thus it is required to have a high resistance to tensile 
forces.  
 
Cancellous bone represents approximately 20% of the total bone mass and is thin 
struts of lamellar bone without Haversian systems. It has a higher turnover rate 
than cortical bone. It is a site for abundant haemopoietic tissue and fat, reducing the 
weight of the bone. The major function of cancellous bone is to withstand the forces 
experienced during weight bearing and thus it is less dense and more elastic than 
cortical bone (Sommerfeldt & Rubin 2001).   
1.2 Embryonic bone formation 
The skeleton forms through two distinct mechanisms both of which are reliant upon 
a complex assimilation of biochemical and morphological events. Intramembranous 
ossification is the direct transformation of mesenchymal cells into osteoblasts and is 
important in the development of the flat bones such as the skull and the clavicle. 
Endochondral ossification is attributed to the formation and longitudinal growth of 
the long bones during both pre- and post-natal life and involves the replacement of 
a hyaline cartilage template by bone (Kronenberg 2003).  
1.2.1 Endochondral ossification 
Endochondral ossification is initiated by the condensation of cells within the limb 
bud during embryogenesis (Fig. 1.2). Initially, committed, undifferentiated 
mesenchymal precursor cells which arise from the somatopleure of the lateral plate 
mesoderm, are recruited to the future sites of skeletal development where they 
produce an extracellular matrix (ECM) which is rich in hyaluronan, fibronectin and 
type I collagen (Dessau et al. 1980; Sandell 1994). Concomitant with cellular 
condensation is an increase in hyaluronidase activity, the expression of adhesion 
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Figure 1.2 Endochondral Ossification 
The process of endochondral ossification. (A) Mesenchymal stem cells condense and 
aggregate to form the cartilage anlagen (B). (C) Pre-chondrocytes differentiate into 
chondrocytes which secrete an extra cellular matrix. (D) These chondrocytes become 
hypertrophic and mineralise their surrounding matrix. (E) The vascular invasion of the 
cartilage analgen allows the infiltration of osteoblasts and osteoclasts, and the formation 
of the primary ossification centre. (F) Bone formation expands towards the epiphysis. (G) 
Bone formation in the epiphysis allows the development of the mature growth plates and 
the secondary ossification centre.  The epiphyseal growth plates function until the point in 
which the two ossification centres fuse and growth ceases (Gilbert, 2006). 
Chapter 1                                                                                                                            Introduction 
~ 6 ~ 
 
molecules such as neural cadherin (N-cadherin) and neural cell adhesion molecule 
(N-CAM), and the expression of the nuclear transcription factor Sox9. Despite not 
being expressed in early mesenchymal condensations, Sox5 and Sox6 are co-
expressed with Sox9 during chondrocyte differentiation (Lefebvre et al. 1998). This 
facilitates further condensation through increasing cell-cell and cell-ECM 
interactions (Dessau et al. 1980; DeLise & Tuan 2002). 
 
Finally, the mesenchymal cells undergo differentiation to the chondrogenic lineage. 
The Wnt signalling pathway is one of many regulators of chondrogenic 
differentiation, namely by influencing the crucial cell adhesion interactions (Staines 
et al. 2012a). Concomitant with chondrogenesis is the expression of chondrocyte-
specific molecules such as collagen type II and aggrecan, the principal cartilage 
proteoglycan (Hall & Miyake 2000; Goldring et al. 2006). This forms the cartilage 
model which expands through chondrocyte proliferation. The chondrocytes then 
undergo hypertrophy and ossification of the cartilage anlagen occurs. Blood vessels, 
bone marrow, osteoclasts (the cartilage- and bone-resorbing cells, section 1.4.2) 
andosteoblast precursors (section 1.4.1) invade the bone to form the primary 
ossification centre. This primary centre expands and secondary ossification centres 
subsequently form at each end of the cartilage model, leaving a developmental 
cartilaginous region between the two, the growth plate. The growth plate is 
responsible for postnatal linear bone growth and is a fundamental aspect of this 
thesis. Currently there are various clonal cell line models used for the in vitro 
analysis of chondrogenic differentiation and matrix mineralisation including CFK-2 
(Bernier & Goltzman 1993), RCJ3.1C5 (Grigoriadis et al. 1996), HCS-2/8 (Takigawa et 
al. 1989), and ATDC5 cells (Atsumi et al. 1990). 
1.2.2 The growth plate 
The epiphyseal growth plate is a highly specialised cartilaginous structure located 
between the head and the shaft of the bone. The growth plate consists of 
chondrocytes arranged in columns that parallel the axis of the bone surrounded by 
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their ECM (Ballock & O'Keefe 2003; Mackie et al. 2008). This matrix consists of 
collagens, proteoglycans and numerous other non-collagenous proteins (NCP) 
(Gentili & Cancedda 2009; Heinegard 2009). The chondrocytes of the growth plate 
sit in distinct cellular zones of maturation, separated by longitudinal and transverse 
septa (Fig. 1.3). The cells proceed through the different stages of differentiation 
whilst maintaining their spatially fixed locations (Fig. 1.4) (Hunziker et al. 1987). 
Interference with the maturational progression of growth plate chondrocytes leads 
to abnormal cartilage formation and abnormalities in bone formation and rates of 
bone formation e.g. rickets and dwarfism. 
1.2.2.1 The resting zone 
The first zone, often known as the resting or germinal zone, consists of the resting 
chondrocytes and undifferentiated progenitors. These cells are located at the top of 
the growth plate, nearest the epiphysis. Unlike the rest of the growth plate, the cells 
of the resting zone are distributed sporadically and are surrounded by large 
volumes of ECM (Ballock & O'Keefe 2003; Melrose et al. 2008). With low 
proliferation rates and low proteoglycan and collagen type II production, the resting 
chondrocytes are rich in lipids and cytoplasmic vacuoles, thought to be stored as a 
nutrient source for subsequent zones (Hunziker et al. 1987; Mackie et al. 2008).  
1.2.2.2 The proliferative zone 
From the resting zone, the chondrocytes progress to a proliferative phenotype in 
which they adopt a flattened, oblate shape and arrange themselves spatially into 
longitudinal columns (Fig. 1.3) (Hunziker et al. 1987). Here the chondrocytes 
undergo high mitotic activity as is determined by numerous factors including 
endocrine regulation, circadian rhythm and age (section 1.3) (Farnum et al. 2002). 
Following the cessation of proliferation, these cells undergo a period of high 
secretory activity as they produce a collagen type II and proteoglycan rich matrix. 
They then progress through the differentiation pathway and exit the cell cycle. At 
this point, the pre-hypertrophic, maturing chondrocytes have minimal 
deoxyribonucleic acid (DNA) synthesis (Hunziker et al. 1987).
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Figure 1.3 The epiphyseal growth plate 
The morphology of a 3-week-old mouse tibia growth plate. Labelled are the various 
zones of the growth plate; the resting, proliferating, pre-hypertrophic and 
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Figure 1.4 Representation of growth plate chondrocyte enlargement and 
longitudinal bone growth  
As longitudinal bone growth occurs, the index cell (shaded) remains in a constant position 
while the growth plate undergoes its developmental changes. Labelled are the resting 
chondrocytes (RC), proliferative chondrocytes (PC), prehypertrophic chondrocytes (PHC) and 
hypertrophic chondrocytes (HC). The mineralised matrix beneath the growth plate is also 
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1.2.2.3 The hypertrophic zone 
In the hypertrophic zone, chondrocytes undergo major phenotypic changes. These 
cells have an increase in cellular volume of approximately 10 times larger than that 
of the proliferative chondrocytes, and a height increase of approximately five fold 
between the proliferative and hypertrophic zones (Fig. 1.3 & 1.5) (Buckwalter et al. 
1986; Hunziker et al. 1987; Farnum et al. 2002).  
 
Initially, the enlargement of the hypertrophic chondrocyte was described as 
hypertrophy associated with an increase in cell organelle volumes such as 
mitochondria, the endoplasmic reticulum and Golgi membranes. There is a two-five 
fold increase in the mean surface area of these organelles (Hunziker et al. 1987). 
However this is only attributable to 15% of the cell volume increase with the 
remaining 85% arising from cytoplasm and nucleoplasm expansion (Buckwalter et 
al. 1986; Hunziker et al. 1987; DeLise et al. 2000). This cell swelling involves the net 
movement of water into the chondrocyte and is governed solely by an osmotic 
gradient (Bush et al. 2008). Despite this, the precise mechanisms which drive this 
expansion remain largely undefined although some evidence is emerging regarding 
the regulatory role of membrane transporters (Bush et al. 2010; Lewis et al. 2011). The 
voluminous increase in chondrocyte size is associated with an increase in organelles 
and is responsible for approximately 80% of bone lengthening (Buckwalter et al. 
1986). 
 
The rate of bone growth varies widely between different species. In the domestic 
fowl, the proximal tibia grows at 0.86mm/day whilst in the rat and rabbit this is 0.22 
and 0.39mm/day respectively. The growth rates of these two species reflect the slow 
rate in mammals as a whole. Indeed in humans, this has been estimated at 
0.04mm/day (Scanes 2003). This rate is controlled by numerous factors including, 
the number of proliferating and hypertrophic cells, the rate of cell proliferation, 
chondrocyte ECM synthesis, the rate of hypertrophic cell voluminous increase and 
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Figure 1.5 Increases in chondrogenic volume from proliferative to 
hypertrophic growth plate zones 
Images of the rat growth plate (A) calcein-labelled chondrocytes (B) selected 
chondrocytes colour coded as to volume analysis. Labelled are the different zones of 
the growth plate. Adapted from (Bush et al. 2008). 
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the final volume attained by these cells (Buckwalter et al. 1986; Hunziker et al. 1994; 
Wilsman et al. 1996). 
 
Associated with this differentiation is the increased expression of collagen type X, 
chondrocalcin, osteonectin and osteopontin, as well as the increased membrane 
activity of alkaline phosphatase (ALP) (Sommer et al. 1996; Shen 2005). It is also 
associated with the decreased expression of collagen type II, and other early 
chondrocyte marker genes, indicative of the final maturation phase. 
 
During this terminal differentiation, the hypertrophic chondrocytes mineralise their 
surrounding matrix, localised to the longitudinal septa of the growth plate 
(Castagnola et al. 1988). This biphasic process facilitates the deposition of 
hydroxyapatite and is integral to this thesis; as such it is described in detail in 
section 1.6.  
1.2.2.4 Vascular invasion of the ECM  
Mineralisation of the ECM not only facilitates the deposition of hydroxyapatite, but 
also enables vascular invasion; a significant phase in endochondral ossification and 
the development of the skeleton. Hypertrophic chondrocytes express factors such as 
vascular endothelial growth factor (VEGF) (Gerber et al. 1999; Horner et al. 1999; 
Zelzer et al. 2002). VEGF has chemo-attractive properties which induce the 
migration of osteoclasts to resorb the cartilaginous mineralised matrix (Engsig et al. 
2000). Furthermore, it facilitates the penetration of blood vessels into the 
cartilaginous mineralised matrix through which osteoblasts migrate to replace this 
degraded cartilage with a bone matrix (Mackie et al. 2011).   
1.2.2.5 The fate of the terminally differentiated chondrocytes 
The fate of the terminally differentiated chondrocyte at the chondro-osseous 
junction is still a matter of debate. However it is well accepted that it does require to 
be removed so as to maintain the steady-state thickness of the growth plate (Fig. 1.3 
& 1.4).  
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There has been significant evidence to suggest that the chondrocytes die by 
apoptosis and this appears the most accepted mechanism (Magne et al. 2003; 
Shapiro et al. 2005). Indeed the activation of caspases and the decreased expression 
of the apoptotic factor Bcl-2 in hypertrophic chondrocytes certainly suggest this 
(Amling et al. 1997; Adams & Shapiro 2002). However, the distinct lack of typical 
apoptotic morphological changes in the terminal hypertrophic chondrocytes has 
challenged this theory (Emons et al. 2009; Carames et al. 2010). It would be expected 
that the condensation of cellular chromatin and the fragmentation of the cell nucleus 
would be visible, associated with the eventual break down of the cell into several 
vesicles which are then phagocytosed. Instead, the presence of autophagic vacuoles 
and the expression of autophagy-regulating genes by growth plate chondrocytes 
suggest these cells undergo processes more similar to autophagy than apoptosis 
(Roach & Clarke 2000; Shapiro et al. 2005).  Furthermore, the transdifferentiation of 
chondrocytes has also been proposed (Cancedda et al. 1995; Roach 1997). This 
involves the division of the terminal hypertrophic chondrocyte to produce one 
daughter cell which undergoes apoptosis and one which trans-differentiates into an 
osteoblast phenotype. However this theory has yet to be fully ratified.    
1.2.2.6 Closure of the growth plate 
Longitudinal bone growth occurs at the growth plate until it closes once sexual 
maturity has been reached. At this point, the primary and secondary ossification 
centres meet and fusion occurs. The chondrocytes of the growth plate reach a state 
of senescence as they exhaust their proliferative potential, and longitudinal bone 
growth is ceased. In humans, gonadal steroids like oestrogen and androgen mediate 
these effects as is described in section 1.3.1 (Nilsson et al. 2005; Mackie et al. 2011). It 
is interesting to note that in mice and rats, whilst growth will eventually slow, the 
growth plate never closes.  
1.3 Regulation of endochondral bone growth  
This growth is tightly regulated by an array of autocrine/paracrine and endocrine 
factors to ensure effective longitudinal bone growth (Fig. 1.6). Genetic mutations in  
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Figure 1.6 Factors regulating endochondral ossification 
The various systemic, local secreted and transcription factors regulating endochondral 
ossification at the growth plate. Stimulation/activation is indicated by a green arrow, 
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the regulatory molecules detailed below result in abnormal chondrocyte phenotypes 
and skeletal dysplasias (Krakow & Rimoin 2010). 
1.3.1 Endocrine factors  
The most significant endocrine factor to affect endochondral bone growth is growth 
hormone (GH). Produced in the anterior pituitary gland, GH acts directly through 
interactions with growth plate chondrocyte GH receptors (GHR) and/or indirectly 
through enhanced levels of systemically derived liver Insulin-like growth factor I 
(IGF-I) (Salmon, Jr. & Daughaday 1957; Isaksson et al. 1982; Nilsson et al. 1986; 
Melmed 1999; Pass et al. 2009). It is likely that these two systems function in a highly 
coordinated manner to regulate growth plate function and linear bone growth. This 
is highlighted by the skeletal abnormalities observed with the dysregulation of the 
GH/IGF-1 axis; excess growth is observed in children with elevated GH levels whilst 
a deficiency of GH leads to impaired growth.  Furthermore, studies with Snell 
(dw/dw) and Ames (df/df) hypopituitary dwarf mice and also mice with global 
inactivation of GHR, GHRHR, IGF-1, and IGF-1 receptor (IGF-1R) all result in 
reduced body weight and growth retardation (Sinha et al. 1975; Li et al. 1990; 
Sornson et al. 1996; Sims et al. 2000; Yakar et al. 2009; Ahmed & Farquharson 2010). 
Moreover, the chondrocyte specific deletion of IGF-1R leads to chondrocyte 
hypoproliferation and increased apoptosis (Wang et al. 2011).   
 
Oestrogen signalling via the oestrogen receptor-α is crucial for normal skeletal 
maturation. Rising levels of oestrogen are associated with increased bone formation 
at the epiphyseal growth plate and this leads to the eventual replacement of the 
growth plate by mineralised bone and as such, the closure of the growth plate and 
the cessation of bone growth. Prior to this, oestrogen stimulates the final 
hypertrophy stage such that bone formation, and thus longitudinal growth, is 
rapidly increased accounting for the pubertal surge noted in both boys and girls 
(Nilsson et al. 2005).  Patients with oestrogen deficiency or defective oestrogen 
receptors display failed growth plate closure and as such, have increased adult 
Chapter 1                                                                                                                            Introduction 
~ 16 ~ 
 
height. Conversely, premature oestrogen production results in the early closure of 
the growth plate and a short stature (Smith et al. 1994; Morishima et al. 1995; 
Nilsson et al. 2005). As well as its direct effects through oestrogen receptors α and β, 
oestrogen is also thought to stimulate GH/IGF-1 signalling (Juul 2001; Borjesson et 
al. 2010; Borjesson et al. 2012). Androgen is another sex steroid involved in growth 
plate regulation directly through stimulating proliferation and hypertrophic 
differentiation of chondrocytes, and indirectly through its conversion to oestrogen 
by the enzyme aromatase (Oz et al. 2001; Nilsson et al. 2005). 
 
Glucocorticoids, such as dexamethasone, are released by the adrenal cortex during 
stress. They act to reduce inflammation and as immunosuppressants, and as such 
they have wide clinical use. However their prolonged use results in an inhibition of 
chondrocyte proliferation and increased apoptosis, and as a result of this, growth 
retardation (Owen et al. 2009; Lui & Baron 2011). The mechanism of action of 
glucocorticoids is through the inhibition of GHR and IGF-1 expression, and 
therefore the subsequent inhibition of IGF-1 mediated chondrocyte proliferation 
(MacRae et al. 2007; Lui & Baron 2011).     
 
Thyroid hormones are also important mediators of the growth plate, as is 
demonstrated by patients with hypothyroidism in which the reduced growth 
observed is attributed to narrower growth plates (Stevens et al. 2000; O'Shea et al. 
2003). This can be explained by the thyroid hormones, triiodothyronine and 
thyroxine which stimulate chondrocyte hypertrophy and increase the expression of 
collagen type X and ALP, potentially though the Wnt signalling pathway (Ballock & 
Reddi 1994; Shao et al. 2006; Wang et al. 2007; Wang et al. 2010b).  
 
Vitamin D has an important role in bone development which is highlighted by its 
deficiency that results in rickets: a disorder in which the growth plate enlarges and 
defective mineralisation occurs (Dean et al. 2001). Vitamin D can be obtained from 
sunlight irradiation of the skin, or from dietary sources. It has to undergo two 
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successive hydroxylations in the liver and kidney to become its active form: 
1,25dihydroxyvitamin D3 (1,25(OH)2D3). This involves the enzymes 25-hydroxylase 
of the liver and 1α-hydroxylase of the kidney, both of which are activated by GH 
and IGF-I. Vitamin D inhibits the proliferation of the growth plate chondrocytes and 
aids the synthesis of collagens and proteoglycans (Nilsson et al. 2005). 
1.3.2 Autocrine and paracrine factors 
In addition to endocrine factors, there are numerous locally acting autocrine and 
paracrine molecules which act to regulate endochondral bone growth (Fig. 1.6). 
Local IGF-1 production and a second IGF, IGF-2, which is also expressed by growth 
plate chondrocytes play critical roles in normal embryonic growth (DeChiara et al. 
1991; van der Eerden et al. 2003; Parker et al. 2007; Ahmed & Farquharson 2010).   
 
A key regulatory pathway of chondrocyte hypertrophy is the feedback loop 
involving parathyroid hormone related peptide (PTHrP), indian hedgehog (Ihh) 
and transforming growth factor (TGF) -β. Cells undergoing hypertrophy secrete Ihh 
which acts upon the proliferating chondrocytes to continue their proliferation and to 
resist their hypertrophy. Ihh also stimulates TGF-β production which in turn 
upregulates PTHrP. This acts on the pre-hypertrophic chondrocytes to prevent their 
further differentiation and thus the production of Ihh (Vortkamp et al. 1996; St-
Jacques et al. 1999; Minina et al. 2002). One such mechanism of action of PTHrP is 
through the phosphorylation of the transcription factor Sox9 (Huang et al. 2001). 
Alternatively, PTHrP inhibits chondrocyte expression of RUNX2. This transcription 
factor, the activity of which is under regulation of oxygen tension, stimulates the 
differentiation of proliferating chondrocytes to a hypertrophic phenotype (Guo et al. 
2006; Hirao et al. 2007).  
   
Bone morphogenetic proteins (BMP) regulate endochondral ossification in 
numerous ways, including through regulation of the Ihh/PTHrP axis. There are 
various members of this family, constituting the TGF-β superfamily and acting to 
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initiate chondrogenesis, maintain chondrocyte proliferation as well as induce 
collagen type X expression by hypertrophic chondrocytes (Minina et al. 2001; Yoon 
et al. 2006). Whilst BMPs can induce Ihh expression, Ihh can in turn induce the 
expression of various BMPs offering a feedback mechanism by which these two 
signalling pathways work in parallel in both a dependent and an independent 
manner (Minina et al. 2001; Grimsrud et al. 2001).  
 
Fibroblast growth factors (FGF) and their receptors (FGFR) constitute a large family 
of growth factors, many of which are expressed throughout endochondral 
ossification (Lazarus et al. 2007). In particular FGFR3 plays an important role as its 
expression by proliferating and pre-hypertrophic chondrocytes negatively regulates 
chondrocyte proliferation and differentiation. Moreover, the mutation of this gene 
in humans results in dwarfism (Shiang et al. 1994). 
1.4 Bone remodelling and modelling 
Throughout life, bone is continuously remodelled; a process that involves bone 
resorption by the osteoclast co-ordinated with bone formation by the osteoblast. 
Tight regulation of this process by autocrine, paracrine and endocrine factors, as 
described in section 1.3, maintains an equilibrium such that disorders of bone mass, 
such as osteoporosis or osteopetrosis, do not occur (Manolagas 2000). Bone 
remodelling of the cancellous bone is responsible for the annual replacement of 
approximately 10% of the adult human skeleton (Frost 1990), is important in 
fracture healing and repair. It involves a motile collection of cells, known as the 
basic multicellular unit. This consists of osteoclasts and osteoblasts working in 
synergy at the area requiring remodelling, as well as blood vessels, nerves and 
connective tissue (Manolagas 2000). Remodelling of bone is under tight local 
control, thought to be primarily regulated by the osteocyte (Hill 1998; Henriksen et 
al. 2009). All 3 bone cell types function in unity to regulate effective bone turnover.   
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1.4.1 Osteoblasts 
Osteoblasts, like chondrocytes, adipocytes and stromal cells, are derived from 
multipotent mesenchymal stem cells originating in the bone marrow (Manolagas 
2000). The primary function of the osteoblast is to synthesise bone matrix, termed 
the osteoid, consisting namely of collagen (94%) in addition to proteoglycans and 
other NCPs. For this reason, osteoblasts are located on the bone surface and they 
have abundant mitochondria, Golgi apparatus, ribosomes and endoplasmic 
reticulum (Dudley & Spiro 1961). It is the subsequent mineralisation of this matrix 
that results in the mineralised bone.  
 
The differentiation of osteoblasts is dependent upon the coordinated expression and 
activation of a number of transcription factors such as RUNX2, osterix, Ihh, sonic 
(Shh) hedgehog, TGFβ and the BMPs (Yamaguchi et al. 2000; Ducy 2000). The Wnt 
signalling pathway is another enticing pathway implicated in bone development, in 
particular in osteoblastogenesis. Activation of the Wnt signalling pathway by the 
binding of Wnt ligands to the frizzled receptor (Frz) and low-density lipoprotein-
related protein (LRP) 5/6 complex promotes osteoblast differentiation and therefore 
increases bone formation (Krishnan et al. 2006a). Several inhibitors of the Wnt 
signalling pathway have been identified in bone including secret frizzled-related 
protein 1 (sFRP-1), the Dickkopf (DKK1) family of proteins, and sclerostin (Kawano 
& Kypta 2003; Bodine et al. 2004; Semenov et al. 2005). Following matrix deposition 
and mineralisation, the osteoblast either remains on the surface of the bone as 
inactive lining cells; undergo apoptosis; or as they become entombed by the matrix 
which they secrete, they differentiate into osteocytes (Dallas & Bonewald 2010).  
1.4.2 Osteoclasts 
Osteoclasts are responsible for the resorption of mineralised bone. They originate 
from a haemopoietic lineage and their differentiation is stimulated by factors such 
as macrophage colony-stimulating factor (M-CSF), osteoprotegerin, and receptor for 
activation of nuclear factor kappa B ligand (RANKL). Despite their opposing roles, 
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compelling evidence now exists to support a pivotal role for osteoblasts in the 
regulation of osteoclast differentiation. Indeed osteoblasts progenitor cells express 
RANKL on their membrane surface, and the RUNX2 knockout mouse model is 
characterised by a deficiency of osteoblasts and interestingly, osteoclasts as well 
(Komori et al. 1997; Manolagas 2000).  
 
Osteoclast precursors are polarised to specific sites and upon maturation, the 
formation of a ruffled border allows the large, multinucleated osteoclast to attach to 
the bone surface. The demineralisation and degradation of the bone ECM occurs at 
this site through the release of protons and enzymes, such as tartrate-resistant acid 
phosphatase (TRAP) and members of the cathepsin and matrix metalloproteinase 
(MMP) families, respectively (Sommerfeldt & Rubin 2001; Mellis et al. 2011). The 
tight regulation of osteoclast function is critical as excessive bone resorption, as is 
observed with age, can lead to a reduction in the overall amount of bone and 
osteoporosis.   
1.4.3 Osteocytes 
Osteocytes are the most abundant bone cell, accounting for approximately 90% of all 
cells and are the terminally differentiated form of the osteoblast cell lineage 
(Bonewald 2007). However, research into their function and development has been 
hindered somewhat by their location deep within the mineralised bone ECM. The 
osteocyte has a characteristic stellate morphology consisting of a cell body with 
many long dendritic processes which connect the osteocyte to other osteocytes, 
osteoblasts and osteoclasts (Bonewald 2002). These cellular projections reside in thin 
channels termed canaliculi and form an intense network through which 
biochemical, electrical and mechanical signals can be transferred. 
 
An early postulated function of the osteocyte is as a mechanosensory cell due to its 
location within the bone ECM, and to its unique morphology. It has long been 
known that the skeleton is able to respond to the external forces placed upon it 
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during every day loading and during exercise. More recently it has been shown that 
osteocytes are integral to this as are able to translate mechanical strain into 
biochemical signals (Rubin & Lanyon 1984; Skerry et al. 1989; Burger & Klein-
Nulend 1999; Bonewald & Johnson 2008). This can bring about a change in the bone 
micro-structure as bone formation occurs independent of bone resorption, known as 
bone modelling (Frost 1990).   
 
Additionally, proteins highly expressed by osteocytes have been shown to be 
involved in mineral metabolism. These include phosphate-regulating gene with 
homologies to endopeptidases on the X chromosome (PHEX), FGF23, and the 
SIBLING family members MEPE and dentin matrix protein 1 (DMP1), all of which 
are known to co-operatively control calcium and phosphate regulation, as is 
discussed in section 1.7.3 (Quarles 2003; Feng et al. 2006; Liu et al. 2007b). 
Accumulating evidence has suggested a role for the osteocyte in bone remodelling. 
The secretion of SCL, an osteocyte specific protein, has identified a mechanism by 
which osteocytes can regulate osteoblast activity. Furthermore, osteocytes can 
recruit osteoclasts to sites of remodelling and can, through Wnt signalling, regulate 
osteoclast activity (Bonewald 2010; Kramer et al. 2010).            
1.5 Matrix mineralisation 
Hypertrophic chondrocytes and osteoblasts mineralise their surrounding ECM 
facilitating the deposition of hydroxyapatite. The hydroxyapatite formed in bone 
and teeth is a highly substituted analogue of the geological mineral hydroxyapatite 
(Ca10(PO4)6(OH)2), and its formation at least in cartilage is widely accepted to 
involve membrane-limited matrix vesicles (MV). These are approximately 200nm in 
diameter and have a trilaminar membrane. They bud off from the hypertrophic 
chondrocyte plasma membrane, and their positioning is limited to areas of 
mineralisation which are the longitudinal septae of the growth plate (Fig. 1.7).
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Figure 1.7 Mineralisation of the extracellular matrix within matrix vesicles 
Mineralisation of the growth plate extracellular matrix occurs within the membrane 
limiting matrix vesicles. These form from the plasma membrane of the hypertrophic 
chondrocyte. Calcium and phosphate precipitate within the matrix vesicles to form 
hydroxyapatite. This then penetrates the membrane to align itself along the collagen 
fibrils of the proteoglycan rich ECM (RZ: resting zone, PZ: proliferative zone, HZ: 
hypertrophic zone, TB: trabecular bone, HC: hypertrophic chondrocyte). 
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Mineralisation is a biphasic process initiated by the accumulation of calcium ions 
(Ca2+) and inorganic phosphate (Pi) within the MVs (Anderson 2003). When 
sufficient concentrations of both exist, calcium phosphate begins to precipitate 
which is firstly non crystalline, but then through a series of intermediates forms 
hydroxyapatite crystals (Fig. 1.7, 1.8A & 1.9A). This initial phase of mineralisation is 
followed by the penetration of the MV trilaminar membrane by the hydroxyapatite 
crystals such that they are exposed to the extracellular fluid, thus permitting their 
further growth and development (Figs. 1.8B & 1.9B & C). Mineral crystals form in 
alignment with the collagen fibrils of the ECM (Figs. 1.10A & B) (Anderson 1995; 
Wu et al. 2002; Anderson 2003; Golub 2011). 
1.6 Regulation of mineralisation 
Mineralisation is dependent upon levels of Ca2+ and Pi that are permissive for 
effective hydroxyapatite formation, and on the presence of mineralisation inhibitors 
such as inorganic pyrophosphate (PPi). The ratio of Pi to PPi controls the deposition 
of bone mineral and this is regulated by ALP, ecto-nucleotide 
pyrophosphatase/phosphodiesterase-1 (NPP1) and the ankylosis protein (ANK). 
More recently, a novel phosphatase PHOSPHO1 has been identified. Moreover, the 
role of key NCPs, namely the SIBLING family of proteins, has been identified as 
critical in the regulation of matrix mineralisation.     
1.6.1 ALP 
ALP is located on the outer membrane of osteoblasts and chondrocytes, and their 
MVs (Fig. 1.11) (Ali et al. 1970; Anderson 1995). Classically, ALP was thought to be 
responsible for hydrolysing the mineralisation inhibitor PPi but evidence has shown 
it also has ATPase activity and generates Pi required for hydroxyapatite formation, 
thus achieving a ratio of Pi/PPi permissive for hydroxyapatite crystal formation and 
growth (Moss et al. 1967; Majeska & Wuthier 1975; Hessle et al. 2002; Anderson 
2003). PPi, in addition to altering mineral accretion, also inhibits the enzymatic 
activity of ALP offering a feedback loop by which mineralisation is mediated 
(Addison et al. 2007). Deactivating mutations of the ALP gene lead to
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Figure 1.8 Electron micrographs of mineral formation 
(A) Within the matrix vesicle, approximately 200nm in diameter, Ca2+ and Pi accumulate 
and form hydroxyapatite crystals. (B) These crystals grow in size and penetrate the matrix 
vesicle membrane allowing their further growth and development outwith the matrix 
vesicle (Anderson 1995). 
Figure 1.9 Initiation and propagation of hydroxyapatite 
(A) Initiation of hydroxyapatite formation within the ~ 200nm diameter membrane 
limiting matrix vesicle (B, C) Propagation of hydroxyapatite as it extrudes the 
matrix vesicle membrane, as indicated by the arrows (Millan 2006).   
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Figure 1.10 Mineral formation in alignment with collagen fibrils 
(A) Analysis of mineralised (M) osteoid (Ost) in wild-type (WT) mice (Anderson et 
al. 2004) (B) Mineral formed within the ECM is in alignment with collagen fibrils of 
the ECM (Millan 2006).   
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Figure 1.11 Ultrastructural localisation of alkaline phosphatase activity 
Black reaction product denotes areas of alkaline phosphatase activity on the outer 
membrane of hypertrophic growth plate chondrocyte matrix vesicles. Arrow indicates 
mineral formation within the matrix vesicles. These are approximately 200nm in 
diameter, in comparison to the hypertrophic chondrocytes which are approximately 
30µm in diameter (Anderson 1995). 
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increased levels of PPi and skeletal hypomineralisation and rickets, as has been 
shown in the knockout mouse (Hessle et al. 2002; Anderson et al. 2004).  This 
hypomineralised pathology of mice deficient in ALP function (Akp2−/−) phenocopies 
the human condition hypophosphatasia, an inborn error of metabolism resulting in 
rickets and osteomalacia (Whyte 1994). 
1.6.2 ANK/NPP1/ATP  
Like ALP, NPP1 is expressed on the surface of osteoblasts and chondrocytes as well 
as MVs derived from these cell types. Contradictory to the ALP null mouse, NPP1 
knockout mice show hypermineralisation defects and spontaneous aortic 
calcification (Johnson et al. 2005; Mackenzie et al. 2012).  
 
It is known that whilst NPP1 ectoplasmically generates extracellular PPi from 
extracellular nucleotides such as adenosine triphosphate (ATP), ANK mediates the 
channelling of that produced intracellularly to the ECM (Hakim et al. 1984; 
Terkeltaub et al. 1994; Ho et al. 2000; Nurnberg et al. 2001). These extracellular 
nucleotides have a dual inhibitory effect on bone mineralisation through P2 
receptor-mediated signalling. In chondrocytes, receptors P2X2, P2Y1, and P2Y2 are 
known to be expressed, and these have been shown to inhibit matrix mineralisation 
and concomitant with this, inhibit ALP expression and activity (Hatori et al. 1995; 
Orriss et al. 2007; Burnstock et al. 2010; Gartland et al. 2012).   
1.6.3 PHOSPHO1 
Since its discovery and characterisation, PHOSPHO1 has been proposed to play a 
crucial role in the accumulation of Pi through a high phosphohydrolase activity 
towards phosphoethanolamine and phosphocholine (Houston et al. 2002; Roberts et 
al. 2004). Unlike the other regulators of mineralisation described above, PHOSPHO1 
is located and is active within the osteoblast- and chondrocyte-derived MVs 
(Stewart et al. 2006). The PHOSPHO1 null mouse, consistent with a role in the 
primary stage of matrix mineralisation, displays spontaneous fractures, bowed long 
bones, osteomalacia, and scoliosis in early life (Huesa et al. 2011).  Although mice 
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deficient for both ALP and PHOSPHO1 are embryonic lethal they are completely 
devoid of a mineralised skeleton at late gestation (E16.5) (Yadav et al. 2011). These 
data are strongly supportive of independent, non-redundant mechanisms of action 
of both phosphatases in the mineralisation process (Yadav et al. 2011). Whilst 
PHOSPHO1 null mice have lower ALP activity and higher PPi levels, normalisation 
of PPi levels by overexpressing ALP did not correct the hypomineralised phenotype 
and resultant bone fractures (Yadav et al. 2011).  The biochemical pathways by 
which PHOSPHO1, NPP1 and ALP act together to regulate Pi/PPi levels and the 
complete subsequent mineralisation process remains unclear. 
1.6.4 SIBLING family of proteins 
In addition to the action of phosphatases, recent progress in biomineralisation 
research has also identified roles for key NCPs in the regulation of hydroxyapatite 
crystal initiation and propagation, namely the small integrin binding ligand N-
linked glycoprotein (SIBLING) family of proteins. This family consists of 
osteopontin (OPN), bone sialoprotein (BSP), dentin sialophosphoprotein (DSPP), 
DMP1 and MEPE.  
 
It is likely that the SIBLING protein family arose from the secretory calcium-binding 
phosphoprotein (SCPP) family by gene duplication, due to their apparent common 
evolutionary heritage (Kawasaki & Weiss 2006; Kawasaki et al. 2007; Kawasaki 2011; 
Rowe 2012a). It is therefore somewhat surprising that the SIBLING proteins have 
little intrinsic sequence homology and yet they share the following characteristics: 
(i) all are located to a 375kb region on the human chromosome 4q21, and 5q in 
mouse (ii) they display similar exon structures (iii) display an Arg-Gly-Asp (RGD) 
motif that mediates cell attachment/signalling (iv) are principally expressed in bone 
and dentin, and are secreted into the ECM during osteoid formation and subsequent 
mineralisation (Rowe et al. 2000; Fisher et al. 2001; Fisher & Fedarko 2003; Rowe 
2004; Qin et al. 2004; Huq et al. 2005; Bellahcene et al. 2008; Rowe 2012a). More 
recently, work by Peter Rowe and colleagues, primarily focused upon MEPE, has 
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identified a new functional domain termed the ASARM peptide (acidic serine- and 
aspirate-rich motif) which is highly conserved across species and is a common 
SIBLING motif (Rowe et al. 2000; Rowe et al. 2004). This peptide is proving critical in 
the functional activity of the SIBLING proteins, as are the varying SIBLING post 
translational modifications such as phosphorylation and glycosylation (Rowe 2004; 
Boskey et al. 2009a; David et al. 2010). 
 
This functional activity, as well as the expression patterns, of OPN, BSP, DSPP and 
DMP1 are summarised in Table 1. This thesis focuses upon the role that MEPE plays 
in chondrocyte matrix mineralisation and as such, the current literature 
surrounding MEPE function will next be detailed.     
1.7 MEPE 
1.7.1 Discovery and localisation 
MEPE was first isolated in 2000 from a patient with tumour induced osteomalacia 
and was further described as an approximately 58kDa bone-specific protein termed 
osteoblast/osteocyte factor 45 (Rowe et al. 2000; Petersen et al. 2000). Mouse Mepe 
was subsequently isolated, highlighting a 56% overall homology with the human 
sequence, and Mepe was subsequently mapped to the 4q21 chromosome along with 
the other SIBLING proteins (MacDougall et al. 1998; Argiro et al. 2001; Fisher & 
Fedarko 2003).   
 
In the mouse skeleton, Mepe is detected as early as 2-days postpartum and it is 
localised to the osteocytes as well as by osteoblasts in the skeleton (Nampei et al. 
2004). It is also expressed by odontoblasts and in the proximal tubule of the kidney 
(Ogbureke & Fisher 2004).  
1.7.2 Function in biomineralisation 
The expression of MEPE increases throughout life and this fuelled the first evidence 
for a direct role of MEPE in bone mineralisation. An increased messenger
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modification
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products in 
mineralisation
Table 1. The functional role of OPN, BSP, DSPP and DMP1 in 
biomineralisation 
The functional role of OPN, BSP, DSPP and DMP1 in biomineralisation as is dependent 
upon their cleavage and post translational modification. Detailed is: (i) the cellular 
expression pattern (ii) the phenotype of the knockout mouse (iii) the phenotype of 
transgenic mice (iv) clinical conditions associated with mutation in this gene (v) 
cleavage products and post translational modification (vi) known role of each cleavage 
product in ECM mineralisation (vii) list of relevant references (Staines et al. 2012b). 
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ribonucleic acid (mRNA) expression level of Mepe is observed during osteoblast 
matrix mineralisation (Petersen et al. 2000; Argiro et al. 2001). This expression is 
under the control of several known regulators including  FGF2, BMP2 and most 
recently, Wnt3a (Siggelkow et al. 2004; Lu et al. 2004; Zhang et al. 2004; Cho et al. 
2011)The development of a MEPE null mouse further fuelled the proposed role for 
MEPE in ECM mineralisation. This mouse model had increased bone mass, with 
associated increased numbers and thickness of trabeculae. The mineral apposition 
rate (MAR) was dramatically increased as was the activity of MEPE null osteoblasts 
in culture (Gowen et al. 2003). Conversely, the overexpression of MEPE in mice, 
under the control of the Col1a1 promotor, leads to a growth and mineralisation 
defect, due to a decrease in bone remodelling. The MEPE transgenic mice displayed 
wider epiphyseal growth plates, and expanded primary spongiosa and a significant 
decrease in the MAR (David et al. 2009).  
 
Like the other SIBLING proteins described in Table 1, it appears that the activity of 
MEPE is dependent upon its state of cleavage and its phosphorylation. Recent work 
has identified the 2.2kDa ASARM peptide of MEPE as the functional component of 
MEPE. This ASARM peptide is highly conserved across the SIBLING proteins and 
in MEPE, is located immediately downstream of a cathepsin B cleavage site (Fig. 
1.12) (Rowe et al. 2000).  
 
The ASARM peptide of MEPE inhibits matrix mineralisation by osteoblasts by 
directly binding to hydroxyapatite crystals (Martin et al. 2008; Addison et al. 2008). 
Integral to this inhibitory effect is the post translational phosphorylation of the 
ASARM peptide at three serine residues. In osteoblasts it appears that without this 
phosphorylation, the ASARM peptide has no effect on mineralisation (Martin et al. 
2008; Addison et al. 2008). Recently it has been reported that a truncated form of 
MEPE which has the ASARM peptide removed, can promote bone mineralisation in 
culture and in mice (Sprowson et al. 2008). Furthermore, a mid-terminal fragment of 
MEPE (termed ‘AC100’ or dentonin) has been shown to enhance cell binding, 
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through the stimulation of focal adhesion kinase and extracellular signal-regulated 
kinases (ERK) (Fig. 1.12) (Hayashibara et al. 2004). Taken together, these results 
highlight the importance of post-translational processing in determining the 
functional role of MEPE.  
 
MEPE was first identified as a substrate for PHEX following analysis of its cleavage 
sites. Since then, the interaction between MEPE and PHEX has been well 
documented in the literature. PHEX plays a central role in the protection of MEPE 
from proteolytic cleavage by cathepsin B; it can bind to MEPE and prevent the 
release of the ASARM peptide (Guo et al. 2002). The Hyp mouse, a spontaneous Phex 
knockout model, has an increased expression of cathepsin D, an upstream activator 
of cathepsin B (Rowe et al. 2006). This therefore suggests that PHEX can alter the 
activation of cathepsin B, and therefore the cleavage of MEPE to the ASARM 
peptide. Furthermore, PHEX can bind to free ASARM peptides therefore 
neutralising their activity by sequestration and hydrolysis (Liu et al. 2007a; Addison 
et al. 2008; Martin et al. 2008). Recently it has been disclosed that sclerostin, a potent 
inhibitor of the canonical Wnt signalling pathway and bone formation, may also act 
through the MEPE-PHEX axis, highlighting its significance in biomineralisation 
(Atkins et al. 2011).   
 
MEPE transgenic mice display a decrease in ALP enzyme activity in both the 
growth plate and the primary spongiosa (David et al. 2009). In vivo, the addition of 
the phosphorylated ASARM peptide also reduced the number of ALP-positive cells 
in an osteoblast cell culture model (Martin et al. 2008). However, this remains 
controversial as normal ALP activity has been reported in osteoblasts treated with 
phosphorylated ASARM (pASARM) peptide (Addison et al. 2008). In the MEPE 
overexpressing mouse vascularisation is increased, as is VEGF expression, 
highlighting a role for MEPE in angiogenesis, an important stage in endochondral 
ossification (David et al. 2009). Consonant with angiogenesis is the infiltration of 
osteoclasts for bone resorption. Interestingly, in mice administered with 
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recombinant MEPE or mice transgenic for MEPE both have a significant decrease in 
the numbers and activity of osteoclasts (Hayashibara et al. 2007; David et al. 2009).  
1.7.3 The PHEX-MEPE-ASARM hypothesis and its function in mineral 
metabolism 
Accumulating evidence has implicated the ASARM peptide and its interactions 
with PHEX, and FGF23 in bone renal Pi homeostasis and mineralisation (Fig. 1.13). 
This hypothesis can be used to explain numerous disorders of mineralisation 
including tumour induced osteomalacia, autosomal-dominant hypophosphatemic 
rickets (ADHR), and X-linked hypophosphatemic rickets (XLH).  
 
XLH is the most common form of inherited rickets, characterised by defective bone 
and tooth mineralisation, growth retardation, and defective renal re-absorption of Pi 
(Carpenter et al. 2011). Mutations in PHEX have been associated with XLH in 
humans, and have led to the development of the Hyp mouse (Holm et al. 1997). 
Hypophosphatemia alone is insufficient to explain the bone defect seen in the Hyp 
mouse as correction of the hypophosphatemia failed to correct the mineralisation 
defect observed (Ecarot et al. 1992; Rowe et al. 2006). Furthermore, when osteoblast 
cells from the Hyp mouse are grown in culture, they have a defective ECM 
production and thus reduced mineralisation (Xiao et al. 1998). This therefore 
suggests that PHEX has multiple substrates which are involved in regulating 
mineralisation directly and this has allowed the creation of the ASARM hypothesis 
(Rowe 2004; David et al. 2010; Rowe 2012a). The ASARM hypothesis is based upon 
the concept of a minhibin, an unknown secreted factor which is a substrate for 
PHEX and therefore would accumulate in the Hyp mouse and in patients with XLH.  
 
MEPE was first identified as a potential substrate for PHEX and this is strengthened 
by the observed increased levels of MEPE-ASARM peptides in the Hyp mouse and 
in patients with XLH (Bresler et al. 2004). However in vitro studies have failed to 
demonstrate PHEX-dependent hydrolysis of MEPE and instead it appears that it is 
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Figure 1.13 ASARM function in biomineralisation and mineral metabolism 
MEPE is cleaved by cathepsin B to ASARM peptide. This peptide has dual roles in 
biomineralisation and phosphate homeostasis which is dependent upon its 
phosphorylation. The ASARM peptide inhibits hydroxyapatite formation in bones. It 
also regulates FGF23 expression through its interaction with PHEX. In turn this inhibits 
renal phosphate regulation. Adapted from (Rowe 2004; Rowe 2012a). 
Figure 1.12 The secondary structure of MEPE 
The predicted secondary structure of MEPE. Detailed are the RDG and dentonin binding motifs. 
Also labelled is the C-terminal ASARM peptide which inhibits matrix mineralisation, and the 












Chapter 1                                                                                                                            Introduction 
~ 35 ~ 
 
the ASARM peptide which PHEX digests (Guo et al. 2002; Addison et al. 2008; 
Martin et al. 2008; Boukpessi et al. 2010; Addison et al. 2010).   
 
It also appears that PHEX regulates FGF23 expression as increased FGF23 
expression is observed in the Hyp mouse and patients with XLH (Liu et al. 2006). 
Accordingly, FGF23 knockout reversed the hypophosphatemia observed in Hyp 
mice (Sitara et al. 2004). Although initial studies appeared to confirm FGF23 as a 
substrate for PHEX, this has not been shown since (Bowe et al. 2001). Interestingly, a 
similar increase in FGF23 expression is observed in models of loss of DMP1, along 
with associated autosomal-recessive hypophosphatemic rickets (ARHR) (Feng et al. 
2006; Lorenz-Depiereux et al. 2006). This has led to the suggestion that a PHEX-
DMP1 interaction is responsible for orchestrating mineralisation through decreasing 
FGF23 expression. Furthermore, current paradigm suggests that ASARM peptides 
can competitively displace this PHEX-DMP1 complex and this would therefore 
increase FGF23 activity as is seen in the Hyp mouse and in patients with XLH 
(David et al. 2010; Martin et al. 2011; Rowe 2012a). 
 
Additionally, the accumulation of ASARM peptides can directly inhibit Na+ -
dependent Pi uptake in the kidney, as has been shown both in vivo and in vitro thus 
exacerbating the upregulation of FGF23 expression, the downregulation of 
1,25(OH)2D3 and the hypophosphatemia observed in XLH, ARHR and ADHR 
(Rowe et al. 2004; Marks et al. 2008; Dobbie et al. 2008; David et al. 2010; Shirley et al. 
2010). The decrease in 1,25(OH)2D3 provides a feedback loop for increased PHEX 
expression through the increased expression of a 100kDa transcription factor, a 
requirement for this PHEX expression (Fig. 1.13) (Ecarot & Desbarats 1999).   
 
This regulatory loop of ASARM, PHEX and FGF23 expression and function 
highlights the multiple and complex functions of the SIBLING ASARM peptides in 
both Pi homeostasis and matrix mineralisation in disease and health. It is therefore 
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vital that we endeavour to fully establish the interactions within this hypothesis to 
allow future therapeutic developments.  
1.8 Aims and strategy 
Despite an emerging role for MEPE in biomineralisation, its impact on chondrocyte 
ECM mineralisation is largely undefined. Therefore, the aim of this project was to 
test the hypothesis that MEPE and its ASARM peptide are essential for the control 
of growth plate cartilage mineralisation and endochondral bone growth.  For this, I 
have completed the following aims: 
 
1. Establish suitable and reproducible in vitro models of endochondral 
ossification  
 
2. Define the localisation of MEPE and its ASARM peptide in the murine 
growth plate 
 
3. Determine the functional role of MEPE in chondrocyte matrix mineralisation 
 
4. Examine the potential regulation of chondrocyte matrix mineralisation by 
osteocytes through MEPE expression  
 
These aims have been achieved through the use of in vitro models which will firstly 
be characterised (Chapter 3) by their mineralisation capability and their expression 
of chondrocyte specific genes. These models include the ATDC5 cell line (a mouse 
embryonal carcinoma-derived cell line), primary murine costochondral 
chondrocytes and an embryonic metatarsal organ culture system. This chapter 
determined the suitability of each specific model for further studies into 
chondrocyte ECM mineralisation.  
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Before attempting to unravel the regulatory mechanisms that MEPE may have in 
mammalian chondrocyte ECM mineralisation, it is first necessary to understand its 
spatial expression pattern within the growth plate (Chapter 4). Therefore the protein 
and gene expression of MEPE, and its ASARM peptide were defined in the murine 
growth plate. Furthermore, their expression in the in vitro models described in 
Chapter 3 was examined.  
 
The localisation of MEPE to sites of mineralisation would serve to cement its pivotal 
role in the regulation of growth plate matrix mineralisation. This role was examined 
in ATDC5 cell and metatarsal organ culture models, with the function of both the 
full length MEPE and its ASARM peptide being investigated (Chapter 5).  
 
It has been suggested that SCL, a known inhibitor of bone formation, may act 
through the MEPE-ASARM axis (Atkins et al. 2011). Therefore, the role of SCL in 
chondrocyte ECM mineralisation was examined as this has yet to be established 
within the literature (Chapter 6). This role was examined with regards to MEPE and 
its ASARM peptide in metatarsal organ cultures, utilising the IDG-SW3 cell line, a 
recently characterised osteocyte-like cell line which is known to express high 
quantities of SCL as the cells differentiate into their osteocyte phenotype (Woo et al. 
2011). This chapter also provided an insight into any potential osteocyte-
chondrocyte crosstalk.   
    
In conclusion, these studies have defined suitable and reproducible models of 
endochondral ossification that have been exploited to examine the functional role of 
MEPE in chondrocyte ECM mineralisation, as has yet to be established. 
Furthermore, these studies have tested the hypothesis that SCL inhibits growth 
plate mineralisation through a MEPE-ASARM dependent mechanism. This will 
enable a more complete picture of the role of MEPE in biomineralisation and will 
therefore allow investigation into its potential therapeutic application to disorders 
of mineralisation.   
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2.1 Reagents and solutions 
All chemicals were purchased from Sigma-Aldrich (Dorset, UK), and tissue culture 
media and buffers were purchased from Invitrogen (Paisley, UK) unless otherwise 
stated. All medium and buffer recipes are shown in Appendix I. 
2.2 Cell Culture 
2.2.1 ATDC5 cells 
Chondrogenic ATDC5 cells (RIKEN cell bank) (Shukunami et al. 1997) were cultured 
in maintenance media (Appendix I) at 37oC with 5% carbon dioxide (CO2) and 
maintained at sub-confluence. Dulbecco’s modified eagle medium (DMEM)/F12 
containing phenol red, a pH indicator, was used. For passaging, cells were rinsed in 
serum-free DMEM/F12 and detached from the culture flasks by addition of trypsin-
ethylenediaminetetraacetic acid (EDTA) at 37oC. Differentiation media (Appendix I) 
containing serum to inactivate the trypsin was then added to the flasks, and cells 
were collected by centrifugation at 1000g for 5 minutes. Cells were resuspended in 
differentiation media, counted using a haemocytometer and then plated in multi-
well plates at a density of 6 x 103/cm2 for experimentation. 10mM β-
glycerophosphate (βGP) and 50µg/ml ascorbic acid were added once the cells had 
reached confluency. Cells were incubated in a humidified atmosphere (37°C, 5% 
CO2) for up to 41 days with medium changed every second or third day. 
2.2.2 Freezing/Thawing ATDC5 cells 
To maintain stocks of ATDC5 cells, cells were trypsinised and counted as described 
in 2.2.1. The cells were centrifuged at 1000g for 5 minutes and resuspended in 50/50 
maintenance media and freezing mix (Appendix I) to give a cell concentration of 3 x 
106 cells/ml. The cells within a cryovial (Corning, Surrey, UK) were then wrapped in 
cotton wool within a polystyrene box and kept at -80C for 4-7 days and then to -
150C for longer term storage. Cells were thawed at 37C and added drop wise to 
5ml of pre-warmed maintenance media. The cell suspension was then mixed and 
spun at 1000g for 5 minutes to remove the dimethyl sulfoxide (DMSO), which acts 
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as a cryoprotectant to prevent cell death during the freezing process. The cell pellet 
was resuspended in maintenance media and transferred to a T175 tissue culture 
flask. 
2.2.3 Isolating primary chondrocytes 
Sternal primary chondrocytes were isolated from 1- to 3-day old wild-type C57/BL6 
mice as previously described (MacRae et al. 2009). The rib cage and sternum were 
dissected and the organs, spine and excess tissue removed. Ribcages were washed 
in sterile phosphate buffered solution (PBS; 1X) and incubated at 37oC in 2mg/ml 
protease in PBS for 30 minutes with agitation. After washing in PBS, the ribcages 
were incubated at 37oC for 15 minutes in sterile collagenase type 2 (Worthington 
Biochemical Corporation, USA) at 3mg/ml in DMEM. Muscle and soft tissue were 
then removed from the ribs and sternum by gentle pipetting. The cartilage rods 
were then finally digested by incubation at 37°C in sterile collagenase type 2 
(3mg/ml in DMEM) for 3 to 4 hours with regular agitation. Cells were filtered 
through a 45μm sieve, pelleted by centrifugation and re-suspended in DMEM 
before being counted using a haemocytometer. Approximately 1 x 106 cells were 
isolated per mouse pup, of which approximately 70% were viable. Cells were plated 
in a 12-well plate at a density of 105/cm2 in primary chondrocyte media (Appendix 
I). For mineralisation studies, once cells had reached confluency, mineralisation was 
induced by supplementation with 10mM βGP and 50μg/ml ascorbic acid. Cells were 
incubated in a humidified atmosphere (37°C, 5% CO2) for up to 28 days with 
medium changed every second or third day. 
2.2.4 IDG-SW3 cells 
The IDG-SW3 cell line, isolated from 3-month-old Immortomouse+/−/Dmp1-green 
fluorescent protein (GFP)+/− mice which carry an interferon gamma (IFN-γ) inducible 
promoter enabling immortalisation of cells, was a generous gift from Professor 
Lynda Bonewald (University of Missouri-Kansas City, Missouri, USA) and was 
cultured as detailed previously (Woo et al. 2011). Cells were expanded in permissive 
conditions, at 33oC in IDG-SW3 cell media (Appendix I) containing 50U/ml IFN-γ, 
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on rat tail type I collagen coated plastic ware. For mineralisation experiments, cells 
were seeded at 8 x 104 cells/cm2 in osteogenic conditions (37oC with 50µg/ml 
ascorbic acid and 4mM βGP) in the absence of IFN-γ.    
2.3 Procedures for ATDC5 mineral assessment 
2.3.1 Fourier transform infrared spectroscopy (FT-IR) 
ATDC5 cells were cultured for 41 days as described in section 2.2.1. The cell 
monolayers were fixed in 95% methanol and embedded in LR white resin. Samples 
were analysed in the laboratory of Professor Adele Boskey (Hospital for Special 
Surgery, New York) using a Thermo-Nicolet 4700 spectrometer (Waltham, MA, 
USA). The spectra were corrected for background and the areas under the 
phosphate (900-1200 cm-1) and amide I (1585-1720 cm-1) peaks were determined. The 
mineral to matrix (Min/AM1) ratio was calculated as the ratio of the two areas. 
2.3.2 Transmission electron microscopy (TEM) 
ATDC5 cells were seeded onto nitrocellulose discs (Nunc, Roskilde, Denmark) in 
24-well plates and cultured in differentiation medium for 15 days, as detailed in 
section 2.2.1. The media were then removed from the cultures and cells were fixed 
in 2.5% glutaraldehyde in 0.1M sodium cacodylate buffer at 37°C for 1 hour. The 
cells were then stored in the glutaraldehyde/cacodylate solution at 4°C until 
required for processing. During processing, the cell monolayers were washed 3 
times in 0.1M sodium cacodylate, post-fixed in 1% osmium tetroxide, then washed 3 
times in distilled H2O (dH2O) and dehydrated through graded alcohols (35%, 70%, 
95% and 100%). The monolayers were then processed to Epon in a vacuum oven at 
60oC, with 3 changes and a final 24 hour incubation. Monolayers were viewed using 
a Phillips CMIRO TEM (FEI Vic Ltd, Cambridge, UK) and images taken on Gatan 
Orius ICD camera (Gratan, Oxford, UK). Sample processing was performed by 
Steve Mitchell at The University of Edinburgh. 
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2.4 Histological procedures of cell cultures 
2.4.1 Alizarin red stain 
Calcium deposition in cell cultures was assessed by alizarin red staining. Cells were 
fixed in 4% paraformaldehyde (PFA) for 5 minutes following rinsing with PBS. 2% 
alizarin red stain pH4.2 was used to stain cell layers for 5 minutes at room 
temperature. Staining was quantified by the addition of 200µl 10 % cetylpyridinium 
chloride for 10 minutes. The optical density of the resultant solution was analysed 
using a spectrophotometer (Thermo Scientific, Northumberland, UK) at a 
wavelength of 570nm. 10 % cetylpyridinium chloride was used as a blank. Reactions 
were completed in triplicate at each cell culture time point. 
2.4.2 Alcian blue stain 
Glycosaminoglycan (GAG) presence was assessed in cell cultures by alcian blue 
staining. Cell layers were fixed in 95% methanol for 20 minutes following rinsing 
with PBS. Alcian blue stain (Thermo Scientific, Roskilde, Denmark) was added for 
18 hours at room temperature. Quantification of staining was completed following 
the addition of 180µl 6M guanidine hydrochloride and analysed at 630nm on a 
spectrophotometer. Guanidine hydrochloride was used as a blank. Reactions were 
completed in triplicate at each cell culture time point. 
2.4.3 Sirius red stain 
The production of collagen was assessed in cell cultures by sirius red staining. 
Following rinsing in PBS, cells were fixed in 4% PFA for 5 minutes. ‘Sircol’ dye 
reagent (Sirius red and picric acid, Biocolor, County Antrim, UK) was added for 1 
hour at room temperature. Unbound dye was removed with 0.001M HCl and the 
fixed stain was leeched from the matrix in 0.1M NaOH. The absorbance of the 
resultant solution was read on a spectrophotometer at a wavelength of 570nm. 0.1M 
NaOH was used as a blank. Reactions were completed in triplicate at each cell 
culture time point.  
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2.5 Ex vivo studies 
2.5.1 Animal welfare  
Animals were maintained under conventional housing conditions with a 12 hour 
light/dark cycle. All animal experiments were approved by The Roslin Institute’s 
Animal Users Committee and the animals were maintained in accordance with 
Home Office guidelines for the care and use of laboratory animals. 
2.5.2 Isolation and culture of embryonic murine metatarsals  
The middle three metatarsals of E17 and E15 mice were isolated under a dissecting 
microscope. Throughout the dissection the bones were kept under preparation 
medium (Appendix I). Metatarsals were cultured in 24-well plates containing one 
bone in 300µl metatarsal media (Appendix I) for up to 12 days. For the E17 
metatarsal bones, the medium was changed every second or third day and for the 
E15 metatarsal bones, the medium was not changed throughout the culture period 
(Haaijman et al. 1999). The total length of the bone through the centre of the 
mineralising zone was determined using image analysis software (DS Camera 
Control Unit DS-L1; Nikon) every second or third day. The length of the central 
mineralisation zone was also measured. Bones were incubated in a humidified 
atmosphere (37oC, 5% CO2).  
2.5.3 Co-culture of embryonic murine metatarsals and IDG-SW3 cells 
For co-culture experiments, 12 Well Thincert, 0.4µm pore diameter, transparent co-
culture plates were used (Grenier Bio-one Inc, Stonehouse, UK). IDG-SW3 cells were 
plated and maintained for up to 21 days as described in section 2.2.4. At this point, 
E15 metatarsal bones were dissected as detailed in section 2.5.2, and were placed 
upon the insert which was suspended above the IDG-SW3 cells to allow diffusion of 
the two cell mediums. Metatarsal bones were cultured for up to 10 days in a 
humidified atmosphere. The total length of the bone through the centre of the 
mineralising zone, as well as the length of the central mineralisation zone, was 
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determined using image analysis software (DS Camera Control Unit DS-L1; Nikon) 
every second or third day.  
2.6 In vivo studies 
2.6.1 Paraffin embedded tissue 
Proximal tibiae from 3-4 week old wild-type male and female C57/BL6 mice were 
dissected and excess tissue was removed immediately after culling of mice by 
cervical dislocation. Tibias dissected were fixed in either 10% neutral buffered 
formalin (NBF; for in situ hybridisation) or in 70% ethanol (for 
immunohistochemistry) for 24 hours. Bones were decalcified in 10% EDTA (pH 7.4) 
with agitation at 4oC for approximately 3 weeks, with regular EDTA changes. Tissue 
was then dehydrated through a series of alcohol steps at room temperature as 
follows: two washes in PBS; two 1 hour incubations in 70% ethanol; two 1 hour 
incubations in 80% ethanol; two 1 hour incubations in 95% ethanol; 1 hour 
incubation in 100% ethanol; overnight incubation in 100% ethanol. The tissue 
specimens were transferred into a wax embedding cassette and rolled in xylene for 2 
hours. The cassettes were then transferred to pre-melted wax at 60°C for 2 hours. 
This allowed wax infiltration of the tissues before they were embedded into plastic 
moulds. Using a microtome (Ernst Leitz AG, Germany; blades used were MX35 
Premier+ Microtome Blades, Thermo Scientific, Cheshire, UK), wax blocks were 
trimmed to expose the sample surface. The paraffin embedded samples were then 
cooled and tissues were sectioned at a 5µm thickness. Sections were transferred to a 
40oC water bath for 1 minute before being transferred to a poly-l-lysine coated 
microscope slide (VWR International Ltd, Lutterworth, UK). Slides were stored at 
room temperature until required. 
2.6.2 Frozen tissue 
For microdissection of the murine growth plate, tissue was frozen so RNA could be 
efficiently extracted. Bone tissue samples were coated in 5% polyvinyl acetate (PVA) 
and then snap frozen in a cooled hexane bath for 30 seconds after which they were 
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stored at -80oC until use. Frozen sections were cut using a cryostat (OTF500/HS-001, 
Brights, Huntingdon, UK) with the knife blade angle set to 25o. Firstly, frozen tissue 
was embedded in optimal cutting temperature (OCT) embedding medium (Brights) 
and attached to a metal chuck. Following trimming of excess OCT, 30µm sections 
were cut at -30oC, and then stored at -80oC. 
2.6.3 Haematoxylin and eosin and von kossa staining 
Paraffin embedded metatarsal sections which had been processed as section 2.6.1 
were stained for von kossa followed by haematoxylin and eosin (H&E) such that 
growth plate zone widths could be measured. Slides were de-waxed in xylene and 
rehydrated through a series of alcohols to dH2O. They were then incubated with 5% 
silver nitrate (BDH, Poole, Dorset; in dH2O) for 30 minutes under a strong light, 
washed in dH2O and fixed in 2.5% sodium thiosulphate. The slides were then 
counterstained with H&E using Leica Autostainer and mounted in DePeX (VWR, 
Lutterworth, UK). The zone widths were measured at x4 magnification using a 
Nikon eclipse TE300 microscope with a digital camera attached, using Image Tool 
(Image Tool Version 3.00).  
2.7 In situ hybridisation 
2.7.1 MEPE plasmid 
A murine Mepe IMAGE clone (ID: 8733911) was purchased as a glycerol stock 
(Source BioScience UK Ltd, Nottingham, UK). The Mepe IMAGE clone glycerol stock 
was streaked onto lysogeny broth (LB) media (Appendix I) ampicillin plates 
(100μg/ml) with a sterilised wire loop, and incubated at 37°C overnight with 
constant agitation for glycerol stocks and minipreps. 
2.7.2 Preparation of glycerol stocks 
Single colonies were picked from the streaked agar plates described in section 2.7.1. 
These were incubated in 5ml LB media containing 100µg/ml ampicillin at 37oC 
overnight with constant agitation. 10µl of the overnight culture was added to 4ml 
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LB media and incubated for approximately 7 hours at 37oC, again with constant 
agitation. This was then mixed with 2ml 50% glycerol and aliquoted for storage at -
80oC until further use.  
2.7.3 Minipreparation of plasmid DNA 
The remaining bacterial culture was used for plasmid DNA production utilising the 
Qiagen miniprep spin kit (Appendix I) (West Sussex, UK) according to the 
manufacturer’s instructions. Briefly the culture was spun at 17,900g for 10 minutes 
and re-suspended in 250μl buffer P1. The cells were then lysed by addition of 250μl 
buffer P2, and incubated at room temperature for 5 minutes. The genomic DNA and 
proteins were precipitated from the lysate by addition of 350μl buffer N3 and 
centrifuged at 17,900g for 15 minutes to clear the lysate. The supernatant was 
centrifuged through a Qiagen column containing a silica membrane to selectively 
adsorb plasmid DNA in the high salt buffer. The membrane was the washed with 
buffer PE and plasmid DNA eluted by centrifugation at 17,900g with 30μl buffer EB. 
DNA obtained was used for sequencing (The Sequencing Service, Dundee).  
2.7.4 EndoFree maxipreparation of plasmid DNA 
The Qiagen Endofree Maxiprep kit was used to isolate endotoxin-free plasmid DNA 
from bacterial cultures according to the manufacturer’s instructions (Appendix I). 
Briefly, 250ml of LB (with 100μg/ml ampicillin) was inoculated with a 100μl aliquot 
of the liquid culture described in section 2.4.3 and grown overnight at 37°C with 
constant agitation. The bacterial cells were harvested by centrifugation at 6000g for 
60 minutes at 4°C. The supernatant was removed and bacterial pellet re-suspended 
in 10ml buffer P1, the cells were then lysed by addition of 10 ml buffer P2, mixed 
thoroughly by inverting and incubated at room temperature for 5 minutes. The 
genomic DNA, proteins, cell debris, and sodium dodecyl sulphate (SDS) were 
precipitated by addition of 10 ml chilled buffer P3, which was mixed by inverting 4–
6 times. The lysate was poured into the barrel of the QIAfilter cartridge and 
incubated at room temperature for 10 minutes. The lysate was then passed into a 
sterile tube and 2.5 ml buffer ER was added to remove endotoxin and incubated on 
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ice for 30 minutes. The filtered lysate was then applied to a QIAGEN-tip 
equilibrated with buffer QBT and allowed to enter the resin by gravity flow. The 
QIAGEN-tip was washed with 2 x 30 ml buffer QC. The DNA was eluted by 
addition of 15 ml buffer QN and precipitated through the addition of 0.7 volumes of 
room temperature isopropanol. This was mixed and centrifuged at 15000g for 90 
minutes at 4°C to pellet the plasmid DNA. The supernatant was decanted and pellet 
washed with 5 ml of endotoxin-free 70% ethanol and centrifuged at 15000g for a 
further 30 minutes. The supernatant was decanted and the pellet left to air dry for 10 
minutes. The DNA pellet was then re-dissolved in 100μl endotoxin-free buffer TE 
and stored at -80°C. 
2.7.5 Restriction digest 
Digestion of DNA using restriction enzymes (Nco1, Roche, Burgess Hill, West 
Sussex) was carried out for linearisation. A typical 10µl digest contained 1µg DNA, 
1µl of Nco1, 1µl of the appropriate 10X reaction buffer and was made up with dH20. 
Digests were left overnight at 37oC and then subjected to agarose gel 
electrophoresis. A 1% agarose gel was prepared using 1x Tris-actetic acid-EDTA 
(TAE) buffer (Appendix I). The agarose/TAE solution was supplemented with 
0.1μl/ml SYBR-Safe, and poured into a mould (with a comb to form the wells) to set. 
The gel was submerged in TAE buffer and DNA samples were mixed with loading 
buffer (Bioline, London, UK) and loaded onto the gel. An electrical current of 120V 
was applied across the gel until the DNA fragments were separated according to 
their size. Fragments were visualised under ultraviolet (UV) light for linearisation.  
2.7.6 Probe synthesis 
Anti-sense and sense digoxigenin-labeled cRNA probes were synthesised using T3 
and T7 RNA polymerases respectively (Roche). A typical 20µl reaction contained 
1µg DNA, 2µl 10x NTP labelling mix, 2µl 10x transcription buffer, 1µl ribonuclease 
(RNase) inhibitor, 2µl Polymerase (T7 or T3) and then was made up with dH2O. The 
reaction was left for 2 hours at 37oC. 2µl DNase I was added for 15 minutes 
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incubation at 37oC, before 2µl 0.2M EDTA was added. Both probes were stored at -
80oC until further use.   
2.7.7 In situ hybridisation technique  
Hybridisations were completed following an optimised in situ hybridisation 
protocol from Imperial College London as previously detailed, using 
diethylpyrocarbonate (DEPC) treated equipment and reagents to diminish RNase 
contamination (Stevens et al. 2000). Paraffin embedded sections (as detailed in 
section 2.6.1) were de-waxed in xylene and rehydrated through a series of graded 
alcohols to dH2O. The mRNA of these deparaffinized sections was exposed by 
digestion with 20µg/ml proteinase K in TE buffer for 15 minutes. Sections were 
acetylated in 0.1M triethanolamine and 0.3 M acetic anhydride for 10 minutes before 
washing, dehydrating, and drying. Hybridization solution (1X Denhardt’s solution, 
50% deionized formamide, 20% dextran sulfate, and 2µg probe) was heated to 80oC 
for 90 seconds, added to sections, and incubated overnight at 50oC. Sections were 
washed in 50% formamide in 0.15M NaCl, 5mM NaH2PO4, 5mM Tris/HCl, and 
2.5mM EDTA (pH 6.8) at 50oC for 30 minutes followed by washing in TNE buffer at 
room temperature every 10 minutes for 1 hour at constant agitation. 3% bovine 
serum albumin (BSA) in 100mM Tris/Cl and 150mM NaCl (pH 7.5), was added to 
sections for 1 hour. ALP-conjugated antidigoxygenin Fab fragments (Roche) were 
diluted 1:500 in blocking solution and added for 1 hour at room temperature. Slides 
were washed in PBS and developed in nitroblue tetrazolium chlorine/5-bromo-4-
chloro-3-indolyl-phosphate-4-toluidine to detect ALP. The sections were rinsed in 
tap water and counterstained with haematoxylin using Leica Autostainer XL. 
Finally, sections were dehydrated through graded alcohols, cleared with xylene and 
mounted in DePeX  
2.8 Microdissection of the murine growth plate 
Frozen sections as detailed in section 2.6.2 were briefly thawed and then passaged 
through the following solutions at room temperature, for 1 minute each: 70% 
ethanol, 100% methanol for fixing, 95% ethanol for washing, staining in eosin (0.2% 
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eosin, 0.5% acetic acid, 75% ethanol). Stained slides were then washed in 70% 
ethanol, dehydrated in 100% ethanol, and finally placed in xylene. Throughout the 
microdissection technique, sections were kept under a xylene droplet. Using an 
inverted microscope, razor blades and hypodermic needles, growth plate sections 
were separated into zones of proliferating chondrocytes, hypertrophic chondrocytes 
and metaphyseal bone based upon the histology of the growth plate as previously 
described (Nilsson et al. 2007). For each zone, tissue dissected from both proximal 
tibial growth plates of three animals (14–22 sections) was pooled in 2.88μl β-
mercaptoethanol and 400µl Solution C (0.322g guanidine thiocyanate, 0.377ml 
nuclease free water (NFW), 0.023ml 0.75M sodium citrate).  
 
RNA isolation was performed as previously described (Heinrichs et al. 1994). 
Samples were diluted in 300µl of buffered proteinase K solution (Appendix I). 
Following a 20 minute digestion at room temperature, RNA was extracted by 
centrifugation in the presence of 150µl of buffer saturated phenol and 150µl 
chloroform: Isoamyl alcohol. 40µl of 3M sodium acetate (pH5.2) added to the 
aqueous phase, along with an equal volume of isopropanol (approximately 440µl). 
The RNA was precipitated at -20°C overnight and collected by centrifugation at 
13,900g for 30 minutes. The resulting pellet was washed in 75% ethanol, dried and 
re-suspended in 20µl DEPC-treated water. 20µl of 8M lithium chloride was added 
for a second RNA precipitation step at -20°C for 3 hours and collected by 
centrifugation at 17,900g for 30 minutes. The supernatant was discarded leaving the 
final pellet which was washed with 75% ethanol, allowed to dry and stored in 10μl 
DEPC-treated water at -80oC until required.   
2.9 Immunohistochemistry 
For immunohistochemical analysis, paraffin embedded sections (as detailed in 
section 2.6.1) were de-waxed in xylene and rehydrated through a series of graded 
alcohols to dH2O. Antibodies were purchased and concentrations used as to 
Appendix III. For the cathepsin B antibody, sections were incubated at 37oC for 30 
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minutes in 0.1% trypsin for demasking. For the MEPE-ASARM antibodies, sections 
were incubated for 1 hour at 37oC in citric acid buffer for demasking. Endogenous 
peroxidise activity was blocked by treatment with 0.03% H2O2 in methanol for 30 
minutes at room temperature.  
 
From this point onwards, the Vectastain ABC kit (Vector Laboratories, 
Peterborough, UK) was used according to the manufacturer’s instructions. Sections 
were given 3 x 5 minute washes in PBS and blocked in blocking buffer (1:50 dilution 
of the appropriate normal serum in PBS) for 30 minutes at room temperature. The 
sections were then incubated in primary antibody, which was diluted to an 
appropriate concentration in blocking buffer (Appendix III), at 4°C overnight. 
Unbound primary antibody was removed by 3 x 5 minute washes in PBS and the 
sections were then incubated in the appropriate secondary antibody (Appendix III) 
at room temperature for 30 minutes. After 3 x 5 minute washes in PBS, sections were 
incubated with ABC reagent (avidin and horseradish peroxidise (HRP)) for 30 
minutes at room temperature before further 3 x 5 minutes washes in PBS. Staining 
was then developed in diaminobenzidine (DAB) solution (0.06% DAB in 0.1% H2O2 
in PBS) for 5 minutes. The sections were rinsed in tap water and counterstained 
with haematoxylin using Leica Autostainer XL. Finally, sections were dehydrated 
through graded alcohols, cleared with xylene and mounted in DePeX. 
2.10 ATDC5 transfections 
2.10.1 ATDC5 blasticidin kill curve 
It is routinely recommended to perform a kill curve for each species, strain, and 
medium used to determine the appropriate concentration of blasticidin to use for 
selecting resistant cells (Gong et al. 2005). Therefore ATDC5 cells were seeded at 1.5 
x 105 cells/cm2 in a 12 well plate and supplemented with varying concentrations of 
blasticidin ranging from 5-35µg/ml. Cell death was observed upon the detachment 
of the cells from the culture plastic and an approximation of the total number of 
dead cells as a percentage of the viable cells was calculated (Fig. 2.1).  
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Figure 2.1 ATDC5 blasticidin kill curve 
Percentage of ATDC5 cells killed upon addition of varying concentrations of 
blasticidin over a 10-day culture period. 
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2.10.2 MEPE overexpressing and knockdown vectors  
pLZ2-Ub.MEPE overexpressing and pLZ2-Ub.Empty vectors were a kind gift from 
Dr Neil Mackenzie (The University of Edinburgh). MEPE shRNA vectors were 
purchased as glycerol stocks from Sigma (Appendix IV). 
2.10.3 Transfection of ATDC5 cells 
For ATDC5 transfection, FuGENE HD (Roche) was used. ATDC5 cells were 
maintained in differentiation medium as previously described (section 2.2.1) and 
seeded in 10cm2 culture dishes at a density of 1.5 x 106 cells/10cm2. The cells were 
transfected when 60-70% confluent. The transfection mix was prepared in Opti-
Mem media containing MEPE-overexpressing and shRNA knockdown constructs at 
a ratio of 7:2 FuGENE HD to DNA. This was pre-incubated at room temperature for 
15 minutes and the transfection reagent:DNA complex added to ATDC5 cells in a 
drop-wise manner. The cells were incubated in a humidified atmosphere (37oC, 5% 
CO2) for 48 hours, after which the medium was changed to maintenance media 
containing 20µg/ml blasticidin as determined by the ATDC5 blasticidin kill curve 
(Fig. 2.1) (section 2.10.1).   
2.10.4 Growing single colonies of transfected cells 
Blasticidin resistant individual colonies, originating from single cells, were picked 
using cloning cylinders, expanded in differentiation medium containing blasticidin 
to maintain selection pressure, frozen and maintained at -150oC until further use. 
Three MEPE-overexpressing and three empty-vector clones were picked for 
analysis.  
2.11 Viral transduction of metatarsals 
2.11.1 Cell culture 
For tissue culture, all liquid waste was aspirated into 1% Virkon solution.  Any 
plastic-ware that was in contact with lentivirus particles was incubated in 1% 
Virkon solution for at least 24 hours. All cells were maintained at 37oC with 5% CO2
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For lentiviral techniques, two cell types were used; Human embryonic kidney 
fibroblasts (293T, a kind gift form Dr. Simon Lillico, The University of Edinburgh), 
and D17 (canine osteosarcoma, ATCC, Teddington, UK).  
2.11.2 Transfections 
For each virus, 4 x T175 flasks were seeded at 0.9x106 HEK293T cells in 6mls media 
(Appendix I). Cells were incubated for 24 hours and transfected at 70-80% 
confluency. The transfection media was prepared in 4ml Optim-Mem media 
containing 56µg of the lentiviral packaging plasmid psPAX2, 28µg of the viral 
envelope coding plasmid vesicular stomatitis Indiana virus – G protein (VSV-G), 
and 42µg of the packaging plasmid for MEPE, or the empty-vector control. To this, 
476μl Fugene HD was carefully added according to the manufacturer’s instructions, 
and incubated at room temperature for 15 minutes. The transfection mix was then 
carefully added to the HEK293T cells prior to overnight incubation at 37oC, 5% CO2.    
2.11.3 Viral harvest 
The supernatant containing viral particles released from the packaging cells was 
removed from each of the flasks at 24 and 48 hours post transfection. The 
supernatant was centrifuged at 2000g for 5 minutes to remove any large cell debris. 
The 24 hour harvest was stored at 4oC overnight until the 48 hour harvest was 
removed, after which the harvests were combined and then filtered through a 
0.45µm filter unit (Nalgene, USA) prior to concentration. 
2.11.4 Concentration of virus 
The viral harvest was centrifuged at 7000g at 4oC in a Sorval RC6 centrifuge 
overnight. The pellet was then resuspended in 10mls TSSM for 30 minutes at 4oC 
with careful agitation, and after 30 minutes the pellet was broken up by careful 
pipetting, ensuring no bubbles are introduced as these are thought to damage the 
envelope proteins of the virus. The viral harvest was then transferred to a Beckman 
ultra-centrifuge tube, topped up to 13ml with PBS to ensure the tube was full prior 
to centrifugation at 20,000g for 2 hours at 4oC in a Beckman XL-70 ultra-centrifuge. 
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The virus was re-suspended by incubation for 1 hour in 200μl TSSM buffer at 4°C 
with gentle agitation. The resultant suspension was centrifuged at 100g for 5 
minutes to remove cellular debris and the concentrated virus was aliquoted and 
stored at -80°C. 
2.11.5 D17 cell blasticidin kill curve 
As in section 2.10.1, to determine the optimum concentration of blasticidin required 
to kill all non-transfected cells, D17 cells (derived from canine osteosarcoma) were 
seeded at 1.5 x 105 cells/cm2 in a 12 well plate and supplemented with concentrations 
of blasticidin ranging from 5-35µg/ml. Cell death was observed upon the 
detachment of the cells from the culture plastic and an approximation of the total 
number of dead cells as a percentage of the viable cells was calculated (Fig. 2.2). 
2.11.6 Titration 
6 x 10-fold dilutions of the concentrated virus were made in D17 cell medium 
supplemented with 8µg/ml Polybrene, starting with a 1/1000 dilution. 500µl of each 
virus were added to D17 cells in duplicate and incubated for 4-6 hours before a 
further 500µl medium was added. The cells were incubated for 8 days, in the 
presences of 20µg/ml blasticidin (Fig. 2.2) with a full medium change after 48 hours. 
Colonies were then counted and the number multiplied by the dilution factor and 
doubled to give a value for effective transducing units in D17 cells per ml of virus 
(TU1080/ml). 
2.11.7 Transduction of E15 metatarsals 
To examine the transduction efficiency and for proof of concept, GFP virus particles 
(a kind gift from Dr. Neil Mackenzie, The University of Edinburgh) were added to 
E15 metatarsals on day 0 of culture with 0.6µl Polybrene at a concentration of 2 x 106 
virus particles/metatarsal bone. Due to production limitations, MEPE-
overexpressing and empty-vector viruses were added to metatarsal bones at a 
concentration of 6 x 104 virus particles/metatarsal bone with 
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Figure. 2.2 D17 blasticidin kill curve 
Percentage of D17 cells killed upon addition of varying concentrations of 
blasticidin over a 10-day culture period. 
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0.6µl Polybrene on day 0 of culture. Bones were left in a humidified atmosphere for 
up to 12 days. 
2.11.8 Morphometric analysis of lentiviral murine metatarsals 
Metatarsals transducted with GFP lentivirus particles were visualised using a Nikon 
EC1 inverted confocal microscope. MEPE-overexpressing and empty-vector 
metatarsals were morphometrically analysed as described in section 2.5.2. 
2.12 RNA methods 
2.12.1 Isolation of total RNA from cells 
Cells (ATDC5 and primary chondrocytes) were scraped from individual wells in 
500µl PBS, pelleted and stored at -80°C. RNA was extracted using a Qiagen RNeasy 
Kit, according to the manufacturer’s instructions. The concentration and quality (the 
ratio of wavelengths 260nm/280nm) of RNA was measured using a nanodrop 
spectrophometer (Thermo Scientific, UK). Samples were diluted to the same 
concentration (that of the lowest sample) in NFW. 
2.12.2 Isolation of total RNA from metatarsals 
For metatarsal organ cultures, 4 bones from each control or experimental group 
were pooled in 100μl Trizol reagent at days 5 and 7 of culture, and RNA extracted 
according to the manufacturer’s instructions. Briefly, metatarsals were homogenised 
using a small hand-held homogeniser and frozen at -80oC until use. 20µl chloroform 
was added to samples and inverted to mix. This was incubated for 3 minutes at 
room temperature before being centrifuged at 12,000g for 15 minutes at 4oC. The 
aqueous phase was removed and 50µl isopropanol was added, mixed and 
incubated at room temperature for 10 minutes. Samples were centrifuged for 10 
minutes at 4oC at 12,000g. The supernatant was discarded and the pellet was 
washed with 100µl 75% ethanol, centrifuged at 7500g for 5 minutes at 4oC and air-
dried in a sterile hood for 10 minutes. The RNA pellet was then dissolved in 20µl 
RNase-free H2O, and then stored at -80oC until further use.  
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2.12.3 Reverse transcription 
Complementary DNA (cDNA) was prepared from total RNA using the enzyme 
reverse transcriptase II. 10µl diluted RNA was incubated with 2µl random 
hexamers (random primers diluted 1:60; Invitrogen) at 70°C for 10 minutes in a 
Hybaid polymerase chain reaction (PCR) Express Thermal cycler (Thermo 
Scientific).  The sample was then rapidly cooled on ice. A master mix of 2µl 10X PCR 
Reaction buffer, 2µl MgCl2 (25mM), 2µl dithiothreitol (DTT) (0.1M), 1µl 
deoxyribonucleotide triphosphate (dNTP) mix (10mM) and 1µl Superscript II RNase 
H enzyme was prepared and 8µl was added to each sample. The samples were run 
on the following programme in the Hybaid PCR machine: 25°C for 10 minutes; 42ºC 
for 50 minutes; 70°C for 15 minutes and held at 4°C. The neat cDNA samples were 
stored at -20°C.  
2.12.4 PCR 
cDNA was diluted to 25ng/µl in NFW. Primers were obtained as to Appendix II. A 
master mix of primer pairs (1µl), Comp A (11.4µl), Comp B (0.6µl) was prepared 
and 13µl of this was added to 4µl of cDNA template. Samples were run for 40 
cycles. A 1.5% agarose gel was prepared containing 2.5µl SYBRsafe DNA gel stain. 
4µl 5x loading buffer (Bioline, London, UK) was added to each sample and samples 
were loaded onto the gel at a volume of 12µl before the gel was run at 150V for 45 
minutes. PCR products were visualised under UV light using a Gel Logic 200 
Imaging System and software (Kodak).  After completion, DNA bands were cut out 
of the gel and DNA purified using a Qiaquick Gel Extraction Kit (Qiagen). DNA 
was sent off for sequencing to The Sequencing Service, University of Dundee. 
2.12.5 Quantitative polymerase chain reaction (qPCR) 
qPCR reactions were conducted in a 96 well plate (Thermo Scientific) and cycled in 
a Stratagene Mx3000P PCR cycler (Agilent Technologies, Santa Clara, USA). Primers 
were purchased as Appendix II. Reactions using primers purchased from Primer 
Design (Southampton, UK) contained 50ng (5μl) cDNA template, 200nM forward 
and reverse primer, 10μl 2x FastStart Universal SYBR Green Master Mix (Roche) 
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and was made up to a volume of 20μl with H2O. The qPCR reaction was cycled 
using the following protocol: 1 cycle of 95°C for 10 minutes followed by 50 cycles of 
95°C for 15 seconds and 60°C for 60 seconds. Reactions using primers purchased 
from MWG Eurofins (London, UK) contained 50ng (5μl) cDNA template, 0.5μl 
forward primer (10pmol/μl), 0.5μl reverse primer (10pmol/μl), 6.5μl NFW, and 
12.5μl FastStart Universal SYBR Green Master Mix (ROX) (Roche). The qPCR 
reaction was cycled using the following protocol: 1 cycle of 2 minutes at 50°C, and 
then 2 minutes at 95°C, followed by 40 cycles of 95oC for 15 seconds, 60°C for 30 
seconds, 95°C for 1 minute, 60°C for 30 seconds, 95°C for 15 seconds and finally 
25°C for 30 seconds. A reaction of H2O in place of cDNA was also amplified as a 
negative control. 
2.12.6 Optimisation of qPCR primers 
To test primer efficiency, serial dilutions of cDNA (known to express the gene of 
interest) were used to create a standard graph line. Primers were considered 
acceptable if the amplification efficiency was within the range of 90-110%, with an 
R2 value between 0.90 and 1.00, and an amplification curve with sigmoid curves at 
regular intervals along the dilution series. Primer specificity was demonstrated by 
the generation of a single peak in the dissociation curve. 
2.12.7 Quantification of gene expression 
Each sample was tested in triplicate and compared to a housekeeping gene using 
MxPro software (Cheshire, UK). The relative expression of the analysed genes was 
calculated using the ΔΔCT method (Livak and Schmittgen 2001) whereby an 
arbitrary amplification threshold is set and relative expression levels of the samples 
are determined by comparison of the number of amplification cycles required to 
cross this threshold (CT).   
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2.13 Protein Methods 
2.13.1 Protein extraction 
Cell monolayers (ATDC5 and primary chondrocytes) were rinsed in ice-cold PBS 
and scraped in an appropriate volume of radio-immunoprecipitation assay (RIPA) 
buffer (Appendix I) containing 0.15 x volume of Complete mini protease inhibitor 
cocktail (Roche). Samples were vortexed and stored at -20oC until further use. 
2.13.2 Quantification of protein 
Once thawed, samples were vortexed aggressively and pelleted. The supernatant 
was removed and its protein content was determined using Bio-Rad DC Protein 
Assay reagents (Bio-Rad Laboratories, Hertfordshire, UK).  Standards were made 
using lyophilised bovine plasma gamma globulin protein, 2mg/ml (Bio-Rad 
Laboratories) in RIPA buffer. Into each well of a 96-well plates, 5µl 
sample/standard, 25μl Reagent A’ (containing 20μl Reagent S per ml Reagent A) 
and 200µl Reagent B was added.  Protein levels were then measured using a 
Multiskan Ascent plate reader at 690nm. The protein concentration in each sample 
was calculated from the standard curve.    
2.13.3 Western blot 
Appropriate volumes of 4x lithium dodecyl sulfate (LDS) sample buffer and 
reducing agent DTT were added to the protein samples as was calculated from the 
DC assay (section 2.13.2). The same quantity of protein was added for each sample, 
depending on the lowest yield achieved. The concentration used was in 10-30ug 
protein range. Samples were denatured at 70°C for 10 minutes. The denatured 
protein samples and a pre-stained molecular weight marker (All Blue, Bio-Rad, 
Hemel Hempstead, UK) were then loaded onto a pre-cast 10% Bis-Tris gel 
(Invitrogen). The gel was run in 1xMOPS running buffer at 200V for 40 minutes to 
separate the proteins using an XCell surelock western blot module. Protein transfer 
onto a Hybond-Electrochemiluminescence (ECL) Nitrocellulose membrane (GE 
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Healthcare, Buckinghamshire, UK) was conducted on ice in a transfer module at 
30V for 2 hours.   
 
Following transfer, the nitrocellulose was washed in TBS/T (Tris-buffered 
saline/Tween-20) and blocked overnight at 4oC in 5% dried skimmed milk/3% 
BSA/0.1% normal serum of the species which the secondary antibody is raised in.  
Primary antibody was prepared as detailed in Appendix III in 5% BSA TBS/T.  The 
nitrocellulose was incubated with primary antibody at 4°C overnight. The 
nitrocellulose was rinsed with TBS/T before probing with the relevant secondary 
antibody (Appendix III). Nitrocellulose membranes were incubated with secondary 
antibody for 1.5 hours at room temperature and washed in TBS/T. Bound antibody 
was detected by chemiluminescence with Amersham ECL Western blotting 
detection reagents A and B (GE Healthcare) at a 1:1 ratio. Chemiluminescence was 
detected with Amersham ECL Hyperfilm (GE Healthcare), which was developed 
using a Medical Film Processor (SRX-101A; Konica Minolta, Banbury, UK). 
2.13.4 Stripping nitrocellulose 
Nitrocellulose membranes were stripped of antibody by incubating in 20ml Restore 
Western Blot Stripping buffer (Thermo Scientific) at 37oC for 30 minutes.  Antibody 
detection by chemiluminescence was repeated to ensure bound antibody had been 
removed.  In the event of significant antibody remaining, this was repeated. 
2.14 Cell proliferation and differentiation assays 
2.14.1 [3H]-thymidine incorporation assay 
On day 7 of culture, 3µCi/ml [3H]-thymidine (Amersham Biosciences, Little 
Chalfont, UK) was added to each metatarsal for the last 6 hours of culture (Mushtaq 
et al. 2004). After washing in PBS (3x15min), the unbound thymidine was extracted 
using 5% trichloroacetic acid (2x30min). Metatarsals were then washed in PBS 
before being solubilised (NCS-II tissue solubiliser, 0.5N, Amersham) at 60oC for 1 
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hour. The DNA incorporating [3H]-thymidine was determined using a scintillation 
counter (Wallac 1410; Pharmacia Biotech, Uppsala, Sweden). 
2.14.2 ALP activity 
At the end of the culture period, ALP activity within the ATDC5 cells and the 
metatarsal bones was determined. The ATDC5 cell layer was lysed in 0.9% NaCl 
and 0.2% Triton X-100 and centrifuged at 12,000g for 15 min at 4oC. The supernatant 
was assayed for protein content and ALP activity (Farquharson et al. 1995). Each 
metatarsal was permeabilised in 100µl of 10mmol/litre glycine (pH 10.5) containing 
0.1mmol/litre MgCl2, 0.01mmol/litre ZnCl2, and 0.1% Triton X-100 by freeze-thawing 
three times (Mushtaq et al. 2004). Each extract was assayed for ALP activity by 
measuring the rate of cleavage of 10mM p-nitrophenyl phosphate. Total ALP activity 
was expressed as nanomoles p-nitrophenyl phosphate hydrolysed per minute per 
metatarsal bone. 
2.15 Statistical analysis 
Data were checked to be normally distributed using a Kolmogorov-Smirnov 
normality test using Sigma Plot (Sigma Plot 11; Germany). Data were analysed by 
one-way analysis of variance (ANOVA) for which suitable post-tests for multiple 
comparisons were conducted, or the Student’s t-test. If data were not normally 
distributed, a suitable non-parametric test was performed. All data are expressed as 
the mean ± standard error of the mean (SEM). Statistical analysis was performed 
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3.1 Introduction 
The growth plate and its primary cell type, the chondrocyte, are integral to 
endochondral ossification and thus the linear growth of the long bones (Kronenberg 
2003). In humans, non-invasive methods have to be adopted to study bone 
development thus limiting investigation into the mechanisms and interactions 
involved. However, the development of in vitro methods such as cell lines, primary 
chondrocytes, and the metatarsal organ culture model, has opened a new chapter in 
chondrocyte biology.   
 
To investigate chondrogenic differentiation and matrix mineralisation, various 
clonal cell model systems have been employed including CFK-2 (Bernier & 
Goltzman 1993), RCJ3.1C5 (Grigoriadis et al. 1996), HCS-2/8 (Takigawa et al. 1989), 
and ATDC5 cells (Atsumi et al. 1990). First isolated from the differentiating 
teratocarcinoma stem cell line AT805, the ATDC5 cell is proving popular in 
chondrocyte in vitro research - to date, there are almost 300 studies in which this cell 
line has been utilised (Atsumi et al. 1990). ATDC5 cells differentiate specifically to a 
chondrocyte phenotype when in the presence of insulin, as evidenced by the 
expression of Col2a1, Col10a1 and aggrecan, typical markers for chondrogenesis 
(Atsumi et al. 1990). In culture, ATDC5 cells proliferate and grow to a point at which 
the spontaneous cessation of growth occurs. Then, an assimilation of hypertrophic 
cell appearance, Col10a1 mRNA expression and increased ALP enzyme activity 
indicates the potential for ATDC5 cells to mineralise their surrounding ECM 
(Shukunami et al. 1996). The ATDC5 cartilage nodules formed stain positive for 
alizarin red, therefore indicating effective ECM mineralisation, after 5 weeks in 
culture. Electron microscopy and electron probe microanalysis confirmed that the 
mineral was initially formed in the MVs, and then deposited along the axis of the 
collagen fibril orientation, as is observed during in vivo endochondral ossification. 
Furthermore, the mineral formed by these ATDC5 cells is similar to apatitic mineral, 
as shown by FT-IR analysis (Shukunami et al. 1997).  
Chapter 3          Establishing a suitable in vitro model of chondrocyte matrix mineralisation 
~ 64 ~ 
 
However, the method developed by Shukunami et al., not only comprises of an 
impractical culture time period, but also requires a change of culture conditions. 
Both the cell culture medium and the CO2 concentration have to be altered after 21 
days of culture to facilitate mineralisation. For this reason, various studies have 
attempted to simplify the culture method whilst maintaining the chondrogenic 
differentiation and formation of physiological mineral. One such study found that 
as well as changing the culture conditions at day 21 of culture, the addition of 4mM 
Pi to the cells at this time point initiated mineralisation within 8 hours, and strongly 
increased it after 24 hours. After 7 days of culture in the presence of Pi, the mineral 
formed by these cells was deemed physiological by TEM and FT-IR assessment. 
Despite this, the sudden and seemingly spontaneous onset of mineralisation in this 
culture system questions its physiological relevance as a model of in vivo 
endochondral ossification (Magne et al. 2003). Another study has detailed that the 
addition of ascorbic acid shortened the proliferation phase of the ATDC5 cells from 
21 days to 7 days (Altaf et al. 2006). Whilst the temporal expressions of markers of 
chondrogenic differentiation were examined, the mineralisation capability of the 
ATDC5 cells under these culture conditions was not. Therefore, the development of 
an ATDC5 culture model which produces both consistent chondrogenesis and ECM 
mineralisation in a more physiological and practical time period would be of great 
benefit in aiding chondrocyte research.    
 
It is however well recognised that transformed cell lines may not represent the 
primary cells from which they were developed. For this reason, primary 
chondrocytes isolated from different anatomical regions have been widely used as a 
more physiologically relevant model to study chondrogenesis. However, it is widely 
known that the de-differentiation of primary chondrocyte cells in monolayer culture 
is a common occurrence, and a major problem. Once cultured, primary 
chondrocytes adopt a flattened and elongated morphology that resembles that of a 
fibroblast as opposed to the more spheroidal morphology expected of a chondrocyte 
(Abbott & Holtzer 1966). This de-differentiation is associated with an upregulation 
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of various genes not associated with chondrogenesis, most notably Col1a1 (Lefebvre 
et al. 1994; Hering et al. 1994). It has been suggested that this phenomenon is in part 
related to the seeding density of the cells, as well as the medium in which the cells 
are cultured in (Hering et al. 1994; Ronziere et al. 1997). Despite these limitations, 
methods which allow for the differentiation and subsequent ECM mineralisation by 
the primary chondrocyte cells have previously been detailed (Garimella et al. 2004; 
Gartland et al. 2005; Rodriguez et al. 2005). A full characterisation of the cellular 
differentiation and mineral formed has not however been conducted thus, whether 
primary chondrocytes are a reliable model for chondrocyte matrix mineralisation is 
yet to be elucidated.  
 
The use of bone organ cultures in bone research was pioneered more than 50 years 
ago by Dame Honor Fell, and since then various types of bones have been used; 
neonatal calvaria, foetal long bones and metatarsal bones (Fell & Mellanby 1952). 
Embryonic metatarsal bones provide a physiological model for studying 
endochondral ossification and bone growth as the growth rate of the bones mimics 
that seen in vivo. Moreover, it allows for the separation of systemic and local factors 
therefore permitting the specific analysis of the local effects on the growth plate. 
Uniquely, the metatarsal organ culture allows the examination of chondrocytes in 
different phases of chondrogenesis and maintains cell-cell and cell-matrix 
interactions, therefore providing conditions closer to the in vivo situation than cells 
in culture (Scheven & Hamilton 1991; Coxam et al. 1996). Foetal murine metatarsal 
bones isolated at different ages, and therefore at different developmental stages, 
have been utilised as models of longitudinal bone growth. However, like primary 
chondrocyte cultures, the assessment of their mineralisation capability has yet to be 
fully characterised.    
 
It is imperative that a model of endochondral ossification is reproducible, reliable, 
and retains both the expected stages of chondrogenic differentiation as well as the 
formation of physiological mineral. Although various models exist, their full 
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characterisation is required to aid future chondrocyte research and ultimately to 
develop novel therapeutic methods.  
3.2 Hypothesis 
The onset of mineralisation in the ATDC5 cell line can be reduced by the addition of 
ascorbic acid and βGP. The differentiation of ATDC5 cells and of primary 
chondrocytes is characterised by the expression of chondrogenic markers, and the 
mineral formed resembles that of true physiological hydroxyapatite. As such, the 
ATDC5 cell line and primary chondrocytes can be used as suitable models for 
endochondral ossification. Furthermore, the isolation and culture of foetal 
metatarsal bones at different developmental stages provides a suitable model of 
chondrocyte matrix mineralisation.  
3.3 Aims 
I Establish the temporal ECM formation and associated expression patterns of 
chondrocyte differentiation markers of the ATDC5 cell line and of the 
primary chondrocyte cell model 
 
II Determine the suitability of the ATDC5 cell line as a model for 
mineralisation through analysis of the mineral formed 
 
III Examine the use of embryonic metatarsal organ cultures as a model for both 
bone growth and mineralisation at different developmental stages 
3.4 Materials and Methods 
3.4.1 ATDC5 and primary cell culture 
ATDC5 cells were seeded at 6 x 104 cells/cm2 in differentiation media and when 
confluent, were supplemented with 10mM βGP and 50µg/ml ascorbic acid, as 
described in section 2.2.1. For levamisole experiments, ATDC5 cells were cultured in 
varying concentrations of levamisole (0-1000µM) for up to 15 days. Primary 
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costochondral chondrocytes were isolated from 1-3 day old mice and cultured as 
described in section 2.2.3. Confluent primary cultures were maintained for up to 28 
days in primary chondrocyte media supplemented with 10mM βGP and 50μg/ml 
ascorbic acid.       
3.4.2 ECM formation 
As outlined in section 2.4.2, to assess the formation of the ECM, ATDC5 cells and 
primary chondrocytes were stained with alcian blue having been fixed in 95% 
methanol. Staining was quantified by spectrophotometry.  
3.4.3 Mineralisation  
The ECM mineralisation of ATDC5 cells and primary chondrocytes was assessed by 
alizarin red staining. Cell monolayers were fixed at defined time points in 4% PFA 
and staining was quantified by spectrophotometry as detailed in section 2.4.1. 
3.4.4 Analysis of ATDC5 mineral deposition 
ATDC5 cells were maintained in culture for 41 days in differentiation media, as 
described in section 2.2.1. Cells were then fixed in 95% methanol and embedded in 
LR white resin (see section 2.3.1). Mineral was analysed by FT-IR in the laboratory 
of Professor Adele Boskey (Hospital for Special Surgery, New York). 
3.4.5 Ultrastructural imaging of ATDC5 mineral deposition 
ATDC5 cells were seeded on nitrocellulose discs and cultured in mineralising 
conditions for 16 days. Cell monolayers were processed for TEM as detailed in 
section 2.3.2 by Steve Mitchell (University of Edinburgh). Samples were visualised 
using a Phillips CMIRO TEM and images taken on a Gatan Orius ICD camera.  
3.4.6 qPCR analysis of chondrocyte differentiation and ECM mineralisation genes 
At defined time points, RNA samples were extracted from ATDC5 cells and 
primary chondrocytes using a Qiagen RNeasy kit according to the manufacturer’s 
instructions. cDNA was prepared (section 2.12.3) and was used at 10ng/µl for qPCR 
analysis, as detailed in section 2.12.5. Results were normalised to the 18S 
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housekeeping gene and the relative gene expression level was calculated using the 
ΔΔCt method (Livak & Schmittgen 2001).  
3.4.7 Metatarsal organ culture  
The middle three metatarsals of E17 and E15 mice were isolated under a dissecting 
microscope, as described in section 2.5.2.  Metatarsals were cultured in metatarsal 
media for up to 10 days. The total length of the bone through the centre of the 
mineralising zone was determined using image analysis software (DS Camera 
Control Unit DS-L1; Nikon) every second or third day. The length of the central 
mineralisation zone was also measured. 
3.4.8 Lactate dehydrogenase activity 
Lactate dehydrogenase (LDH) activity was determined in the culture medium of 15-
day-old 0mM and 10mM βGP treated ATDC5 cells using a kit from Roche 
Diagnostics (Lewes, East Sussex, UK). LDH activity was related to the total LDH 
activity of the cultures. 
3.5 Results 
3.5.1 Chondrogenic differentiation of ATDC5 cells 
ATDC5 cell monolayers reached confluence after six days of culture and adopted a 
more spheroidal morphology (Fig. 3.1A). At this point, ATDC5 cells were cultured 
with the addition of βGP, a commonly used organic phosphate source (Coe et al. 
1992), and ascorbic acid which is required for collagen processing and secretion into 
the ECM and has previously been shown to reduce the onset of mineralisation (Altaf 
et al. 2006). This initiated cell condensation and the formation of cell aggregates, 
which produce a vast ECM (Fig 3.1B). In the centre of these condensations, the cells 
become hypertrophic and increase in size which is the main drive for longitudinal 
bone growth, as discussed in section 1.2.2.3. The cells mineralise their surrounding 
extracellular matrix as visualised at day 15 of culture (Fig. 3.1C). From this point 
onwards, mineral formation radiates throughout the culture monolayer (Fig. 3.1D). 
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Figure 3.1 Phase contrast images of ATDC5 cell cultures  
Phase contrast images of ATDC5 cells cultured for up to 20 days in the presence of ascorbic acid and βGP (A) Day 6. Cells reach confluency by day 6 
of culture and have a spheroidal morphology (B) Day 10. By this point, cells begin to condense and form aggregates whilst producing large volumes 
of ECM (arrows) (C) Day 15. Opaque regions form in the ECM which indicate mineral formation (arrows) (D) Day 20. Cell aggregations conjoin and 
mineralisation increases (arrows). Scale bars are 1mm. 
A B 
C D 
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The formation of an ECM is a vital component of chondrogenic differentiation. 
ATDC5 monolayers began to form their ECM at day 8 of culture, as visualised by 
alcian blue staining for glycosaminoglycans (Fig. 3.2A). This was increased 
throughout the time course (Fig. 3.2B), significantly so between days 13 and 10 
(P<0.01), days 15 and 13 (P<0.01), and days 17 and 15 (P<0.001). In comparison to 
day 8, alcian blue staining was significantly increased from day 13 onwards 
(P<0.001). This provided indication that the ATDC5 cells underwent the expected 
stages of differentiation observed in endochondral ossification. Furthermore mRNA 
expression levels of Col2a1, the major component of the cartilage ECM, were 
significantly increased at day 10 of culture in comparison to day 8 of culture (P<0.05, 
Fig. 3.2C). Concomitant with this, the mRNA expression of Col10a1 increased at 
days 13 and 17 of culture, as is in concordance with its specific expression by the 
hypertrophic chondrocytes (in comparison to day 8 of culture, P<0.001, Fig. 3.2D).   
3.5.2 Mineralisation of ATDC5 cell matrix  
The deposition of mineral by ATDC5 cells was determined by alizarin red staining 
and quantified by spectrophotometry. For maximal mineralisation at day 15 of 
culture, ATDC5 cells require culturing in the presence of both insulin and βGP, as 
indicated by the significantly reduced alizarin red staining when ATDC5 cells were 
cultured without these components (P<0.001, in comparison to ATDC5 cells 
cultured in the presence of both insulin and βGP, Fig. 3.3C). ATDC5 cells were 
therefore cultured in media containing insulin, with the addition of βGP over a 20-
day culture period. Alizarin red positive mineral formation was observed initially at 
day 13 of culture. At day 15, mineral formation was significantly increased in 
comparison to day 13 of culture (P<0.001), and from this point onwards, mineral 
formation was significantly increased in comparison to day 8 of culture (P<0.001, 
(Figs. 3.3A & B). The levels of Alpl mRNA expression, for the membrane bound 
enzyme ALP, were examined throughout the culture period. Alpl mRNA increased 
up to day 15 of culture (P<0.001 compared to day 8, Fig. 3.3D) after which it 
decreased at day 17 (P<0.01 compared to day 15), and remained so at day 20 of 
Chapter 3          Establishing a suitable in vitro model of chondrocyte matrix mineralisation 
































Figure 3.2 The chondrogenic differentiation of ATDC5 cells 
(A) Alcian blue staining of ATDC5 cells cultured in the presence of ascorbic acid and βGP for 
up to 20 days (B) Quantification of alcian blue staining by spectrophotometry. From day 13 
onwards, staining was significantly increased in comparison to day 8 (P<0.001). Significance 
between consecutive time points is indicated on graph (C) Col2a1 mRNA expression in 
ATDC5 cells as determined by qPCR in comparison to day 8 (D) Col10a1 mRNA expression 
in ATDC5 cells as determined by qPCR in comparison to day 8. Data are represented as 
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Chapter 3          Establishing a suitable in vitro model of chondrocyte matrix mineralisation 































Figure 3.3 Mineralisation of ATDC5 cell cultures 
(A) Alizarin red staining of ATDC5 cells cultured in the presence of ascorbic acid and βGP 
for up to 20 days (B) Quantification of alizarin red staining by spectrophotometry. From day 
15 onwards, staining was significantly increased in comparison to day 8 (P<0.001). 
Significance between consecutive time points is indicated on graph (C) Effects of culturing 
without insulin and/or βGP on ATDC5 cell ECM mineralisation in comparison to cells 
cultured in the presence of both insulin and βGP (D) Alpl mRNA expression in ATDC5 cells 
by qPCR. Data are represented as mean ± S.E.M (n=3 replicates) **P<0.01, ***P<0.001.   
 
A B 
Insulin             +             +              -               - 
βGP                +              -              +              -  
D C 
Day 8 Day 10 Day 13 
Day 15 Day 17 Day 20 
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culture (Fig. 3.3D). The use of βGP in cell culture is rather controversial, with 
studies detailing the formation of dystrophic mineral that does not resemble true 
physiologic hydroxyapatite (Khouja et al. 1990). Levamisole, a well-established 
inhibitor of ALP, was therefore added to ATDC5 cultures. Levamisole inhibited 
ATDC5 ECM mineralisation at concentrations in excess of 300µM at day 15 of 
culture (P<0.001) (Figs. 3.4A & B) with no apparent alterations in the ATDC5 cells 
morphology. This therefore indicates that the enzyme ALP is required and the 
mineral formed is not simply a precipitation of calcium and Pi and therefore 
dystrophic.  
 
Furthermore, FT-IR and TEM were adopted as two well recognised methods to 
determine whether the mineral formed in culture is similar to that which forms in 
nature (Boskey & Roy 2008). The mineral formed was assessed at the ultrastructural 
level by TEM. Mineral deposition was observed which appeared to be aligned along 
the axis of the collagen fibrils, as is seen in endochondral ossification (Fig. 3.5A-C). 
The spectrum formed by analysis of the ATDC5 cell cultures was similar to that 
formed by E14 embryonic bone, with similarities in the regions of interest to the 4-
week-old post-natal bone (Fig. 3.5D). The parameters of ATDC5 cell ECM 
mineralisation shown here were also comparable to that seen in embryonic bone 
(Table 3.1) (Anderson et al. 2004; Boskey et al. 2009b).  
3.5.3 Characterisation of the primary chondrocyte model 
To examine whether primary chondrocytes can be used as a reliable model for 
chondrocyte matrix mineralisation, cells were isolated from 1-3 day old mice and 
cultured at a density of 105 cells/cm2, in the presence of ascorbic acid and βGP. After 
9 days in culture, primary chondrocytes appeared confluent and had begun to form 
aggregations. Cells were producing large volumes of ECM as indicated by alcian 
blue staining for glycosaminoglycans (Figs. 3.6A-D). By day 14, cells had begun to 
mineralise their surrounding ECM as shown in the phase contrast images (Fig. 
3.7B). This was confirmed by quantification of alizarin red staining (compared to
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Figure 3.4 Levamisole inhibits mineralisation of ATDC5 cultures 
Levamisole, an inhibitor of ALP enzyme activity, was added to ATDC5 cell cultures 
from when they reached confluency (A) Levamisole dose dependently inhibited 
ATDC5 ECM mineralisation as indicated by quantification of alizarin red staining (B) 
Alizarin red stained images of control cells and cells treated with 300µM levamisole 
at day 15 of culture. Data are represented as mean ± SEM (n=3 replicates) in 
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Figure 3.5 Analysis of ATDC5 cell mineral deposition  
Transmission electron microscopy images of ATDC5 cultures at day 16 of culture (A) Collagen fibres are present in the ECM (arrows) (B) 
Mineral deposition can be seen along collagen fibres; arrows indicate an electron-dense material, likely to be mineralisation spreading along 
the collagen fibres within the ECM (C) Mineral deposition within the ECM (arrows) (D) FT-IR analysis of (a) ATDC5 monolayer at 41 days of 
culture; (b) mineralised embryonic mouse bone at E14; (c) cortical bone from the tibia of four-month old mouse. Absorbance of the phosphate 
peaks (900-1200 cm-1), which represents mineralisation, and the amide-I peak (1585-1725 cm-1), which indicates protein, were used to estimate 
the mineral-to-matrix ratio of the mineralised ECM. Absorbance values for each plot are arbitrary and not to scale.  
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Sample Mineral-to-matrix Carbonate-to-mineral    Crystallinity 
A  3.000 ± 0.917  0.008 ± 0.005       1.128 ± 0.009 
B  2.200 ± 2.500  0.005 ± 0.002           1.072 ± 0.062 




















Table 3.1 Mineralisation parameters from FT-IR analysis 
Using peak areas from FT-IR spectra, the mineral-to-matrix ratio (900-1200 cm-1 / 1585-1725 
cm-1), carbonate-to-mineral ratio (850-950 cm-1 / 900-1200 cm-1) and crystallinity (1030 cm-1 / 
1020 cm-1) were calculated for mineralised regions of (A) ATDC5 monolayer grown to 41 
days of culture, (B) mineralised E14 mouse bone, (C) cortical bone from the tibia of four-
month old mouse. 
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day 7, P<0.001) (Figs. 3.7C & D). This alizarin red staining for mineral significantly 
increased at day 21 of culture and remained so at day 28 (compared to day 8, 
P<0.001) (Fig. 3.7E). 
 
Although primary chondrocytes are commonly used their de-differentiation in 
monolayer culture is well documented (Abbott & Holtzer 1966; Hering et al. 1994; 
Lefebvre et al. 1994). Therefore, to fully establish the chondrogenic differentiation of 
the primary chondrocytes used in this model, Col10a1, Col2a1 and Col1a1 mRNA 
expression was assessed by qPCR throughout the culture period. Rather 
surprisingly, the mRNA expression of Col2a1 decreased throughout the culture 
period (compared to day 7, P<0.05) (Fig. 3.8A), as did that of Col10a1 (compared to 
day 7, P<0.05) (Fig. 3.8B). Rather, it would be expected that the mRNA expression of 
these genes would increase during the culture period. Therefore, this is not 
indicative of normal chondrogenic differentiation as is observed in the ATDC5 
cultures (Fig. 3.5) and suggests that the primary chondrocytes had indeed de-
differentiated. This was further confirmed by the mRNA expression pattern of 
Col1a1 which would be expected to be negligible in these cultures. However mRNA 
expression increased at day 14 of culture (in comparison to day 7, P<0.01) before 
decreasing at days 21 and 28 of culture (at day 28, in comparison to day 14, P<0.001) 
(Fig. 3.9).  
3.5.4 Embryonic metatarsal organ culture  
When isolated, E17 metatarsal bones display a central core of mineralised cartilage 
juxtaposed by a translucent area on both sides representing the hypertrophic 
chondrocytes (Fig. 3.10B). These metatarsal bones increased in total length (up to 
80% compared to day 0, P<0.001) (Figs. 3.10B, C & E) after 10 days in culture in the 
presence of βGP. Concomitant to this, the length of the mineralisation zone also 
increased (up to 590%, compared to day 0, P<0.01) (Figs. 3.10B, C & D). When 
isolated at an earlier time point (E15), metatarsal bones consist of early proliferating 
cartilage and there is no evidence of a mineralised core (Fig. 3.11B). After 6 days in
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Figure 3.6 De-differentiation of primary chondrocyte cell cultures 
Phase contrast images of alcian blue stained primary chondrocytes at (A) day 7 (B) day 14 
(C) day 21 and (D) day 28 of culture. Alcian blue staining increased throughout the culture 
period as quantified by spectrophotometry (E). Data are represented as mean ± SEM (n=3 
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Figure 3.7 Mineralisation of primary chondrocyte cell cultures 
Phase contrast images of alizarin red stained primary chondrocytes at (A) day 7 (B) day 14 
(C) day 21 and (D) day 28 of culture. Alizarin red staining increased throughout the culture 
period as quantified by spectrophotometry (E). Data are represented as mean ± SEM (n=3 
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Figure 3.8 Decreased expression of Col2a1 and Col10a1 mRNA in primary 
chondrocyte cultures 
The temporal expression pattern of the chondrogenic marker genes (A) Col2a1 (B) 
Col10a1. Data are represented as mean ± SEM (n=3 replicates) in comparison to day 7 of 
culture *P<0.05, **P<0.01.  
Figure 3.9 Temporal expression of Col1a1 mRNA expression 
The mRNA expression pattern of Col1a1 in primary chondrocytes over a 28 day 
culture period. Data are represented as mean ± SEM (n=3 replicates) **P<0.01, 
***P<0.001. 
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Figure 3.10 Growth trajectory and mineralisation capability of E17 metatarsal 
bones 
Measurements of digital images of E17 mouse metatarsal bones in culture with clearly 
delineated mineralising zones (A) Calibrated ruler used for metatarsal length 
measurements (B) E17 metatarsal bone on day of harvest, termed day 0 of culture. 
Clearly shown are the locations of the proliferating (PZ), hypertrophic (HZ) and 
mineralising (MZ) zones, as well as the total length measurement (C) E17 metatarsal 
bone after 10 days in culture (D) Percentage change in the length of the MZ from 
baseline, taken on the day 0 (E) Percentage change in the total metatarsal length from 
baseline over the 10 day culture period. Data are represented as mean ± SEM of six bones 
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Figure 3.11 Growth trajectory and mineralisation capability of E15 metatarsal 
bones 
Measurements of digital images of E15 mouse metatarsal bones in culture (A) Percentage 
change in the total metatarsal length from baseline over the 6 day culture period (B) E15 
metatarsal bone on day of harvest, termed day 0 of culture. The bones consist of 
proliferating cartilage and no evidence of a mineralised core (asterisk) (C) E15 metatarsal 
bone after 6 days of culture. The total length of the bone is increased and the central core 
of mineralised cartilage has formed (MZ). The hypertrophic zone (HZ) and proliferative 
zone (PZ) of chondrocytes are labelled as are the measurements taken. Data are 
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culture, these bones grew in total length (up to 65%, compared to day 0, P<0.001) 
(Fig. 3.11A) and the chondrocytes in the centre of the bone became hypertrophic, as 
visualised by microscopy and histology, and mineralised their surrounding matrix 
(Fig. 3.11C). Both E17 and E15 metatarsal isolated at an earlier time point (E15), 
metatarsal bones consist of early proliferating organ cultures are therefore 
physiological models of endochondral ossification. 
 3.6 Discussion 
Attempts to unravel the underlying mechanisms of endochondral ossification have 
been limited by current models. The data presented in this chapter identifies two 
mineralisation models as practical and useful tools for studying physiological 
chondrocyte ECM mineralisation that are highly reproducible. 
 
Immortalised cell lines provide a homogenous population of cells which can 
theoretically allow reproducible and reliable results. The ATDC5 cell line has been 
used extensively within chondrocyte research. However, for mineralisation studies 
it is currently limited by a complex culture method and an extensive culture time 
period. The method proposed by Shukunami et al., involved reducing the CO2 
concentration. The pH of cell culture medium is entirely dependent upon the fine 
balance between dissolved carbon dioxide and bicarbonate ions. Therefore any 
alterations in the atmospheric CO2 levels will undoubtedly change the pH of the 
culture medium which is known to have significant effects on cell matrix 
mineralisation (Arnett 2003; Brandao-Burch et al. 2005; Orriss et al. 2007; Arnett 
2010). Exposing the ATDC5 cultures to a lower CO2 concentration will increase the 
pH of the culture medium and therefore will favour mineralisation conditions. The 
method proposed in this thesis removes this conflicting factor as it uses a constant 
CO2 concentration. 
 
Furthermore, the method proposed by Shukunami and colleagues involved 
changing the culture medium after 21 days of culture to one which contained 
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ascorbate. The use of ascorbic acid in skeletal cell culture systems is common as it is 
an essential cofactor for prolyl lysyl hydroxylase, an enzyme which is key to 
collagen production (Schwarz et al. 1981). It has also been found that ascorbate 
stimulates GAG production, increases the mRNA expression of chondrogenic 
differentiation markers in bovine articular cartilage, and in chick chondrocytes it 
increases ALP activity and Col10a1 mRNA expression (Leboy et al. 1989; Kao et al. 
1990; Hering et al. 1994; Farquharson et al. 1995). A deficiency of ascorbic acid in 
humans results in scurvy, and at the growth plate there is decreased chondrocyte 
proliferation with an associated impairment of ECM synthesis (Kipp et al. 1996). 
ATDC5 cells have previously been cultured with ascorbic acid and this was shown 
to reduce the proliferation phase of the cells and promote their differentiation (Altaf 
et al. 2006; Temu et al. 2010). Here cells were cultured in the presence of 50µg/ml 
ascorbic acid from when they reached confluency and in concurrence with previous 
studies, this promoted their ECM formation. The increased mRNA expression of the 
chondrogenic marker Col2a1 correlated with the onset of alcian blue stained 
cartilaginous nodules and the increased mRNA expression of Col10a1 with the 
differentiation of the cells to a hypertrophic phenotype (Fig. 3.2).       
 
In addition to ascorbic acid, an exogenous phosphate source is routinely added to 
cell cultures to induce and stimulate mineralisation of the ECM. Here, ATDC5 cells 
showed significant mineral formation from day 15 of culture (Fig. 5.4). This is 
consistent with a previous study in which ATDC5 cells were cultured for 
mineralisation assessment (Idelevich et al. 2011). The use of an exogenous phosphate 
source to induce mineralisation has been a matter of concern with studies 
questioning whether the mineral formed is physiological, or whether it is simply an 
indication of calcium and Pi presence within the cultures and thus dystrophic 
mineral as has previously been found (Gronowicz et al. 1989; Rohde & Mayer 2007). 
 
In bone biology, βGP is a preferential exogenous organic phosphate source as it is a 
substrate for ALP and therefore the cells indirectly dictate when the Pi increase 
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occurs through their differentiation to a hypertrophic phenotype. This is 
advantageous as mineralisation occurs in a more temporal manner as opposed to 
the seemingly spontaneous mineral formation described in the study by Magne et 
al., 2003. It is therefore necessary that the membrane-bound enzyme ALP is present 
for chondrocyte ECM mineralisation and in the method of ATDC5 cell culture 
developed here, the mRNA expression levels of ALP increase concomitantly with 
the onset of mineralisation. This is consistent with previous studies in which the 
activity of ALP has been investigated in ATDC5 cells (Shukunami et al. 1997). 
Furthermore, the addition of levamisole, a potent inhibitor of ALP to ATDC5 
cultures inhibited their mineralisation, as did cells cultured in the presence of βGP 
but not insulin (Figs. 3.3 & 3.4) (Borgers 1973; Van 1976). This therefore suggests that 
mineral formation is dependent upon both chondrogenic differentiation and the 
subsequent presence of ALP. Additionally, the inhibition of mineralisation when 
cells were cultured without insulin further emphasises that the mineral formed here 
is not dystrophic.  
 
Routinely used as indicators of mineralisation, alizarin red stain reacts with calcium 
and other cations whilst von kossa stain visualises phosphate and carbonate anions 
(Puchtler et al. 1969). However, neither stain is sufficient when determining mineral 
formation as the presence of calcium and/or phosphate does not indicate 
hydroxyapatite formation per se (Bonewald et al. 2003). For this reason, various 
methods exist to examine whether the mineral formed in culture is of a similar size 
and structure to physiologic hydroxyapatite crystals, and whether these crystals 
form in alignment with the collagen fibrils of the ECM, as is seen in endochondral 
ossification (Boskey & Roy 2008). Here, FT-IR and TEM were adopted and 
confirmed that the addition of 10mM βGP to ATDC5 cells produced mineral that 
could be comparable to physiological hydroxyapatite (Fig. 3.5). In concordance with 
other studies, TEM showed mineral deposits to be associated with banded collagen 
fibrils (Shukunami et al. 1997; Magne et al. 2003). Examination of the amide and 
phosphate (PO4) peaks determined by FT-IR analysis by Shukunami et al., suggests a 
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lesser mineral-to-matrix ratio than the cultures here. This mineral-to-matrix ratio 
has been investigated in various studies of chondrocyte mineralisation and ranges 
from 1.9 to 5.48 in 10-week-old mice (Wu et al. 1989; Boskey et al. 1996; Paschalis et 
al. 1996; Anderson et al. 2004). Despite the distinct variation, the value obtained here 
(3.0) was within the range observed in other studies. Furthermore, the crystallinity 
of this mineral was similar to that seen in previous studies of 10-day-old mouse 
growth plates (Anderson et al. 2004), and 10-week-old mice (Boskey et al. 2009b).    
  
Primary chondrocytes cultured for up to 28 days appeared to form mineralised 
regions associated with the development of an ECM as indicated by histochemical 
analysis. However the de-differentiation of these cells is a common occurrence. 
Here, attempts were made to limit the de-differentiation of primary chondrocyte 
cells such that they could be used as a model for chondrocyte matrix mineralisation 
by increasing the plating density of the cells, and by culturing the cells in the 
presence of ascorbic acid and βGP. Other methods which could have been examined 
to limit the de-differentiation include the micromass culture system however 
previous attempts of this by others within the group were unsuccessful (data not 
shown). Despite attempts to limit de-differentiation, primary cell cultures still 
exhibited a decreased expression of Col2a1 and Col10a1 mRNA expressions and an 
increase in Col1a1 mRNA expression as has been previously reported (Fig. 3.6 & 3.7) 
(Lefebvre et al. 1994; Hering et al. 1994). These patterns of expression are consistent 
with the de-differentiation of the cells into a fibroblastic phenotype. It has been 
shown in chick chondrocyte cultures that an increased mRNA expression of Col1a1 
in these cultures is not necessarily translated into protein (Focht & Adams 1984; 
Bennett et al. 1989). A steady-state expression of Col1a1 mRNA may suggest a lack of 
de-differentiation however that is not the case here (Gartland et al. 2005; Goldring 
2005). However, here the significant increase in Col1a1 mRNA expression at day 14 
of culture, concomitant with the significant decreases in Col2a1 and Col10a1 mRNA 
expression suggests that the primary chondrocyte cells do not undergo normal 
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differentiation as seen in vivo and thus cannot be considered as a suitable model of 
endochondral ossification. 
 
3-dimensional culture systems have been previously suggested as solutions to the 
de-differentiation seen when culturing primary cells. Classically, alginate gels have 
been used as a supporting matrix for entrapping articular chondrocyte cells 
providing a more physiological model through increased cell-cell interactions. The 
use of alginate gels allows the chondrocyte cells to maintain their normal 
phenotype, as is lost when cultured in monolayer. Similarly, growth plate derived 
chondrocytes can be used in this manner to investigate differentiation processes 
(Albrecht et al. 2009). However, the use of alginate gels as a model for mineralisation 
has yet to be established and the practicalities surrounding this method are 
equivocal.    
 
The metatarsal organ culture provides conditions closer to the in vivo situation 
compared to cell cultures as the chondrocytes within the bones exist in the three 
principal stages of chondrogenesis whilst retaining direct interactions with each 
other. Nevertheless, careful consideration is required when extrapolating the results 
seen due to the artificial environment in which they are cultured. Commonly, a 
postnatal metatarsal organ culture is used to delineate the mechanisms surrounding 
postnatal bone growth as it is understood that postnatal bone growth and foetal 
bone growth are regulated differently (Andrade et al. 2011). However, foetal 
metatarsals have a greater capacity for studying chondrogenesis and mineralisation 
as they are at an earlier stage of development. Here foetal metatarsal bones were 
aseptically dissected at E15 and at E17 and cultured for up to 10 days. 
Developmentally, the skeletal system first appears around day 10.5 post coitum in 
mice. By E15, most precartilage structures have been replaced by cartilage and 
despite a considerable degree of periosteal ossification occurring in the long bones, 
the metatarsal bones exist as a precartilage model. By E17, this ossification has 
started to occur (Kaufman, 1992). This mineralisation is apparent in the bones 
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dissected here. Like in vivo, these E17 bones have an increase in their longitudinal 
growth as well as increased mineralisation when cultured (Fig. 3.9). Similarly, E15 
bones display an increased longitudinal growth and the central mineralisation zone 
develops after approximately 2 days in culture, as is consistent with the in vivo 
development described (Fig. 3.10). The metatarsal organ culture systems described 
here therefore share many important characteristics with chondrocyte in vivo 
differentiation and mineralisation.       
 
In conclusion, ATDC5 cells cultured using the method defined here show evidence 
of chondrogenic differentiation and subsequent mineralisation of their ECM that 
resembles that seen in endochondral ossification. The method allows for a more 
practical time period without the seemingly spontaneous onset of mineralisation as 
described upon the addition of Pi as a phosphate source (Magne et al. 2003). 
Furthermore, the foetal metatarsal organ culture model can provide the examination 
of chondrocytes in different phases of chondrogenesis as well as of their 
mineralisation capability. These features therefore allow these models to be 
considered as practical and suitable in vitro models of chondrocyte matrix 
mineralisation
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4.1 Introduction 
The epiphyseal growth plates are the cartilage anlagen, developed from 
mesenchymal precursors, through which linear bone growth occurs by 
endochondral ossification. The growth plate consists of chondrocytes arranged in 
columns that parallel the axis of the bone surrounded by their ECM (Ballock & 
O'Keefe 2003; Mackie et al. 2008; Mackie et al. 2011). The chondrocytes sit in distinct 
cellular zones of maturation as are clearly visible, and proceed through various 
stages of differentiation whilst maintaining their spatially fixed locations (Fig. 1.4) 
(Hunziker et al. 1987). It is the terminally differentiated hypertrophic chondrocyte 
that mineralises its surrounding ECM, localised to the longitudinal septa of the 
growth plate (Castagnola et al. 1988). Mineralisation is a highly regulated biphasic 
process. MVs are widely believed to be the initial sites for hydroxyapatite formation 
by providing an environment permissive for calcium and Pi ion precipitation. This 
initial phase of mineralisation is followed by the penetration of the MV trilaminar 
membrane by the hydroxyapatite crystals such that they are exposed to the 
extracellular fluid, thus permitting their further growth and development in 
alignment with the collagen fibrils of the ECM (Anderson 1995; Anderson 2003; 
Golub 2011). This cartilagenous ECM is rich in collagens, proteoglycans and 
numerous other NCPs (Gentili & Cancedda 2009; Heinegard 2009; Mackie et al. 
2011). 
 
The SIBLING family of proteins are one such family of NCPs and include OPN, BSP, 
DMP1, DSPP and MEPE. The SIBLING family of proteins share some structural and 
functional characteristics; all are located to a 375kb region on the human 
chromosome 4q21, and 5q in mouse, and have similar exon structures. Additionally, 
all SIBLING proteins undergo similar post translational modifications (PTM) such 
as phosphorylation and glycosylation, the extent of which is crucial in determining 
their function (Boskey et al. 2009a). It has long been known that the SIBLING 
proteins have an Arg-Gly-Asp (RGD) sequence which facilitates cell attachment and 
cell signalling by binding to cell surface integrins (Fisher et al. 2001). More recently, 
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work primarily focused upon MEPE has identified a new functional domain termed 
the ASARM peptide which is highly conserved across species (Rowe et al. 2000; 
Rowe et al. 2004). This peptide is proving critical in the functional activity of the 
SIBLING proteins. Similarly, the SIBLING proteins are principally expressed in 
bone and dentin, and are secreted into the ECM during osteoid formation and 
subsequent mineralisation (Fisher & Fedarko 2003; Huq et al. 2005; Staines et al. 
2012b).  
 
MEPE was first identified in 2000 from patients with tumour induced osteomalacia, 
and quickly after rat and mouse MEPE were cloned (Petersen et al. 2000; Rowe et al. 
2000; Argiro et al. 2001).  In concordance with the other SIBLING proteins, MEPE 
was soon established to be expressed in bone and dentin, as well as the renal 
proximal convoluted tubule highlighting its role in phosphate homeostasis (Fisher 
& Fedarko 2003; Ogbureke & Fisher 2005). Analysis of Mepe mRNA in the rat bone 
compartments indicated its presence in tibial shaft, the metaphysis and the growth 
plate (Petersen et al. 2000). More specifically, in bone MEPE is primarily expressed 
by osteocytes and osteoblasts, whilst in dentin it is expressed by odontoblasts 
(MacDougall et al. 1998; Nampei et al. 2004). Analysis of the developing mouse 
skeleton indicates Mepe mRNA to be detected as early as 2-days postpartum (Lu et 
al. 2004).  
 
The expression of Mepe mRNA is increased during osteoblast matrix mineralisation 
suggesting a function for MEPE in bone mineralisation (Petersen et al. 2000; Argiro 
et al. 2001). This has been further fuelled by analysis of the MEPE null mouse in 
which the ablation of MEPE leads to an increased bone mass due to increased 
numbers and activity of osteoblasts (Gowen et al. 2003). Recent work has identified 
the 2.2kDa ASARM peptide of MEPE as the central provider for the mineralisation 
activity of MEPE. Located immediately downstream of a cathepsin B cleavage site, 
this ASARM peptide inhibits osteoblast ECM mineralisation (Rowe et al. 2000; 
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Martin et al. 2008; Addison et al. 2008). However, the functional role of MEPE in 
chondrocyte matrix mineralisation has yet to be established.    
 
Before attempting to unravel the regulatory mechanisms that MEPE may have in 
mammalian chondrocyte matrix mineralisation, it is first necessary to understand its 
spatial expression pattern within the growth plate. Despite some evidence for MEPE 
expression in the growth plate, this has yet to be fully established (Petersen et al. 
2000). The localisation of MEPE to sites of mineralisation would serve to strengthen 
its potential role within growth plate matrix mineralisation.  
4.2 Hypothesis 
MEPE is expressed by murine growth plate chondrocytes and ATDC5 cells with its 
localisation within the growth plate consistent with a role in ECM mineralisation.  
4.3 Aims 
I  To determine the gene and protein localisation pattern of MEPE and its 
ASARM peptide within the murine growth plate in vivo by in situ 
hybridisation and immunohistochemistry, respectively  
 
II To quantify Mepe mRNA expression within the murine growth plate 
 
III To determine the gene and protein expression of MEPE within mineralising 
ATDC5 cells, murine metatarsal organ cultures and primary chondrocyte 
cells   
4.4 Materials and Methods 
4.4.1 ATDC5 cells 
As outlined in section 2.2.1, ATDC5 cells were cultured at a density of 6 x 104 
cells/cm2 in a humidified atmosphere (37°C, 5% CO2) for up to 20 days. When 
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confluent, cells were supplemented with 10mM βGP and 50µg/ml ascorbic acid with 
the medium being changed every 2-3 days.  
4.4.2 RNA analysis of ATDC5 cells 
RNA was isolated from ATDC5 cells at specific time points using a Qiagen RNeasy 
kit according to the manufacturer’s instructions and cDNA was prepared (section 
2.12.3). For PCR analysis, cDNA was used at 25ng/µl and amplified as described in 
section 2.12.4. PCR products were analysed on a 1.5% agarose gel and visualised 
under UV light using a Gel Logic 200 Imaging System and software (Kodak). For 
qPCR analysis, cDNA was used at 10ng/µl, as detailed in section 2.12.5. Results 
were normalised to the 18S housekeeping gene and the relative gene expression 
level was calculated using the ΔΔCt method (Livak & Schmittgen 2001). Primers 
used are detailed in Appendix II.  
4.4.3 Protein extraction from ATDC5 cells and western blotting 
At defined time points, protein was extracted from ATDC5 cells in RIPA buffer as 
detailed in section 2.13.1. Protein samples were quantified (section 2.13.2) and 
appropriate quantities were used for western blot analysis (section 2.13.3). MEPE 
protein expression was determined using a sheep anti-mouse anti-MEPE antibody 
at a dilution of 1:200 and a HRP-labelled donkey anti-sheep secondary antibody 
(1:5000).  Antibody labelling was visualized using the ECL detection kit. Equality of 
protein loading was confirmed by also probing the membrane with mouse 
monoclonal HRP-labelled anti-β actin antibody (1:50000). 
4.4.4 Primary chondrocytes 
Primary chondrocytes were extracted from the rib cages of 1-3 day old mice as 
detailed in section 2.2.3. Cells were cultured for 2 days at 37oC in primary cell 
culture media before RNA was extracted and reverse transcribed (sections 2.12.1 
and 2.12.3). For PCR analysis, cDNA was used at 25ng/µl and amplified as 
described in section 2.12.4. PCR products were analysed on a 1.5% agarose gel and 
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visualised under UV light using a Gel Logic 200 Imaging System and software 
(Kodak). Primers used are detailed in Appendix II. 
4.4.5 Murine metatarsals 
Murine metatarsals were isolated at E15 as described in section 2.4.2. Metatarsals 
were cultured under the calcifying conditions described in section 2.4.2 for 7 days. 
After this, RNA was extracted and reverse transcribed for PCR analysis (sections 
2.12.2, 2.12.3, and 2.12.4). PCR products were analysed on a 1.5% agarose gel and 
visualised under UV light using a Gel Logic 200 Imaging System and software 
(Kodak). Primers used are detailed in Appendix II. 
4.4.6 Immunohistochemical staining of the murine growth plate in vivo  
4-week old and 10-day old C57BL/6 mice were sacrificed by cervical dislocation and 
the tibiae were dissected and fixed in 70% ethanol for 24 hours. The tibiae were 
decalcified in 10% EDTA and processed into wax as described in section 2.6.1. 
Immunohistochemical staining of 5µm-thick tibiae sections was performed using 
antibodies for MEPE-ASARM (1:200), MEPE-mid terminal (1:200), and cathepsin B 
(1:50) and the Vectastain ABC kit, as outlined in section 2.9 and Appendix III. 
Immunohistochemical labelling was visualised using DAB chromagen. Appropriate 
immunoglobulin G (IgG) concentrations were used instead of the primary 
antibodies as negative controls.  
4.4.7 In situ hybridisation of MEPE in the murine growth plate 
For in situ hybridisation, 3-week old and 10-day old C57BL/6 mice were sacrificed 
by cervical dislocation. Tibiae were dissected, fixed in 10% NBF for 24 hours, and 
processed to wax following decalcification in 10% EDTA, as described in section 
2.6.1. MEPE sense and antisense digoxigenin-labelled cRNA probes were 
synthesised as detailed in sections 2.7.1-2.7.6. In situ hybridisation was performed 
following an optimised protocol from Imperial College London as detailed in 
section 2.7.7.  
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4.4.8 Microdissection of the murine growth plate 
3-week old C57BL/6 mice were sacrificed by cervical dislocation and the proximal 
part of the tibiae was coated in 5% PVA and then immersed in a cooled hexane bath 
for 30 seconds. Sections were prepared as described in section 2.6.2. Microdissection 
of the murine growth plate was performed under a xylene droplet using an inverted 
microscope. Growth plate sections were separated into the proliferating zone (PZ), 
hypertrophic zone (HZ) and metaphyseal bone (MB). For each zone, tissue dissected 
from both proximal tibias of three animals (14–22 sections) was pooled. RNA 
isolation was performed as described in section 2.8. cDNA was prepared (section 
2.12.3) and was used at 10ng/µl for qPCR analysis, as detailed in section 2.12.5. 
Results were normalised to the 18S housekeeping gene and the relative gene 
expression level was calculated using the ΔΔCt method (Livak & Schmittgen 2001). 
The accuracy and validity of the microdissection technique was assessed by 
quantification of Col10a1 mRNA expression.  
4.5 Results      
4.5.1 Temporal expression of MEPE in ATDC5 cells 
To determine whether MEPE is expressed by growth plate chondrocytes, MEPE 
expression was first examined in ATDC5 cells. Cells were cultured under calcifying 
conditions for up to 20 days and RNA extracted at days 8, 15 and 20 of culture. PCR 
analysis indicated Mepe mRNA (129bp) to be expressed throughout the ATDC5 cell 
culture period as was normalised to 18S mRNA (488bp) (Fig. 4.1A). This was further 
confirmed by western blotting at days 8, 15 and 20 of ATDC5 culture for MEPE 
protein expression (Fig. 4.1B). The C-terminal fragment of MEPE (~37kDa) is known 
to contain the ASARM peptide (Rowe et al. 2000). This fragment appeared to be 
slightly increased at day 15 of culture in comparison to day 8 of culture (Fig. 4.1B).  
 
This therefore warranted the analysis of the temporal expression of Mepe mRNA in 
ATDC5 cells over a mineralisation time course. The time course selected 
represented the ATDC5 cells at times points before (days 8 & 10), at the onset of 
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Figure 4.1 The expression of MEPE in ATDC5 cells 
To examine the expression of MEPE by growth plate chondrocytes, ATDC5 cells 
were cultured for up to 20 days under calcifying conditions. (A) PCR analysis 
indicated MEPE presence at days 8, 15 and 20 of culture. 18S mRNA expression 
was used as a control (B) Western blotting further confirmed MEPE expression in 
ATDC5 cells. β-actin was used as a loading control (C) The temporal expression 
of Mepe mRNA was examined in ATDC5 cells by qPCR in comparison to day 8. 
Results were normalised to the 18S housekeeping gene. Data are represented as 
mean ± S.E.M (n=3 replicates) **P<0.01.   
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(days 13 & 15) and after (days 17 & 20) matrix mineralisation, as defined in Chapter 
3. RNA was extracted at defined time points and analysed by qPCR. In comparison 
to day 8 of culture, Mepe mRNA expression was significantly decreased at day 10 of 
culture (P<0.01) and at day 17 of culture (P<0.01) (Fig. 4.1C). At days 13, 15 and 20 of 
culture, there were no significant changes in Mepe mRNA expression (Fig. 4.1C). 
These temporal changes in MEPE protein and mRNA expression in vitro warrant 
investigation into its expression patterns in vivo.    
4.5.2 Mepe mRNA expression in primary chondrocytes and in E15 murine 
metatarsal bones 
To establish whether the expression of MEPE in ATDC5 cells mimics that seen in a 
more physiological model, primary chondrocytes were isolated and cultured for 3 
days before RNA was extracted. This allowed analysis of primary cells without the 
de-differentiation observed in a mineralisation model as described in Chapter 3. 
Mepe mRNA was expressed in primary chondrocytes as indicated by PCR analysis 
(Fig. 4.2). This was also the case with mineralised E15 metatarsals (Fig. 4.2) thus 
confirming the expression of MEPE in growth plate chondrocytes. 
4.5.3 Mepe mRNA expression in the murine growth plate 
For examination of the spatial localisation of Mepe mRNA in the murine growth 
plate, in situ hybridisation was adopted in 10-day old murine tibiae. Mepe mRNA 
was expressed abundantly by both growth plate chondrocytes and by osteoblasts 
within the metaphysis. Observed was a particularly high expression in the HZ of 
chondrocytes (Fig. 4.3A). This led to the analysis of 3-week old tibiae to assess 
whether a similar spatial localisation is observed at this developmental age in which 
the growth plate has fully formed between the primary and secondary ossification 
centres. Indeed Mepe mRNA was similarly expressed abundantly by growth plate 
chondrocytes and by osteoblasts within the metaphysis (Fig. 4.4A). In the growth 
plate, high levels of Mepe mRNA were observed, especially in the hypertrophic 
chondrocytes (Figs. 4.4B & C). Representative images of the sense probe analysis are 
shown (Figs. 4.3C and 4.4D & E). This spatial expression pattern was further
Chapter 4                          The expression and localisation of MEPE in the murine growth plate 

































Figure 4.2 The expression of Mepe mRNA in mouse primary chondrocyte 
cells and E15 metatarsals 
Mepe mRNA was present in both primary chondrocyte cells cultured for 3 days 
and in E15 metatarsals cultured for 7 days, as indicated by PCR analysis. 18S 
mRNA expression was used as a control. Each lane represents individual primary 
cell cultures of groups of 4 pooled metatarsal bones. 
Chapter 4                          The expression and localisation of MEPE in the murine growth plate 









Figure 4.3 In situ hybridisation of Mepe mRNA expression in the 10 day old 
murine growth plate  
In situ hybridisation of Mepe mRNA in 10 day old mouse tibia (A) Mepe was found to 
be abundantly expressed by growth plate chondrocytes and osteoblasts of the 
metaphysis (B) Expression was high in the HZ of the growth plate, as indicated by 
the arrows (C) Analysis of the Mepe sense probe indicated no specific binding to Mepe  
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Figure 4.4 In situ hybridisation of Mepe mRNA expression in the 3 week old 
old murine growth plate  
In situ hybridisation of Mepe mRNA in 3-week-old mouse tibia (A) Mepe was found to 
be abundantly expressed by growth plate chondrocytes and osteoblasts of the 
metaphysis (B) Expression was present in both the PZ and the HZ of the growth 
plate, as indicated by the arrows (C) There was an apparent increase in expression in 
the HZ of chondrocytes (D) Analysis of the Mepe sense probe indicated no specific 
binding to Mepe mRNA. Positive Mepe mRNA indicated by blue stain. 
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examined and quantified by microdissection of 3-week old growth plates. To 
validate the microdissection technique, qPCR of Col10a1 mRNA expression was 
conducted to ensure that the HZ could be considered as an enriched pool of 
hypertrophic chondrocytes (Fig. 4.5A). There was approximately a ten-fold increase 
in Col10a1 mRNA expression in the HZ in comparison to the PZ (P<0.01). This 
increase in Col10a1 mRNA expression is in concordance with previous studies done 
using a similar technique (Hutchison et al. 2007). Mepe mRNA had a significantly 
higher expression (P<0.05) in the HZ in comparison to the PZ of the growth plate 
(Fig. 4.5B) therefore confirming the in situ hybridisation data.    
4.5.4 Immunohistochemical staining of the murine growth plate  
To assess whether the spatial expression of MEPE protein mimicked that of its 
mRNA expression pattern, immunolocalisation of MEPE was conducted in 14-day 
old and 4-week old murine growth plates. Indeed this verified the in situ 
hybridisation and microdissection data as demonstrated by its preferential 
localisation to the HZ of chondrocytes (Figs. 4.6A - D).  
 
The immunolocalisation of the MEPE-ASARM peptide was also examined in the 
two ages of growth plates. This too was localised to the hypertrophic chondrocytes 
(Figs. 4.7A - D). This ASARM peptide is cleaved from MEPE by the protease 
cathepsin B thus the immunolocalisation of cathepsin B was examined in the 14-day 
old and 4-week old murine growth plates to determine if its localisation was 
associated with regions of MEPE-ASARM expression (Figs. 4.8A - D). Cathepsin B 
was expressed at the chondro-osseous junction as is in concordance with previous 
studies (Lee et al. 1995; Gartland et al. 2009). Representative images of the 
appropriate negative controls are shown (Figs. 4.6, 4.7 & 4.8 E & F). Together these 
data indicate that MEPE-ASARM peptide is preferentially expressed by 
hypertrophic chondrocytes of the growth plate and this localisation is consistent 
with a role for this peptide in regulating cartilage mineralisation. 
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Figure 4.5 Microdissection of the murine growth plate 
Microdissection of the growth plate was adopted to assess Mepe mRNA expression. (A) 
The accuracy of the microdissection technique was determined by the relative change 
in Col10a1 mRNA expression throughout the zones of the growth plate (PZ, HZ) and 
the MB (B) This was then used to examine the relative change in Mepe mRNA 
expression in these zones Values generated by qPCR and normalised to 18S 
housekeeping gene. Data are represented as mean ± S.E.M, in comparison to the PZ, 
*P<0.05 **P<0.01. 
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Figure 4.6 Immunolocalisation of MEPE in the murine growth plate 
Immunohistochemistry shows MEPE to be expressed in (A) the tibia of 14-day old mice 
(B) Its expression in the growth plate is limited to the hypertrophic zone of chondrocytes 
as indicated by the arrows (C & D) A similar localisation is observed in 4-week old 
growth plates. Representative images of appropriate negative control are shown (E) 14-
day old growth plate (F) 4-week old growth plate. Positive MEPE protein is indicated by 
brown stain. 
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Figure 4.7 Immunolocalisation of MEPE-ASARM in the murine growth plate 
Immunohistochemistry shows the ASARM peptide to be expressed in (A) the tibia of 
14-day old mice (B) Its expression in the growth plate is limited to the hypertrophic 
chondrocytes as indicated by the arrows (C & D) A similar localisation is observed in 4-
week old growth plates. Representative images of appropriate negative control are 
shown (E) 14-day old growth plate (F) 4-week old growth plate. Positive MEPE stain is 
indicated by brown stain. 
 
Chapter 4                          The expression and localisation of MEPE in the murine growth plate 





















Figure 4.8 Immunolocalisation of cathepsin B in the murine growth plate 
Immunohistochemistry shows cathepsin B to be expressed in (A) the tibia of 14-day old 
mice (B) Its expression in the growth plate is limited to the chondro-osseous junction as 
indicated by the arrows (C & D) A similar localisation is observed in 4-week old growth 
plates. Representative images of appropriate negative control are shown (E) 14-day old 
growth plate (F) 4-week old growth plate. Positive MEPE protein is indicated by brown 
stain. 
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4.6 Discussion 
MEPE is a member of the SIBLING family of proteins and has previously been 
shown to be expressed by mature osteoblasts, osteocytes, odontoblasts and the 
proximal convoluted tubules of the kidney (Gowen et al. 2003; Ogbureke & Fisher 
2004; Rowe et al. 2006; Boukpessi et al. 2010). Moreover, there has been some 
indication of MEPE expression in the rat growth plate (Petersen et al. 2000). Here, 
the expression and spatial localisation of MEPE within the murine growth plate and 
its primary cell type, the chondrocyte, was determined (Fig. 4.1). ATDC5 cells, 
primary chondrocyte cell cultures, and embryonic metatarsal bones all expressed 
Mepe mRNA. The mineralisation capability of ATDC5 cells has previously been 
defined in Chapter 3. This was then utilised to examine the expression of Mepe 
mRNA over a 20-day culture period. In ATDC5 cells Mepe mRNA had a differential 
expression pattern, possibly suggesting MEPE to have a role in the chondrocyte 
matrix mineralisation process. However, in comparison to osteoblast cultures in 
which the mRNA expression of Mepe was temporally increased in line with 
mineralisation of the cell’s ECM, here a decrease was observed (Petersen et al. 2000). 
 
Furthermore, the ATDC5 data is seemingly contradictory to the 
immunohistochemistry and in situ hybridisation data here in which Mepe mRNA 
and protein were observed in the growth plate respectively (Figs. 4.3-5 & 4.6-8). In 
particular, a higher expression of MEPE was observed in the hypertrophic zone of 
chondrocytes, as was confirmed by microdissection of the growth plate (Fig. 4.5). It 
is these hypertrophic cells that mineralise their surrounding ECM and thus the 
localisation of MEPE to this zone strengthens its hypothesised role in chondrocyte 
matrix mineralisation. The reasons behind the discrepancy between ATDC5 cell line 
and growth plate expression are unclear however the differences between in vitro 
and in vivo culture systems could provide some explanation.  
 
The in situ hybridisation and microdissection data are in concordance with a 
microarray study in which Mepe mRNA was found to be upregulated in 
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hypertrophic cartilage (Horvat-Gordon et al. 2010). Since the commencement of 
these studies, the expression of MEPE within the growth plate has since been 
examined in the MEPE overexpressing mouse in comparison to its wild-type 
counterpart by immunohistochemistry (David et al. 2009). MEPE was found to be 
expressed in wild-type growth plates, in particular in the hypertrophic zone of 
chondrocytes, as is in concordance with the results shown here. Similarly, the 
MEPE-overexpressing mouse displayed expression of MEPE in the hypertrophic 
chondrocytes, at a greater level than that in its wild-type counterparts. This was 
associated with wider epiphyseal growth plates, expanded primary spongiosa and 
shorter bones in the MEPE-overexpressing mouse.   
 
The authors of this study, David et al, also investigated the localisation of the MEPE-
ASARM peptide in the MEPE-overexpressing and wild-type mice. The ASARM 
peptide was first identified by Peter Rowe and colleagues as the functional domain 
of MEPE, located immediately downstream of a cathepsin B cleavage site, within the 
C-terminal fragment of MEPE (Rowe et al. 2000). In concordance with the 
localisation of MEPE, its ASARM peptide was expressed in the hypertrophic zone of 
chondrocytes in wild-type mice. Similarly, here the ASARM peptide was shown to 
be localised to the hypertrophic chondrocytes in both 14-day old and 4-week old 
murine growth plates by immunohistochemistry. Moreover, the differential 
regulation of the protein expression of this ASARM peptide, as determined by 
western blotting, indicates its presumed role in chondrocyte matrix mineralisation.  
 
This presumed role of MEPE in chondrocyte ECM mineralisation is further 
indicated by the widened growth plates observed in the MEPE-overexpressing 
mouse. However it is worth noting that this growth plate disruption may be a 
consequence of other activities within the growth plate outwith mineralisation, for 
example altered proliferation, differentiation or vascular invasion. Analysis of the 
Hyp mouse, a spontaneous Phex knockout model also provides evidence for a 
presumed role for MEPE in mineralisation. The Hyp mouse is the mouse model of 
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the hypophosphatemic disorder XLH. It is well documented that the ASARM 
peptide is upregulated in these mice (Bresler et al. 2004). Like in the MEPE-
overexpressing mouse, studies of this Hyp mouse show severe morphological 
widening of the growth plate with widened epiphysis. This disruption was partially 
corrected by the administration of cathepsin inhibitors, including the specific 
cathepsin B inhibitor CA074 (Rowe et al. 2006). Cathepsin B is known to cleave 
MEPE, releasing its functional ASARM peptide. The localisation of cathepsin B at 
the chondro-osseous junction here is in concordance with previous studies detailing 
the cathepsin B rich septoclast (Fig. 4.8) (Lee et al. 1995; Gartland et al. 2009). These 
cells, thought to be of macrophage or osteoclast origin, are postulated to play a key 
role in the degradation of unmineralised cartilage (Lee et al. 1995). It is likely that the 
cathepsin B provided at the chondro-osseous junction cleaves MEPE at its distal 
COOH-region to the ASARM peptide.  
 
PHEX, a cell membrane associated glycoprotein, plays a central role in the 
protection of MEPE from proteolytic cleavage by cathepsin B. It acts by binding to 
MEPE and preventing the release of the ASARM peptide (Guo et al. 2002). The Hyp 
mouse has an increased expression of cathepsin D, an upstream activator of 
cathepsin B (Rowe et al. 2006). This therefore suggests that PHEX can alter the 
activation of cathepsin B, and therefore the cleavage of MEPE to the ASARM 
peptide. Similar to the expression of MEPE, PHEX protein expression is observed in 
the hypertrophic chondrocytes, as well as the proliferative zone, of wild-type mouse 
growth plates (Miao et al. 2004). This suggests a regulatory mechanism for MEPE 
expression in the murine growth plate and further indicates a role for MEPE in 
chondrocyte matrix mineralisation. 
 
In conclusion, in this study MEPE has been shown to be expressed by growth plate 
chondrocytes with a spatial localisation to the hypertrophic zone of the growth 
plate. The ASARM peptide, the functional component of MEPE, is also localised to 
the hypertrophic chondrocytes. This spatial expression data is consistent with data 
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which was published during the completion of these studies. As it is the 
hypertrophic chondrocytes that mineralise their ECM, this therefore suggests a role 
for MEPE and its ASARM peptide in chondrocyte ECM mineralisation.  
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5.1 Introduction 
Chondrocyte matrix mineralisation is a biphasic process which is under tight 
enzymatic, protein and membrane control so as to ensure levels of Ca2+ and Pi are 
permissive for effective hydroxyapatite formation (Anderson 1995). Molecules such 
as ALP, NPP1, ANK and PHOSPHO1, have been identified as imperative in 
regulating matrix mineralisation (Meyer 1984; Anderson 1995). However, the 
identification of a key group of NCPs, the SIBLING family of proteins, has allowed 
new insights into the mechanisms surrounding the formation of hydroxyapatite. 
One such SIBLING protein is MEPE, a 58kDa protein first isolated from a patient 
with tumour induced osteomalacia (Rowe et al. 2000). 
 
Although little is known about MEPE function in chondrocytes, it has been 
investigated in other cell types including bone cells. The first evidence for a direct 
role of MEPE in bone mineralisation came from the increased mRNA expression 
levels of Mepe seen during osteoblast matrix mineralisation (Petersen et al. 2000; 
Argiro et al. 2001). This role has been further fuelled by analysis of the MEPE null 
mouse in which the ablation of MEPE in mice leads to an increased bone mass due 
to increased numbers and activity of osteoblasts (Gowen et al. 2003). Furthermore, 
using the Col1a1 promoter, the specific overexpression of MEPE in osteoblasts of 
mice, leads to defective mineralisation. Associated with this defect are increased 
levels of an acidic 2.2kDa peptide, the ASARM peptide (David et al. 2009). 
 
In vitro studies have identified that the observed inhibitory effect of MEPE on 
osteoblast and odontoblast matrix mineralisation is dependent upon its cleavage to 
this ASARM peptide (Rowe et al. 2004; Martin et al. 2008; Wang et al. 2010a). This 
cleavage-dependent activity of MEPE is seemingly characteristic of the SIBLING 
family of proteins (Boskey et al. 2009a; Staines et al. 2012b). In MEPE, the ASARM 
peptide is located immediately downstream of a cathepsin B cleavage site, and it is 
responsible for the mineralisation defect observed in XLH, the most common form 
of inherited rickets (Rowe et al. 2000; Rowe et al. 2004; Martin et al. 2008). This defect 
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can be reversed by administration of cathepsin inhibitors CAO74 or pepstatin 
(Rowe et al. 2006). PHEX plays a central role in the protection of MEPE from 
proteolytic cleavage by cathepsin B; it can bind to MEPE and prevent the release of 
the ASARM peptide (Guo et al. 2002). The Hyp mouse, a spontaneous Phex knockout 
model, has an increased expression of cathepsin D, an upstream activator of 
cathepsin B (Rowe et al. 2006). Therefore PHEX may also assist in decreasing the 
activation of cathepsin B.       
 
Previous studies have shown that the post translational modification of the MEPE-
ASARM peptide is key to its functional role. MEPE has a number of potential casein 
kinase II phosphorylation motifs, and it is here that the ASARM motif is 
phosphorylated at 3 serine residues (Rowe et al. 2000). When released as this 
phosphorylated peptide, it can inhibit mineralisation in murine calvarial osteoblasts 
and in bone marrow stromal cells by the direct binding of the MEPE-ASARM 
peptide to hydroxyapatite crystals. Without phosphorylation, the ASARM peptide 
has no effect on osteoblast matrix mineralisation (Martin et al. 2008; Addison et al. 
2008). The role of MEPE in osteoblast matrix mineralisation is established however 
its functional role in growth plate chondrocyte matrix mineralisation and 
endochondral ossification has yet to be elucidated.  
5.2 Hypothesis 
MEPE has a direct functional role in chondrocyte matrix mineralisation which is 
dependent upon the release of its pASARM peptide  
5.3 Aims 
I. Examine the overexpression and knockdown of MEPE on ATDC5 
cell matrix and embryonic metatarsal mineralisation 
 
II.  Analyse the effects of the ASARM peptide on ATDC5 matrix 
mineralisation 
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III. Exploit the embryonic metatarsal culture to investigate the effects of 
the ASARM peptide on chondrocyte matrix mineralisation 
5.4 Materials and Methods 
5.4.1 ATDC5 and embryonic metatarsal organ culture  
ATDC5 cells were seeded at 6 x 103 cells/cm2 in differentiation media and when 
confluent, were supplemented with 10mM βGP and 50µg/ml ascorbic acid, as 
described in section 2.2.1. Cells were cultured for up to 15 days at 37oC, 5% CO2. 
Metatarsals were isolated from E17 and E15 embryonic mice and cultured as 
described in section 2.5.2 for up to 10 days. The total length of the bone  through the 
centre of the mineralising zone was determined using image analysis software every 
second or third day. The length of the central mineralisation zone was also 
measured. All results are expressed as a percentage change from harvesting length 
which was regarded as baseline. 
5.4.2 Establishment of stable MEPE-overexpressing ATDC5 cells 
pLZ2-Ub.MEPE and pLZ2-Ub.Empty vectors were a kind gift from Dr Neil 
Mackenzie (The University of Edinburgh) (Appendix IV). ATDC5 cells were 
maintained in differentiation medium as described in section 5.4.1 and seeded at 
150,000 cells/cm2. Cells were transfected with pLZ2-Ub.MEPE and pLZ2-Ub.EMPTY 
constructs at a ratio of 7:2 FuGENE HD to DNA, according to the manufacturer’s 
instructions (section 2.10.3). Blasticidin resistant colonies were picked using cloning 
cylinders, expanded, frozen and maintained at -150oC until further use as described 
in section 2.10.4. Three MEPE-overexpressing and three empty-vector clones were 
picked for analysis. 
5.4.3 Overexpression of MEPE in murine E15 metatarsals 
For proof of concept, GFP virus particles (Dr. Neil Mackenzie, The University of 
Edinburgh) were added to E15 metatarsal cultures for 7 days, as detailed in section 
2.11.7.  GFP is a protein that exhibits green fluorescence when exposed to UV light, 
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therefore making it a useful tool as a reporter for expression. Metatarsal bones were 
incubated with 4',6-diamidino-2-phenylindole (DAPI) stain for 5 minutes. A Nikon 
EC1 inverted confocal microscope was used for GFP and DAPI visualisation. MEPE-
overexpressing and empty-vector viruses were produced as described in sections 
2.11.1 - 2.11.6. Viruses were added to E15 metatarsal bones at a concentration of 6 x 
104 virus particles/metatarsal bone with 0.6µl Polybrene on day 0 of culture. Bones 
were left in a humidified atmosphere for 12 days. The total length of the bone 
through the centre of the mineralising zone was determined using image analysis 
software every second or third day. The length of the central mineralisation zone 
was also measured (section 2.5.2).  
5.4.4 shRNA knockdown of MEPE in ATDC5 cells 
MEPE short hairpin ribonucleic acid (shRNA) glycerol stocks were obtained from 
Sigma (Appendix IV) and plasmid DNA was obtained through maxi preparation as 
described in section 2.7.4. ATDC5 cells were maintained in differentiation medium 
as described in section 5.4.1 and seeded at 150,000 cells/cm2. Cells were transfected 
with 2 different shRNA MEPE plasmids and a negative shRNA plasmid as a control 
(a kind gift from Dr. Neil Mackenzie). FuGENE HD was used at a ratio of 7:2, 
according to the manufacturer’s instructions (section 2.10.3). Cells were left for 24, 
48 and 72 hours before RNA and protein were extracted for analysis as described in 
sections 2.12 and 2.13 
5.4.5 MEPE-ASARM peptide 
MEPE ASARM peptide were synthesised (Peptide Synthetics, Bishops Waltham, 
UK) as pASARM with the sequence RDDSSESSDSG(Sp)S(Sp)SSE(Sp)SDGD, and 
also non-phosphorylated ASARM (npASARM) with the sequence 
RDDSSESSDSGSSSESDGD (Sp: serine phosphorylation). pASARM and npASARM 
peptides were added to cultures at concentrations of 10, 20 and 50µM, with controls 
treated with a DMSO carrier (0.1%). In further studies, peptides were added at a 
final concentration of 20µM with experiments being performed at least 3 times. 
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5.4.6 Histological staining of cell cultures 
ATDC5 cell cultures were stained for calcium deposition (alizarin red), collagen 
production (Sirius red), and glycosaminoglycan presence (alcian blue) as described 
in section 2.4. The optical densities of the resultant stains were analysed using a 
spectrophotometer (Thermo Scientific, Northumberland, UK) along with an 
appropriate blank control. Reactions were completed in triplicate at each time point.  
5.4.7 RNA analysis of ATDC5 cells and metatarsals 
RNA was extracted from ATDC5 cell cultures using an RNeasy mini kit according 
to the manufacturer’s instructions (section 2.12.1). For metatarsal organ cultures, 4 
bones from each control or experimental group were pooled in 100μl Trizol reagant 
at either day 5 or 7 of culture, and RNA was extracted according to the 
manufacturer’s instructions (section 2.12.2). For each sample, total RNA content was 
assessed by absorbance at 260nm and purity by A260/A280 ratios, and then reverse-
transcribed as described in section 2.12.3. qPCR was performed using the SYBR 
green detection method on a Stratagene Mx3000P real-time qPCR system as detailed 
in section 2.12.5. Primers were purchased from PrimerDesign Ltd, or designed in 
house and synthesised by MWG Eurofins (Appendix II). Reactions were run in 
triplicate and routinely normalised against 18S. Sequences are detailed in 
Supplemental Table S1. qPCR analysis of angiogenesis markers was performed in 
collaboration with Dr. Claire Clarkin, University of Southampton, and normalised 
to β-actin mRNA transcript levels.   
5.4.8 3D-microtomography of metatarsals 
Metatarsal bones were fixed in 70% ethanol and stained with eosin dye (for 
visualisation) at day 7 of culture. 3D-microtomography of metatarsals was 
performed in collaboration with Ms. Lesya Zelenchuk and Prof. Peter Rowe, The 
University of Kansas Medical Center, Kansas City USA. Briefly, metatarsal bones 
were embedded in paraffin blocks and then were scanned with a high-resolution 
micro computed tomography (µCT) (µCT40; Scanco Medical, Southeastern, PA) as 
previously described (Rowe et al. 2006; David et al. 2009). Data were acquired at 55 
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KeV with 6µm3. Three-dimensional reconstructions for bone samples were 
generated with the following parameters: Gauss Sigma = 4.0; Support = 2, Lower 
Threshold= 90 and Upper Threshold =1000. Tissue mineral density was derived 
from the linear attenuation coefficient of threshold bone through precalibration of 
the apparatus for the acquisition voltage chosen. The bone volume (BV) / tissue 
volume (TV) was measured using sections encompassing the entire metatarsal on a 
set of 85 sections that was geometrically aligned for each sample. 
5.4.9 Metatarsal [3H]-thymidine proliferation assay 
As described in section 2.14.1, metatarsal bones were incubated with 3 µCi/ml [3H]-
thymidine for the last 6 hours of their 7-day culture. Metatarsals were solubilised at 
60oC for an hour and then the DNA incorporating [3H]-thymidine determined using 
a scintillation counter.  
5.4.10 ALP enzyme activity 
ALP activity was determined in metatarsal bones at day 7 of culture using an assay 
for ALP according to the manufacturer’s instructions. The method is detailed in 
section 2.14.2. Total ALP activity was expressed as nanomoles p-nitrophenyl 
phosphate hydrolysed per minute per bone. 
5.5 Results 
5.5.1 Overexpression of MEPE in ATDC5 cells  
To examine the functional role of MEPE in chondrocyte matrix mineralisation, 
MEPE overexpressing ATDC5 cells were generated for culture in mineralising 
conditions as characterised in Chapter 3. The efficiency of this overexpression was 
assessed by qPCR and western blotting. Mepe mRNA was increased in all three 
MEPE overexpressing clones by > 43 fold (average = 61 fold in comparison to 
average of empty vector clones, Fig. 5.1A P<0.001). Intriguingly, assessment of 
MEPE protein expression by western blotting failed to detect any significant change 
in MEPE protein level between empty and MEPE-overexpressing clones (Fig. 5.1B).    
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Figure 5.1 The overexpression of Mepe mRNA in ATDC5 cells 
Chondrogenic ATDC5 cells were transfected with MEPE-overexpressing and empty vector 
constructs. Three clones for each were examined for Mepe mRNA and protein expression. (A) 
Mepe mRNA was significantly increased in all three clones in comparison to empty-vector 
controls as determined by qPCR (B) Western blot analysis revealed no apparent changes in 
MEPE protein level between empty and MEPE-overexpressing clones. Results are normalised 
to the 18S housekeeping gene. Data are represented as mean ± SEM (n=3 replicates) ***P<0.001. 
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5.5.2 Inhibition of ATDC5 cell matrix mineralisation by overexpression of MEPE 
When cultured under mineralising conditions for up to 15 days (Chapter 3), 
individual MEPE-overexpressing clones showed an inhibition of mineralisation as 
visualised by alizarin red staining and quantified by spectrophotometry at days 8, 
12 and 15 of culture (Fig. 5.2A & C). Average quantification of alizarin red staining 
showed significant decreases in mineralisation of MEPE-overexpressing clones at 
the aforementioned time points (in comparison to empty vector clones, Fig. 5.2B, 
P<0.01). The mRNA expression of Col2a1, Col10a1 and Alpl were examined by qPCR 
as markers of endochondral ossification and these were unchanged between MEPE-
overexpressing and empty-vector controls at day 15 of culture (Fig. 5.3 A – C). 
Further chondrocyte marker genes of differentiation and mineralisation (Ank, 
Enpp1, Atf3, PthIh, Ihh and Mmp13) were examined for mRNA expression and again 
no differences were found between the MEPE-overexpressing and the empty-vector 
controls (Fig. 5.4). Interestingly, Phex mRNA levels were significantly decreased in 
MEPE-overexpressing clones in comparison to empty-vector controls at day 15 of 
culture (Fig. 5.3D, P<0.05).   
5.5.3 Overexpression of MEPE in E15 metatarsals 
Following the successful overexpression of MEPE in ATDC5 cells (section 5.5.1), this 
was attempted in the E15 metatarsal organ culture model defined in Chapter 3. To 
establish proof of concept, E15 metatarsal bones were transfected with GFP virus 
particles and visualised for GFP uptake following 7 days in culture. This was 
achieved successfully (Fig. 5.5A - C) and as such, MEPE lenti-virus constructs were 
made for transfection of E15 metatarsal bones. However, due to time and procedure 
constraints, the MEPE overexpressing lenti-virus and its empty-virus control were 
added to the metatarsals at a lesser concentration than that optimised with GFP 
virus particles (2 x 106 virus particles/metatarsal bone, section 2.11.7). No differences 
in the mineralisation capability or in the longitudinal growth of the bones were 
observed (Fig. 5.6A & B).     
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Figure 5.2 The overexpression of Mepe mRNA inhibits ATDC5 culture mineralisation  
Chondrogenic ATDC5 cells were transfected with Mepe mRNA-overexpressing and empty-vector 
constructs and cultured for up to 15 days in mineralising conditions. Three individual clones for 
each were examined for mineralisation by alizarin red staining. (A) Quantification of staining 
indicated decreased mineralisation in all individual MEPE-overexpressing clones (M1, M2 and 
M3) in comparison to all individual empty-vector clones (E1,E2 and E3) at days 8, 12 and 15 of 
culture (B) Average absorbance of all MEPE and all empty-vector clones indicated an average 
significant inhibition of matrix mineralisation in MEPE-overexpressing cells in comparison to 
empty-vector controls (C) Single representative images of alizarin red staining in all six clones at 
day 15 of culture. Data are represented as mean ± SEM (n=3 separate cultures) in comparison to 
empty-vector controls **P<0.01, ***P<0.001. 
Empty vector 
clones 
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Figure 5.3 Gene expression in MEPE-overexpressing ATDC5 cells 
MEPE-overexpressing ATDC5 cells showed no differences in the mRNA 
expression of (A) Col2a1 (B) Col10a1 (C) Alpl. However Phex mRNA expression was 
significantly decreased in comparison to empty-vector controls (D). Data are 
represented as mean of 3 clones ± SEM *P<0.05. 
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Figure 5.4 The lack of effect of MEPE overexpression on chondrocyte 
differentiation and mineralisation gene expression  
Analysis of mRNA expression in MEPE-overexpressing and empty-vector control 
clones after 15 days of culture (A) Ank (B) Enpp1 (C) Atf3 (D) PthIh (E) Ihh (F) Mmp13 
Data are represented as mean of 3 clones ± SEM (n=3 replicates). 
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Figure 5.5 E15 metatarsals transfected with GFP virus particles 
E15 metatarsal bones were transfected with GFP virus particles for proof of concept (A) 
and stained with DAPI stain for DNA visualisation using a confocal microscope (B). 
Dual images indicated successful transfection of GFP virus throughout the metatarsal 
bone (C). 
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Figure 5.6 The lack of effect of MEPE overexpression on E15 metatarsal 
bones 
(A) The growth rate of E15 metatarsal bones was not affected by the overexpression 
of MEPE when cultured for up to 12 days (B) The change in mineralisation zone as 
a percentage of the total length was also unchanged during the culture period. Data 
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5.5.4 Analysis of MEPE shRNA knockdown in ATDC5 cells 
To further elucidate the role of MEPE in chondrocyte matrix mineralisation, ATDC5 
cells were transfected with vectors containing a shRNA sequence targeted against 
MEPE. This technique is routinely used in various cells to knockdown various genes 
of interest. The efficiency of the MEPE knockdown was assessed after 48 and 72 
hours at the mRNA and protein level by qPCR and western blotting respectively in 
comparison to empty shRNA and non-transfected control cells.     
 
qPCR analysis indicated no differences in Mepe mRNA expression in ATDC5 cells 
subjected to shRNA MEPE knockdown after 48 hours (Fig. 5.7A). Neither was there 
any difference observed between knockdown and control cells at the protein level 
(Fig. 5.7C). After 72 hours, there were still no differences (Fig. 5.7B & C) thus 
suggesting that the knockdown was ineffective at both the mRNA and protein level. 
This experiment was repeated but effective knockdown could not be confirmed.       
5.5.5 Dose- and phosphorylation-dependent effects of the ASARM peptide on 
ATDC5 cell matrix mineralisation  
It is known that PHEX prevents the cleavage of MEPE to its ASARM peptide, a 
2.2kDa peptide common to the SIBLING family of proteins. The decreased mRNA 
expression of Phex in ATDC5 cells overexpressing MEPE (Fig. 5.3) suggests that the 
ASARM peptide is the functional component of MEPE in this system. Therefore to 
determine the role of the ASARM peptide in chondrocyte matrix mineralisation, the 
mineralisation capability of ATDC5 cells in response to MEPE-ASARM peptides 
was examined.  
 
The posttranslational modifications of the SIBLING proteins are important in 
determining their function (Staines et al. 2012b). As such, varying concentrations of 
the MEPE ASARM peptide in both its pASARM and npASARM form were added to 
ATDC5 cell cultures under mineralising conditions over a 15-day culture period.
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Figure 5.7 MEPE shRNA knockdown efficiency  
Quantification of Mepe mRNA by RT-qPCR in ATDC5 cells transfected with 2 different 
MEPE shRNA vectors (A and B) and an empty shRNA vector after (A) 48 hours (B) 72 
hours. mRNA levels are expressed as a fold change in comparison to the control, non-
transfected cells. Data are normalised to 18S mRNA and  are represented as mean ± SEM 
(n= 3 separate transfections) (C) MEPE protein expression in MEPE shRNA and empty 
shRNA  cells as well as control cells. β-actin was used as a loading control. 
MEPE ~ 37kDa  
β-actin 
 A         B       NEG   CON    A        B      NEG   CON 
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There was no apparent morphological difference between control and ASARM-
treated cells. pASARM peptide inhibited mineralisation in a dose-dependent 
manner as visualised by alizarin red staining and quantified by spectrophotometry 
(at 20μM and 50μM in comparison to control; P<0.01) (Fig. 5.8A). Interestingly, it 
was found that npASARM peptide promoted mineralisation over the 15-day culture 
period (at 20μM and 50μM in comparison to control; P<0.01) (Fig. 5.8B). Due to the 
physiological relevance of 20µM in XLH patients and Hyp mice, this concentration 
was selected for use in future experiments (Addison et al. 2008). 
5.5.6 Absence of an effect of MEPE-ASARM peptides on ATDC5 cell 
differentiation 
To investigate whether the MEPE-ASARM peptides affect chondrocyte 
differentiation, the ability of the ATDC5 cells to produce a collagenous matrix when 
treated with the MEPE-ASARM peptides was examined. Collagen deposition (Fig. 
5.9A) and glycosaminoglycan production (Fig. 5.9B), as visualised by sirius red and 
alcian blue stains respectively, were unaffected by addition of 20µM pASARM or 
npASARM peptide. Furthermore, cellular expression of Alpl mRNA and ALP 
activity were unchanged (Fig 5.10 B & C), as were concentrations of the 
mineralisation inhibitor PPi (Fig. 5.10A). 
5.5.7 pASARM peptide inhibit the mineralisation capability of E17 metatarsal 
bones 
The data determined in ATDC5 cells are supportive of a direct role for MEPE-
ASARM peptides in chondrocyte matrix mineralisation and thus to next examine 
these effects in a more physiologically relevant model, the metatarsal organ culture 
model was used. When dissected, E17 mice metatarsals display a central core of 
mineralised cartilage juxtaposed by a translucent area on both sides representing 
the hypertrophic chondrocytes (Mushtaq et al. 2004). These bones were cultured in 
the presence of varying concentrations of pASARM and npASARM peptides over a 
10- day period to examine their effects on longitudinal bone growth and the growth 
of the central mineralisation zone. These data indicated that MEPE-ASARM 
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Figure 5.8 Dose- and phosphorylation-dependent effects of the ASARM peptide 
on ATDC5 matrix mineralisation  
Mineralisation of ATDC5 matrix in the presence of varying concentrations (0-50µM) of (A) 
pASARM and (B) npASARM peptides was visualised by alizarin red staining (images) and 
quantified after 15 days of culture. Data are represented as mean ± SEM of three wells 
analysed in triplicate **P<0.01. 
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Figure 5.9 The lack of effect of MEPE-ASARM peptides on ATDC5 cell 
differentiation 
Quantification of sirius red staining (A) and alcian blue staining (B) (images) of ATDC5 
cells following 15 days of culture with 20µM pASARM and npASARM peptides. Data 
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Figure 5.10 The lack of effect of MEPE-ASARM peptides on known 
regulators of mineralisation 
(A) Concentration of PPi was unchanged in ATDC5 cultures treated with 20µM 
pASARM and npASARM peptides in comparison to control cultures. (B) Alpl 
mRNA expression was also unchanged as was (C) ALP activity. Data are 
represented as mean ± SEM of three wells analysed in triplicate. 
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peptide inhibit mineralisation of metatarsal bones across a range of concentrations 
(Fig. 5.11B, P<0.01) despite no significant difference in the total longitudinal bone 
growth (Fig. 5.11A). In concordance with the ATDC5 cell data, 20µM MEPE-
ASARM peptides were used in future experiments.  
 
Metatarsal bones cultured in the presence of 20µM pASARM and npASARM 
peptides grew in length at the same rate as the control bones (up to 80%) after 7 
days in culture (Figs. 5.12C - F). However, whereas in the control and npASARM 
treated metatarsals the central mineralisation zone increased in length throughout 
the culture period (increased approximately 5-6 fold from initial lengths, Fig. 5.12C, 
D & G), in the pASARM treated cultures no changes in mineralisation zone length 
were noted (p<0.01 at day 6, p<0.001 at days 8 and 10 in comparison to the control 
bones, Fig. 5.12C, E & G).  
5.5.8 pASARM peptide inhibit the mineralisation capability of E15 metatarsal 
bones 
To examine this apparent inhibitory effect further, the E15 metatarsal model 
characterised in Chapter 3 was utilised. As previously described, these bones consist 
of early proliferating chondrocytes (Fig. 5.13B) and no evidence of a mineralised 
core. After 7 days in culture, the chondrocytes in the centre of the bone become 
hypertrophic and mineralise their surrounding matrix as is previously documented 
and described in Chapter 3 (Haaijman et al. 1999) (Fig. 5.13C).  
 
This central core of mineralised cartilage formed in control bones and bones treated 
with 20µM npASARM peptide (Figs. 5.13C & D), however it was minimal in 
metatarsal bones treated with 20µM pASARM peptide (Fig. 5.13E), as seen in the 
phase contrast images. 
 
This was further confirmed by von kossa staining of histological sections for 
mineralisation (Fig. 5.14B & C) and by µCT scanning of the metatarsal bones to 
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Figure 5.11 The inhibition of E17 metatarsal bone mineralisation by the 
pASARM peptide 
(A) The growth rate of E17 metatarsal bones was not affected by treatment with 10, 20 
or 50µM MEPE-ASARM peptides when cultured for up to 10 days (B) The percentage 
change in mineralisation zone increased in control and npASARM treated bones 
whereas the mineralisation zone in bones treated with pASARM peptides did not 
increase at all during the culture period. Data are represented as mean ± SEM of at 
least six bones **P<0.01, ***P<0.001 Error bars are too small to be visualised due to the 
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Figure 5.12 pASARM inhibition of E17 metatarsal mineralisation 
Measurements of digital images of E17 mouse metatarsal bones in culture with clearly 
delineated mineralising zones (B-E) were taken using a calibrated ruler (A). Images clearly 
show the harvesting length (B) with the locations of the proliferating (PZ), hypertrophic 
(HZ) and mineralising (MZ) zones, as well as the total length measurement. A control 
metatarsal bone is illustrated in (C) and bones treated with continuous 20µM npASARM (D) 
and pASARM peptides (E) after 10 days of culture. The growth rate of the embryonic 
metatarsal bones was not affected by treatment with 20µM MEPE-ASARM peptides (F) 
when cultured for up to 10 days. There was no significant difference in the percentage 
change in mineralisation length between control and npASARM treated bones, both of 
which increased over the culture period. However the mineralisation zone length in bones 
treated with pASARM peptides remained the same during the culture period (G). Data are 
represented as mean ± SEM of at least six bones **P<0.01, ***P<0.001 in comparison to 
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Figure 5.13 pASARM inhibition of E15 metatarsal mineralisation 
Measurements of digital images of E15 mouse metatarsal bones in culture were taken 
using a calibrated ruler (A). At time of harvesting, bones did not have a central 
mineralisation zone as indicated by the asterisk (B). After 7 days in culture, control (C) 
and npASARM (D) treated bones formed a large mineralisation zone however this was 
inhibited in pASARM treated bones (E). Despite this, all metatarsal bones grew at a 
similar rate (F). Data are represented as mean ± SEM of at least six bones. 
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Figure 5.14 The lack of effect of the MEPE-ASARM peptides on metatarsal 
chondrocyte differentiation  
There was no difference in the proliferation of the chondrocytes within the control and 
MEPE-ASARM treated bones (A). Histological sections (C) showed control and 
npASARM treated bones to have abundant mineral as indicated by von kossa staining. 
This was not seen in pASARM treated metatarsals. There was no difference in the 
widths of the PZ and HZ of chondrocytes between the different groups of metatarsals at 





Control        npASARM            pASARM 
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allow the visualisation of the bones in a 3D context (Fig. 5.15B). In comparison to the 
control and npASARM treated bones, metatarsal bones cultured in the presence of 
pASARM peptide had a significantly reduced BV/TV (P<0.001) (Fig. 5.15A), as is 
clearly visible in the µCT scan images (Fig. 5.15B). This unequivocally shows the 
inhibition of mineralisation in metatarsal bones by the pASARM peptide. Despite 
the increase in ATDC5 ECM mineralisation upon addition of npASARM peptide, 
here the mean density of the mineralised bone was unchanged between control and 
npASARM treated bones (control 163.4 ±12.1mg hydroxyapatite/ccm, npASARM 
173.2 ±21.9mg hydroxyapatite/ccm, not significant) suggesting that the result seen in 
the ATDC5 cell cultures may be artifactual.    
 
Apart from the inhibition of mineralisation by the pASARM peptide, there were no 
other obvious morphological differences in the development of these bones in 
comparison to the control bones.  All bones grew at the same rate (increased 
approximately 65% from initial lengths) (Fig. 5.13B - F) and by incorporating [3H]-
thymidine into the bones at the end of the culture period, day 7, it was determined 
that the proliferation rate of the chondrocytes was unchanged (Fig. 5.14A). The 
lengths of the PZ and HZ zones of chondrocytes were also measured. The MEPE-
ASARM peptides had no effect on the percentage sizes of the maturational zones of 
the metatarsal bones, or on the cell numbers within the bones (Control: 1139.13 ± 
172.01, pASARM: 1594.97 ± 226.9, npASARM 1233.71 ± 126.08) (Fig. 5.14B & C). 
 
This therefore suggests that the MEPE-ASARM peptides had no effect on the 
differentiation capability of the metatarsal chondrocytes. To examine this further, 
the mRNA expressions of chondrocyte differentiation markers were determined 
(Col10a1, Col2a1, Atf3, PthIh and Ihh). There were no significant differences between 
the control and pASARM treated bones at days 5 and 7 of culture (Fig. 5.16A - E, 
Fig. 5.17A - E), as is in concordance with the histological and proliferation data. 
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Figure 5.15 Inhibition of E15 metatarsal mineralisation by µCT analysis 
µCT analysis of E15 metatarsal bones treated with npASARM and pASARM 
peptides and cultured for 7 days. Bones treated with pASARM had a significantly 
reduced BV/TV in comparison to the control and npASARM treated bones (A). 
This was clearly visible in the µCT images (B). Data are represented as mean ± 
SEM of three bones ***P<0.001.  
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Figure 5.16 The lack of effects of the pASARM peptide on chondrogenic gene 
expression in E15 after 5 days of culture 
Analysis of mRNA expression in E15 control and pASARM treated metatarsals at day 5 
of culture (A) Col10a1 (B) Col2a1 (C) Atf3 (D) PthIh (E) Ihh (F) Enpp1 (G) Ank (H) Alpl (I) 
Phospho1 (J) Mepe (K) Phex Data are represented as mean ± SEM of 3 groups of 4 pooled 
bones.     
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Figure 5.17 The lack of effect of the pASARM peptide on chondrogenic gene 
expression in E15 after 7 days of culture 
Analysis of mRNA expression in E15 control and pASARM treated metatarsals at day 7 of 
culture (A) Col10a1 (B) Atf3 (C) PthIh (D) Mmp13 (E) Ihh (F) Enpp1 (G) Ank (H)  Phospho1. 
Data are represented as mean ± SEM of 3 groups of 4 pooled bones.   
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To examine the mechanism of inhibition by the pASARM peptide, the expression 
and activity of key enzymes associated with cartilage mineralisation were 
determined. Interestingly after 7 days of culture, there was no significant difference 
in the activity of ALP (Fig. 5.18A), a well-recognised regulator of chondrocyte 
matrix mineralisation. This was further confirmed by mRNA expression analysis of 
Alpl by qPCR at days 5 and 7 of culture (Fig. 5.16H & 5.18B). Analysis of the mRNA 
expression of other mineralisation regulators, Ank, Enpp and Phospho1, also showed 
no difference between control and treated bones at days 5 and 7 of culture (Fig. 
5.16F - I, Fig. 5.17F - I).  
 
To assess the possible interactions of PHEX with MEPE, the mRNA expression of 
Phex was examined and like in the MEPE-overexpressing ATDC5 cultures (Fig. 
5.3D), was found to be significantly decreased in the pASARM treated bones 
compared to the control bones at day 7 of culture (P<0.05, Fig. 5.18C). Furthermore, 
Mepe mRNA expression was significantly increased (P<0.001) (Fig. 5.18D). At day 5 
of culture, there was no significant difference in the mRNA expression of Mepe or 
Phex (Fig. 5.16J & K). 
 
The vascular invasion of the cartilage model via VEGF stimulated angiogenesis is 
critical for matrix mineralisation (Gerber et al. 1999). Thus, the effects of the 
expression levels of Cd31, Cd34, and VEGFR2/Flk1 following 7 days of culture in the 
presence of 20µM pASARM compared to control bones (P<0.05, Figs. 5.19A - C). 
pASARM peptide on the mRNA expression of endothelial cell specific markers and 
VEGF was examined. qPCR indicated a significant decrease in the mRNA 
Furthermore, there was also a concomitant decrease in VEGF isoform expression 
specifically VEGF164 and VEGF120 (Figs. 5.19E - G). VEGF188 was not detected in either 
control or treated metatarsals. MMP13, which has been implicated in VEGF-induced 
angiogenesis (Nagai & Aoki 2002; Zijlstra et al. 2004) also had a significantly 
decreased mRNA expression (in pASARM treated bones compared to control; 
P<0.05, Fig. 5.19D).   
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Figure 5.18 The effects of pASARM peptides on alkaline phosphatase and 
the PHEX-MEPE axis in E15 metatarsal bones 
ALP activity was unchanged in metatarsal bones treated with 20µM pASARM peptides 
in comparison to control bones (A). Alpl mRNA expression was also unchanged (B). 
Phex mRNA expression was significantly decreased in pASARM treated bones (C) 
whilst Mepe mRNA expression was increased (D). Data are represented as mean ± SEM 
*P<0.05 ***P<0.001 of 3 groups of 4 pooled bones at day 7 of culture. 
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Figure 5.19 The inhibition of endothelial cell markers in E15 metatarsals 
treated with the pASARM peptide 
mRNA expression of endothelial cell markers Cd31 (A), Cd34 (B), VEGFR2/Flk1 (C) and 
Mmp13 (D) in control and pASARM treated bones at day 7 of culture. PCR analysis of 
pro-angiogenic VEGF-A splice variants (E) and densitometry of the VEGF164 isoform 
(F) and the VEGF120 isoform (G). Data are represented as mean ± SEM *P<0.05, **P<0.01 
of 3 groups of 4 pooled bones. PCR analysis represents replicates of pooled bones at 
day 7 of culture.  
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5.6 Discussion 
The hypertrophic chondrocytes of the epiphyseal growth plate mineralise their 
surrounding ECM and facilitate the deposition of hydroxyapatite, a process 
imperative for longitudinal bone growth. Determining the function of key proteins 
involved in this process is crucial in furthering our understanding. MEPE has been 
proposed as one such protein due to its emerging direct and indirect roles in 
biomineralisation, however its function as a regulator of chondrocyte matrix 
mineralisation has yet to be elucidated (Martin et al. 2008; Addison et al. 2008). 
 
MEPE is a member of the SIBLING family of proteins which is degraded by 
cathepsin B to an acidic, negatively charged ASARM peptide. Patients with XLH 
have elevated serum levels of this ASARM peptide as does the mouse model of 
XLH, the Hyp mouse  (Bresler et al. 2004). Further studies of the Hyp mouse show 
severe morphological disruption of the growth plate which can be corrected by the 
administration of cathepsin inhibitors (Rowe et al. 2006). Moreover, the MEPE 
transgenic mice displayed wider epiphyseal growth plates, expanded primary 
spongiosa and a significant decrease in the MAR therefore suggesting dysregulation 
of endochondral bone growth (David et al. 2009). In concordance with this, the 
studies described here show an inhibition of chondrocyte matrix mineralisation by 
MEPE. 
 
The engineering of cells to over-express a gene of interest is a commonly used in 
vitro method to determine the effects of this gene. Here Mepe mRNA was increased 
in expression in mineralising ATDC5 cells however there was a lack of 
overexpression of the protein product therefore suggestive of a post-translational or 
post-transcriptional regulatory mechanism of MEPE expression (Fig. 5.1). Several 
mechanisms of such regulation exist including micro ribonucleic acid (miRNA) 
silencing, histone modification and protease degradation (Halbeisen et al. 2008). The 
activity of miRNAs in chondrocytes, and in ATDC5 cells, has been reported 
however it is more likely that the unreported overexpression of MEPE protein is 
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due to its rapid cleavage to its functional component, the ASARM peptide (Swingler 
et al. 2012; Dong et al. 2012). To fully elucidate the role of MEPE in chondrocyte 
matrix mineralisation, it would be beneficial to ablate MEPE and examine the matrix 
mineralisation observed. In order to do this, attempts were made to target Mepe 
using shRNA constructs. These attempts were unfortunately unsuccessful with no 
significant decreased expressions of MEPE protein or mRNA levels (Fig. 5.7). The 
reasons behind this are unclear but could be due to a lack of the specific complex 
cellular machinery required to process and guide shRNA to target mRNA in this 
immortalised cell line. Whilst a MEPE knockout mouse has been generated, there 
has not been a histomorphometric characterisation of its growth plate however this 
analysis would also be beneficial in fully understanding the precise role of MEPE in 
chondrocyte matrix mineralisation (Gowen et al. 2003).  
     
Like the other SIBLING proteins, the activity of MEPE is dependent upon its state of 
cleavage and its phosphorylation with recent work identifying the 2.2kDa ASARM 
peptide of MEPE as its functional component. Previous studies have shown the 
ASARM peptide to inhibit matrix mineralisation in in vitro osteoblast cultures 
(Rowe et al. 2004; Addison et al. 2008; Atkins et al. 2011). This was unequivocally 
corroborated here in the ATDC5 cells and the metatarsal organ culture model, a 
well-established model of cartilage mineralisation and endochondral bone growth 
which occurs without the vascular supply (Figs. 5.8, 5.12 & 5.13). Although a 
widening of the hypertrophic zone of chondrocytes would be expected as seen in 
XLH and as is observed in the MEPE-overexpressing mouse, here no differences in 
the widths of the cartilage zones in the metatarsal bones were observed (Fig. 5.14) 
(David et al. 2009). However, this is not surprising as there was also no difference in 
the growth potential, chondrocyte proliferation or mRNA expression of 
chondrocyte differentiation markers, of the treated and untreated bones. This 
therefore suggests that the MEPE-ASARM peptide has no effect on chondrocyte 
function per se. Instead it affects chondrocyte matrix mineralisation directly, as is in 
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concordance with studies done on bone mineralisation (Addison et al. 2008; Martin 
et al. 2008). 
 
It is well recognised that ALP activity is a key regulator of cartilage matrix 
mineralisation. ALP is located to the outer surface of the trilaminar membrane of 
MVs, which form from the hypertrophic chondrocytes (Anderson 2003). It is widely 
accepted that ALP generates Pi for hydroxyapatite formation and its lack of activity 
results in an excess of PPi (Addison et al. 2007). The interaction between ALP, PPi 
and other SIBLING proteins has previously been documented (Wang et al. 2006; 
Addison et al. 2007). It was therefore postulated that the effects of the pASARM 
peptide could act through a decrease in ALP activity/expression as has been shown 
in a previously and as is observed in the MEPE overexpressing mouse (Martin et al. 
2008; David et al. 2009). However, no effect on ALP activity or expression by the 
ASARM peptide was observed (Fig. 5.18). This is in concordance with a previous 
study investigating the role of MEPE in osteoblast mineralisation (Addison et al. 
2008).  
 
Furthermore no differences were observed in the expression of NPP1 which cleaves 
extracellular nucleotides such as ATP to generate the mineralisation inhibitor PPi 
(Fig. 5.16). These nucleotides have a dual inhibitory effect on matrix mineralisation 
through purinergic signalling (Orriss et al. 2007; Burnstock et al. 2010; Gartland et al. 
2012). Although this was not examined here, there is currently nothing in the 
literature to suggest that the ASARM peptide increases ATP levels, and this is 
certainly corroborated by the unchanged PPi levels observed here. The pASARM 
peptide had no effect on PHOSPHO1 expression, which together with ALP 
regulates bone and cartilage mineralisation suggesting that in the models utilised 
here, the mechanism of inhibition is not a result of decreased enzyme activity 
(Yadav et al. 2011; Huesa et al. 2011). Rather, it is likely that the pASARM peptide 
exerts its effects by a physio-chemical interaction through its direct binding to the 
hydroxyapatite as has previously been suggested (Addison et al. 2008).  
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It has recently been shown that a truncated form of MEPE which has the ASARM 
peptide removed, can promote bone mineralisation in culture and in mice 
(Sprowson et al. 2008). Furthermore, a mid-terminal fragment of MEPE has been 
shown to enhance cell binding and taken together these results highlight the 
importance of the post translational processing of MEPE in determining its 
functional role (Hayashibara et al. 2004). The data presented here have shown that 
the phosphorylation of the ASARM peptide is crucial in determining its functional 
role. Despite the observed promotion of mineralisation by the npASARM peptide in 
the ATDC5 cultures, this was not corroborated by the metatarsal data. Furthermore 
in other in vitro studies, it has been shown that the function of the MEPE-ASARM 
peptide is entirely dependent upon its phosphorylation (Martin et al. 2008; Addison 
et al. 2008; Boskey et al. 2009a). Indeed it is likely that the npASARM peptide does 
not physiologically exist and is in fact inactive. One can reasonably infer that since 
the pASARM serine-phosphorylated casein kinase sites are highly conserved across 
species (including whales, dolphins, primates, rodents, marsupials, elephants, dogs, 
and cats) and the phosphorylated form is active that there might be a physiological 
mechanism that plays a role in regulating the ASARM-phosphorylation status 
(Rowe 2012b). 
 
PHEX  protects MEPE from cathepsin B cleavage in vitro (Guo et al. 2002; Rowe et al. 
2005) thus the inhibition of Phex mRNA expression in pASARM treated metatarsal 
bones and in ATDC5 cells overexpressing MEPE suggests a feedback mechanism by 
which ASARM peptides can prevent PHEX expression (Fig. 5.3 & 5.18). This, in 
correlation with an increase in Mepe expression seen, would allow the release of 
ASARM peptides therefore further increasing the inhibition of mineralisation. 
Furthermore, the reduction in Phex mRNA expression may be due to the ASARM 
peptide protecting itself from sequestration and hydrolysis by PHEX, as has 
previously been suggested (Liu et al. 2007a; Martin et al. 2008; Addison et al. 2008). A 
decrease in Phex mRNA has also been observed in osteoblast cell cultures treated 
with the pASARM peptide, concomitant with an increase in FGF23 expression 
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(Martin et al. 2008). In the MEPE-overexpressing mouse however, an increase in 
Phex mRNA is observed and this, coupled with the expected hydrolysis of the 
ASARM peptide, leads to altered MEPE processing and therefore the 
hyperphosphatemia observed in this mouse model (David et al. 2009). These data 
are also in agreement with previous reports showing increased MEPE expression by 
osteoblasts of Hyp mice and this positive regulation of MEPE expression by 
pASARM may exacerbate the condition (Rowe et al. 2000; Argiro et al. 2001; Rowe et 
al. 2004; Liu et al. 2007a). It is reasonable to speculate that physiologically there must 
be a regulatory mechanism to ensure that there is not an overproduction of ASARM 
peptides and as such a pathological state. The precise nature of the counter 
balancing mechanism is presently unknown but as the SIBLING proteins are closely 
related and it is possible that one of the other members of this family may be 
responsible.  
 
Key to endochondral ossification is the vascularisation of the mineralised matrix 
(Gerber et al. 1999). MMPs proteolytically degrade the mineralised cartilage matrix, 
facilitating blood vessel penetration into the growth plate and allowing the 
recruitment of osteoclast precursors and osteoblast progenitors. Pro-angiogenic 
VEGF is produced by hypertrophic chondrocytes of the growth plate and VEGF164/188 
deletion from the cartilage of developing mice results in delayed recruitment of 
blood vessels to the perichondrium along with a delayed invasion of vessels into the 
primary ossification centre (Zelzer et al. 2002). Here a decrease in Mmp13 mRNA 
expression following pASARM treatment was observed (Fig. 5.14). Of the 
collagenases, MMP13 has been considered to have an important role in skeletal 
biology in view of its exclusive presence in the skeleton during embryonic 
development in cartilaginous growth plates and primary centers of ossification. 
Deficiencies in MMP13 have been shown to cause a transient elongation in the 
hypertrophic zone in the growth plate during the early stages of growth and 
development (Nagai & Aoki 2002; Stickens et al. 2004; Behonick et al. 2007). 
Additionally, a lack of MMP13 can also lead to a significant delay in the fracture 
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healing process further endorsing a role for MMP13 in the regulation of the 
vasculature in bone (Kosaki et al. 2007).  
 
Furthermore, the pASARM peptide reduced the levels of endothelial cells present 
during metatarsal organ culture due to the vessel invasion of the bones at 
approximately E14 - E15 (Fig. 5.14). This was associated with reduced VEGF120/164 
mRNA expression levels. It is entirely possible that the influence of the pASARM 
peptide on endothelial cell populations is indirect; by impacting hypertrophic 
chondrocyte VEGF expression. However, any direct effects of the pASARM peptide 
on endothelial cell function remain under investigated. The possible implications of 
MEPE on bone renal vascularisation has recently been described in the MEPE-
overexpressing mouse, which in contrast to the results here exhibits defective 
mineralisation associated with increased blood vessels (David et al. 2009). It is likely 
that in the Mepe-overexpressing mice, unknown compensatory mechanisms could 
exist to allow for effective vascularisation of the skeleton. Like MEPE, DMP1, 
another SIBLING protein, has also been suggested as an inhibitor of VEGF receptor 
2 mediated angiogenesis although the precise role of its ASARM peptide in this 
circumstance has yet to be elucidated (Pirotte et al. 2011). 
 
To conclude, these studies detail MEPE as a key protein in regulating the pace of 
endochondral bone growth due the apparent inhibitory effects of its pASARM 
peptide on chondrocyte matrix mineralisation and the vascularisation of the 







Chapter 6                                                           Osteocyte regulation of endochondral ossification 















Chapter 6                                                           Osteocyte regulation of endochondral ossification 
~ 149 ~ 
 
6.1 Introduction 
Endochondral bone growth is regulated by numerous autocrine, paracrine and 
endocrine factors (section 1.3) which work in synergy to allow effective matrix 
mineralisation. Whilst this thesis has defined the role of MEPE in this phenomenon, 
it has not yet examined the potential interaction of MEPE with other regulators of 
mineralisation. Of particular interest is sclerostin, an inhibitor of bone formation 
that has promising therapeutic potential.  
 
sclerostin was only identified fairly recently as the product of the SOST gene, 
mutations of which cause high-bone mass diseases in humans such as Van Buchem 
disease and sclerosteosis (Balemans et al. 2001; Brunkow et al. 2001). This high bone 
mass is also seen in SOST null mice, and mice administrated with neutralising 
antibodies to sclerostin (Li et al. 2009; Li et al. 2010). sclerostin is a known antagonist 
of the Wnt signalling pathway through its specific binding to the Wnt coreceptor 
LRP5 and 6 (Winkler et al. 2003; Semenov et al. 2005; Li et al. 2005; van Bezooijen et 
al. 2007; Staines et al. 2012a). More recently, LRP4 has been implicated as a receptor 
for sclerostin (Choi et al. 2009). The binding of Wnt ligands to these coreceptors 
activates the Wnt signalling pathway which regulates osteoblast differentiation and 
bone formation (Ott 2005; Krishnan et al. 2006b). The Wnt signalling pathway has 
also been implicated as a critical regulator of cartilage homeostasis with expression 
throughout the development of the skeleton and with known roles in chondrocyte 
proliferation and hypertrophy (Witte et al. 2009; Staines et al. 2012a).  
 
A comprehensive recent study has determined that sclerostin may function through 
mechanisms outwith the Wnt signalling pathway. It has been shown that sclerostin 
increases Mepe mRNA expression in human primary osteoblasts with a concomitant 
decrease in Phex mRNA. Most importantly, antibody-mediated neutralisation of 
MEPE-ASARM antagonised the effects of recombinant sclerostin on matrix 
mineralisation, as did the PHEX synthetic peptide SPR4 (Atkins et al. 2011). This 
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therefore suggests that sclerostin may act, at least in part, through the regulation of 
the MEPE-ASARM/PHEX axis in the process of osteoblast matrix mineralisation.  
 
However, whether sclerostin has a functional role in chondrocyte matrix 
mineralisation has yet to be elucidated. There is some evidence of sclerostin 
expression in the mineralised hypertrophic chondrocytes of the growth plate and if 
this is confirmed, then this certainly is suggestive of a function for sclerostin 
(Winkler et al. 2003; van Bezooijen et al. 2009). However if there is not local 
production of sclerostin by the growth plate chondrocytes, then it is plausible to 
suggest that there is a paracrine mechanism by which osteocytes cross-talk with 
growth plate chondrocytes through sclerostin expression. Indeed osteocytes are 
suitable for this function since they form an extensive network with each other, 
lining cells, and osteoblasts through gap junction connections (Klein-Nulend et al. 
2003; Bonewald 2006). More recently, it has been shown that osteocytes can 
communicate with osteoclast cells through RANKL expression (Xiong et al. 2011; 
Nakashima et al. 2011). Determination of the intercellular communications 
regulating growth plate matrix mineralisation will provide new insights into the 
molecular mechanisms surrounding endochondral ossification.    
6.2 Hypothesis 
Local chondrocyte sclerostin and/or osteocyte sclerostin inhibits chondrocyte matrix 
mineralisation through a MEPE dependent mechanism. 
6.3 Aims 
I. Examine the expression of sclerostin in growth plate chondrocytes 
 
II.  Analyse the effects of sclerostin on chondrocyte matrix 
mineralisation 
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III. Establish whether sclerostin acts through a MEPE-dependent 
mechanism 
6.4 Materials and Methods 
6.4.1 Immunohistochemical staining of the murine growth plate in vivo  
4-week old C57BL/6 mice were sacrificed by cervical dislocation and the tibiae were 
dissected and fixed in 70% ethanol for 24 hours. The tibiae were decalcified in 10% 
EDTA and processed into wax as described in section 2.6.1. Immunohistochemical 
staining of 5µm-thick tibiae sections was performed using antibodies for sclerostin 
(1:100) and the Vectastain ABC kit, as outlined in section 2.9 and Appendix III. 
Immunohistochemical labelling was visualised using DAB chromagen. Appropriate 
IgG concentrations were used instead of the primary antibodies as negative 
controls.  
6.4.2 Primary cell cultures 
Primary chondrocytes were extracted from the rib cages of 1-3 day old mice as 
detailed in section 2.2.3. Cells were cultured for 2 days at 37oC in primary cell 
culture media before RNA was extracted and reverse transcribed (sections 2.12.1 
and 2.12.3). For PCR analysis, cDNA was used at 25ng/µl and amplified as 
described in section 2.12.4. PCR products were analysed on a 1.5% agarose gel and 
visualised under UV light using a Gel Logic 200 Imaging System and software 
(Kodak). Primers used are detailed in Appendix II. 
6.4.3 IDG-SW3 cell line  
The IDG-SW3 cell line, isolated from 3-month-old Immortomouse+/−/Dmp1-GFP+/− mice 
which carry an IFN-γ inducible promoter enabling immortalisation of cells, was a 
generous gift from Professor Lynda Bonewald (University of Missouri-Kansas City, 
Missouri, USA) and was cultured as detailed previously (section 2.2.4) (Woo et al. 
2011). For mineralisation experiments, cells, at passage 12, were seeded at 8 x 104 
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cells/cm2 in osteogenic conditions (37oC with 50μg/ml ascorbic acid and 4mM βGP) 
in the absence of IFN-γ for up to 28 days.  
6.4.4 ATDC5 cells 
As outlined in section 2.2.1, ATDC5 cells were cultured at a density of 6 x 103 
cells/cm2 in a humidified atmosphere (37°C, 5% CO2) for up to 30 days. When 
confluent, cells were supplemented with 10mM βGP and 50µg/ml ascorbic acid with 
the medium being changed every 2-3 days.  
6.4.5 Metatarsal organ culture 
The middle three metatarsals of E15 mice were isolated under a dissecting 
microscope, as described in section 2.5.2.  Metatarsals were cultured in metatarsal 
media for up to 7 days. The total length of the bone through the centre of the 
mineralising zone was determined using image analysis software (DS Camera 
Control Unit DS-L1; Nikon) every second or third day. The length of the central 
mineralisation zone was also measured. 
6.4.6 IDG-SW3 conditioned media 
IDG-SW3 cells were cultured in T175 flasks as described in section 6.4.3. Media was 
changed every 3 days and on days 4 and 21 was removed from the cells, centrifuged 
to remove particulates and frozen at -20oC until required. In ATDC5 and E15 
metatarsal cultures, 20% conditioned media was added every other day. As a 
control, IDG-SW3 media (Appendix I) was used.  
6.4.7 Co-culture of embryonic murine metatarsals and IDG-SW3 cells 
For co-culture experiments, 12 Well Thincert, 0.4µm pore diameter, transparent co-
culture plates were used (Grenier Bio-one Inc, Stonehouse, UK). IDG-SW3 cells were 
plated and maintained for up to 21 days as described in section 6.4.3. At this point, 
E15 metatarsal bones were dissected as detailed in section 2.5.2, and were placed 
upon the insert which was suspended above the IDG-SW3 cells to allow diffusion of 
the two cell mediums. Metatarsal bones were cultured for up to 7 days in a 
Chapter 6                                                           Osteocyte regulation of endochondral ossification 
~ 153 ~ 
 
humidified atmosphere. The total length of the bone through the centre of the 
mineralising zone, as well as the length of the central mineralisation zone, was 
determined using image analysis software (DS Camera Control Unit DS-L1; Nikon) 
every second or third day. 
6.4.8 SPR4 peptides, CA074 and sclerostin neutralising antibodies 
SPR4, a single PHEX peptide (4.2 kDa) was synthesised as 
TVNAFYSASTNYPRSLSYGAIGVIVGHEFTHGFDNNGRGENIADNG (Peptide 
Synthetics, Bishops Waltham, UK). This was added to co-cultures at a concentration 
of 20µM with controls treated with a DMSO carrier (0.1%). CA074, a specific 
cathepsin B inhibitor, was purchased (Merck, Darmstadt, Germany) and also added 
to co-cultures at a concentration of 20µM with controls treated with a DMSO carrier 
(0.1%). sclerostin neutralising antibodies were obtained from Eli Lilly (Indianapolis, 
USA) for use in this project under a material transfer agreement. Antibodies were 
added to co-cultures at varying concentrations (0-2nM) to examine their effects. 
Concentrations were determined as to section 6.5.5.  
6.4.9 Histochemical analysis of IDG-SW3 cultures  
IDG-SW3 cell cultures were stained for calcium deposition (alizarin red), collagen 
production (Sirius red), and glycosaminoglycan presence (alcian blue) as described 
in section 2.4. The optical densities of the resultant stains were analysed using a 
spectrophotometer (Thermo Scientific, Northumberland, UK) along with an 
appropriate blank control. Reactions were completed in triplicate at each time point.  
6.4.10 RNA analysis of IDG-SW3 cells and metatarsals 
RNA was extracted from IDG-SW3 cell cultures using an RNeasy mini kit according 
to the manufacturer’s instructions (section 2.12.1). For metatarsal organ cultures, 4 
bones from each control or experimental group were pooled in 100μl Trizol reagant 
at either day 5 or 7 of culture, and RNA was extracted according to the 
manufacturer’s instructions (section 2.12.2). For each sample, total RNA content was 
assessed by absorbance at 260nm and purity by A260/A280 ratios, and then reverse-
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transcribed as described in section 2.12.3. RT-qPCR was performed using the SYBR 
green detection method on a Stratagene Mx3000P real-time qPCR system as detailed 
in section 2.12.5. Primers were purchased from PrimerDesign Ltd, or designed in 
house and synthesised by MWG Eurofins (Appendix II). Reactions were run in 
triplicate and routinely normalised against 18S.  
6.4.11 ELISA analysis of sclerostin expression 
A mouse Quantikine® ELISA kit for sclerostin was purchased (R&D systems, 
Minneapolis, USA). This was a sandwich ELISA where a monoclonal antibody 
specific for mouse/rat SOST was pre-coated onto the microplate. 50µl of assay 
diluent was added to each well of the provided microplate. Standards, controls, and 
samples were prepared according to the manufacturer’s instructions and added at 
50µl/well before being incubated at room temperature for 3 hours. Each well was 
then aspirated and washed with the provided wash buffer for a total of five washes. 
100µl of mouse SOST conjugate was added to each well and incubated for 1 hour at 
room temperature. Wells were subsequently aspirated and washed for a total of five 
washes. 100µl of substrate solution was added to each well and was incubated for 
30 minutes at room temperature, protected by light. Then, 100µl stop solution was 
added before the optical density was determined using a microplate reader (Thermo 
Scientific, Northumberland, UK) at 450nm. Concentration of sclerostin was 
calculated according to the manufacturer’s instructions.    
6.4.12 Recombinant sclerostin 
Recombinant sclerostin was added to E15 murine metatarsal bones (section 6.4.5) at 
concentrations of 0 - 1000µM from day one of culture. Recombinant sclerostin was 
added to cultured metatarsal bones every second day for up to six days of culture. 
The total length of the bone and the length of central mineralisation zone was 
determined using image analysis software (DS Camera Control Unit DS-L1; Nikon).  
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6.5 Results 
6.5.1 Expression of sclerostin by growth plate chondrocytes   
There is currently conflicting evidence regarding the expression of sclerostin by 
growth plate chondrocytes thus its protein localisation in the growth plate was 
examined by immunohistochemistry. sclerostin was not expressed by the resting, 
proliferating or hypertrophic chondrocytes of 4-week old murine growth plates (Fig. 
6.1A). Neither was sclerostin expression apparent in the osteoblasts. As a positive 
control, the osteocytes of these bones were found to stain positive for sclerostin 
immunolocalisation confirming the specificity of the sclerostin antibodies (Fig. 6.1B). 
Representative images of the appropriate negative control are shown (Fig. 6.1C & 
D). Interestingly, primary chondrocytes cultured for 2 days were positive for Sost 
mRNA expression as examined by PCR analysis possibly suggesting that sclerostin 
expression by growth plate chondrocytes is below the detection level of IHC (Fig. 
6.1E).  
6.5.2 Characterisation of IDG-SW3 osteocyte-like cells 
Sclerostin protein is evidently not expressed by growth plate chondrocytes, but as it 
is a secreted protein of the mature osteocyte it is plausible that it could still act to 
regulate growth plate development and/or mineralisation. The cell line IDG-SW3 is 
a novel and exciting cell line that is capable of overcoming the current limitations 
that exist in current osteocyte cell lines. Existing osteocyte-like cell lines, for example 
MLO-Y4 and MLO-A5, are limited by their transformation, their lack of sclerostin or 
FGF-23 expression, and/or their absence of a mineralised matrix. Although a full 
characterisation of these cells has previously been published, it was deemed 
necessary to examine their differentiation and expression of sclerostin before the 
cells could be utilised here to examine the effects of sclerostin on the growth plate 
(Woo et al. 2011). 
 
Visualisation of cells by phase contrast microscopy indicated IDG-SW3 cells to 
differentiate into an osteocyte phenotype by day 7 with clearly visible dendritic  
Chapter 6                                                           Osteocyte regulation of endochondral ossification 
~ 156 ~ 
 
Figure 6.1 The lack of expression of sclerostin by growth plate chondrocytes 
Immunohistochemical staining of a 4-week old murine tibia for sclerostin. No expression 
was observed in the growth plate (A), however there was positive expression in the 
osteocytes of the cortical bone (B). Representative images of the appropriate controls are 
shown (C & D). Brown stain indicates sclerostin expression. Sost mRNA was present in 
primary chondrocyte cells as indicated by PCR analysis. 18S mRNA expression was used as 
a loading control (n=2 separate cell cultures, A & B). The molecular weight marker (Sost – 
40kDa) is in the left hand lane (E).  
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Figure 6.2 Phase contrast images of IDG-SW3 cells 
Phase contrast images of IDG-SW3 cells cultured for up to 21 days in the presence of ascorbic acid and 4mM βGP (A) Cells reach confluency by 
day 2 of culture and by day 7 (B) display an osteocyte phenotype. This is associated with mineralisation of the matrix throughout the culture 
period (C & D). Scale bars are 1mm. 
 
~ 157 ~ 
Chapter 6                                                           Osteocyte regulation of endochondral ossification 
~ 158 ~ 
 
processes (arrows, Fig. 6.2B). Associated with these cells was apparent focal nodular 
mineralisation which increased throughout the culture period to day 21 (Fig. 6.2C & 
D). Assessment of collagen deposition by Sirius red stain indicated increased matrix 
formation at day 21 of culture in comparison to day 4 of culture (Fig. 6.3A). 
 
Concomitant with this was increased matrix mineralisation, as assessed by alizarin 
red staining (Fig. 6.3B). Examination of mRNA expression levels by qPCR at day 21 
of culture in comparison to day 4 indicated increased expression of Mepe (Fig. 6.3C, 
P<0.001). There was no difference in Phex mRNA expression levels (Fig. 6.3D). 
Furthermore, ELISA analysis of sclerostin expression in these cells indicated that 
almost no detectable sclerostin protein was present in the conditioned medium of 
day 4 cultures but this was significantly higher (184pg/ml P<0.05, in comparison to 
day 4 cultures, Fig. 6.4B) in day 21 conditioned medium. 
6.5.3 The effects of IDG-SW3 conditioned media on ATDC5 mineralisation 
To examine the potential crosstalk between osteocytes and chondrocytes, 
mineralising ATDC5 cells were cultured with 20% conditioned media from day 4 
(CM4) and day 21 (CM21) IDG-SW3 cells. Mineralisation of ATDC5 cells was 
assessed at days 15, 20, 25 and 30 of culture by alizarin red staining and this was 
quantified by spectrophotometry.  Overall there was little consistent effect of 
conditioned medium on ATDC5 matrix mineralisation.  However, at day 15, ATDC5 
cells cultured in the presence of CM4 and CM21 displayed a significantly decreased 
matrix mineralisation (Fig. 6.5A & B, P<0.05). There were no effects observed at days 
20 and 25 of culture, however a small decreased mineralisation was also observed at 
day 30 in CM21 cultured ATDC5 cells (Fig. 6.5A & B, P<0.05).  
6.5.4 The effects of IDG-SW3 conditioned media on E15 metatarsal bones 
Due to the somewhat inconsistent results observed in the ADTC5 cultures and to 
establish the effects of IDG-SW3 conditioned medium in a more physiologically 
relevant model, the E15 metatarsal organ culture model was adopted. Similar to the 
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Figure 6.3 Characterisation of IDG-SW3 osteocyte-like cells 
Sirius red stain for collagen deposition indicated increased matrix formation at day 21 of 
culture in comparison to day 4 of culture (A). Alizarin red staining indicated increased 
matrix mineralisation at day 21 in comparison to day 4 of culture (B). qPCR analysis 
indicated that Mepe mRNA was significantly increased at day 21 of culture in comparison 
to day 4 (C) whereas there was no difference in Phex mRNA expression levels (D). Data 
are represented as mean ± S.E.M (n=3 replicates), ***P<0.001. 
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Figure 6.4 Sclerostin ELISA of IDG-SW3 cells 
Mouse sclerostin ELISA standard graph line (A) and ELISA analysis of mouse 
sclerostin concentration in the conditioned media of 4-day old and 21-day old IDG-
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Figure 6.5 Effects of IDG-SW3 conditioned media on ATDC5 matrix mineralisation 
20% conditioned media (CM) from day 4 and day 21 IDG-SW3 cells was added to mineralising 
ATDC5 cells for up to 30 days of culture. Alizarin red staining was conducted (A) and 
quantified (B) to evaluate matrix mineralisation at days 15, 20, 25 and 30 of culture. Data are 
represented as mean ± SEM (n=3 replicates) in comparison to control cultures *P<0.05. 
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ATDC5 cultures, these bones were cultured in the presence of 20% CM4 and CM21 
for up to 7 days. In comparison to control bones and CM4 treated bones, bones 
cultured with CM21 had a significantly decreased percentage change in total length 
from baseline at days 5 and 7 (Fig. 6.6A-D, P<0.001). Furthermore, the formation of 
the central mineralisation zone of these bones was noticeably inhibited as visualised 
under the microscope (Fig. 6.6A - C). The length of the mineralisation zone as a 
proportion of the total bone length (MZ/TL) in the CM21-treated bones was 
significantly different from control and CM4-treated bones at days 5 and 7 of culture 
(P<0.05, Fig. 6.6E).      
6.5.5 Co-culture of metatarsal bones and IDG-SW3 cells 
Whilst the culture of metatarsal bones in 20% IDG-SW3 conditioned media provides 
an indication of the potential cross talk between osteocytes and chondrocytes, the 
co-culture of these bones with the IDG-SW3 cells would allow for better 
examination of this as it more closely replicates the in vivo situation. Therefore a co-
culture system was conducted between IDG-SW3 cells and E15 metatarsal bones so 
that the two distinct cell populations could be cultured in close proximity in the 
same culture environment.  
 
Mineralisation of metatarsal bones was inhibited by co-culture with 21-day old IDG-
SW3 cells in comparison to control co-cultures and to IDG-SW3 cells at day 4 of 
culture (P<0.001 at days 3, 5, and 7 of culture, Fig. 6.7A, B, C, E). There were no 
differences in the total length of the bones except at day 3 at which point 21-day old 
IDG-SW3 co-cultures grew significantly more from baseline than the control 
counterparts (P<0.05, Fig. 6.7D). This therefore suggests that the IDG-SW3 cells are 
producing a mineralisation inhibitory factor at day 21 of culture that is not 
produced at day 4 of culture. The qPCR analysis of Mepe mRNA and the ELISA 
analysis of sclerostin in section 6.5.2 suggest that these could be the inhibitory 
factor, or as has been proposed in previous studies a combined effect of the two.   
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Figure 6.6 The inhibition of E15 metatarsal mineralisation by IDG-SW3 conditioned media  
Conditioned media (CM) from day 4 and day 21 IDG-SW3 cells was added to E15 metatarsal bones and cultured for up to 7 days.  A control 
metatarsal bone (with 20% IDG-SW3 day 0 medium) is illustrated in (A) and bones treated with continuous 20% CM4 (B) and CM21 (C) for 7 
days of culture. The growth rate of the embryonic metatarsal bones treated with 20% CM21 was significantly inhibited at days 5 and 7 of 
culture (D). There was no significant difference in the mineralisation zone as a percentage of the total length (MZ/TL) between control and 
CM4 treated bones, both of which increased over the culture period (A, B & E). However the mineralisation zone length in bones treated with 
20% CM21 was minimal and significantly different from control and CM4 cultures at days 5 and 7 of culture (C & E). Data are represented as 
mean ± SEM of at least six bones *P<0.05, ***P<0.001 in comparison to control bones at equivalent days of culture. 
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Figure 6.7 Inhibition of E15 metatarsal mineralisation upon co-culture with 21-day-old IDG-SW3 cells 
E15 metatarsals were co-cultured with IDG-SW3 cells at days 4 and 21 of culture for 7 days. A control metatarsal bone 
(cultured in the presence of no IDG-SW3 cells) is illustrated in (A) and bones co-cultured with day 4 IDG-SW3 cells (B) 
and day 21 IDG-SW3 cells (C) after 7 days in culture. The growth rate of the embryonic metatarsal bones co-cultured 
with day 4 cells was unchanged in comparison to control cultures; bones co-cultured with day 21 cells had a significant 
promotion of total length growth at day 3 of culture (D). There was no significant difference in the mineralisation zone as 
a percentage of the total length (MZ/TL) between control and day 4 IDG-SW3 cell co-cultures, both of which increased 
over the culture period. However the mineralisation zone length in bones co-cultured with day 21 IDG-SW3 cells was 
minimal and significantly different from control and day 4 cultures at days 3, 5 and 7 of culture (E). Data are represented 
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To examine whether this inhibition of mineralisation by day 21 IDG-SW3 cells is 
mediated by MEPE and its ASARM peptide, inhibitors of MEPE cleavage were 
added to the co-cultures. SPR4 is a PHEX peptide which binds to the ASARM 
peptide thus preventing its release (Martin et al. 2008). 20µM SPR4 was added to co-
cultures to prevent the ASARM inhibition of mineralisation shown in Chapter 5. 
There were no differences in the MZ/TL of bones treated with SPR4 and those 
treated with a DMSO-carrier (Fig, 6.8A). As such, the metatarsal bones co-cultured 
with 21-day old IDG-SW3 cells still showed a significant inhibition of 
mineralisation, despite treatment with SPR4, in comparison to control and IDG-SW3 
cells at day 4 of culture (Fig 6.8A, P<0.01). Furthermore CA074, a specific cathepsin 
B inhibitor, was added to co-cultures at a concentration of 20µM. Similar to SPR4, 
CA074 was unable to rescue the inhibition of mineralisation seen in the metatarsal 
bones co-cultured with IDG-SW3 cells at day 21 of culture (Fig. 6.8B, P<0.001). This 
inability of SPR4 and CA074 to rescue the mineralisation of the metatarsal bones co-
cultured with 21-day old IDG-SW3 cells therefore suggests that the inhibition of 
mineralisation seen is not due to a MEPE-ASARM mediated effect. 
 
Furthermore, and in support of a non MEPE mediated role, qPCR analysis of Mepe 
mRNA expression indicated no significant differences between metatarsals cultured 
as controls, with day 4 IDG-SW3 cell co-cultured bones and with day 21 IDG-SW3 
cell co-cultured bones (Fig. 6.9A). Nor were there any differences in Phex mRNA 
expression (Fig. 6.9B). However, interestingly metatarsal bones co-cultured with day 
21 IDG-SW3 cells showed a decreased mRNA expression of Dmp1 (P<0.01, Fig. 
6.9C).  
 
This therefore suggests that the inhibitory effects of the day 21 IDG-SW3 cells on 
chondrocyte matrix mineralisation are not due to the increased MEPE levels and 
instead suggests the direct involvement of the increased sclerostin expression levels, 
independent of a MEPE mechanism. 
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Figure 6.8 Addition of MEPE inhibitors to E15 metatarsal and IDG-SW3 co-cultures fails 
to rescue the inhibition of mineralisation seen  
E15 metatarsals were co-cultured with IDG-SW3 cells at days 4 and 21 of culture for 7 days and 
measurements of the mineralisation zone as a percentage of the total length (MZ/TL) made. (A) 
20µM SPR4 was added to co-cultures with a DMSO carrier as a control. There were no differences 
between SPR4 and DMSO treated bones and a significant inhibition of MZ/TL was observed in all 
bones co-cultured with day 21 IDG-SW3 cells.  (B) 20µM CA074 was added to co-cultures with a 
DMSO carrier as a control. There were no differences between CA074 and DMSO treated bones and 
a significant inhibition of MZ/TL was observed in all bones co-cultured with day 21 IDG-SW3 cells. 
Data are represented as mean ± SEM of at least six bones **P<0.01, ***P<0.001 in comparison to 
control bones at equivalent days of culture. 
A 
B 
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Figure 6.9 Gene expression in E15 metatarsal and IDG-SW3 co-cultures  
Analysis of mRNA expression in E15 metatarsals following co-culture with day 4 and day 21 
IDG-SW3 cells for 7 days (A) Mepe (B) Phex (C) Dmp1 Data are represented as mean ± SEM of 
3 groups of 4 pooled bones.  
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6.5.5 The effects of sclerostin on E15 metatarsal matrix mineralisation 
To further investigate the potential role for sclerostin on the inhibition of 
mineralisation seen, sclerostin neutralising antibodies were obtained under a MTA 
from Eli-Lilly and were added to E15 metatarsal bones and IDG-SW3 cell co-
cultures at varying concentrations to examine whether they could rescue the 
inhibition of metatarsal matrix mineralisation seen in the presence of the 21-day old 
cells. 
 
The maximum concentration of sclerostin present in the cell cultures was calculated 
from the ELISA results (Fig. 6.4) and then this was used to calculate the 
concentrations of antibodies used. The antibody affinity for mouse sclerostin is very 
high (personal communication, Stuart Kuhstoss, Eli Lilly) and therefore it effectively 
neutralises sclerostin on a molar basis. Furthermore, because the antibody has 2 
arms, one antibody molecule can block two sclerostin molecules. For these reasons, 
it was estimated that 0.02nM antibody would effectively neutralise the sclerostin in 
these co-cultures. However, whilst this concentration was based on a number of 
assumptions it has not been empirically derived and therefore to cover a range of 
sclerostin concentrations in conditioned medium and antibody binding affinities 
excess concentrations (0.2 and 2nM) were also used. 
 
Measurements of total length showed a significant difference between control and 
IDG-SW3 co-cultured bones at day 7 of culture, similar to that seen in Fig. 6.7D 
(P<005, Fig. 6.10A). However, the sclerostin neutralising antibodies had no effect on 
the total length of the bones in the control, day 4 IDG-SW3 and day 21 IDG-SW3 co-
cultures (Fig. 6.10B – D). Determination of the effects of the sclerostin antibodies on 
the mineralisation zone length of the metatarsal bones indicated no effects of the 
varying concentrations of antibodies on control and day 4 IDG-SW3 co-cultured 
metatarsal bones (Fig. 6.11A-C). The mineralisation zone length was significantly 
inhibited in all E15 metatarsal bones co-cultured with 21-day old IDG-SW3 cells as 
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Figure 6.10 The lack of effect of 0-2nm sclerostin neutralising antibodies on the 
total length of E15 metatarsals co-cultured with IDG-SW3 cells 
E15 metatarsals were co-cultured with IDG-SW3 cells at days 4 and 21 of culture for 7 days in 
the presence on varying concentrations of sclerostin neutralising antibodies (Ab) (0-2nM). As 
a control, metatarsal bones were cultured in IDG-SW3 media with no cells present. 
Measurements of the total length of the bones were made as a percentage of the baseline 
value (A). There was a significant difference in the total length of the control bones in 
comparison to the day 4 and day 21 IDG-SW3 cell co-cultured bones at day 7. When divided 
into separate graphs, there were no differences in the total lengths of the bones treated with 
the varying concentration of antibodies in control (B), day 4 IDG-SW3 (C) and day 21 IDG-
SW3 (D) co-cultures. Data are represented as mean ± SEM of six bones *P<0.05 in comparison 
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Figure 6.11 The lack of effect of 0-2nM sclerostin neutralising antibodies on the 
mineralisation capability of E15 metatarsals co-cultured with IDG-SW3 cells 
E15 metatarsals were co-cultured with IDG-SW3 cells at days 4 and 21 of culture for 7 days in 
the presence on varying concentrations of sclerostin neutralising antibodies (Ab) (0-2nM). As a 
control, metatarsal bones were cultured in IDG-SW3 media with no cells present. 
Measurements of the mineralisation zone (MZ) as a percentage of the total length (TL) of the 
bones were made as a percentage of the baseline value (A). When divided into separate 
graphs, there were no differences in the MZ/TL treated with the varying concentration of 
antibodies in control (B), day 4 IDG-SW3 (C) treated bones. However in the day 21 IDG-SW3 
co-cultures there appeared to be increased MZ/TL in the 2nM antibody treated cultures, 
although this did not reach statistical significance (D). Data are represented as mean ± SEM of 




Chapter 6                                                           Osteocyte regulation of endochondral ossification 
~ 171 ~ 
 
is in concordance with the data presented in Fig. 6.7E (Fig. 6.11A & D, Fig. 6.12). 
Whilst there appeared to be a moderate increase in mineralisation, indicating 
possible rescue from sclerostin inhibitory effects, in the metatarsal co-cultures 
treated with 2nM sclerostin antibodies, this was not significantly different from 
those treated with the lesser concentrations and without any antibodies (Fig. 6.11& 
6.12). 
 
This is possibly due to an underestimation of the concentration of antibody required 
to neutralise the sclerostin present in the cultures. To this end, the sclerostin 
production by the E15 metatarsal bones was examined by ELISA analysis. This 
showed the metatarsal bones to produce large amounts of sclerostin (<109pg/ml) at 
days 2, 5 and 7 days of culture (Fig. 6.13). This therefore warrants the future 
investigation of the effects of higher concentrations of sclerostin antibodies on 
metatarsal matrix mineralisation.   
 
Because of this slight trend towards a rescued inhibition of mineralisation in the 
sclerostin antibody treated bones, recombinant sclerostin was added to metatarsal 
cultures to further determine whether it is sclerostin which is mediating the 
inhibition seen. Interestingly the addition of varying concentrations of recombinant 
sclerostin (0-1000µM) to cultured metatarsals had no effect on the percentage 
change in the total length of the bone (Fig. 6.14C), or in the percentage change in the 
size of the mineralisation zone (Fig. 6.14A, B, D). 
6.6 Discussion 
Identification of the intercellular communications regulating endochondral 
ossification will provide new insights into potential therapeutic targets. Recent 
evidence suggests the osteocyte as playing a pivotal role in intercellular cross talk 
within the bone microenvironment (Klein-Nulend et al. 2003; Bonewald 2006; Xiong 
et al. 2011; Nakashima et al. 2011). Sclerostin is an osteocyte secretory product which 
accumulating evidence has implicated as a key regulator of bone formation, 
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Control 
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A 
B 
Figure 6.12 The effects of 2nM sclerostin antibodies on E15 metatarsal matrix 
mineralisation 
The percentage change in the mineralisation zone (MZ) as a percentage of the total length (TL) 
of E15 metatarsal bones cultured in the presence and absence of 2nM sclerostin neutralising 
antibodies (Ab) (A). Displayed are representative images of the metatarsal bones (B). Data are 
represented as mean ± SEM of six bones, *** P<0.001. 
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Figure 6.13 Expression of sclerostin by cultured E15 metatarsals by ELISA 
analysis  
ELISA analysis of mouse sclerostin concentrations in the conditioned medium of E15 
metatarsal bones cultured for up to 7 days. Data are represented as mean ± SEM of 
three bones. 
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Figure 6.14 The lack of effect of 0-1mM recombinant sclerostin on E15 metatarsal 
mineralisation 
E15 metatarsals were treated with varying concentrations of recSCL (0-1000µM) for 6 days. A 
control metatarsal bone is illustrated in (A) and a bone treated with 1000µM in (B) after 6 
days in culture. The growth rate of all the embryonic metatarsal bones was unchanged (C). 
Similarly there was no significant difference in the mineralisation zone as a percentage of the 
total length (MZ/TL) between control and recSCL treated bones (D). Data are represented as 
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however little is known about its target cell type, mechanism of action and precise 
function. Recently it has been shown that sclerostin inhibits osteoblast matrix 
mineralisation through a MEPE-dependent mechanism (Atkins et al. 2011). It has yet 
to be established whether sclerostin could have a similar function in chondrocyte 
matrix mineralisation through either a local or paracrine mechanism. 
 
Current data regarding the expression of sclerostin by chondrocytes is somewhat 
limited and conflicting. In the growth plate, sclerostin has been reported in the 
mineralising hypertrophic chondrocytes by immunohistochemistry (Winkler et al. 
2003; van Bezooijen et al. 2009). However, analysis of Sost mRNA in the developing 
long bones showed no expression in the cartilaginous primordium except for in the 
perichondrium of the hypertrophic chondrocyte region. Sclerostin was also absent 
from the skull and rib cartilaginous tissue (Kusu et al. 2003). Similarly, here 
immunohistochemical staining failed to detect sclerostin protein in the growth 
plates of 4-week-old murine tibias. However, interestingly, PCR analysis did 
indicate Sost mRNA in costochondral primary chondrocytes cultures after 3 days 
(Fig. 6.1).  This could likely be due to developmental differences, the differing 
populations of cells examined, or due to the sensitivity of the techniques used. 
 
Despite this potential lack of local chondrocyte sclerostin expression the osteocytes 
of tibial cortical bone stained positive for sclerostin expression, as would be 
expected. The morphology of the osteocyte is suggestive of a role in 
mechanosensation and due to its reported crosstalk with other bone cell types 
including other osteocytes, osteoblasts and osteoclasts (Klein-Nulend et al. 2003; 
Bonewald 2006; Xiong et al. 2011; Nakashima et al. 2011). Here it was hypothesised 
that the osteocyte may have a functional role in the regulation of chondrocyte 
matrix mineralisation. The use of osteocytes for in vitro studies has been somewhat 
limited due to their location deep within the mineralised matrix and the resultant 
difficulty in isolating purified populations. The IDG-SW3 osteocyte-like cells, an 
immortomouse/Dmp1-GFP–derived bone cell line, have recently been characterised 
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and replicate the normal in vivo differentiation process, representing a late osteocyte 
cell phenotype after 21 days in culture (Woo et al. 2011). This is in comparison to the 
widely used MLO-Y4 and MLO-A5 cell lines both of which express early osteocyte 
markers such as E11/gp38 (Kato et al. 1997; Kato et al. 2001; Prideaux et al. 2012). 
Unlike these two well established cell lines, the IDG-SW3 cells express high levels of 
sclerostin, as has been shown here and as was originally characterised (Fig. 6.3) 
(Woo et al. 2011).  
 
The role of sclerostin in osteoblast matrix mineralisation is well documented. An 
increase in sclerostin expression in mineralising cultures has been reported, and 
whilst PTH treatment and mechanical loading suppress this expression and 
promote bone formation, the pro-inflammatory cytokines tumour necrosis factor 
(TNF)-α and TNF-related weak inducer of apoptosis induce it (Sutherland et al. 
2004; Ohyama et al. 2004; Poole et al. 2005; Silvestrini et al. 2007; Irie et al. 2008; 
Robling et al. 2008; Vincent et al. 2009; Atkins et al. 2009). This implicates sclerostin in 
diseases such as rheumatoid arthritis in which it is known that TNF-α plays a 
critical role (Franchimont et al. 1988). Indeed anti-TNF-α therapy has revolutionised 
treatment for rheumatoid arthritis (Tanaka 2012). It was hypothesised that the high 
IDG-SW3 osteocyte production of sclerostin has an inhibitory role in chondrocyte 
matrix mineralisation, and the results presented certainly suggest this with 
conditioned media and co-cultures of IDG-SW3 cells inhibiting the mineralisation 
capability of E15 murine metatarsals (Figs. 6.6 & 6.7).  
 
The problems associated with using conditioned media should certainly be 
considered. As the media is taken from cells which have been cultured for long 
periods of time, it is likely that it contains large amounts of ATP which has 
previously been shown to be a potent inhibitor of osteoblast and chondrocyte matrix 
mineralisation directly and through the acidification of the culture medium (Hatori 
et al. 1995; Brandao-Burch et al. 2005; Orriss et al. 2007). However, the inhibition of 
mineralisation was not observed in cultures using 4-day old IDG-SW3 cells. Whilst 
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it is possible that there are differences in ATP production between the two time 
points, these are currently undocumented and likely to be minimal. Furthermore, it 
is entirely possible that the pH of the media is different and may be tending towards 
the lower end of the pH scale. This has previously been shown to inhibit osteoblast 
matrix mineralisation in vitro and as such, should be considered upon interpretation 
of the results presented here (Brandao-Burch et al. 2005). 
 
Another potential explanation for the inhibition of matrix mineralisation seen upon 
co-culture with the day 21 IDG-SW3 cells is that these cells produce significantly 
more MEPE in comparison to day 4 IDG-SW3 cells. As has been shown in this thesis 
thus far, MEPE inhibits chondrocyte matrix mineralisation through its ASARM 
peptide (Chapter 5) (Staines et al. 2012c). CA074 is a cathepsin B inhibitor which can 
correct the mineralisation defect seen in Hyp mice due to its inhibition of MEPE 
cleavage by cathepsin B (Murata et al. 1991; Rowe et al. 2006). Similarly, SPR4 is a 
single PHEX peptide (4.2 kDa) that was found to bind to the pASARM peptide and 
inhibit the pASARM mediated inhibition of osteoblast matrix mineralisation (Martin 
et al. 2008). The addition of these specific inhibitors of MEPE function to the co-
cultures was unable to rescue the inhibition of mineralisation seen (Fig. 6.8). This 
therefore suggests that the effects on chondrocyte matrix mineralisation seen are not 
due to MEPE expression. This is inconsistent with the recent publication detailing 
the interaction of sclerostin with MEPE in mineralising osteoblast cultures (Atkins et 
al. 2011). The reasons for this are unclear however it could be due to the differential 
regulation of sclerostin in differing cell types.  
 
To confirm the role of sclerostin in the inhibition of mineralisation seen, antibodies 
which inhibit the biological activity of sclerostin were used (Eli-Lilly). These are 
currently an attractive therapeutic approach for stimulating bone formation; a 
strategy that has already been successful with Denosumab, an antibody against 
RANKL (Cummings et al. 2009). Sclerostin antibodies increase bone mineral density, 
bone volume and bone strength in ovariectomised rats and primates. They are also 
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effective in fracture healing (Li et al. 2009; Ominsky et al. 2010; Agholme et al. 2010). 
More recently, a study in post-menopausal women showed that a single injection of 
the sclerostin antibody significantly increased bone mineral density as well as 
markers of bone formation such as bone-specific ALP and osteocalcin expression 
(Padhi et al. 2011).  
 
These antibodies were utilised here to examine the hypothesis that the inhibition of 
metatarsal matrix mineralisation seen is dependent upon sclerostin production.  
Administration of increasing concentrations of sclerostin antibodies failed to rescue 
the inhibition seen, however there did appear to be a marginal increase in matrix 
mineralisation by day 7 of culture which warrants their further investigation using 
higher concentrations of antibodies (Fig. 6.12). Moreover, the high production of 
sclerostin expression by E15 metatarsal bones presented here further suggests that 
higher concentrations of antibodies may be required to elicit a response (Fig. 6.13).  
 
Whether the source of this sclerostin production is the chondrocytes of the 
metatarsal bones is unknown. It is entirely plausible that the perichondrium could 
be synthesising these high levels of sclerostin concentration, as has been shown in a 
previous study (Kusu et al. 2003). Certainly the perichondrium is known to produce 
essential factors that act to regulate endochondral bone growth and this could be the 
case here (Haaijman et al. 1999; Alvarez et al. 2001). Future investigations could 
examine the production of sclerostin in metatarsal bones cultured with the 
perichondrium removed. It is also interesting to note that the sclerostin production 
in these metatarsal bones remained fairly consistent throughout the culture period.  
 
Interestingly, the inhibitory effects of sclerostin on metatarsal mineralisation were 
non-existent in metatarsal organ cultures treated with recombinant sclerostin (Fig. 
6.14). This could be explained by a potential difference between the in vivo 
concentration of sclerostin produced by the osteocytes, and with those tested in this 
experiment. However the results presented here from the sclerostin ELISA placed 
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the concentrations of sclerostin from the IDG-SW3 cells in the pica-molar range 
whereas recombinant sclerostin was added in the micro-molar range, therefore 
suggesting that this is not the case. Instead it is entirely possible that the 
recombinant sclerostin could non-specifically bind to the cell surface through its 
heparan sulfate proteoglycan binding domain and therefore be inactive (Stuart 
Kuhstoss, Eli Lilly, personal communications). To examine this further, the use of 
such compounds as dextran sodium sulphate would allow release of recombinant 
sclerostin from the cell surface and would hopefully allow it to function as seen in 
vivo. Furthermore it is possible that there are differences in the biological activity of 
recombinant proteins depending upon their source. Therefore the lack of response 
to recombinant sclerostin, here purchased from R&D systems, could be due to 
dubious biological activity and the sclerostin produced by the IDG-SW3 cells is in 
fact more efficacious. Whilst there is currently no evidence to suggest such 
problems, this is certainly something that should be considered in the interpretation 
of these results.  
 
The mechanism by which sclerostin functions to inhibit matrix mineralisation is 
unclear. It is well established that sclerostin specifically binds to the LRP5/6 Wnt 
coreceptors antagonising the Wnt pathway (Semenov et al. 2005). This has 
significant effects on both chondrogenesis and chondrocyte hypertrophy (Staines et 
al. 2012a). It would certainly be worth investigating whether sclerostin is inhibiting 
Wnt signalling in the metatarsal bones and whether this alters the histology of the 
chondrocytes within the bones.  
 
Whilst the co-culture of E15 metatarsals and IDG-SW3 cells had no effect on Mepe or 
Phex mRNA expression, interestingly it significantly inhibited the expression of 
Dmp1 mRNA (Fig. 6.9). This is in concordance with a previous study in which the 
addition of recombinant sclerostin decreased Dmp1 mRNA expression in 
mineralising osteoblasts (Atkins et al. 2011). In bone, DMP1 is primarily expressed 
by osteocytes but also by osteoblasts and hypertrophic chondrocytes (Toyosawa et 
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al. 2001; Fen et al. 2002; Feng et al. 2003). Whilst, like the other SIBLING proteins, 
DMP1 has an ASARM motif which is thought to inhibit matrix mineralisation, it has 
also a well described role as a hydroxyapatite nucleator (Narayanan et al. 2001; 
Martin et al. 2008; Staines et al. 2012b). The DMP1 deficient mouse displays a highly 
widened growth plate suggesting an impairment of mineralisation at the chondro-
osseous junction (Ye et al. 2005). It is therefore plausible that sclerostin may function 
through diminishing the activity of DMP1. Furthermore, although not investigated 
here, it is likely that sclerostin regulates the other members of the SIBLING family of 
proteins and this should be investigated in future studies.  
 
In conclusion, these studies detail the potential for cross-talk between the osteocytes 
of the cortical bone and the adjacent growth plate chondrocytes through the 
expression of the Wnt signalling antagonist sclerostin. Contradictory to previous 
studies, it was found that the inhibitory effects of sclerostin on chondrocyte matrix 
mineralisation are independent of MEPE expression.  
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7.1 General discussion 
Biomineralisation of the growth plate is a key process allowing effective 
longitudinal bone growth. It is therefore imperative that we unravel the precise 
mechanisms controlling this complex process to prevent clinical disorders of bone 
development. Recent advances in this field have identified a group of NCPs and 
based upon the hypothesis that they are key regulators of matrix mineralisation the 
focus of these studies was on one such NCP, namely MEPE, and its functional role 
in maintaining the fine balance of mineral formation at the growth plate.  
 
The absence of a practical and accessible in vitro chondrocyte mineralisation model 
has hindered a fuller appreciation of how cartilage mineralisation and endochondral 
ossification are disrupted by factors such as cytokines and drugs that are 
responsible for impaired linear bone growth in children. It is well recognised that 
primary chondrocyte cells undergo de-differentiation, as was reported here, and as 
such, a mineralising method for the chondrogenic ATDC5 cell line was 
characterised (Lefebvre et al. 1994; Hering et al. 1994). The work presented in 
Chapter 3 showed that under the conditions defined these ATDC5 cells undergo the 
expected stages of chondrogenic differentiation and produce a physiologic 
mineralised matrix after 15 days in culture. This method will enable future research 
into chondrocyte matrix mineralisation in the context of both endochondral bone 
growth, and in the in vitro examination of pathological chondrocyte hypertrophy 
and matrix mineralisation seen in such diseases as osteoarthritis (Kirsch et al. 2000; 
Johnson & Terkeltaub 2004). It will also help us understand better the underpinning 
molecular mechanisms responsible for poor linear bone growth which is observed 
in a number of chronic diseases such as cystic fibrosis, chronic kidney disease, 
rheumatological conditions and inflammatory bowel disease. Despite this it is well 
recognised that as with all in vitro systems, problems still remain. It is difficult to 
achieve precise replication of the cells normal environment and thus to this end, the 
metatarsal organ culture system was also adopted. 
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The embryonic metatarsal organ culture provides an idea model as it provides 
conditions closer to the in vivo situation as the chondrocytes within the bones exist 
in the three principal stages of chondrogenesis whilst retaining their direct 
interactions with each other and their matrix. This allows the metatarsal bones to be 
cultured devoid of serum, therefore removing a potential confounding variable. 
This ex vivo culture system is widely used within chondrocyte research and here 
was developed to allow assessment of matrix mineralisation, and the potential role 
that MEPE may play.  
 
It was important before such role could be defined, to establish the spatial 
expression of MEPE in the growth plate. The localisation patterns presented in 
Chapter 4 serve to strengthen its potential role in this phenomenon. Specifically, 
MEPE was preferentially expressed by the hypertrophic chondrocytes as is in 
concordance with a previous microarray study and as is observed in the MEPE 
overexpressing mouse (David et al. 2009; Horvat-Gordon et al. 2010). Moreover, the 
data presented here localised a 2.2kDa cleavage product of MEPE, the ASARM 
peptide, to sites of ossification. This is similar to another SIBLING family member, 
DMP1, which is processed into two fragments, the COOH-terminal fragment of 
which contains the ASARM peptide and in the growth plate, is localised to the 
calcification front and ossification zone (Martin et al. 2008; Maciejewska et al. 2008). 
This suggests a co-localisation of the DMP1 and MEPE ASARM peptides, 
potentiating their effects.  
 
Whilst these effects have been established in osteoblast matrix mineralisation, this 
thesis presents for the first time the precise role of the ASARM peptide in the 
growth plate. Specifically MEPE was shown to have an inhibitory role on 
chondrocyte matrix mineralisation dependent upon its cleavage and 
phosphorylation of the ASARM peptide. Despite this it was suggested that the 
MEPE-ASARM peptide has no effect on chondrocyte function per se and instead 
affects the process of mineralisation directly, as is in concordance with previous 
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studies examining osteoblast matrix mineralisation (Addison et al. 2008; Martin et al. 
2008). The critical activity of the ASARM peptide is evidenced by the ASARM 
hypothesis proposed by Peter Rowe which describes the role of the SIBLING 
ASARM peptides, PHEX, and FGF23 in bone renal Pi homeostasis as well as in 
matrix mineralisation both at the osteoblast, and now at the chondrocyte level 
(Rowe 2004; David et al. 2010).  
 
This inhibitory effect of the MEPE ASARM peptide has been shown here to be 
further potentiated by a positive feedback loop induced by ASARM peptides. The 
data presented here suggests that the pASARM peptide enhances MEPE expression, 
whilst negatively regulating the expression of PHEX, a known inhibitor of MEPE 
functional activity (Liu et al. 2007a; Addison et al. 2008; Martin et al. 2008). This 
observation is consistent a previous study in which osteoblast cell cultures treated 
with pASARM peptide displayed decreased PHEX expression (Martin et al. 2008). 
Because of this, it is reasonable to speculate that physiologically there must be a 
regulatory mechanism to ensure that there is not an overproduction of ASARM 
peptides and as such a pathological state. Although the precise nature of the counter 
balancing mechanism has yet to be elucidated, it is plausible to suggest that one of 
the other SIBLING family members is responsible due to their similar structural 
features and yet differing functions (Staines et al. 2012b). When this postulated 
regulatory mechanism does dysfunction, the resulting pathology would be 
characterised by increased MEPE expression and an abundance of ASARM 
peptides.  
 
Certainly in patients with XLH and in the Hyp mouse model of this hereditary 
hypophosphatemic disease, an increased expression of ASARM peptides is 
observed (Rowe et al. 2000; Argiro et al. 2001; Rowe et al. 2004; Bresler et al. 2004; Liu 
et al. 2007a). Caused by an inactivating mutation in the Phex gene, patients with 
XLH display defective bone and tooth mineralisation, growth retardation, and 
defective renal re-absorption of Pi (Carpenter et al. 2011). Moreover, analysis of the 
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Hyp mouse growth plate indicates severe morphological disruption (Liu et al. 2006). 
The data presented in this thesis certainly indicates a critical role for MEPE and its 
ASARM peptide in this disorder. Furthermore, the MEPE positive feedback loop 
described acts to exacerbate the condition. It is plausible to suggest that the 
administration of a PHEX peptide or of cathepsin inhibitors may provide some 
therapeutic intervention in patients with XLH as these would inhibit the cleavage of 
MEPE to the ASARM peptide. Certainly this seems viable as their administration to 
the Hyp mouse has been shown to correct the mineralisation defect seen (Rowe et al. 
2006).  
 
It is evident that much remains to be learnt regarding the in vivo role of the SIBLING 
proteins and the ASARM peptide in bone diseases. This is not just in disorders 
related to Pi homeostasis, but to other bone diseases such as osteoporosis and 
osteoarthritis. Indeed there are close links between the SIBLING proteins and 
osteoarthritis with microarray data and gene analysis studies highlighting MEPE 
and DMP1 as being differentially expressed in osteoarthritic tissues (Hopwood et al. 
2007; Sanchez et al. 2008). Furthermore serum BSP and OPN levels significantly 
correlate with osteoarthritic disease severity (Petersson et al. 1998; Hasegawa et al. 
2011). There is increasing evidence for a role for developmental processes in the 
pathology of osteoarthritis and this highlights the importance of the work presented 
in this thesis (Pitsillides & Beier 2011).  
 
Osteoporosis is a pervasive public health issue worldwide and recent genetic 
studies have highlighted MEPE as a gene of interest associated with risk of fracture 
(Estrada et al. 2012). The process of fracture healing is highly complex and involves 
a well-orchestrated series of biological events. The results here further implicate 
MEPE in endochondral fracture healing. Indeed MEPE expression has also been 
observed in both the early stages of non-stabilised tibia fracture repair and during 
fracture healing (Lu et al. 2004). 
 
Chapter 7                                                                                                                     Final Discussion 
~ 186 ~ 
 
It is also interesting to note that recent seminal and exciting discoveries have 
described the skeleton as a dynamic endocrine organ that plays a critical role in the 
regulation of energy metabolism and fat mass (Confavreux et al. 2009). Concomitant 
with this, there is exciting new data that implicates the ASARM hypothesis as a key 
orchestrator in the evidenced cross talk between the skeleton and energy 
metabolism (David et al. 2009; David et al. 2010).  
 
The Wnt signalling pathway is emerging as a potent regulator of cellular 
development and function in a variety of tissues (Macsai et al. 2008; Macsai et al. 
2012). Post-natally, Wnt signalling is crucial for the regulation of skeletal bone mass 
throughout life and over the past two decades, studies have identified the Wnt 
signalling pathway as having a crucial role in growth plate biology, bone formation 
and skeletal remodelling (Krishnan et al. 2006b; Staines et al. 2012a). Of the Wnt 
signalling inhibitors identified, sclerostin is proving the most interesting from a 
therapeutic standpoint. Clinical trials are currently underway for an antibody which 
neutralises sclerostin activity, a potent Wnt signalling antagonist, in an attempt to 
stimulate bone formation in osteoporotic patients. This strategy has already proved 
successful in targeting osteoporosis with Denosumab, an antibody against RANKL 
(Cummings et al. 2009). The results certainly look promising with sclerostin 
antibodies increasing bone formation in ovariectomized rats and primates, and in 
post-menopausal women subjected to a single injection of the antibody (Li et al. 
2009; Ominsky et al. 2010; Agholme et al. 2010; Padhi et al. 2011). 
 
The recently described interaction between MEPE and sclerostin is an exciting 
development in the field of biomineralisation due to the known anabolic effects of 
the sclerostin-neutralising antibodies on osteoporosis (Li et al. 2009; Li et al. 2010; 
Atkins et al. 2011). This could therefore warrant investigation into the potential 
therapeutic use of MEPE in osteoporosis and potentially in osteoarthritis due to the 
ever emerging role of sclerostin in this debilitating disease (Power et al. 2010; Chan 
et al. 2011; gado-Calle et al. 2011).  
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Although unable to determine a local production of sclerostin by growth plate 
chondrocytes, the work presented in Chapter 6 details the potential for cross-talk 
between osteocytes and chondrocytes in the regulation of chondrocyte matrix 
mineralisation. This is in concordance with another study which utilised a 
computational model to detail the regulation of mineralised cartilage turnover by 
adjacent osteocytes (Cox et al. 2011). Indeed the osteocyte is certainly suited to this 
function as structurally it has extensive processes which, through gap junction 
connections, form an extensive syncytium with other osteocytes and osteoblasts 
(Klein-Nulend et al. 2003; Bonewald 2006). The recent discovery that osteocytes have 
a greater capacity to support osteoclastogenesis than osteoblasts due to their high 
expression of RANKL highlights their complex and crucial role in the bone 
microenvironment (Nakashima et al. 2011; Xiong et al. 2011). sclerostin, along with 
nitric oxide and prostaglandins, has been suggested as the mediator of the osteocyte 
mechano-response (van Bezooijen et al. 2004; Bonewald 2006). The data presented 
here, although it cannot confirm conclusively a role for sclerostin, it does suggest a 
potential function for it in the regulation of endochondral bone growth. 
 
In conclusion, this thesis has identified a critical inhibitory role for MEPE and its 
ASARM peptide in regulating the fine balance of effective mineral formation at the 
growth plate (Table. 7.1). Moreover, mechanisms which may exist to exacerbate the 
expression of MEPE have been identified. Whilst the studies presented here 
complement previous findings of MEPE and its role in biomineralisation, it also 
highlights the multiple and complex functions of the SIBLING ASARM peptides in 
both Pi homeostasis and matrix mineralisation in disease and health. It is therefore 
vital that we endeavour to fully establish the interactions within this hypothesis to 
allow future therapeutic developments.  
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Table 7.1 The functional role of MEPE in biomineralisation 
The functional role of MEPE in biomineralisation as is dependent upon its cleavage and post translational modification. Detailed is (i) the cellular 
expression pattern (ii) the phenotype of the knockout mouse (iii) the phenotype of the transgenic mouse (iv) clinical conditions association with mutation 
in this gene (v) cleavage products and post translational modifications (vi) known role of each cleavage product in ECM mineralisation (vii) list of 
relevant references (adapted from (Staines et al. 2012b)). 
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7.2 Directions for future research 
The results presented in this thesis have identified a critical role for MEPE in 
regulating chondrocyte matrix mineralisation. They have pinpointed this functional 
role to be dependent upon the phosphorylation and cleavage of the ASARM 
peptide, and have investigated the potential interaction of MEPE with the already 
known mineralisation inhibitor, sclerostin. However, further work is necessary to 
fully elucidate the mechanism by which MEPE exerts its function in endochondral 
ossification and its regulation in the physiological context.  
 
Certainly the examination of the growth plates of the MEPE knockout and 
overexpressing mice would be of great benefit in furthering our understanding of 
the role of MEPE in endochondral ossification. Both these mice have been generated 
but were unattainable in this PhD. Whilst the growth plates of MEPE 
overexpressing mice display considerable widening, the precise histomorphometric 
phenotype of the growth plate has not been examined. This has also not been 
examined in the MEPE knockout mouse. Due to the known role of MEPE in 
regulating Pi homeostasis, what would be of greater benefit would be a cartilage 
specific deletion of MEPE using the Cre recombinase-LoxP system.  
  
These mice could also be used to better examine the role of MEPE-ASARM peptides 
on angiogenesis. Here it was reported that the pASARM peptide inhibited 
endothelial cell specific markers, and therefore it would be interesting to examine 
the direct effects of the pASARM peptide on endothelial cell function. Access to the 
aforementioned mouse models would allow further examination of this. 
Concomitant with this, MMP mRNA profiling would be useful in identifying 
whether the MEPE-ASARM interacts with any other MMPs in addition to MMP13.   
 
In this thesis, a feedback system was reported by which the ASARM peptide 
prevented PHEX expression allowing their further release and thereby increasing 
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the inhibition of matrix mineralisation. However it is likely that in vivo there is a 
physiological mechanism regulating this to ensure that there is not an increased 
expression of ASARM peptides. Similarly there must be a regulatory mechanism 
controlling ASARM-phosphorylation as its function is dependent upon this 
phosphorylation. It is plausible that the other SIBLING proteins may be acting to 
regulate this and it would be interesting to examine the interactions of MEPE with 
the other SIBLING proteins, and their place within the current ASARM hypothesis 
(section 1.7.3). This will allow the investigation into their potential therapeutic 
application to disorders of mineralisation including disorders of 
hypophosphatemia, osteoporosis and osteoarthritis. 
 
Canonical Wnt signalling is a potent regulator of cartilage development and 
function and it has recently been suggested that it can enhance MEPE expression in 
osteoblasts through, somewhat confusingly, either the Wnt ligand Wnt3a or by the 
Wnt inhibitor, sclerostin (Cho et al. 2011; Atkins et al. 2011; Staines et al. 2012a). 
Attempts were made here to examine the potential interaction of MEPE and 
sclerostin in the growth plate and these were unfortunately proved as non-existent. 
However it would certainly be interesting to elucidate the precise regulation of 
MEPE expression by the Wnt signalling pathway in the growth plate, and establish 
this as a therapeutic approach to disorders of bone and cartilage mineralisation. The 
work in this thesis also identified the potential for cross-talk between chondrocytes 
and osteocytes. The proteins released by the osteocyte, including sclerostin, are 
therefore of great interest in determining the precise mechanisms and signalling 
pathways surrounding the apparent complex conversation between osteocytes and 
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Cell culture buffers  
ATDC5 Maintenance medium  
DMEM/F-12 (1:1) with GlutaMAX I, supplemented with 5% foetal bovine serum 
(FBS), 3x10-8M sodium selenite, 10μg/ml human transferring, 1mM sodium 
pyruvate, and 0.05mg/ml gentamicin  
 
ATDC5 Differentiation medium 
DMEM/F-12 (1:1) with GlutaMAX I containing 5% FBS, 1X insulin transferrin 
selenium (ITS), 1mM sodium pyruvate and 0.05mg/ml gentamicin 
 
Freezing mix 
60% DMEM/F-12; 20% FBS; 20% DMSO 
 
Primary chondrocyte medium  
DMEM; 4.5g/L glucose and L-Glutamine containing 5% FBS and 0.05% gentamicin 
 
IWG-SW3 cell medium 
α-MEM with 0.1% gentamicin and 10% FBS 
 
HEK293T medium 
DMEM-glutamax with 10% FCS and 1X Non-essential amino acids 
In vivo studies 
Metatarsal preparation medium  
0.8ml αMEM medium (without ribonucleosides), 10.45ml sterile PBS, 22.5mg BSA 
(Fraction V)  
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Metatarsal medium 
αMEM medium (without ribonucleosides) supplemented with 0.2% BSA (Fraction 
V); 5μg/ml L-ascorbic acid phosphate; 1mM βGP; 0.05mg/ml gentamicin; 1.25μg/ml 
fungizone 
In situ hybridisation 
TE buffer 
10mM Tris-Cl; and 1mMS EDTA, pH 7–8 
 
TNE buffer 
0.5M NaCl, 0.1M Tris/Cl, pH 7.4 0.2M EDTA 
 
LB media  
1% bacto-tryptone, 0.5% bacto-yeast extract, 150mM NaCl, adjusted to pH 7.5 
 
LB agar  
LB supplemented with 1.5% bactoagar 
 
TAE  
40mM Tris, 1mM EDTA, 0.1 % acetic acid 
Qiagen kit buffer compositions  
Maxiprep re-suspension buffer P1 
50 mM Tris-HCl, pH 8.0; 10 mM EDTA; 100 μg/ml RNase A  
 
Maxiprep bacterial lysis buffer P2 
200 mM NaOH, 1% SDS  
 
Maxiprep elution buffer EB 
10 mM Tris-HCl, pH 8.5  
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Maxiprep neutralisation buffer P3 
3M potassium acetate, pH 5.5  
 
Maxiprep equilibration buffer QBT  
750 mM NaCl; 50 mM 3-[N-morpholino] propanesulfonic acid (MOPS), pH 7.0; 15% 
isopropanol (v/v); 0.15% Triton X-100 (v/v) 
 
 Maxiprep column wash buffer QC 
1M NaCl, 50mM MOPS pH7.0, 15% isopropanol (v/v) and 0.15% Triton X-100 (v/v)  
 
Maxiprep elution buffer QN  
1.6 M NaCl, 50 mM MOPS, pH 7.0, 15 % isopropanol (v/v)  
 
DNA re-suspension buffer TE  
10 mM Tris HCl, pH 8.0, 1 mM EDTA 
Immunohistochemistry 
10mM Citric acid buffer 
1.92g citric acid / L dH2O at pH 3.0 
 Viral Transductions 
Cell Culture medium 
DMEM-Glutamax, 10% Foetal calf serum (FCS), 1X NEAA 
 
TSSM 
To make up 1L add 4.84g Trizma base, 11.8g NaCl, 20g sucrose and 20g D-mannitol 
to 1L sterile H20, pH to 7.4 and filter 
Western Blotting  
RIPA buffer 
20mM Tris-HCl (pH8), 135mM NaCl, 10% Glycerol, 1% IGEPAL, 0.1% SDS, 0.5% Na 
Deoxycholate, 2mM EDTA  
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LDS Sample reducing agent  
40% glycerol, 4% LDS, 4% Ficoll*-400, 0.8 M triethanolamine-Cl pH 7.6, 0.025% 
phenol red, 0.025% coomassie G250, 2mM EDTA disodium 
 
1X Transfer buffer 
100ml 10X transfer buffer, 200ml 98% Ethanol, 700ml dH2O.  
 
10X Transfer buffer 




Tris-buffered saline/Tween-20 consisting of 50mM Tris-HCl, 300mM NaCl, 0.1% 
Tween-20 
 
MOPS running buffer  









Appendix II                              Primer sequences 
Appendix II 
Gene Source   Sequence (5'-3') 
Mepe Primer Design 
F AGAAATATCACGCAGCCTGTAA 
R GGAGACTTTAGCATCATTGACATC 
Phex Primer Design 
F CTAACCACCCACTCCCACTT 
R CCAATAGACTCCAAACCTGAAGA 
Alpl Primer Design 
F GGGACGAATCTCAGGGTACA 
R AGTAACTGGGGTCTCTCTCTTT 
Phospho1 Primer Design 
F TTCTCATTTCGGATGCCAACA 
R TGAGGATGCGGCGGAATAA 
Ank Primer Design 
F GATGCCACTAGAGCGAGAAG 
R TCAGAAGTTACGAGACAAGACC 
Enpp1 Primer Design 
F GCTAATCATCAGGAGGTCAAG 
R GCTAATCATCAGGAGGTCAAG 
Mmp13 Primer Design 
F CCAACCCTAAGCATCCCAAA 
R TCCTCGGAGACTGGTAATGG 
Ihh Primer Design 
F TTCTTCACACGCATTCCATCT 
R GCCAACAGTAAAGTCACAATCC 
PthIh Primer Design 
F CGGTTTGGGTCAGACGATG 
R GCTTGCCTTTCTTCTTCTTC 
Atf3 Primer Design 
F ACTGGTATTTGAGGATTTTGCTAAC 
R TGTTGTTGACGGTAACTGACTC 
Dmp1 Primer Design 
F ATACCACAATACTGAATCTGAAAGC 
R CACTATTTGCCTGTCCCTCTG 
Cd31 Dr Claire Clarkin 
F GAGCCCAATCACGTTTCAGTT 
R TCCTTCCTGCTTCTTGCTAGC 
Cd34 Dr Claire Clarkin 
F GTTACCTCTGGGATCCCTTCA 
R GAATAACGTAACCAGTGGAGA 
Flk-1 Dr Claire Clarkin 
F TCTGTGGTTCTGCGTGGAGA 
R GTATCATTTCCAACCAACCCT 
VEGF Dr Claire Clarkin 
F GAAGTCCCATGAAGTGATCCAG 
R TCACCGCCTTGGCTTGTCA 
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F Not available 
R Not available 
Col2a1 MWG Eurofins 
F GTAACCCGTTGAACCCCATT 
R CCATCCAATCGGTAGTAGCG 
Col10a1 MWG Eurofins 
F CATAAAGGGCCCACTTGCTA 
R CAGGAATGCCTTGTTCTCCT 
18S MWG Eurofins 
F CGGTCCTACGGTGTCAGG 
R GCAGAGGACATTCCCAGTGT 
Appendix III           Antibodies 















MEPE Sheep R&D Western Blotting 1:200 
Cathepsin B Goat R&D Immunohistochemistry 1:50 
Sclerostin Goat R&D Immunohistochemistry 1:100 
β-actin (HRP-
linked) 
Mouse Sigma Western Blotting 1:50000 
 
Secondary antibodies  
Antibody Source Use Dilution 
Rabbit anti-goat Dako 
Western 
Blotting 
1 in 5000 
Goat anti-rabbit Dako 
Western 
Blotting 
1 in 5000 
Donkey anti-sheep  Abcam 
Western 
Blotting 
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Abstract. The development of chondrogenic cell lines has led 
to major advances in the understanding of how chondrocyte 
differentiation is regulated, and has uncovered many signal-
ling pathways and gene regulatory mechanisms required to 
maintain normal function. ATdc5 cells are a well established 
in vitro model of endochondral ossification; however, current 
methods are limited for mineralisation studies. In this study 
we demonstrate that culturing cells in the presence of ascorbic 
acid and 10 mM β-glycerophosphate (βGP) significantly 
increases the rate of extracellular matrix (EcM) synthesis 
and reduces the time required for mineral deposition to occur 
to 15 days of culture. Furthermore, the specific expression 
patterns of Col2a1 and Col10a1 are indicative of ATdc5 
chondrogenic differentiation. Fourier transform-infrared 
spectroscopy analysis and transmission electron microscopy 
(TEM) showed that the mineral formed by ATdc5 cultures 
is similar to physiological hydroxyapatite. Additionally, we 
demonstrated that in cultures with βGP, the presence of 
alkaline phosphatase (ALP) is required for this mineralisation 
to occur, further indicating that chondrogenic differentiation 
is required for EcM mineralisation. Together, these results 
demonstrate that when cultured in the presence of ascorbic 
acid and 10 mM βGP, ATdc5 cells undergo chondrogenic 
differentiation and produce a physiological mineralised EcM 
from day 15 of culture onwards. The rapid and novel method 
for ATdc5 culture described in this study is a major improve-
ment compared with currently published methods and this 
will prove vital in the pursuit of underpinning the molecular 
mechanisms responsible for poor linear bone growth observed 
in a number of chronic diseases such as cystic fibrosis, chronic 
kidney disease, rheumatological conditions and inflammatory 
bowel disease.
Introduction
The growth plate and its primary cell type, the chondrocyte, 
are integral to endochondral ossification and thus the linear 
growth of the long bones (1). The continuing development 
of in vitro chondrocyte cell lines has furthered our under-
standing of the underlying mechanisms of endochondral 
ossification.
The ATdc5 cell line, which was first isolated from 
the differentiating teratocarcinoma stem cell line AT805, 
is commonly used as a model for in vitro chondrocyte 
research (2). To date, the ATdc5 cell line has been utilised 
in approximately 300 studies. Previous studies have detailed 
a well-characterised method of ATdc5 differentiation 
and mineralisation, initially by Shukunami et al (3). This 
method has provided a reliable model of in vitro chondrocyte 
mineralisation for a number of years and has been widely 
used in the field since its publication; however it does contain 
some drawbacks. For example, mineralisation studies require 
a culture time of at least 34 days and a change of culture 
conditions. Both the cell culture medium and the cO2 concen-
tration have to be altered after 21 days of culture to facilitate 
extracellular matrix (EcM) mineralisation 13 days later. 
Since its publication, a number of groups have attempted to 
simplify the culture method. For example, the addition of 
inorganic phosphate to ATdc5 cultures has been shown to 
increase differentiation and the rate of EcM mineralisation 
(4,5). Another study has detailed that the addition of ascorbic 
acid shortened the proliferation phase of the ATdc5 cells 
from 21 to 7 days (6); while the temporal expression of 
markers of chondrogenic differentiation was examined, the 
EcM mineralisation capability of the ATdc5 cells under 
these culture conditions was not.
Therefore, our aim was to develop a culture model for 
ATdc5 cells which produced both consistent chondrogenesis 
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and physiological EcM mineralisation in a reduced time period 
for in vitro experimentation. In this study, β-glycerophosphate 
(βGP) was added throughout the culture period. βGP is cleaved 
by alkaline phosphatase (ALP) and other phosphohydro-
lases produced by the chondrocytes once they have reached 
hypertrophy to release inorganic phosphate, thus mimicking 
the phosphate availability in vivo (3,7,8). It was hypothesised 
that this strategy would facilitate an incremental increase in 
mineral deposition once an appropriate EcM had been depos-
ited. This would thereby increase the rate of mineralisation 
compared with previous methods while retaining the expected 
stages of chondrogenic differentiation as well as crucially, the 
formation of physiological mineral.
Materials and methods
Cell culture. chondrogenic ATdc5 cells (Riken cell Bank, 
Ibaraki, Japan) (3) were cultured in a differentiation medium 
[dMEM/F-12 (1:1) with GlutaMAx I containing 5% FBS, 
1% insulin transferrin and selenium, 1% sodium pyruvate 
and 0.5% gentamicin (Invitrogen, Paisley, UK)] at a density 
of 6,000 cells/cm2 in multi-well plates (Iwaki Cell Biology; 
Sterilin, Feltham, UK) (9,10). cells were left for 6 days to reach 
confluency at which point the medium was supplemented with 
10 mM βGP and 50 µg/ml L-ascorbate-2-phosphate (ascorbic 
acid). Cells were incubated in a humidified atmosphere (37˚C, 
5% cO2) for up to 41 days and the medium was changed every 
second or third day. For levamisole experiments, ATdc5 cells 
were cultured in varying concentrations of levamisole (Sigma, 
Gillingham, UK) (0-1,000 µM) for up to 15 days.
Histochemical staining. calcium deposition in ATdc5 cells 
was evaluated by Alizarin red staining as described previ-
ously (11). Briefly, cells were fixed in 4% paraformaldehyde 
and then 2% Alizarin red (Sigma, ph 4.2) was added to 
the cell layers for 5 min at room temperature. cells were 
washed with distilled water (dh20) and images were captured. 
Alizarin red-stained cultures were extracted with 10% cetyl-
pyridinium chloride for 10 min and the optical density (Od) 
of the digests was measured at 570 nm by spectrophotometry 
(Multiskan Ascent; Thermo Electron Corporation, Vantaa, 
Finland). Proteoglycan synthesis was evaluated by staining 
the cell layers with Alcian blue (Sigma). Cells were fixed in 
95% methanol for 20 min and stained with 1% Alcian blue 
8Gx in 0.1 M hcl overnight. cells were washed in dh20 
and images were captured. Alcian blue-stained cultures 
were extracted with 6 M guanidine-hcl for 6 h at room 
temperature and the Od was determined at 630 nm by 
spectrophotometry (11).
Real-time quantitative PCR (qRT-PCR). RNA was extracted 
using the RNeasy Mini kit (qiagen Ltd., crawley, west Sussex, 
UK), according to the manufacturer's instructions. For each 
sample, total RNA content was assessed by absorbance at 
260 nm and purity by A260/A280 ratios, and then reverse-
transcribed. cdNA was diluted to 10 ng/µl in nuclease-free 
water (Sigma), and stored at -20˚C. qRT-PCR reactions were 
conducted with a Mx3000P qPcR machine (Stratagene, 
Stockport, UK) using a SyBR-Green detection method. 
Primers were designed in-house and synthesised by MwG 
Eurofins, London, UK. Reactions were run in triplicate and 
routinely normalised against GAPdh. Primer sequences: 
Col2a1, forward, 5'-cGGTccTAcGGTGTcAGG-3' and 
reverse, 5'-GCAGAGGACATTCCCAGTGT-3'; Col10a1, 
forward,  5'-cATAAAGGGcccAcTTGcTA-3'  and 
reverse,5'-CAGGAATGCCTTGTTCTCCT-3'; GAPDH 
forward, 5'-TGAGGccGGTGcTGAGTATGTcG-3' and 
reverse, 5'-ccAcAGTcTTcTGGGTGGcAGTG-3'. qRT-PcR 
products were sequenced by the GenePool, University of 
Edinburgh.
Transmission electron microscopy (TEM). ATdc5 cells were 
cultured at 6,000 cells/cm2 on nitrocellulose discs (Nunc, 
Roskilde, denmark) in mineralising conditions for 15 days. 
cells were fixed in 2.5% glutaraldehyde in 0.1 M sodium 
cacodylate buffer at 37˚C for 1 h. During processing, the 
cell monolayers were washed in 0.1 M sodium cacodylate, 
post-fixed in 1% osmium tetroxide and dehydrated through 
graded alcohols (35, 70, 95 and 100%). The monolayers were 
then processed to Epon in a vacuum oven at 60˚C. Monolayers 
were viewed using a Phillips cMIRO TEM (FEI vic Ltd., 
cambridge, UK) and images were captured on Gatan Orius 
Icd camera (Gatan, Oxford, UK).
Fourier transform-infrared spectroscopy (FTIR). ATdc5 
cells were cultured for 41 days in mineralising conditions 
as previously described. cell monolayers were fixed in 
95% methanol and embedded in LR white. Spectral images of 
2 µm-thick culture sections were collected using a Spectrum 
Spotlight 100 system (Perkin-Elmer, waltham, MA, USA) 
with a spectral resolution of 4 µm and 6.25 µm pixel size in 
transmission mode. The collected spectra were truncated, 
base-lined and the contribution of LR white was spectrally 
subtracted using ISyS software (Spectral dimensions, Olney, 
Md, USA) and then analysed using ISys chemical Imaging 
software. Spectra extracted from these images were analysed 
using Grams/32 software (Thermo Electron corporation, 
waltham, MA, USA). The parameters measured included 
mineral/matrix ratio, carbonate/phosphate ratio, crystallinity 
and collagen maturity (12).
Statistics. data were analysed by one-way analysis of vari-
ance (ANOvA), with Tukey simultaneous tests used to 
identify differences between individual time-points, using 
SigmaPlot 11.0 software (Systat Software UK Ltd., London, 
UK). cell culture experiments were repeated at least twice 
and P<0.05 was considered statistically significant.
Results
ATDC5 cells undergo the expected stages of chondrocyte 
differentiation. Images collected by light microscopy over 
a 34-day time-course indicated comparable differentiation 
to previously characterised ATdc5 cultures (3,4). ATdc5 
cell cultures reached confluency 6 days after seeding with no 
extensive EcM formation (Fig. 1A). At this point, ATdc5 
cells were then cultured in the presence of 10 mM βGP and 
50 µg/ml ascorbic acid. This facilitates cell differentiation 
and the secretion of an extensive EcM which assembles 
around the cells as visualised at day 13 of culture by the 
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Figure 1. chondrogenic differentiation of ATdc5 cells. ATdc5 cells were grown over a period of 34 days and light microscopy images were collected 
during this time period. (A) Image captured at confluence, Day 6 of culture. (B) Arrows indicate translucent ECM which begins to form in discrete locations 
at day 13 of culture. (c) The arrows denote opaque regions which represent the onset of mineralisation within the EcM at day 14. (d) The nodules of EcM 
conjoin over the EcM and mineralisation increases. 
Figure 2. Chondrocyte marker analysis during ATDC5 cell differentiation. (A) The monolayer was fixed following 34 days of culture and stained for GAG 
using Alcian blue. (B) Quantification of Alcian blue staining was conducted over 10 time-points. (C) qRT-PCR analysis of Col2a1 and (d) qRT-PcR analysis 
of Col10a1 transcription, normalised to GAPdh, over 10 time-points in the ATdc5 monolayers. Mean (n=3) ± SEM, with the exception of Col10a1 at day 10 
where n=2; aP<0.05; bP<0.01; cP<0.001, where all significant differences between consecutive time-points are shown. 
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Figure 3. ATdc5 cell EcM mineralisation. (A) Mineralisation was examined by Alizarin red staining of monolayers fixed at day 34 of culture. 
(B) Quantification of Alizarin red staining was conducted over 10 time-points. Mean (n=3) ± SEM; aP<0.05; bP<0.01; cP<0.001, where all significant differ-
ences between consecutive time-points are shown. (c) Levamisole, an inhibitor of ALP enzyme activity, was added to ATdc5 cell cultures from when they 
reached confluency. Levamisole dose-dependently inhibited ATDC5 ECM mineralisation as indicated by quantification of Alizarin red staining. (D) Alizarin 
red stained images of the control cells and cells treated with 300 µM levamisole at day 15 of culture. data are represented as the means ± SEM (n=3 repli-
cates) in comparison to 0 µM levamisole cP<0.001. 
Figure 4. Analysis of ATDC5 mineral deposition. TEM images of ATDC5 cultures at Day 16 of culture. (A) Collagen fibers are present in the ECM; arrows 
denote collagen fibers. (B) Mineral deposition is noted along collagen fibers; arrows indicate an electron-dense material, likely to be mineralisation spreading 
along the collagen fibers within the ECM. (C) Mineral deposition within the ECM; arrows indicate electron-dense mineralised regions of the ECM. (D) FTIR 
analysis of (a) ATDC5 monolayer at 41 days of culture; (b) mineralised embryonic mouse bone at E14; (c) cortical bone from the tibia of a 4-month-old mouse. 
Absorbances of the phosphate peaks (900-1200 cm-1), which represents mineralisation and the amide-I peak (1585-1725 cm-1), which indicates protein, were 
used to estimate the mineral-to-matrix ratio of the mineralised EcM. Absorbance values for each plot are arbitrary and not to scale. 
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phase contrast images (Fig. 1B) and by Alcian blue staining 
(data not shown). As differentiation continues, these nodules 
increased in area and began to conjoin (Fig. 1c). A large 
proportion of each ATdc5 monolayer was Alcian blue-
positive by day 34 of culture, indicating that ATdc5 cells 
produced a glycosaminoglycan (GAG)-rich EcM and under-
went chondrogenesis (Fig. 2A). The temporal increase in 
GAG-deposition over a 34-day time-course was established 
by quantifying Alcian blue staining (Fig. 2B). GAG-deposition 
progressively increased from day 6, such that there were 
significant increases in Alcian blue staining between various 
time-points within the culture period.
To examine the process of chondrogenesis and hypertro-
phic differentiation of the ATdc5 cells during monolayer 
culture, Col2a1 and Col10a1 gene transcription at specific 
time-points was analysed by qRT-PcR. Col2a1 transcrip-
tion increased significantly between each time-point from 
Day 6 to 13; transcription then decreased but even at Day 34, 
transcription was greater compared to day 6 (by >58-fold, 
P<0.001) (Fig. 2c). Col10a1 transcription also increased 
significantly over the first 4 time-points up to Day 13 over a 
10,000-fold range, which by day 34 progressed to a greater 
than 50,000-fold increase in transcription compared to that of 
day 6 (Fig. 2d).
ATDC5 cells mineralise their surrounding ECM, producing 
physiological mineral. Phase contrast images indicated 
mineralisation of the ATdc5 EcM from day 14 onwards and 
this was confirmed by Alizarin red staining over a 34-day 
time-course (Fig. 1C and D, Fig. 3A and B). Quantification of 
this staining indicated that after an initial delay, presumably 
while early differentiation stages were occurring, calcium 
accumulation increased rapidly from day 17 to 34 (Fig. 3B) 
(P<0.001).
Levamisole, a well established inhibitor of ALP, inhib-
ited ATdc5 EcM mineralisation at day 15 of culture at 
concentrations in excess of 300 µM (P<0.001) (Fig. 3c) with 
no apparent alterations in the morphology of the ATdc5 
cells (Fig. 3d) (13). This indicated that the enzyme ALP is 
required, and therefore that chondrogenic differentiation of 
the ATdc5 cells is necessary for effective mineralisation.
FTIR and TEM were adopted as two well recognised 
methods to determine whether the properties of the mineral 
formed in culture is similar to that which is formed by 
mineralised cartilage in vivo (14). ATdc5 cells were shown 
to produce a collagenous EcM by TEM in which banded 
fibers, synonymous with collagen fibers, were present in 
the ECM (Fig. 4A) (15). Along some of the collagen fibers, 
electron-dense regions were present, indicative of the onset of 
mineralisation (Fig. 4B). In some discrete regions of the EcM, 
electron-dense spheres of ~200-500 nm were present which 
were also associated with the collagenous fibers (Fig. 4C); 
these are possibly mineralised matrix vesicles (Mvs) (1,8,9). 
These results suggest that ATdc5 cells produce a collagenous 
EcM and that the mineral formed is in alignment with the 
collagen fibrils, as is observed in endochondral ossification. 
ATdc5 cells were cultured for 41 days for FTIR analysis 
(Fig. 4d-a). The FTIR spectra were compared with those 
of E14 embryonic mouse bone (Fig. 4d-b) and 4-month-old 
cortical mouse bone (Fig. 4d-c), and were used to generate 
numerical parameters which may be compared with in vivo 
samples (Table I). The resulting data strongly suggest that the 
mineralisation of the ATdc5 monolayers resembles that of 
embryonic mouse bone.
Discussion
Attempts to unravel the underlying mechanisms of endochon-
dral ossification have been limited by current models. The 
data presented in this manuscript characterise a novel, rapid 
culture method for studying physiological chondrocyte EcM 
mineralisation using ATdc5 cells that we observed to be 
highly reproducible. A mineralisation method for ATdc5 cell 
culture was first described by Shukunami et al (3), however 
its drawbacks have been identified by several other groups 
and thus the method has been gradually developed with time. 
In this study, we cultured ATdc5 cells in the presence of 
ascorbic acid and 10 mM βGP.
ATdc5 cells have previously been cultured with ascorbic 
acid, which facilitates collagen synthesis. This reduces the 
proliferation phase of the cells and promotes their differen-
tiation (6,16). Ascorbic acid has also been shown to promote 
the hypertrophic differentiation of cultured primary chick 
chondrocytes (17). In the present study, cells were cultured 
in the presence of 50 µg/ml ascorbic acid from when they 
reached confluency and in concurrence with previous studies, 
this promoted EcM formation. The increased mRNA expres-
sion of the chondrogenic marker Col2a1 correlated with the 
onset of Alcian blue-stained cartilaginous nodules and the 
increased mRNA expression of Col10a1 with the differen-
tiation of the cells to a hypertrophic phenotype. The delayed 
onset of Col10a1 transcription at day 10 is consistent with the 
2 stages of differentiation that must occur from day 6 for the 
cells to become hypertrophic. The observation that Col10a1 
Table I. Mineralisation parameters from FTIR samples.
Sample Mineral-to-matrix ratio carbonate-to-mineral ratio crystallinity
A 3.000±0.917 0.008±0.005 1.128±0.009
B 2.200±2.500 0.005±0.002 1.072±0.062
c 6.500±0.900 0.006±0.001 1.130±0.030
Using peak areas from FTIR spectra, the mineral-to-matrix ratio (900-1,200 cm-1/1,585-1,725 cm-1), carbonate-to-mineral ratio (850-
950 cm-1/900-1,200 cm-1) and crystallinity (1,030 cm-1/1,020 cm-1) were calculated for mineralised regions of (A) ATdc5 monolayer grown to 
41 days of culture, (B) mineralised E14 mouse bone and (c) ortical bone from the tibia of a 4-month-old mouse.
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expression preceded the first observations of mineral forma-
tion provides further evidence that the model is able to mimic 
the in vivo endochondral ossification. During differentiation 
the histology of the cultures was similar to that described by 
Shukunami et al (3).
In addition to ascorbic acid, an exogenous phosphate 
source is routinely added to cell cultures to induce and 
stimulate mineralisation of the EcM. βGP is a preferential 
exogenous organic phosphate source as it is a substrate for 
ALP and therefore the cells directly dictate when it is cleaved 
to release inorganic phosphate with their differentiation to a 
hypertrophic phenotype. In this study we cultured ATdc5 
cells in the presence of 10 mM βGP and observed mineral 
formation from Day 15 of culture upon collagen fibrils and 
within Mvs. however, in a number of osteoblast and chon-
drocyte cultures, the growth of cells in the presence of βGP 
has been shown to lead to the formation of sporadic mineral 
formation on the cell surface and in the culture medium and 
not upon collagen fibrils which is regarded to be dystrophic 
mineralisation and not physiological hydroxyapatite (18,19).
In the present study we showed that the presence of ALP 
is necessary for βGP-induced ATdc5 mineralisation. This is 
consistent with previous studies in which the activity of ALP 
has been investigated in ATdc5 cells (3). Furthermore, the 
addition of levamisole, a potent inhibitor of ALP, to ATdc5 
cultures inhibited their EcM mineralisation. Mineralisation 
was also inhibited in cells cultured in the presence of βGP 
and in the absence of insulin, which is required for their 
differentiation (data not shown) (20). This result, therefore, 
suggests that mineral formation is dependent upon both 
chondrogenic differentiation and the subsequent presence 
of ALP. Additionally, the inhibition of EcM mineralisation 
when ATdc5 cells were cultured without insulin further 
emphasises that the mineral formed is not dystrophic and is 
dependent on their differentiation status.
Although routinely used as indicators of mineralisa-
tion, Alizarin red and von Kossa staining are not sufficient 
to conclude that mineralisation is physiological since the 
presence of calcium and/or phosphate does not indicate hA 
formation per se (21). For this reason, we adopted FTIR and 
TEM to examine whether or not the mineral formed in culture 
is physiological (14).
Shukunami et al (3) have previously used TEM for 
ATdc5 analysis and reported the presence of extremely 
dark calcium-containing spherites which they identified as 
mineralised Mvs in discrete regions between the cells, associ-
ated with collagenous fibers. In the present study, structures 
were noted in our TEM analysis which were indistinguishable 
in shape and size from those reported by Shukunami et al 
(3). The Mvs derived from ATdc5 cells are of a similar size 
and appearance to Mvs derived from in vivo tissues including 
chicken growth plate chondrocytes and rat epiphyseal hyper-
trophic chondrocytes (22). These results indicate that the 
ultrastructure of the collagenous fibrils appears as expected 
and that mineralisation of ATdc5 cultures appears to form in 
a physiological manner.
Furthermore, in this study we showed that the spectra of 
the ATdc5 monolayer more closely resembled that of the 
developing embryonic bone compared to the fully developed 
cortical bone. The mineral-to-matrix ratio of the ATdc5 
cultures, a key determinant of mineral composition is similar 
to the values for mineralised embryonic bone, E14, which is 
the earliest point at which mineralisation occurs in the mouse 
(23). The mineral-matrix ratios in other publications provide 
additional comparisons: in 10-day-old and 10-week-old 
wild-type mouse calcified growth plate cartilage the ratios 
have been calculated as 2.7 and 5.48, respectively (24,25). 
There is a considerable variation in these parameters, but 
the mineral-matrix ratio within the ATdc5 monolayer is 
within the expected region. The ATdc5 monolayer model 
characterised by Shukunami et al (3) was analysed by FTIR 
and spectra were compared with those of cultured primary 
rabbit chondrocytes, resulting in spectra which were almost 
super-imposable. These spectra show that the absorbance is 
greater in the amide-range compared to the phosphate-range, 
thus although the mineral-to matrix ratio is not provided, 
it is certainly less than those reported in the present study. 
Therefore, EcM mineralisation is greater in this ATdc5 
model compared to the method generated by Shukunami et al 
(3). If mineralisation in the cultures is ectopic and mineral is 
accumulated simply due to ALP cleavage of βGP, the ratio 
of mineral-to-matrix would be expected to be extremely 
high, which is not the case. A study by huitema et al (26), 
demonstrated this; inorganic phosphate was added to medium 
conditioned by ATdc5 cells which generated flat, miner-
alised structures, with extremely small amide-I peaks, relative 
to phosphate peaks.
The minera l ised product of the ATdc5 mono-
layer produced a phosphate peak with a clear shoulder 
at approximately 1,130 cm-1. This is characteristic of the 
hydroxyapatite containing acid phosphate which is gradually 
lost as the crystal matures; thus both the ATDC5 monolayer 
and the embryonic bone contain this peak, which is absent 
in the mature hydroxyapatite sample (27,28). The values 
obtained from the carbonate substitution and crystallinity 
are within the range of biologically relevant in vivo samples, 
which also indicates that this ATdc5 model generates physi-
ologically relevant mineral (24,29).
The development and characterisation of a rapidly miner-
alising chondrocyte model has the potential to assist us in 
better understanding the underpinning molecular mechanisms 
responsible for poor linear bone growth which is observed in 
a number of chronic diseases such as cystic fibrosis, chronic 
kidney disease, rheumatological conditions and inflammatory 
bowel disease. chondrocyte models, including the ATdc5 
cell line, have proved invaluable for determining the effects of 
pro-inflammatory cytokines and glucocorticoids on chondro-
cyte proliferation, differentiation and gene expression (9,10). 
however, the absence of a practical and accessible in vitro 
chondrocyte mineralisation model has hindered a fuller 
appreciation of how cartilage mineralisation and endochon-
dral ossification are disrupted by factors e.g. cytokines and 
drugs, that are responsible for impaired linear bone growth in 
children.
In conclusion, in this study we developed and character-
ised an improved and rapid method of ATdc5 differentiation 
which develops a physiologic mineralised EcM 15 days after 
seeding. To our knowledge, this is the earliest report of 
mineralisation in which physiological attributes of the mineral 
have been characterised.
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Matrix extracellular phosphoglycoprotein (MEPE) belongs to the SIBLING protein family which play key roles
in biomineralization. Although the growth plates of MEPE-overexpressing mice display severe morphological
disruption, the expression and function of MEPE in growth plate matrix mineralization remains largely
undefined. Here we show MEPE and its cleavage product, the acidic serine aspartate-rich MEPE-associated
motif (ASARM) peptide, to be localised to the hypertrophic zone of the growth plate. We also demonstrate
that the phosphorylated (p)ASARM peptide inhibits ATDC5 chondrocyte matrix mineralization. Stable
MEPE-overexpressing ATDC5 cells also had significantly reduced matrix mineralization in comparison to
the control cells. Interestingly, we show that the addition of the non-phosphorylated (np)ASARM peptide
promoted mineralization in the ATDC5 cells. The peptides and the overexpression of MEPE did not affect
the differentiation of the ATDC5 cells. For a more physiologically relevant model, we utilized the metatarsal
organ culture model. We show the pASARM peptide to inhibit mineralization at two stages of development, as
shown by histological and μCT analysis. Like in the ATDC5 cells, the peptides did not affect the differentiation
of the metatarsals indicating that the effects seen on mineralization are direct, as is additionally confirmed by
no change in alkaline phosphatase activity or mRNA expression. In themetatarsal organ cultures, the pASARM
peptide also reduced endothelial cell markers and vascular endothelial growth factormRNA expression. Taken
together these results show MEPE to be an important regulator of growth plate chondrocyte matrix mineral-
ization through its cleavage to an ASARM peptide.
© 2012 Elsevier Inc. All rights reserved.
Introduction
Linear bone growth involves the replacement of a cartilaginous
template by mineralized bone through endochondral ossification. This
growth process is orchestrated by various actions at the growth plate,
a developmental region consisting of chondrocytes in distinct cellular
zones. The proliferation, hypertrophy and apoptosis of these growth
plate chondrocytes are regulated by a tight array of factors ensuring
effective cartilage mineralization and thus longitudinal growth [1].
Hydroxyapatite (HA) crystals form associated with the trilaminar
membrane bound matrix vesicles (MV) which in the growth plate
are localised to the mineralized longitudinal septae and form from
the plasma membrane of the terminal hypertrophic chondrocytes [2].
Mineralization is a biphasic process which is under tight control so as
to ensure levels of calcium (Ca2+) and inorganic phosphate (Pi) are per-
missive for effective HA formation [2]. Threemolecules have been iden-
tified as imperative in controlling levels of the mineralization inhibitors
inorganic pyrophosphate (PPi), and osteopontin [2,3]. These are alkaline
phosphatase (ALP), a nucleotide pyrophosphatase/phosphodiesterase
isozyme (NPP1), and the Ankylosis protein (ANK). However, mecha-
nisms beyond the supply and hydrolysis of PPi likely exist to control
chondrocyte matrix mineralization.
Once such mechanism could involve matrix extracellular phospho-
glycoprotein (MEPE, OF45). This was originally isolated and cloned
from tumors of oncogenic hypophosphatemic osteomalacia (OHO)
as a candidate substrate for phosphate-regulating gene with homol-
ogies to endopeptidases on the X chromosome (PHEX) [4]. MEPE is
a 56–58 kDa SIBLING (small integrin-binding ligand N-linked glyco-
sylated) protein alongwith dentinmatrix protein 1 (DMP1), osteopontin
(OPN), dentin sialophosphoprotein (DSPP) and bone sialoprotein (BSP)
[5]. SIBLING proteins are expressed in bone and dentin, and have roles
in extracellular matrix (ECM) formation and mineralization [6]. Their
structures are similar; all display an Arg-Gly-Asp (RGD) motif which
facilitates cell attachment, and all are commonly located on the human
chromosome 4q21-23 [4,7,8].
In bone, MEPE is primarily expressed by osteocytes, but Mepe
mRNA expression has also been observed in osteoblasts [9]. The
expression of MEPE is increased during osteoblast matrix mineraliza-
tion suggesting a function for MEPE in bone mineralization [10,11].
This has been further fuelled by analysis of the MEPE null mouse in
which the ablation of MEPE leads to an increased bone mass due to
increased numbers and activity of osteoblasts [12]. Furthermore, the
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overexpression of MEPE in mice, under the control of the Col1a1 pro-
moter, leads to defective mineralization coupled with an increased
level of MEPE-ASARM peptides in bone [13]. The MEPE-overexpressing
mice displayed wider epiphyseal growth plates, with associated ex-
panded primary spongiosa and a significant decrease in mineral apposi-
tion rate [13]. Further studies in vitro have confirmed the inhibitory
effect of MEPE on mineralization and have identified that MEPE is
cleaved to a 2.2 kDa ASARM peptide which causes this effect [14,15].
The ASARM motif is located immediately downstream of a cathepsin B
cleavage site, and it is responsible for the mineralization defect ob-
served in X-linked hypophosphatemic rickets, the most common form
of inherited rickets [4,14,15]. This defect can be reversed by adminis-
tration of cathepsin inhibitors CAO74 or pepstatin [16]. PHEX plays a
central role in the protection of MEPE from proteolytic cleavage by
cathepsin B; it can bind to MEPE and prevent the release of the ASARM
peptide [17]. The Hyp mouse, a spontaneous Phex knockout model,
has an increased expression of cathepsin D, an upstream activator of
cathepsin B [16]. Therefore PHEX may also assist in decreasing the acti-
vation of cathepsin B.
Previous studies have shown that the post translational modifica-
tion of the MEPE-ASARM peptide is key to its functional role. MEPE
has a number of potential casein kinase II phosphorylation motifs,
and it is here that the ASARM peptide is phosphorylated at 3 serine
residues [4]. This has been shown to inhibit mineralization in murine
calvarial osteoblasts and in bone marrow stromal cells by the direct
binding of the MEPE-ASARM peptide to HA crystals [14,18].
To elucidate the interactions of MEPE in the growth plate, this
study was undertaken to examine the presence and function of
MEPE and its ASARM peptide in growth plate matrix mineralization
during the endochondral ossification process. The data indicated
that MEPE is expressed by growth plate chondrocytes, in particular
in the hypertrophic zone of chondrocytes consistent with a potential
role in matrix mineralization. MEPE has a functional role in the inhi-
bition of chondrocyte ECM mineralization, involving its cleavage,
and subsequent phosphorylation, to the ASARM peptide.
Materials and methods
Animals
Proximal tibiae from 3‐ and 4‐week‐old C57/BL6 mice were dis-
sected and excess tissue was removed before preparation of the tissues
for in situ hybridization, immunohistochemistry and microdissection
of the growth plate. For metatarsal organ culture, the middle three
metatarsals were aseptically dissected from E17 and E15 C57/BL6
mice. All experimental protocols were approved by Roslin Institute's
Animal Users Committee and the animals were maintained in accor-
dancewithUKHomeOffice guidelines for the care and use of laboratory
animals.
In situ hybridization
Bone tissue was fixed in 10% neutral buffered formalin (Sigma,
Gillingham, UK) for 48 h at 4 °C, before being decalcified in 10%
ethylenediaminetetraacetic acid (EDTA) (Sigma) pH 7.4 at 4 °C for
approximately 4 weeks with regular changes. Tissues were dehydrated
and embedded in paraffinwax using standard procedures, before being
sectioned at 5 μm. A full length murine MEPE cDNA IMAGE clone
(ID: 8733911) was purchased (Source BioScience UK Ltd, Nottingham).
Anti-sense and sense constructs were linearised, using Nco1, and
digoxigenin-labeled cRNA probes were synthesised using T3 and T7
RNA polymerases respectively (Roche, Burgess Hill, UK). Hybridizations
were completed following an optimised in situ hybridization protocol
as previously detailed [19].
Growth plate microdissection
Bone tissue samples were coated in 5% polyvinyl acetate and then
immersed in a cooled hexane bath for 30 s after which they were
stored at −80 °C until use. Using optimal cutting temperature
(OCT) embedding medium (Brights, Huntingdon, UK) 30 μm sections
were cut at −30 °C (Brights, OT model cryostat), and then stored at
−80 °C. Slides were briefly thawed and then microdissection was
performed as previously detailed [20]. For each zone, tissue was dis-
sected from both proximal tibias of three animals (14–22 sections)
and RNA isolation was performed as previously described [21].
Immunohistochemistry
After dissection, tissue was fixed in 70% ethanol for 24 h at 4 °C
before being decalcified in 10% EDTA (pH 7.4) for approximately
4 weeks at 4 °C with regular changes. Tissues were finally dehydrated
and embedded in paraffin wax, using standard procedures, after
which they were sectioned at 5 μm. For immunohistochemical analy-
sis, sections were dewaxed in xylene and rehydrated. Sections were
incubated at 37 °C for 30 min in 0.1% trypsin (Sigma) for antigen
demasking. Endogenous peroxidases were blocked by treatment
with 0.03% H2O2 in methanol (Sigma). From this point onwards, the
Vectastain ABC (Goat) kit (Vector Laboratories, Peterborough) was
used according to the manufacturer's instructions. ASARM and MEPE
primary antibodies were used at a dilution of 1/200 with rabbit IgG
used as a control [13]. Cathepsin B primary antibodies (R&D Systems,
Abingdon, UK)were used at a dilution of 2 μg/mlwith goat IgG used as
an appropriate control. The sections were dehydrated, counterstained
with haematoxylin and mounted in DePeX.
MEPE‐ASARM peptides
MEPE-ASARM peptides were synthesised (Peptide Synthetics, UK)
as phosphorylated ASARM (pASARM) with the sequence RDDSSESSD
SG(Sp)S(Sp)SSE(Sp)SDGD, andnon-phosphorylatedASARM(npASARM)
with the sequence RDDSSESSDSGSSSESDGD. pASARM and npASARM
peptides were added to ATDC5 cells and metatarsal organ cultures at
concentrations of 10, 20 and 50 μM, with controls treated with a DMSO
(Sigma) carrier only. In further studies, peptides were added at a final
concentration of 20 μM with experiments being performed at least 3
times.
Metatarsal organ culture
Embryonic metatarsal organ cultures provide a well‐established
model of endochondral bone growth [22–24]. Metatarsal bones were
cultured in a humidified atmosphere (37 °C, 5% CO2) in 24-well plates
for up to 10 days. Each culture well contained 300 μl α-minimum
essential medium (MEM) supplemented with 0.2% BSA Fraction V;
1 mmol/lβ-glycerophosphate (βGP); 0.05 mg/ml L-ascorbic acid phos-
phate; 0.05 mg/ml gentamicin and 1.25 μg/ml fungizone (Invitrogen,
Paisley, UK) as previously described [22]. For the E17 bones, the medi-
um was changed every second or third day and for the E15 bones, the
medium was not changed throughout the culture period [25]. Concen-
trations of peptide andDMSO carrierwere however added every second
day.
Morphometric analysis of metatarsals
The total length of the bone through the centre of the mineralizing
zone was determined using image analysis software (DS Camera
Control Unit DS-L1; Nikon) every second or third day. The length of
the central mineralization zone was also measured. All results are
expressed as a percentage change from harvesting length which was
regarded as baseline.
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3D-Microtomography of metatarsals
Metatarsals were fixed in 70% ethanol, stained with eosin dye
(for visualisation) and then embedded in paraffin blocks. Samples
were then were scanned with a high-resolution μCT (μCT40; Scanco
Medical, Southeastern, PA) as previously described [13,16]. Data
were acquired at 55 KeV with 6 μm cubic voxels. Three-dimensional
reconstructions for bone samples were generated with the following
parameters: Gauss Sigma=4.0; Support=2, Lower Threshold=90
and Upper Threshold =1000. Tissue mineral density was derived
from the linear attenuation coefficient of threshold bone through
precalibration of the apparatus for the acquisition voltage chosen.
The bone volume (BV/TV)wasmeasured using sections encompassing
the entire metatarsal on a set of 85 sections that was geometrically
aligned for each sample.
Metatarsal [3H]-thymidine proliferation assay
Onday 7 of culture, 3 μCi/ml [3H]-thymidine (AmershamBiosciences,
Little Chalfont, UK) was added to each metatarsal for the last 6 h of
culture [22]. After washing in PBS, the unbound thymidine was
extracted using 5% trichloroacetic acid (Sigma). Metatarsals were then
washed in PBS before being solubilised (NCS-II tissue solubiliser,
0.5 N, Amersham) at 60 °C for 1 h. [3H]-thymidine incorporated into
DNA was determined using a scintillation counter.
Cell culture
Chondrogenic ATDC5 cells (RIKEN cell bank, Ibaraki, Japan) were
utilized as a well-established model of chondrocyte matrix minerali-
zation with previous studies detailing their chondrogenic differen-
tiation and subsequent mineralization [26]. Cells were cultured in
differentiation medium (DMEM/F-12 (1:1) with GlutaMAX I con-
taining 5% FBS, 1% insulin transferrin and selenium, 1% sodium pyru-
vate and 0.5% gentamicin (Invitrogen)) at a density of 6000 cells/cm2.
10 mM beta-glycerophosphate (βGP) and 50 μg/ml ascorbic acid
were added once the cells had reached confluency. Cells were incu-
bated in a humidified atmosphere (37 °C, 5% CO2) for up to 15 days
with medium changed every second or third day.
Plasmid construction
The full length murine MEPE cDNA (IMAGE clone ID: 8733911)
was supplied within a pCR4.TOPO vector (Source BioScience UK Ltd,
Nottingham). The cDNA sequence was excised by digestion with
EcoRI and sub-cloned into the pEN.Tmcs (MBA-251; LGC Standards,
Middlesex, UK) using T4 DNA ligase (Roche). The expression vector
pLZ2-Ub-GFP (kind gift from D. Zhao, Roslin Institute) was digested
with BamHI and XbaI to remove the GFP cDNA. The MEPE cDNA was
excised from the pEN.T-MEPE sub-cloning vector using BamHI and
XbaI and ligated into pLZ2-Ub backbone to create a Ubiquitin driven
MEPE expression construct, pLZ2-Ub.MEPE. To create the empty vec-
tor control (pLZ2-Ub.EMPTY) the pLZ2-Ub backbone was blunted
using T4 polymerase (New England Bioscience, Hitchin, UK) and
re-ligated.
Establishment of stable MEPE-overexpressing ATDC5 cells
ATDC5 cells were maintained in differentiation medium as previ-
ously described and seeded at 150,000 cells/cm2. Cells were trans-
fected with pLZ2-Ub.MEPE and pLZ2-Ub.EMPTY constructs at a ratio
of 7:2 FuGENE HD (Roche) to DNA, according to the manufacturer's
instructions. Blasticidin resistant colonies were picked using cloning
cylinders (Sigma), expanded, frozen and maintained at −150 °C until
further use. Three MEPE-overexpressing and three empty vector clones
were picked for analysis.
Real-time quantitative PCR (RT-qPCR)
RNA was extracted from ATDC5 cell cultures using an RNeasy mini
kit (Invitrogen) according to the manufacturer's instructions. For
metatarsal organ cultures, 4 bones from each control or experimental
group were pooled in 100 μl Trizol reagent (Invitrogen) at days 5 and
7 of culture, and RNA was extracted according to the manufacturer's
instructions. For each sample, total RNA content was assessed by
absorbance at 260 nm and purity by A260/A280 ratios, and then
reverse-transcribed. RT-qPCR was performed using the SYBR green
detection method on a Stratagene Mx3000P real-time qPCR system
(Stratagene, CA, USA), or a LC480 instrument (Roche). Primers were
purchased (PrimerDesign Ltd, Southampton, UK) or designed in house
and synthesised by MWG Eurofins, London, UK, or Sigma. Sequences
are detailed in Supplemental Table S1. Reactions were run in triplicate
and routinely normalized against 18S or β-actin.
Endpoint PCR analysis
Expression of specific pro-angiogenic vascular endothelial growth
factor (VEGF)-A isoforms namely VEGF120,164 and 188 was analysed as
previously detailed [27]. The VEGF isoform primer sequences were:
forward GAAGTCCCATGAAGTGATCCAG and reverse TCACCGCCTTGG
CTTGTCA. Located on exon 3 (forward) and exon 8 (reverse), these
amplify all the isoforms of murine VEGF. Different isoform mRNA
expression profiles were identified in a 2.5% agarose (Sigma) gel
according to the molecular weight of PCR products using cDNA
synthesised from equal amounts of RNA. Product band densities were
analysed using Image J software (U. S. National Institutes of Health,
Maryland, USA).
Histological procedures
After 15 days of culture, calcium and collagen deposition in ATDC5
cells were evaluated by alizarin red stain (Sigma) and sirius red stain
(Biocolor Ltd., Newtownabbey, UK) respectively [28]. Cells were fixed
in 4% paraformaldehyde following washes with PBS. 2% alizarin red
(pH 4.2) was added to the cell layers for 5 min at room temperature
and then rinsed off with distilled water. Alizarin red-stained cultures
were extracted with 10% cetylpyridinium chloride for 10 min [28–30].
Sirius red was added to cell cultures for 1 h at room temperature before
being rinsed with distilled water. 0.001 M hydrochloric acid was then
used to remove unbound dye. To quantify staining, 0.1 M sodium
hydroxide was used for 30 min. The optical density (OD) of the alizarin
red and sirius red digests was measured at 570 nm by spectrophotom-
etry (Multiskan Ascent, Thermo Electron Corporation, Vantaa, Finland).
Proteoglycan synthesis contentwas evaluated by staining the cell layers
with alcian blue (Sigma). Cells were fixed in 95% methanol for 20 min
and stained with 1% alcian blue 8GX in 0.1 M HCl overnight. Alcian
blue-stained cultures were extracted with 1 ml of 6 M guanidine–HCl
for 6 h at room temperature and the OD was determined at 630 nm
by spectrophotometry [28].
Alkaline phosphatase enzyme activity
At the end of the culture period, alkaline phosphatase (ALP) activ-
ity within the metatarsal bones was determined using an assay for
ALP (Thermo Fisher Scientific, Epsom, UK) according to the man-
ufacturer's instructions. Briefly, each metatarsal was permeabilized
in 100 μl of 10 mmol/l glycine (pH 10.5) containing 0.1 mmol/l
MgCl2, 0.01 mmol/l ZnCl2, and 0.1% Triton X-100 by freeze-thawing
three times [22]. Each extract was assayed for ALP activity by measur-
ing the rate of cleavage of 10 mM p-nitrophenyl phosphate. Total
ALP activity was expressed as nanomoles p-nitrophenyl phosphate
hydrolysed per minute per bone.
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Lactate dehydrogenase activity
Lactate dehydrogenase (LDH) activity was determined in the cul-
ture medium of 15-day-old 0 mM and 10 mM βGP treated ATDC5
cells using a kit from Roche Diagnostics (Lewes, East Sussex, UK).
LDH activity was related to the total LDH activity of the cultures.
Statistical analysis
Data were analysed by one-way analysis of variance (ANOVA), the
Student's t-test, or a suitable non-parametric test using Sigma Plot 11
(Germany). All data are expressed as the mean±SEM.
Results
The expression of MEPE in the murine growth plate
To assess the expression of MEPE by growth plate chondrocytes
we examined Mepe mRNA localization in the murine growth plate of
3-week-old mice by in situ hybridization. Mepe was expressed abun-
dantly by growth plate chondrocytes and by osteoblasts within the
metaphysis (Fig. 1A). In the growth plate, high levels of Mepe mRNA
were observed, especially in the hypertrophic chondrocytes (Fig. 1B
and C). This spatial expression pattern was further examined and
quantified by microdissection of growth plates. To validate the micro-
dissection technique, RT-qPCR of collagen type X mRNA expression
was conducted to ensure that the hypertrophic zone could be consid-
ered as an enriched pool of hypertrophic chondrocytes (Fig. 1D). There
was approximately a 10-fold increase in collagen type X mRNA ex-
pression in the hypertrophic zone in comparison to the proliferative
zone (Pb0.001). This is in concordance with previous studies done
using a similar technique [31]. Mepe mRNA had a significantly higher
expression (Pb0.05) in the hypertrophic zone in comparison to the
proliferative zone of the growth plate (Fig. 1E). Immunolocalization
of MEPE and the MEPE-ASARM peptide in 4-week-old growth plates
verified the in situ hybridization and microdissection data as demon-
strated by its localization to the hypertrophic zone of chondrocytes
(Fig. 1F and H). This ASARM peptide is cleaved from MEPE by cathep-
sin B; thus, we examined the immunolocalization of cathepsin B in
the growth plate (Fig. 1J). Here we show it to be expressed at the
chondro-osseous junction as is in concordance with previous studies
[32,33]. Representative images of the appropriate negative controls
are shown (Fig. 1G, I and K). Together these data indicate that
MEPE-ASARM peptide is preferentially expressed by hypertrophic
chondrocytes of the growth plate and this localization is consistent
with a role for this peptide in regulating cartilage mineralization.
The functional role of MEPE in ATDC5 cells
It is known that the C-terminal fragment is the active form of
MEPE. This fragment contains the ASARM peptide; thus, we next
determined the role of the ASARM peptide in chondrocyte matrix
mineralization by examining the mineralization capability of ATDC5
cells in response to MEPE-ASARM peptides. The ATDC5 cell line is a
teratocarcinoma derived cell line which has been shown to display
the multistep chondrogenic differentiation process, from mesenchy-
mal condensation to matrix mineralization [26,34], at approximately
day 15 of culture. The culture method used here did not result in
metabolic stress leading to cell death as indicated by assessment of
released LDH activity as a percentage of total LDH release (0 mM
βGP 33.5%±2.5, 10 mM βGP 35.2%±0.9, NS). Here we added pAS-
ARM and npASARM peptides to ATDC5 cell cultures under calcifying
conditions over a 15-day culture period. There was no apparent
morphological difference between control and ASARM-treated cells.
pASARM peptides inhibited mineralization in a dose-dependent man-
ner as visualised by alizarin red staining and quantified by spectro-
photometry (at 20 μM and 50 μM in comparison to control; Pb0.01)
(Fig. 2A). Interestingly, it was found that npASARM promoted miner-
alization over the 15-day culture period (at 20 μM and 50 μM in
comparison to control; Pb0.01) (Fig. 2B). Given that MEPE has been
postulated to have direct effects on osteoblast mineralization and
not via altered matrix production [14,18], we investigated whether
this was the case with ATDC5 cells by examining their ability to pro-
duce their collagenous matrix when treated with the MEPE-ASARM
peptides. Collagen deposition (Fig. 2C) and glycosaminoglycan pro-
duction (Fig. 2D), as visualised by sirius red and alcian blue stains,
respectively, were unaffected by addition of 20 μM pASARM or
npASARM peptide. These data are therefore supportive of a direct
role for MEPE-ASARM peptides in chondrocyte matrix mineralization.
We next overexpressed MEPE in ATDC5 cells to examine this
functional role further. When cultured under calcifying conditions,
MEPE-overexpressing cells showed an inhibition of matrix minerali-
zation throughout the culture period as visualised by alizarin red
staining and quantified by spectrophotometry (at day 8 in compari-
son to empty vector control Pb0.01, at days 12 and 15 in comparison
to empty vector control Pb0.001) (Fig. 3A). RT-qPCR amplifications
showed that stable individualMEPE-overexpressing ATDC5 cell clones
expressed significantly higher Mepe mRNA levels than individual
empty vector clones (Pb0.001) (Fig. 3B). Phex mRNA levels were
significantly decreased in theMEPE-overexpressing clones in compar-
ison to the empty vector controls (Pb0.05) (Fig. 3C). Chondrocyte
marker genes of differentiation and mineralization were examined
for mRNA expression and no differences were found between the
MEPE-overexpressing and the empty vector controls (Fig. 3D and E,
Supplemental Fig. S1).
Phosphorylated MEPE-ASARM peptides inhibit the mineralization
capability of E17 metatarsal bones
We next wanted to examine the effects of the MEPE-ASARM pep-
tides on a more physiologically relevant model. Primary chondrocytes
provide difficulties when culturing as they tend to dedifferentiate
to a fibroblastic-like phenotype during long-term culture [35–38];
thus, we utilized the metatarsal organ culture model. When dissected,
E17 mice metatarsals display a central core of mineralized cartilage
juxtaposed by a translucent area on both sides representing the hy-
pertrophic chondrocytes [22] (Fig. 4B). These bones were cultured
in the presence of varying concentrations of pASARM and npASARM
peptides over a 10-day period to examine their effects on longitudinal
bone growth and the growth of the central mineralization zone.
This preliminary data indicated that MEPE-ASARM peptides inhibit
mineralization of metatarsal bones across a range of concentrations
(Supplemental Fig. S2). Due to the physiological relevance of 20 μM
in XLH patients andHypmice, this concentrationwas used throughout
Fig. 1. In situ hybridization of Mepe in 3-week-old mouse tibia. Mepe was found to be abundantly expressed by growth plate chondrocytes and osteoblasts of the metaphysis (A).
Expression was present in both the proliferating zone (PZ) and the hypertrophic zone (HZ) of the growth plate, as indicated by the arrows (B), with an apparent increase in
expression in the hypertrophic zone of chondrocytes (C). Microdissection of the growth plate was adopted to assess Mepe mRNA expression. The accuracy of the microdissection
technique was determined by the relative change in col10a1mRNA expression throughout the zones of the growth plate and the trabecular bone (D). This was then used to examine
the relative change in Mepe mRNA expression in these zones (E). Immunohistochemistry shows MEPE (F and G) and the MEPE-ASARM peptide (I and J) to be expressed in the
tibia of 4-week-old growth plates. Its expression in the growth plate is limited to the hypertrophic zone (HZ) of chondrocytes, as indicated by the arrows. Cathepsin B
immunolocalization (L and M) was exclusive to the chondro-osseous junction, as highlighted by the arrows. Representative images of appropriate negative control are shown
(H, K, and N). Values generated by RT-qPCR and normalized to 18S. Data are represented as mean±SEM, in comparison to the PZ, *Pb0.05 **Pb0.005. Scale bars are (A, B, F, H,
I, K, L, N) 0.5 mm, (C) 0.1 mm, and (G, J, M) 0.01 mm.
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these experiments [18]. Bones treated with 20 μMMEPE-ASARM pep-
tides grew in length at the same rate as the control bones (up to 80%)
after 7 days in culture (Fig. 4C–F). However, whereas in the control
and npASARM treated metatarsals the central mineralization zone
increased in length throughout the culture period (increased approx-
imately 5–6 fold from initial lengths, Fig. 4D and E), in the pASARM
treated cultures no changes in length were noted (Pb0.01 at day 6,
Pb0.001 at days 8 and 10 in comparison to the control) (Fig. 4C, E
and G).
The effects of the MEPE-ASARM peptides on E15 metatarsal bones
To examine this apparent inhibitory effect further, we next deter-
mined the effects of the pASARM and npASARM peptides on E15meta-
tarsal bones. These bones consist of early proliferating chondrocytes
(Fig. 5A) and no evidence of a mineralized core. After 7 days in culture,
the chondrocytes in the centre of the bone become hypertrophic and
mineralize their surrounding matrix as is previously documented [25]
(Fig. 5B). This central core of mineralized cartilage formed in control
bones and bones treated with 20 μM npASARM peptides (Fig. 5B and
C); however, it was minimal in metatarsal bones treated with 20 μM
pASARM peptides (Fig. 5D), as seen in the phase contrast images. This
was further confirmed by von kossa staining of histological sections
for mineralization (Fig. 5H) and by μCT scanning of the metatarsal
bones to allow the visualisation of the bones in a 3D context. In compar-
ison to the control and npASARM treated bones, metatarsal bones cul-
tured in the presence of pASARM peptides had a significantly reduced
BV/TV (Pb0.001) (Fig. 5I), as is clearly visible in the μCT scan images
(Fig. 5J). This unequivocally shows the inhibition of mineralization in
metatarsal bones by the pASARM peptide. Despite the increase in
ATDC5 ECM mineralization upon addition of npASARM peptides, here
themeandensity of themineralised bonewas unchanged between con-
trol and npASARM treated bones (control 163.4±12.1 mg HA/ccm,
npASARM 173.2±21.9 mg HA/ccm, not significant).
Fig. 2. Mineralization of ATDC5 matrix in the presence of (A) pASARM and (B) npASARM peptides was visualised by alizarin red staining (images) and quantified after 15 days of
culture. Quantification of sirius red staining (C) and alcian blue staining (D) (images) of ATDC5 cells following 15 days of culture with 20 μM pASARM and npASARM peptides. Data
are represented as mean±SEM of three wells analysed in triplicate. **Pb0.01.
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Apart from the inhibition of mineralization by the pASARM pep-
tide, there were no other obvious morphological differences in the
development of these bones in comparison to the control bones.
All bones grew at the same rate (increased approximately 65% from
initial lengths) (Fig. 5E) and by incorporating [3H]-thymidine into
the bones at the end of the culture period, day 7, it was determined
that the proliferation rate of the chondrocytes was unchanged
(Fig. 5F). The lengths of the proliferating (PZ) and hypertrophic
(HZ) zones of chondrocytes were also measured. The MEPE-ASARM
peptides had no effect on the percentage sizes of the maturational
zones of the metatarsal bones, or on the cell numbers within the
bones (Control: 1139.13±172.01, pASARM: 1594.97±226.9, npASARM
1233.71±126.08). This therefore suggests that the MEPE-ASARM
peptides had no effect on the differentiation capability of the metatarsal
chondrocytes (Fig. 5G). To examine this further, we looked at mRNA
expressions of chondrocyte differentiation markers for which there
were no significant differences between the control and pASARM treated
bones at days 5 and 7 of culture (Supplemental Fig. S3, Supplemental
Fig. S4) as is in concordance with our histological and proliferation data.
We also examined the expression and activity of key enzymes as-
sociated with cartilage mineralization to establish whether these are
involved in the mechanism of inhibition by the pASARM peptides. In-
terestingly there was no significant difference in the activity of ALP
(Fig. 6A), a well recognised regulator of chondrocyte matrix mineral-
ization. This was further confirmed by mRNA expression analysis of
Alpl by RT-qPCR (Fig. 6B). Analysis of the mRNA expression of other
mineralization regulators, Ank, Enpp and Phospho1, also showed no
difference between control and treated bones at days 5 and 7 of cul-
ture (Supplemental Figs. S3 and S4).
To assess the possible interactions of PHEX with MEPE, we exam-
ined mRNA expression of Phex and found it to be significantly de-
creased in the pASARM treated bones compared to the control bones
at day 7 of culture (Pb0.05) (Fig. 6C). Furthermore, Mepe mRNA
expression was significantly increased (Pb0.001) (Fig. 6D). At day 5
of culture, there was no significant difference in the mRNA expression
of Mepe or Phex (Supplemental Fig. S3).
The vascular invasion of the cartilage model via VEGF stimulated
angiogenesis is critical for matrix mineralization [39]. Thus, we exam-
ined the effects of the pASARM peptide on the mRNA expression of
endothelial cell specific markers and VEGF. We found a significant
decrease in the expression levels of Cd31, Cd34, and VEGFR2/Flk1 fol-
lowing 7 days of culture in the presence of 20 μM pASARM compared
to controls (Pb0.01, Pb0.05) (Fig. 7A–C). Furthermore, we also found
a concomitant decrease in VEGF isoform expression specifically
VEGF164 and 120 (Fig. 7D–F). VEGF188 was not detected in either con-
trol or treated metatarsals. Matrix metalloproteinase 13 (MMP13),
which has been implicated in VEGF-induced angiogenesis [40,41],
also had a significantly decreased mRNA expression following 5 days
of culture (in pASARM treated bones compared to control; Pb0.05)
(Fig. 7G). Despite this there was histologically no apparent inhibition
of vascularization in the metatarsal bones.
Discussion
The hypertrophic chondrocytes of the epiphyseal growth plate
mineralize their surrounding ECM and facilitate the deposition of HA,
a process imperative for longitudinal bone growth. It is widely accepted
that ALP, NPP1 and ANK are all central regulators of levels of PPi, a min-
eralization inhibitor, and thus the deposition of HA [42–46]. Recently
it has come to light that mechanisms beyond the supply and hydrolysis
of PPi also exist to control matrix mineralization. Studies into rare
genetic disorders, such as X-linked hypophosphatemic rickets (XLH),
have identified a family of proteins, FGF23, PHEX, and MEPE which act
through a bone-kidney axis to modulate phosphate homeostasis and
thus bone mineralization indirectly [4,47–49]. However, these proteins
have been shown to have direct effects on mineralization, independent
Fig. 3. MEPE-overexpressing ATDC5 cells showed inhibited mineralization in comparison to empty vector cells at days 8, 12 and 15 of culture as visualised by alizarin red staining
and quantified by spectrophotometry (A). Mepe mRNA expression was significantly increased in MEPE-overexpressing ATDC5 clones (B), whilst Phex mRNA expression was sig-
nificantly decreased in comparison to empty vector controls (C). There was no difference in mRNA expression levels of (D) Col2a1 or (E) Alpl. Data are represented as mean of
3 clones±SEM. *Pb0.05, **Pb0.01, ***Pb0.001.
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of the bone-kidney axis [50,51]. Hereweprovide evidence forMEPE as a
novel regulator of growth plate cartilage mineralization.
MEPE is a member of the SIBLING family of proteins and is
expressed by mature osteoblasts, osteocytes, odontoblasts and the
proximal convoluted tubules of the kidney [12,16,52,53]. It is degrad-
ed by cathepsin B to an acidic, negatively charged ASARM peptide
which inhibits osteoblast matrix mineralization by directly binding
to HA [14,15,18]. Patients with XLH have elevated serum levels of
this ASARM peptide as does the mouse model of XLH, the Hyp mouse
[54]. Further studies of the Hyp mouse show severe morphological
disruption of the growth plate which can be corrected by the adminis-
tration of cathepsin inhibitors [16]. This growth plate disruption is
also observed in mice overexpressing MEPE [13]. Here we provide
evidence of the spatial localization pattern of MEPE and its mRNA in
the growth plate; more specifically we have shown it to be predomi-
nantly expressed by the terminally differentiated hypertrophic cho-
ndrocytes. It is recognised that due to the binding nature of MEPE to
HA, EDTA decalcification may in fact provide an underestimation of
the total MEPE/ASARM protein produced however the results seen
here are consistent with those observed in the MEPE-overexpressing
mouse and with a presumed role for MEPE in regulating the fine bal-
ance of mineral formation at the growth plate. The localization of
cathepsin B at the chondro-osseous junction is in concordance with
previous studies detailing the cathepsin B rich septoclast [32,33].
These cells, thought to be of macrophage or osteoclast origin, are pos-
tulated to play a key role in the degradation of unmineralized cartilage
Fig. 4. Measurements of digital images of E17 mouse metatarsal bones in culture with clearly delineated mineralizing zones (B–D) were taken using a calibrated ruler (A). Images
clearly show the harvesting length (B) with the locations of the proliferating (PZ), hypertrophic (HZ) andmineralizing (MZ) zones, as well as the total lengthmeasurement. A control
metatarsal bone is illustrated in (C) and bones treated with continuous 20 μM npASARM (D) and pASARM peptides (E) after 10 days of culture. The growth rate of the embryonic
metatarsal bones was not affected by treatment with 20 μMMEPE-ASARM peptides (F) when cultured for up to 10 days. There was no significant difference in the percentage change
in mineralization length between control and npASARM treated bones, both of which increased over the culture period. However the mineralization zone length in bones treated
with pASARM peptides remained the same during the culture period (G). Data are represented as mean±SEM of six bones. **Pb0.01, ***Pb0.001 in comparison to control bones
at equivalent days of culture. Error bars are too small to be visualised.
Fig. 5. Measurements of digital images of E15 mouse metatarsal bones in culture. At time of harvesting, bones did not have a central mineralization zone as indicated by the asterisk
(A). After 7 days in culture, control (B) and npASARM (C) treated bones formed a largemineralization zone; however, this was inhibited in pASARM treated bones (D). All metatarsal
bones grew at a similar rate (E) and there was no difference in the proliferation of the chondrocytes within (F). Histological sections (H) showed control and npASARM treated bones
to have abundant mineral as indicated by von kossa staining. This was not seen in pASARM treated metatarsals. There was no difference in the widths of the proliferating zone (PZ)
and hypertrophic zone (HZ) of chondrocytes between the different groups of metatarsals at either day 5 or day 7 of culture (G). Data are represented asmean±SEM of six bones. μCT
analysis of metatarsal bones treatedwith npASARM and pASARMpeptides. Bones treated with pASARMhad a significantly reduced BV/TV in comparison to the control and npASARM
treated bones (I). This was clearly visible in the μCT images (J). Data are represented as mean±SEM of three bones. ***Pb0.001.
425K.A. Staines et al. / Bone 51 (2012) 418–430
426 K.A. Staines et al. / Bone 51 (2012) 418–430
[33]. It is likely that the cathepsin B provided at the chondro-osseous
junction cleavesMEPE at its distal COOH-region to the ASARMpeptide
whichwe have shown here to be localised exclusively to the hypertro-
phic chondrocyte region.
Previous studies have shown the ASARM peptide to inhibit matrix
mineralization in in vitro osteoblast cultures [15,18,55]. It is well
recognised that the post translational phosphorylation of the MEPE-
ASARM peptide is essential for its inhibitory role. Here we utilized
the metatarsal organ culture model, a well‐established model of car-
tilage mineralization and endochondral bone growth. Developmen-
tally in mice by E15, the point at which we use metatarsal bones in
these studies, despite a considerable degree of periosteal ossification
occurring in the long bones, the metatarsal bones exist as a cartilage
model. Here our results unequivocally show that the phosphorylated
ASARM peptide (pASARM) has a significant inhibitory role on chon-
drocyte matrix mineralization. Here we report no difference in the
widths of the cartilage zones in the metatarsal bones. A widening of
the hypertrophic zone would be expected as seen in hypophos-
phatemic rickets, and as is observed in the MEPE-overexpressing
mouse [13]. This is not surprising though as there was also no differ-
ence in the growth potential, chondrocyte proliferation or mRNA
expression of chondrocyte differentiation markers, of the treated
and untreated bones. This therefore suggests that the MEPE-ASARM
peptide has no effect on chondrocyte function per se. Instead it affects
chondrocyte matrix mineralization directly, as is in concordance with
studies done on bone mineralization [14,18].
It is well recognised that ALP activity is a key regulator of cartilage
matrix mineralization. ALP is located to the outer surface of the
trilaminar membrane of MVs, which form from the hypertrophic
chondrocytes [56]. It is widely accepted that ALP generates Pi for HA
formation and its lack of activity results in an excess of PPi [57]. The
interaction between ALP, PPi and other SIBLING proteins has previ-
ously been documented [57,58]. It was therefore postulated that
the effects of the pASARM peptide could act through a decrease in
ALP activity/expression as has been shown in a previous study of
bone mineralization and as is observed in the MEPE‐overexpressing
mouse [13,14]. However here we show no effect on ALP activity or
expression by the ASARM peptide and as is in concordance with a
previous study investigating the role of MEPE in osteoblast miner-
alization [18]. No effect was also seen on PHOSPHO1 expression,
which together with ALP regulates bone and cartilage mineralization
suggesting that in the models utilized here, the mechanism of inhibi-
tion is not a result of decreased enzyme activity [59,60]. Rather, it is
likely that the pASARM peptide exerts its effects through its direct
binding to the HA as has previously been suggested.
It has recently been shown that a truncated form of MEPE, which
has the ASARM peptide removed, can promote bone mineralization
in culture and in mice [61]. Furthermore, a mid-terminal fragment
of MEPE has been shown to enhance cell binding and taken together
these results highlight the importance of the post translational pro-
cessing of MEPE in determining its functional role [62]. Here we
have shown that the phosphorylation of the ASARM peptide is crucial
Fig. 6. Alkaline phosphatase (ALP) activity was unchanged in metatarsal bones treated with 20 μM pASARM peptides in comparison to control bones (A). AlplmRNA expression was
also unchanged (B). Phex mRNA expression was significantly decreased in pASARM treated bones (C) whilst Mepe mRNA expression was increased (D). Data are represented as
mean±SEM. *Pb0.05 ***Pb0.001 of 3 groups of 4 pooled bones at day 7 of culture.
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Fig. 7. mRNA expression of endothelial cell markers Cd31 (A), Cd34 (B), and VEGFR2/Flk1 (C) in control and pASARM treated bones at day 7 of culture. PCR analysis of pro-angiogenic VEGF-A splice variants (D) and densitometry of the
VEGF164 isoform (E) and the VEGF120 isoform (F). mRNA expression ofMmp13 in control and pASARM treated bones at day 5 of culture (G). Data are represented as mean±SEM. *Pb0.05, **Pb0.01 of 3 groups of 4 pooled bones. PCR analysis












in determining its functional role. Despite the observed promotion
of mineralization by the npASARM peptide in the ATDC5 cultures,
this was not corroborated by our metatarsal data. Furthermore in
other in vitro studies, it has been shown that the function of the
MEPE-ASARM peptide is entirely dependent upon its phosphorylation
[14,18,63]. Indeed it is likely that the npASARM peptide does not
physiologically exist and is in fact inactive. One can reasonably infer
that since the pASARM serine-phosphorylated casein kinase sites
are highly conserved across species (including whales, dolphins,
primates, rodents, marsupials, elephants, dogs, and cats) and the
phosphorylated form is active that there might be a physiological
mechanism that plays a role in regulating the ASARM-phosphorylation
status [64].
PHEX protects MEPE from cathepsin B cleavage in vitro [17,65];
thus, the inhibition of Phex mRNA expression in pASARM treated
metatarsal bones and in ATDC5 cells overexpressing MEPE suggests
a feedback mechanism by which ASARM peptides can prevent PHEX
expression. This, in correlation with an increase in Mepe expression
seen, would allow the release of ASARM peptides therefore further
increasing the inhibition of mineralization. Furthermore, the reduc-
tion in Phex mRNA expression may be due to the ASARM peptide
protecting itself from sequestration and hydrolysis by PHEX, as has
previously been suggested [14,18,66]. A decrease in Phex mRNA has
also been observed in osteoblast cell cultures treated with the pAS-
ARM peptide, concomitant with an increase in FGF23 expression [14].
In the MEPE-overexpressing mouse, however, an increase in Phex
mRNA is observed and this, coupled with the expected hydrolysis of
the ASARM peptide, leads to altered MEPE processing and therefore
the hyperphosphatemia observed in this mouse model [13]. These
data are also in agreement with previous reports showing increased
MEPE expression by osteoblasts of HYP mice and this positive regula-
tion of MEPE expression by pASARM may exacerbate the condi-
tion [4,10,15,66]. It is reasonable to speculate that physiologically
there must be a regulatory mechanism to ensure that there is not
an overproduction of ASARM peptides and as such a pathological
state. The precise nature of the counter balancing mechanism is pres-
ently unknown but as the SIBLING proteins are closely related and it
is possible that one of the other members of this family may be
responsible.
Key to endochondral ossification is the vascularization of the
mineralized matrix [39]. Matrix metalloproteinases (MMPs) proteo-
lytically degrade the mineralized cartilage matrix, facilitating blood
vessel penetration into the growth plate and allowing the recruitment
of osteoclast precursors and osteoblast progenitors. Pro-angiogenic
VEGF is produced by hypertrophic chondrocytes of the growth plate
and VEGF164/188 deletion from the cartilage of developing mice results
in delayed recruitment of blood vessels to the perichondrium along
with a delayed invasion of vessels into the primary ossification centre
[67]. Here we have shown that the pASARMpeptide reduces the levels
of endothelial cells present during metatarsal organ culture due to
the vessel invasion of the bones at approximately E14– E15. This was
associated with reduced VEGF120/164 mRNA expression levels. It is
entirely possible that the influence of the pASARM peptide on endo-
thelial cell populations is indirect, by impacting hypertrophic chon-
drocyte VEGF expression. However, any direct effects of the pASARM
peptide on endothelial cell function remain uninvestigated. The possi-
ble implications of MEPE on bone renal vascularization have recently
been described in the MEPE-overexpressing mouse, which in contrast
to our studies exhibits defective mineralization associated with
increased blood vessels [13]. Similarly, we also found a decrease in
Mmp13 mRNA expression following pASARM treatment which has
been implicated in angiogenesis despite there being a lack of impair-
ment of vascularization in the Mmp13 knockout mouse [40,41,68]. It
is likely that in the Mmp13 knockout and the Mepe-overexpressing
mice, unknown compensatory mechanisms could exist to allow for
effective vascularization of the skeleton. Like MEPE, DMP1, another
SIBLING protein, has also been suggested as an inhibitor of VEGF re-
ceptor 2 mediated angiogenesis although the precise role of its
ASARM peptide in this circumstance has yet to be elucidated [69].
To conclude, our studies detail for the first time the functional role
that MEPE and its ASARM peptide have in chondrocyte matrix miner-
alization. We have shown MEPE to be expressed by growth plate
chondrocytes, in particular in the hypertrophic zone of chondrocytes
consistent with a role in matrix mineralization. We have shown this
role to be dependent upon the extent of the cleavage and subsequent
phosphorylation of MEPE, and that mechanisms may exist which pos-
itively regulate the further expression of MEPE. Our studies comple-
ment previous findings of MEPE and its role in biomineralization;
however, much remains to be learnt regarding the in vivo role of
MEPE and the ASARM peptide in bone disease.
Supplementary data related to this article can be found online at
http://dx.doi.org/10.1016/j.bone.2012.06.022.
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Abstract
The small integrin-binding ligand N-linked glycoprotein
(SIBLING) family consists of osteopontin, bone sialoprotein,
dentin matrix protein 1, dentin sialophosphoprotein and
matrix extracellular phosphoglycoprotein. These proteins
share many structural characteristics and are primarily located
in bone and dentin. Accumulating evidence has implicated
the SIBLING proteins in matrix mineralisation. Therefore,
in this review, we discuss the individual role that each of
the SIBLING proteins has in this highly orchestrated
process. In particular, we emphasise how the nature and
extent of their proteolytic processing and post-translational
modification affect their functional role. Finally, we describe
the likely roles of the SIBLING proteins in clinical
disorders of hypophosphataemia and their potential thera-
peutic use.
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Introduction
The skeleton is a highly intricate and complex organ that has a
range of functions spanning from locomotion to ion
homoeostasis. It is structurally adapted to suit its function:
strong and stiff to withstand loading and yet light for
movement and flexible to prevent fracture. The organic
component of bone, termed the osteoid, comprises an
extracellular matrix (ECM) primarily composed of collagen
type I together with several non-collagenous proteins (NCPs).
One such family of NCPs is the small integrin-binding
ligand N-linked glycoprotein (SIBLING) family. This consists
of osteopontin (OPN), bone sialoprotein (BSP (IBSP)),
dentin matrix protein 1 (DMP1), dentin sialophosphoprotein
(DSPP) and matrix extracellular phosphoglycoprotein
(MEPE). It is likely that this protein family arose from the
secretory calcium-binding phosphoprotein family by gene
duplication due to their apparent common evolutionary
heritage, as is elegantly reviewed by Kawasaki & Weiss (2006),
Kawasaki et al. (2007), Kawasaki (2011) and Rowe (2012).
It is therefore somewhat surprising that the SIBLING proteins
have little intrinsic sequence homology and yet they share
the following characteristics: i) all are located to a 375 kb
region on the human chromosome 4q21 and mouse
chromosome 5q, ii) display similar exon structures,
iii) display an Arg-Gly-Asp (RGD) motif that mediates cell
attachment/signalling and iv) are principally expressed in
bone and dentin and are secreted into the ECM during
osteoid formation and subsequent mineralisation. These
similarities in SIBLING gene and protein structure have
been well illustrated in other reviews (Rowe et al. 2000,
Fisher et al. 2001, Fisher & Fedarko 2003, Qin et al. 2004,
Rowe 2004, 2012, Huq et al. 2005, Bellahcene et al. 2008).
All SIBLING proteins undergo similar post-translational
modifications such as phosphorylation and glycosylation, the
extent of which is crucial in determining their function
(Boskey et al. 2009). It has long been known that the
SIBLING proteins have an RGD sequence that facilitates cell
attachment and cell signalling by binding to cell surface
integrins (Fisher et al. 2001). More recently, work by Rowe
et al. (2000, 2004), primarily focused on MEPE, has identified
a new functional domain termed the acidic serine- and
aspirate-rich motif (ASARM) peptide, which is highly
conserved across species. This peptide is proving critical in
the functional activity of the SIBLING proteins, as is
evidenced by the ASARM hypothesis proposed by Peter
Rowe (Rowe 2004, David et al. 2010). This hypothesis
describes the role of the SIBLING ASARM peptides, the cell
membrane-associated glycoprotein phosphate-regulating
endopeptidase homologue, X-linked (PHEX) and fibroblast
growth factor 23 (FGF23) in bone renal phosphate (Pi)
homoeostasis and mineralisation. This hypothesis can be
used to explain numerous disorders of mineralisation inclu-
ding tumour-induced osteomalacia, autosomal-dominant
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hypophosphataemic rickets (ADHR) and X-linked hypopho-
sphataemic rickets (XLH) and will be discussed in more detail
in this review.
The SIBLING proteins have been extensively reviewed
individually; however, in the present review, we focus on
the role that each of the SIBLING proteins has on skeletal
matrix mineralisation and bone remodelling, as well as their
clinical relevance in disorders of bone matrix mineralisation
and bone remodelling (Denhardt & Guo 1993, Ganss et al.
1999, Sodek et al. 2000, Fisher et al. 2001, Prasad et al. 2010).
Matrix mineralisation and bone remodelling
Endochondral ossification is a carefully orchestrated process
responsible for the formation and postnatal linear growth of
the long bones. It involves the replacement of a cartilage
scaffold by mineralised bone. Integral to this process is the
epiphyseal growth plate, a highly specialised cartilaginous
structure derived from a mesenchyme precursor that is
located between the head and the shaft of the bone. The
growth plate consists of chondrocytes arranged in columns
that parallel the axis of the bone surrounded by their ECM
that is rich in collagens, proteoglycans and numerous other
NCPs (Ballock & O’Keefe 2003, Mackie et al. 2008, 2011,
Gentili & Cancedda 2009, Heinegard 2009). The chon-
drocytes of the growth plate sit in distinct cellular zones of
maturation and proceed through various stages of differen-
tiation while maintaining their spatially fixed locations
(Hunziker et al. 1987). It is the terminally differentiated
hypertrophic chondrocyte that mineralises its surrounding
ECM, localised to the longitudinal septa of the growth plate
(Castagnola et al. 1988).
Chondrocyte, as well as osteoblast, mineralisation of the
ECM is widely accepted to involve membrane-limited matrix
vesicles (MVs) within which calcium (Ca2C) and inorganic Pi
accumulate to initiate the biphasic process of mineralisation
(Anderson 2003). When sufficient concentrations of both
exist, Ca2C and Pi begins to precipitate to form hydro-
xyapatite (HA) crystals. This initial stage of mineralisation is
followed by the penetration of HA crystals through the MV
trilaminar membrane and the modulation of ECM compo-
sition, promoting the propagation of HA outside of the MVs
(Anderson 1995, 2003, Wu et al. 2002, Golub 2011).
Mineralisation of the ECM is a tightly regulated process
such that concentrations of Ca2C and Pi are permissive for
effective mineralisation and that the levels of mineralisation
inhibitors such as inorganic pyrophosphate (PPi) and matrix
gla protein are balanced. Extracellular PPi is a well-recognised
and potent inhibitor of mineralisation that is regulated by
ALP (Meyer 1984). In bone, ALP is an ectoenzyme located
on the cell membrane’s outer surface of osteoblasts and
chondrocytes as well as on the membrane of their MVs
(Anderson 1995). Classically, ALP was thought to generate
the Pi required for HA formation; however, it has since been
shown to also hydrolyse PPi, thus achieving a ratio of Pi/PPi
permissive for HA crystal formation and growth (Moss et al.
1967, Majeska & Wuthier 1975, Hessle et al. 2002, Anderson
2003). PPi inhibits the enzymatic activity of ALP, offering a
feedback loop by which mineralisation is regulated (Addison
et al. 2007).
Other regulators of ECM biomineralisation include
nucleotide pyrophosphatase phosphodiesterase 1 (NPP1)
and the ankylosis protein (ANK) that work in synergy to
increase extracellular PPi levels. While NPP1 ectoplasmically
generates PPi from nucleoside triphosphates, ANK mediates
its intracellular to extracellular channelling (Hakim et al. 1984,
Terkeltaub et al. 1994, Ho et al. 2000). Analysis of mutant
mice deficient in ALP function (Akp2K/K (AlplK/K)), which
were surprisingly found to exhibit normal levels of bone
mineralisation at birth, led us to search for other phosphatases
that might also contribute to bone mineralisation, and this
led to our description of PHOSPHO1 (Houston et al. 2002).
As its discovery and characterisation, PHOSPHO1 has been
proposed to play a crucial role in the accumulation of Pi
within the MVand bone mineralisation (Houston et al. 2002,
Stewart et al. 2006, Roberts et al. 2007, 2008, MacRae et al.
2010, Huesa et al. 2011). PHOSPHO1 has a non-redundant
functional role during bone mineralisation, and the ablation
of both PHOSPHO1 and ALP results in the complete
lack of bone mineralisation throughout the whole skeleton
(Yadav et al. 2011).
Mineralisation of the ECM not only facilitates the
deposition of HA but also enables vascular invasion, a
significant phase in endochondral ossification and the
development of the skeleton. Hypertrophic chondrocytes
express factors such as vascular endothelial growth factor
(VEGF) that induce vascular invasion, allowing the infiltra-
tion of osteoclasts and differentiating osteoblasts that resorb
the cartilaginous mineralised matrix and replace it with
trabecular bone respectively (Zelzer et al. 2002). This process
of bone remodelling continues throughout life and is
responsible for the annual replacement of w10% of the
adult skeleton (Frost 1990). Tight regulation of this process
maintains an equilibrium such that disorders of bone mass,
such as osteoporosis or osteopetrosis, do not occur (Manolagas
2000). During bone resorption, osteoclasts adhere to the bone
surface forming a tight connection and allowing efficient
resorption through extracellular acidification (Palokangas
et al. 1997, Mellis et al. 2011). Like bone formation, this is
under tight control by a variety of autocrine, paracrine, and
endocrine factors and is thought to be primarily regulated by
the terminally differentiated osteoblast, the osteocyte (Hill
1998, Manolagas 2000, Henriksen et al. 2009).
The SIBLING family of proteins
The SIBLING family of proteins consists of OPN, BSP,
DMP1, DSPP and MEPE, all of which share common
characteristics. Despite this, they display differential tissue
distributions and functions that are highly dependent on their
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post-translational modifications. The key role that each of the
SIBLING proteins plays in biomineralisation is described in
detail below (Fig. 1).
Matrix extracellular phosphoglycoprotein
MEPE, originally identified as a substrate for PHEX, is
primarily expressed by osteocytes as well as by osteoblasts
(Nampei et al. 2004). In the mouse skeleton, Mepe is detected
as early as 2 days post partum, and several regulators of this
expression have been documented in the literature (Lu et al.
2004). The addition of FGF2 to osteoblasts downregulates
Mepe levels in a dose-dependent manner. The mechanism of
action is part through the MAPK pathway (Zhang et al. 2004).
Furthermore, osteoblasts stimulated by bone morphogenetic
protein 2 (BMP2) also display a decreased Mepe expression
level (Siggelkow et al. 2004). Recently, it has been shown that
Wnt3a, a canonical Wnt signalling stimulator, induces
this BMP2 signal and also as has its own direct stimulatory
effects on Mepe expression through b-catenin and LEF1
(Cho et al. 2011).
The first evidence for a direct role of MEPE in bone
mineralisation came from the increased mRNA expression
levels of Mepe seen during osteoblast matrix mineralisation
(Petersen et al. 2000, Argiro et al. 2001). The development of
a Mepe null mouse further fuelled the proposed role of MEPE
in mineralisation. This mouse model had increased bone mass
with associated increased numbers and thickness of trabe-
culae. The mineral apposition rate (MAR) was dramatically
increased as was the activity of Mepe null osteoblasts in culture
(Gowen et al. 2003). Conversely, the overexpression of MEPE
in mice, under the control of the col1a1 promoter, leads to
a growth and mineralisation defect due to a decrease in
bone remodelling. Mepe transgenic mice displayed wider
epiphyseal growth plates and expanded primary spongiosa
and a significant decrease in the MAR (David et al. 2009).
Like the other SIBLING proteins, the activity of MEPE is
dependent on its state of cleavage and its phosphorylation.
Recent work has identified the 2.2 kDa ASARM peptide of
MEPE as the functional component of MEPE. This ASARM
peptide is highly conserved across the SIBLING proteins,
and in MEPE it is located immediately downstream of a
Figure 1 A schematic figure detailing the (A) expression and (B) function of the SIBLING
family of proteins: dentin sialophosphoprotein (DSPP), dentin matrix protein 1 (DMP1), bone
sialoprotein (BSP), matrix extracellular phosphoglycoprotein (MEPE) and osteopontin (OPN).
MEPE is expressed by osteoblasts and the terminally differentiated osteoblast (indicated by the
dashed arrow), the osteocyte. MEPE directly inhibits hydroxyapatite (HA) formation in bone
through its cleavage product, a small acidic serine- and aspirate-rich motif (ASARM) that
undergoes post-translational phosphorylation. MEPE also inhibits the numbers and activities
of osteoclasts. OPN has similar functional effects to MEPE in bone mineralisation; however,
along with BSP, it is also expressed by osteoclasts. BSP is well established as a HA nucleator
and is proving pivotal in diseases of increased bone formation as it increases
osteoclastogenesis. DMP1 and DSPP are both expressed by bone and both are processed into
numerous fragments. While DSPP promotes biomineralisation in both bones and teeth,
DMP1 inhibits it. The full details of the cleavage products of the SIBLING proteins and their
roles in biomineralisation are detailed in Table 1.
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cathepsin B cleavage site (Rowe et al. 2000). The
administration of the MEPE–ASARM peptide in vitro and
in vivo can inhibit the uptake of Pi. This is likely through a
decreased expression of the type II sodium-dependent Pi
cotransporter NPT2a, or through the promotion of FGF23
expression, a potent inhibitor of Pi (Liu et al. 2007, Dobbie
et al. 2008, Marks et al. 2008, Martin et al. 2008, David et al.
2010, Shirley et al. 2010). It has, however, been suggested that
MEPE may have a direct effect on matrix mineralisation
outwith the supply and demand of Pi. The ASARM peptide
of MEPE inhibits mineralisation by osteoblasts by directly
binding to HA crystals (Addison et al. 2008, Martin et al.
2008). Integral to this inhibitory effect is the post-translational
phosphorylation of the ASARM peptide at three serine
residues. In osteoblasts, it appears that without this
phosphorylation, the ASARM peptide has no effect on
mineralisation (Addison et al. 2008, Martin et al. 2008). This is
not the only evidence for a role for MEPE in the promotion
of mineralisation. Recently, it has been shown that a
truncated form of MEPE, which has the ASARM peptide
removed, can promote bone mineralisation in culture and in
mice (Sprowson et al. 2008). Furthermore, a mid-terminal
fragment of MEPE (termed ‘AC100’) has been shown to
enhance cell binding, through the stimulation of focal adhesion
kinase and ERK (Hayashibara et al. 2004). Taken together,
these results highlight the importance of post-translational
processing in determining the functional role of MEPE.
The interaction between MEPE and PHEX is well
documented in the literature. PHEX plays a central role in
the protection of MEPE from proteolytic cleavage by
cathepsin B; it can bind to MEPE and prevent the release of
the ASARM peptide (Guo et al. 2002). The Hyp mouse, a
spontaneous Phex knockout model, has an increased
expression of cathepsin D, an upstream activator of
cathepsin B (Rowe et al. 2006). This therefore suggests that
PHEX can alter the activation of cathepsin B and therefore
the cleavage of MEPE to the ASARM peptide. Furthermore,
PHEX can bind to free ASARM peptides, therefore
neutralising their activity by sequestration and hydrolysis
(Liu et al. 2007, Addison et al. 2008, Martin et al. 2008).
Recently, it has been shown that sclerostin (SCL), a potent
inhibitor of the canonical Wnt signalling pathway, may act
through the MEPE–PHEX axis, highlighting its significance
in biomineralisation (Atkins et al. 2011).
Mepe transgenic mice display a decrease in ALP enzyme
activity in both the growth plate and the primary spongiosa
(David et al. 2009). In vivo, the addition of the phosphorylated
ASARM peptide also reduced the number of ALP-positive
cells in an osteoblast cell culture model (Martin et al. 2008).
However, this remains controversial as normal ALP activity
has been reported in osteoblasts treated with phosphory-
lated ASARM peptide (Addison et al. 2008). In the
MEPE-overexpressing mouse, vascularisation is increased, as
is VEGF expression, highlighting a role for MEPE in
angiogenesis, an important stage in endochondral ossification
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infiltration of osteoclasts for bone resorption. Interestingly,
mice administered with recombinant MEPE or transgenic for
MEPE had a significant decrease in the numbers and activity
of osteoclasts (Hayashibara et al. 2007, David et al. 2009).
This therefore suggests that MEPE is highly relevant to both
bone mineralisation and Pi homoeostasis. Future studies
should focus on the interactions between MEPE and the Wnt
signalling pathway due to its known implications in bone and
cartilage mechanobiology.
Osteopontin
OPN, also known as secreted phosphoprotein 1 (SPP1), is a
34 kDa protein, originally identified as the bridge between
the cells and HA in the ECM of bone (Sodek et al. 2000).
The protein and gene structures, as well as the localisation, of
OPN are well described in several excellent reviews
(Denhardt & Guo 1993, Sodek et al. 2000, Fisher et al.
2001). In bone, OPN is produced by osteoblasts and
osteocytes, as well as osteoclasts (Dodds et al. 1995, Sodek
et al. 1995, Zohar et al. 1997). It has also been localised to
hypertrophic cartilage of the growth plate (Landis et al. 2003).
Several studies have documented the inhibitory role of
OPN in HA formation and growth (Boskey et al. 1993, 2012,
Hunter et al. 1994). It has also been shown to inhibit
mineralisation in vascular smooth muscle cells (Wada et al.
1999, Jono et al. 2000). This inhibitory role of OPN is
confirmed further by analysis of the Opn knockout mouse
that has increased mineral content and size, as shown by
Fourier transform infrared spectroscopy analysis in two
different lines of OpnK/K mice at two different ages (Boskey
et al. 2002). More specifically, it has recently been shown that
the ASARM peptide of OPN inhibits ECM matrix
mineralisation by binding to HA crystals (Addison et al.
2010, Boskey et al. 2012). Furthermore, a recent study by
Boskey et al. showed the C- and N-terminal fragments of
OPN, in this study, derived from milk OPN to promote
de novo HA formation. Conversely, a central fragment
inhibited it as is similar to bone OPN (Boskey et al. 2012).
This highlights the importance of the post-translational
fragmentation of OPN in determining its function. The
study by Addison et al. (2010) also showed that, like MEPE,
the ability of the OPN-ASARM to inhibit mineralisation is
dependent on its phosphorylation at specific serine residues.
The importance of post-translational phosphorylation is
further confirmed when examining the interaction between
OPN, ALP and PPi. Several studies have shown that ALP
dephosphorylates OPN, thus preventing much of its
inhibitory activity on HA formation and growth (Boskey
et al. 1993, Hunter et al. 1994, Jono et al. 2000). Furthermore,
PPi directly upregulates Opn expression in osteoblasts, and
therefore the hydrolysis of PPi by ALP will have a significant
effect on the expression levels of OPN (Addison et al. 2007).
This is in concordance with the Enpp1-deficient mouse
in which PPi deficiency brings about a deficiency
in OPN ( Johnson et al. 2003). The Akp2-deficient mouse
displays a similar decreased PPi and OPN with an associated
hypomineralisation. This hypomineralisation can be partially
rescued by the double knockout: the Akp2K/K/OpnK/K
mouse (Harmey et al. 2006). Although previous studies have
implicated a Pi-dependent mechanism (Beck et al. 2000, Beck
& Knecht 2003), work by Addison et al. has implicated the
MAPK signalling pathways responsible for the regulation of
OPN by PPi.
Analysis of the OpnK/K mouse has also indicated a role for
OPN in the function and activity of osteoclasts. In these mice,
there is an increase in osteoclast production, which could be a
compensatory mechanism for the observed disabled motility
and resorption activity of the osteoclast cells (Rittling et al.
1998, Chellaiah et al. 2003). Further studies have attempted to
elucidate the precise role of OPN in bone resorption and have
implicated CD44, a major cell surface receptor for
hyaluronate (Aruffo et al. 1990) and a receptor for OPN
(Suzuki et al. 2002, Chellaiah et al. 2003).
The loading of the skeleton in daily function results in the
continuous modelling and remodelling of the skeleton (Frost
1990). This loading upregulates OPN expression in bone
in vivo, and more recently it has been shown that the cyclical
loading of rabbit joints has shown increased cellular OPN
expression in the cartilage as well (Terai et al. 1999, Morinobu
et al. 2003, Gross et al. 2005, King et al. 2005, Fujihara et al.
2006). This upregulation in response to loading has also been
shown in in vitro cell cultures, and it is thought that MAPKs
are involved in the transduction of the stimulus for OPN
expression (Klein-Nulend et al. 1997, Owan et al. 1997,
You et al. 2001). These intriguing results provide some clues
into the molecular mechanisms underpinning adaptive
bone remodelling.
Bone sialoprotein
BSP is a 70–80 kDa protein for which its gene and protein
structures have been extensively reviewed (Ganss et al. 1999).
The localisation of BSP is unique to the SIBLING family of
proteins as it is exclusively located to the mineralised tissues
such as bone, dentin and mineralising cartilage (Bianco et al.
1991, Chen et al. 1991). In bone, it is expressed in abundance
by osteoblasts, as well as by osteoclasts, osteocytes and
chondrocytes (Fisher & Fedarko 2003, Gordon et al. 2007).
During embryogenesis, BSP is first expressed at the onset of
bone formation, thus suggesting it to be a strong candidate for
a role in HA nucleation (Chen et al. 1992). This certainly
seems convincing as numerous studies have documented BSP,
which is localised to MVs, to be involved in the initial
formation of HA (Harris et al. 2000, Fisher et al. 2001,
Tye et al. 2003, Wang et al. 2006, Nahar et al. 2008). Indeed,
the Bsp null mouse displays shorter, hypomineralised bones
with associated higher trabecular bone mass with low bone
turnover (Malaval et al. 2008). Moreover, it has been shown
that as little as 9 nM BSP is required to nucleate HA,
and recently the overexpression of BSP in osteoblasts has
been shown to enhance mineralisation (Hunter et al. 1996,
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Gordon et al. 2007). Similarly, osteoblast cultures grown in
the presence of an anti-BSP antibody exhibit reduced
mineralisation (Cooper et al. 1998, Mizuno et al. 2000). This
nucleation potency is increased on BSP binding to collagen,
suggesting a cooperative relationship (Baht et al. 2008).
The role of BSP as a HA nucleator is thought to involve the
membrane-bound enzyme, ALP. Indeed, in the presence of
BSP, high levels of ALP activity can promote the initiation of
mineral deposition (Wang et al. 2006). This is further
confirmed in BSP-overexpressing cell cultures that have a
higher ALP activity (Valverde et al. 2008). It is likely that,
like the other SIBLING proteins, the function of BSP is
highly dependent on its post-translational modification
(Stubbs et al. 1997).
BSP increases osteoclastogenesis and therefore bone
resorption, making it crucial in the homoeostasis of bone
remodelling (Ross et al. 1993, Raynal et al. 1996, Malaval et al.
2008, Valverde et al. 2008). This has been further examined in
BSP transgenic mice in which an uncoupling of bone
formation and resorption resulted in an osteopenia-like
phenotype (Valverde et al. 2008). Furthermore, serum BSP
expression in bone diseases characterised by excessive bone
resorption, e.g. Paget’s disease, is abnormally high (Valverde
et al. 2008). This highlights the need to investigate whether
antibodies to BSP could decrease the pathological bone loss
observed in the Bsp transgenic mouse and as such be an
important therapeutic target for patients with bone diseases
characterised by high BSP.
Dentin sialophosphoprotein
The role of DSPP in biomineralisation has recently been
reviewed (Prasad et al. 2010). Although originally thought to
be exclusively expressed by dentin, DSPP is also expressed in
bone, cementum and in non-mineralising tissues including
the lung and kidney (Qin et al. 2002, Baba et al. 2004, Alvares
et al. 2006, Ogbureke & Fisher 2007, Verdelis et al. 2008).
Analysis of the Dspp knockout mouse reveals defects in
dentin mineralisation (Sreenath et al. 2003), as well as bone
hypomineralisation (Verdelis et al. 2008). In humans, a
mutation in the DSPP gene results in dentinogenesis
imperfecta, characterised by dentin hypomineralisation and
significant tooth decay (Kim et al. 2005). Of particular interest
are the variations in the mineralisation properties observed at
different ages in the DsppK/K mouse. At 5 weeks of age, these
mice displayed accelerated mineralisation, while at 9 months
of age significant changes in bone structural properties were
observed. This therefore suggests that DSPP has roles not only
in the initial mineralisation of bone but also in the
remodelling of the skeleton and therefore on bone turnover
(Verdelis et al. 2008).
DSPP is proteolytically processed to two fragments: dentin
phosphoprotein and dentin sialoprotein (DSP), both of which
have important functions in mineralisation. Interestingly, a
third fragment called dentin glycoprotein (DGP) has been
identified as being cleaved from the C-terminal end of DSP
by matrix metalloproteinase 2 (MMP2) and MMP20
(Yamakoshi et al. 2005). It has been suggested that the
proteolytic processing of DSPP to DPP, DSP and DGP is the
activating stage in the mechanism of DSPP function (Zhang
et al. 2001, Qin et al. 2004, Prasad et al. 2010). The cleavage
of DPP from DSPP is catalysed by a group of zinc
metallopeptidases that includes BMP1, and it is this fragment
of DSPP that contains the ASARM peptide (Tsuchiya et al.
2011). Various studies have shown DPP to be important in
the formation and growth of HA as it has a strong affinity to
Ca2C when bound to collagen fibrils (Boskey et al. 1990,
Saito et al. 1997, He et al. 2005). The phosphorylation of DPP
is believed to be crucial to its function as removal of the
phosphate groups results in a loss of its role in HA promotion
(Saito et al. 1997). On the other hand, although DSP has been
shown to be involved in the initiation of mineralisation, it
appears not to have a functional role in the maturation of the
tissue (Suzuki et al. 2009). The mechanism by which DSPP
regulates HA formation is thought to involve the canonical
BMP2 signalling pathway as BMP2 has been shown to
increase Dspp expression via BMPR Smads, Runx2 and DIx5
(Iohara et al. 2004, Chen et al. 2008, Cho et al. 2010).
The vast information obtained about the DPP and DSP
fragments over the past few decades serves to strengthen
knowledge on the role of DSPP in biomineralisation. Future
studies should focus on the recently identified DGP fragment
and its specific functional role, as well as further detailing the
mechanisms of DSP and DPP functions.
Dentin matrix protein 1
DMP1 was first cloned from dentin and has since been
identified in dentin, bone and cementum as well as in other
non-mineralised tissues (George et al. 1993, MacDougall et al.
1998, Sun et al. 2011). In bone, DMP1 is primarily expressed
not only by osteocytes but also by osteoblasts and
hypertrophic chondrocytes (Toyosawa et al. 2001, Fen et al.
2002, Feng et al. 2003).
The first evidence of a role for DMP1 in biomineralisation
was its promotion of ECM mineralisation in MC3T3 cells
overexpressing DMP1 (Narayanan et al. 2001). The gener-
ation of a Dmp1-null mouse has further fuelled the potential
role of DMP1 in bone mineralisation. The knockout mice
have significantly lower mineral content when compared
with their control counterparts (Ling et al. 2005). Interest-
ingly, the re-expression of DMP1 in these Dmp1 null mice
rescues the skeletal defects seen (Lu et al. 2011).
Additionally, the Dmp1-deficient mice displayed a severe
defect in cartilage formation as is similar to the human
hereditary hypophosphatemic disease autosomal recessive
hypophosphatemic rickets (ARHR) that is caused by
mutations in Dmp1 (Feng et al. 2006, Farrow et al. 2009).
These mice display a highly widened growth plate, suggesting
an impairment of mineralisation at the chondro-osseous
junction. Indeed, this cartilage defect results in a phenotype
resembling dwarfism with chondrodysplasia (Ye et al. 2005).
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It has since been shown that the distorted growth plates seen
in the Dmp1 null mouse are in fact due to disorganisation as
opposed to growth plate enlargement (Sun et al. 2010).
Interestingly, the Dmp1 null mouse displays increased serum
FGF23 levels and associated hypophosphataemia (Feng et al.
2006). Correction of this hypophosphataemia, by a high Pi
diet, restored the Dmp1 null mouse growth plate defect (Feng
et al. 2006). Furthermore, the DMP1K/K and FGF23K/K
double knockout mice display growth plate widths similar to
that seen in the single Fgf23 null mouse (Liu et al. 2008). This
therefore suggests that the defective cartilage mineralisation
observed in the Dmp1 null mouse is not simply a direct
consequence of the lack of DMP1. More recently, a transgenic
mouse has been developed the expresses a mutant form of
Dmp1. The substitution of Asp213 with Ala213 blocks the
processing of mouse Dmp1. Crossing this transgenic mouse
with the Dmp1 null mouse recovered the growth plate
disorganisation seen in the null mouse alone (Sun et al. 2011).
Like other SIBLING proteins, the proteolytic processing
of DMP1 appears essential to its function and localisation.
In bone and dentin, DMP1 is processed to two fragments: one
37 kDa fragment originating from the NH2-terminal and
one 57 kDa fragment originating from the COOH-terminal
(Qin et al. 2003). In DMP1, it is the COOH-terminal fragment
that contains the ASARM peptide (Martin et al. 2008). The
full-length DMP1 is expressed at much lower levels than its
fragments, which themselves have different localisation patterns
in bone (Huang et al. 2008, Maciejewska et al. 2008). In the
growth plate, while the NH2-terminal fragment is localised
to the resting, proliferation and pre-hypertrophic zones, the
COOH-terminal fragment is found in the calcification front
and ossification zone (Maciejewska et al. 2008).
The localisation of the COOH-terminal fragment is
consistent with areas that are targets for the vascular invasion
of the cartilage, a significant phase in matrix mineralisation.
DMP1 has been postulated to play a role in angiogenesis as
treatment with DMP1-induced vascular endothelial cadherin
(VE-cadherin) and inhibited the VEGFR2 activity, therefore
suggesting DMP1 to be an inhibitor of VEGF-induced
angiogenesis (Pirotte et al. 2011). The direct role of DMP1 on
HA formation is highly dependent on its processing and its
post-translational modification. When phosphorylated, full-
length DMP1 has been shown to inhibit the formation and
growth of HA; however, its dephosphorylated form and its
two fragments are well-established nucleators of HA
formation (He et al. 2003, Tartaix et al. 2004, Gericke et al.
2010). Thus, native DMP1 inhibits mineralisation unless it
becomes cleaved or dephosphorylated, in which case it
initiates mineralisation (Tartaix et al. 2004).
In addition to the ASARM peptide, signalling pathways are
involved in DMP1 function and have recently been
investigated in osteoblasts. Wu et al. (2011) showed that
DMP1, through the activation of the avb3 integrin, activated
the downstream effectors of the MAPK pathway, ERK and
JNK (Wu et al. 2011). Concomitant to this is the stimulation
of phosphorylated JNK translocation coupled with an
upregulation of phosphorylated c-jun activation (Wu et al.
2011). Furthermore, it has been shown that the internal-
isation of DMP1 not only results in a release of stored Ca2C
but also activates p38 MAP kinase (Eapen et al. 2011). Dmp1
null mice have distinct abnormalities in the morphology and
maturation of their osteocytes (Feng et al. 2006). The two
DMP1 fragments also display differing localisation patterns in
osteocytes (Maciejewska et al. 2009), suggesting that
osteocytes may play a critical role in ECM mineralisation
that involves DMP1. This is further supported by the
stimulation of DMP1 expression in response to mechanical
loading (Gluhak-Heinrich et al. 2007). Furthermore, the
deletion of DMP1 leads to a dramatic increase in Fgf23
expression in the osteocytes, likely due to the defects seen in
osteoblast–osteocyte transition (Feng et al. 2006, Qin et al.
2007). FGF23, a hormone produced by osteoblasts and
osteocytes, has allowed the definition of bone as an endocrine
organ as it targets the kidney to regulate Pi homoeostasis. This
therefore suggests that DMP1 can control Pi levels, as is
consistent with the hypophosphataemia observed in the
Dmp1 null mouse (Ye et al. 2005, Feng et al. 2006). This
important discovery has allowed the further development of
the ASARM hypothesis and has implicated DMP1 as central
to biomineralisation and Pi homoeostasis.
The ASARM hypothesis and bone diseases
Accumulating evidence has implicated the members of the
SIBLING family of proteins in bone and mineralisation
diseases. Their varying involvements in the process of matrix
mineralisation make them potentially attractive candidates
for therapeutic targets and therapies.
XLH is the most common form of inherited rickets,
characterised by defective bone and tooth mineralisation,
growth retardation and defective renal reabsorption of Pi
(Carpenter et al. 2011). Mutations in PHEX have been
associated with XLH in humans and have led to the
development of the Hyp mouse (Holm et al. 1997).
Hypophosphataemia alone is insufficient to explain the
bone defect seen in the Hyp mouse as correction of the
hypophosphataemia failed to correct the mineralisation defect
observed (Ecarot et al. 1992, Rowe et al. 2006). Furthermore,
when osteoblast cells from the Hyp mouse are grown in
culture, they have defective ECM production and thus
reduced mineralisation (Xiao et al. 1998). This therefore
suggests that PHEX has multiple substrates that are involved
in regulating mineralisation directly and this has allowed the
creation of the ASARM hypothesis, as previously mentioned
and as has recently been elegantly reviewed (Rowe 2004,
2012, David et al. 2010). The ASARM hypothesis is based on
the concept of a minhibin, an unknown secreted factor that is
a substrate for PHEX and therefore would accumulate in the
Hyp mouse and in patients with XLH.
MEPE was first identified as a potential substrate for
PHEX; however, in vitro studies have failed to demonstrate
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PHEX-dependent hydrolysis of MEPE (Guo et al. 2002).
It has also been suggested that PHEX is likely responsible for
the cleavage of DMP1 and DSPP, as it has a strong preference
for cleaving bonds at the N-terminal of these two SIBLING
proteins (Qin et al. 2004). However, analysis of the Hyp
mouse indicated no differences in Dmp1 and Dspp expression
in comparison with their WT controls, suggesting that DMP1
and DSPP are in fact properly processed in the Phex-deficient
mouse (Zhang et al. 2010). In addition to this, there is an
accumulation of SIBLING ASARM peptides in the Hyp
mouse and patients, thus challenging the hypothesis that the
SIBLING proteins are substrates for PHEX. Instead, it
appears that it is the ASARM peptide that PHEX digests
(Addison et al. 2008, 2010), and the rise in SIBLING
ASARM peptides in the Hyp mouse and XLH therefore
further implicates them as substrates for PHEX (Bresler et al.
2004, Martin et al. 2008, Boukpessi et al. 2010).
It also appears that PHEX regulates Fgf23 expression as
increased Fgf23 expression is observed in the Hyp mouse and
patients with XLH (Liu et al. 2006). Accordingly, Fgf23
knockout reversed the hypophosphataemia observed in Hyp
mice (Sitara et al. 2004). Although initial studies appeared to
confirm FGF23 as a substrate for PHEX, this has not been
shown since (Bowe et al. 2001). Interestingly, a similar
increase in FGF23 expression is observed in models of loss
of DMP1, along with associated ARHR (Feng et al. 2006,
Lorenz-Depiereux et al. 2006). This has led to the suggestion
that a PHEX–DMP1 interaction is responsible for orche-
strating mineralisation through decreasing FGF23 expression.
Furthermore, current paradigm suggests that ASARM
peptides can competitively displace this PHEX complex
and this would therefore increase FGF23 activity, as is seen
in the Hyp mouse and in patients with XLH (David et al.
2010, Martin et al. 2011, Rowe 2012).
Additionally, the accumulation of ASARM peptides can
directly inhibit NaC-dependent Pi uptake in the kidney, as
has been shown both in vivo and in vitro, thus exacerbating
the upregulation of FGF23 expression, the downregulation
of 1,25(OH)2D3 and the inhibition of hypophosphataemia
observed in XLH, ARHR and ADHR (Rowe et al.
2004, Dobbie et al. 2008, Marks et al. 2008, David et al.
2010, Shirley et al. 2010). The decrease in 1,25(OH)2D3
provides a feedback loop for increased PHEX expression
through the increased expression of a 100 kDa transcription
factor, a requirement for this PHEX expression (Ecarot &
Desbarats 1999).
This regulatory loop of ASARM, PHEX and FGF23
expression and function highlights the multiple and complex
functions of the SIBLING ASARM peptides in both Pi
homoeostasis and matrix mineralisation in disease and
health. It is therefore vital that we endeavour to fully establish
the interactions within this hypothesis to allow future
therapeutic developments.
Certainly, much remains to be learnt regarding the in vivo
role of the SIBLING proteins and the ASARM peptide in
bone diseases. This is not just in disorders related to Pi
homoeostasis but also to other bone diseases such as
osteoporosis and osteoarthritis (OA). Indeed, there are close
links between the SIBLING proteins and OA, with serum
BSP and OPN levels significantly correlating with OA disease
severity (Petersson et al. 1998, Hasegawa et al. 2011).
Furthermore, microarray data and gene analysis studies have
highlighted MEPE and DMP1 as being differentially expressed
in OA tissues (Hopwood et al. 2007, Sanchez et al. 2008). The
interaction between MEPE and SCL, as described previously,
is an exciting development due to the known anabolic effects
of the SCL-neutralising antibodies on osteoporosis (Li et al.
2009, 2010, Atkins et al. 2011). This could therefore warrant
investigation into the potential therapeutic use of MEPE in
osteoporosis and potentially in OA due to the ever emerging
role of SCL in this debilitating disease (Power et al. 2010, Chan
et al. 2011, Delgado-Calle et al. 2011).
Conclusions
The aim of this review is to present an overview of the role of
each member of the SIBLING family of proteins in matrix
mineralisation. The SIBLING proteins are principally found
in bone and dentin and are secreted into the ECM during its
formation and subsequent mineralisation. It is apparent that
the functional role of the SIBLING proteins is highly
dependent on their state of cleavage and their post-
translational modification (Table 1). Furthermore, the
identification of the ASARM peptide, which is present across
the SIBLING proteins, is proving critical in the functional
activity of the SIBLING proteins. Future investigations
should focus on determining the underpinning interactions
between the SIBLING proteins and their place within the
current ASARM hypothesis. This will allow the investigation
into their potential therapeutic application to disorders of
mineralisation including disorders of hypophosphataemia,
osteoporosis and OA.
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Cartilage development and degeneration: a Wnt Wnt situation
Katherine Ann Staines*, Vicky Elizabeth MacRae and Colin Farquharson
The Roslin Institute and Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Easter Bush, Midlothian, Scotland
The Wnt signaling pathway plays a crucial role in the development and homeostasis of a variety of adult tissues and, as such, is emerging as
an important therapeutic target for numerous diseases. Factors involved in the Wnt pathway are expressed throughout limb development and
chondrogenesis and have been shown to be critical in joint homeostasis and endochondral ossification. Therefore, in this review, we discuss
Wnt regulation of chondrogenic differentiation, hypertrophy and cartilage function. Moreover, we detail the role of the Wnt signaling path-
way in cartilage degeneration and its potential to act as a target for therapy in osteoarthritis. Copyright © 2012 John Wiley & Sons, Ltd.
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INTRODUCTION
The Wnt signaling pathway is emerging as a potent regula-
tor of cellular development and function in a variety of
tissues and as such has been the focus of numerous studies
and review articles. More specifically, Wnt signaling is
required for many embryonic developmental processes
including sex determination and organ development.1,2
Post-natally, Wnt signaling is crucial for the regulation
of skeletal bone mass throughout life, and over the past
2 decades, the role of Wnt in cartilage development and
function has been established.3
Cartilage is a tough, flexible and elastic connective tissue,
which has numerous functions. It is mainly composed of an
abundant collagen and proteoglycan-rich extracellular
matrix (ECM) in which the primary cell type of cartilage,
the chondrocyte, resides. This composition gives rise to a
highly hydrated tissue, which allows effective completion
of its primary functions; to disperse forces on the joints
during movement and to act as a template for bone formation
and longitudinal bone growth. Abnormalities in the ECM
cause a multitude of skeletal malformation syndromes, as
well as degenerative diseases, such as osteoarthritis (OA)
and rheumatoid arthritis (RA), which will be discussed within
this review.
The expression of Wnt factors in the embryonic skeleton
have been well detailed in comprehensive studies by
Summerhurst et al. and Witte et al.4,5 The vast array of
Wnt factors expressed throughout the development of the
embryonic skeleton suggests an important role for Wnt
signaling pathway in this process. This review summarizes
the current knowledge on the role of the Wnt signaling
components in cartilage development and function and
highlights their potential therapeutic use. Despite numerous
reviews about Wnt signaling, one which explores all these
themes has not been published in recent years.
Wnt signaling
Wnts constitute a family of secreted signaling proteins that
bind with their respective receptors and activate such signal-
ing pathways as the Wnt/b-catenin pathway, the Wnt/Ca2+
pathway, the Wnt/planar cell polarity (Wnt/PCP) pathway
and the Wnt/protein kinase A (Wnt/PKA) pathway.6–8 The
repertoire of Wnt ligands, Wnt receptors and Wnt agonists
and antagonists is large and complex, with various interac-
tions occurring that are important in embryogenesis, postna-
tal development and tissue homeostasis throughout life. For
this reason, the Wnt signaling pathway, in particular the
Wnt/b-catenin pathway, is one of the most intensively
studied signaling pathways in mammalian cells.
The Wnt/b-catenin pathway. The Wnt/b-catenin pathway,
often referred to as the canonical Wnt pathway, is activated
upon binding of Wnt to Frizzled (Fz) receptors and low-
density lipoprotein receptor-related protein (LRP) 5/6
co-receptors at the cell surface.9–11 Currently, there are at
least 7 of the 19 known Wnt proteins that activate this path-
way. In the absence of appropriate Wnt ligands, b-catenin is
phosphorylated using glycogen synthase kinase 3 (GSK3)
and, subsequently, is targeted for ubiquitination and degrad-
ation via the proteasome (Figure 1).12 However, in the pres-
ence of a Wnt ligand, its binding to the receptor complex
initiates the activation of an intracellular protein termed
Dishevelled (Dvl) which in turn inhibits GSK3 activity.13
Therefore, b-catenin is not targeted for degradation and
instead it accumulates and translocates to the nucleus. Here
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it activates the transcription of a wide range of Wnt asso-
ciated genes such as c-myc and cyclin D1 (Figure 1).14
There are several known activators of the Wnt/b-catenin
pathway including norrin and R-spondin.15 The R-spondin
family of proteins have recently been described, and
although they are structurally unrelated to the classic Wnt
ligands, they also are able to activate the Wnt/b-catenin
signaling pathway through interacting with the LRP5/6
co-receptor complex. Furthermore, the R-spondins, of
which, there are four described, are able to prevent the
interaction of the LRP5/6 complex with the Wnt antagonists
later described.16–18 Although knockout models of all
R-spondins have been described, it is only the R-spondin2
null mouse, which exhibits a skeletal phenotype.19–21
The non-canonical Wnt signaling pathway. In animal cells,
the three non-canonicalWnt pathways described in the litera-
ture remain poorly understood. These pathways function
independently of b-catenin, and thus, Wnt binds solely to
Fz receptors and to co-receptors such as ROR2 and RYK
but not to LRP5/6 co-receptors.22 Wnt binding activates the
Wnt/Ca2+ pathway, the Wnt/PCP pathway or the Wnt/PKA
pathway. The Wnt/PCP pathway influences the planner
organization of cells by inducing modifications to the actin
cytoskeleton through activation of the small GTPase RhoA
and c-Jun amino (N)-terminal kinase (JNK).23 The Wnt/
PKA pathway plays a role in myogenic gene expression
through the activation of cyclic AMP.24 The Wnt/Ca2+
pathway increases intracellular calcium levels through
Fz-activated phospholipase C and phosphodiesterase. This
subsequently regulates cell adhesion and motility.25 The
Wnt/Ca2+ pathway also inhibits the canonical Wnt pathway
by promoting GSK3-independent b-catenin degradation.26
Wnt signaling antagonists. There are several reported
antagonists of Wnt signaling, reflecting its complexity and
importance in cellular function. These known inhibitors
include Dickkopfs (Dkks), secreted Fz-related proteins
(sFRPs) and sclerostin (SCL). sFRPs antagonize the Wnt
pathway by binding directly to Wnt proteins or by prevent-
ing their binding to the Fz receptors, therefore blocking both
Wnt pathways.27 Interestingly, the sFRPs compete with
each other to facilitate their actions.28 The Dkk family of
proteins consist of four members (Dkk1-Dkk4), which are
known to antagonize Wnt signaling by binding to the
LRP5/6 Wnt co-receptors, thus blocking the canonical
pathway.27 Additionally, Dkks also bind to another cell sur-
face protein, Kremen.29 In a similar fashion to Dkk, SCL, a
secretory product of the mature osteocyte, also specifically
binds to the LRP5/6 Wnt coreceptors antagonizing the
Wnt pathway.30 More recently, LRP4 has been implicated
as a receptor for SCL.31 Other known antagonists of the
Wnt signaling pathway include Wnt-1-induced secreted pro-
tein (WISE), Wnt-inhibitory factor 1 (Wif-1) and Chibby.1
Figure 1. The canonical Wnt signaling pathway. Wnt ligands bind to Fz receptors and LRP5/6 coreceptors to initiate the canonical Wnt pathway. (A) Upon
binding, Dishevelled is activated, which in turn, inhibits GSK3 activity. This allows translocation of b-catenin to the nucleus where it activates the transcription
of Wnt-associated genes. (B) In the absence of appropriate Wnt ligand binding, because of inhibitors such as sFRP, Dkk1 and SCL, GSK3 becomes
phosphorylated, which in turn, phosphorylates b-catenin. Phosphorylated b-catenin is subsequently targeted for ubiquitination and proteasomal degradation
k. a. staines ET AL.
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The role of Wnt in chondrogenesis
Chondrogenesis, the differentiation of mesenchymal precur-
sor cells into chondrocytes, is critical for cartilage develop-
ment. These mesenchymal precursors arise from three
sources: cells derived from the neural crest, which give rise
to the craniofacial bones, the somites, which give rise to the
axial skeleton, and the somatopleure of the lateral plate
mesoderm, which gives rise to the appendicular skeleton.32
The mesenchymal cells have the ability to differentiate into
either cartilage, fat, muscle or bone cells; however, for
chondrocyte differentiation, there are four recognized steps
involved. Initially, the mesenchyme precursors are recruited
to the future sites of skeletal development where they
produce an ECM which is rich in hyaluronan and collagen
type I.33 Following this, cellular aggregation and then
condensation occur. Concomitant with cellular condensation
is an increase in hyaluronidase activity, the expression of
adhesion molecules such as neural cadherin (N-cadherin)
and neural cell adhesion molecule (N-CAM) and the expres-
sion of the nuclear transcription factor Sox9. Despite not
being expressed in early mesenchymal condensations, Sox5
and Sox6 are co-expressed with Sox9 during chondrocyte
differentiation.34 Finally, the mesenchymal cells undergo
differentiation to the chondrogenic lineage with simultaneous
expression of chondrocyte-specific molecules such as colla-
gen type II and aggrecan.35,36
It is well established that chondrogenesis is highly
dependent upon cell–ECM and cell–cell adhesion interac-
tions. Several studies have demonstrated that Wnt signal-
ing can influence chondrogenesis by acting upon these
interactions (Figure 2). Wnt3a has been shown to be upregu-
lated in response to bone morphogenic protein (BMP) 2.
Wnt3a also induces cytoskeleton reorganization, a crucial
step in mesenchymal chondrogenesis.37–39 It has also been
shown that Wnt3a enhances BMP2-mediated chondrogen-
esis.40 This stands in contrast to further experiments in which
Wnt3a was shown to inhibit chondrogenesis through a
b-catenin dependent mechanism. More specifically, Wnt3a
was shown to stabilize cell–cell adhesion through promoting
sustained expression of N-cadherin and of b-catenin.41
Recently,Wif-1, an inhibitor ofWnt signaling, has been loca-
lized to areas of chondrocyte condensation in the developing
chick limb.4 Importantly, Wif-1 is able to neutralize Wnt3a-
mediated inhibition of chondrogenesis.42 Furthermore,
Sox9 has been suggested as a target for Wnt3a-mediated
inhibition of chondrogenesis.43 This transcription factor has
also been implicated in the inhibitory role of Wnt6 in chon-
drogenesis. This inhibition is at an early stage of chondrogen-
esis, upstream of Sox9 and, therefore, prior to chondrogenic
differentiation.44 The effects of Wnt3a on chondrogenesis
mimic those seen in studies investigating the role of other
Wnt factors. Retroviral-mediated misexpression of Wnt7a,
Wnt4, Wnt9a (formerly known as Wnt14) and Wnt1 inhibits
cell condensation and thus chondrogenesis.45–48 Similarly,
the conditional overexpression of Wnt4 in mice leads to
dwarfism with associated craniofacial abnormalities.49 Like
Wnt3a, the effects of Wnt7a have been attributed to the
prolonged stabilization of N-cadherin.47,50 It has also been
shown that Wnt7a signaling can be inhibited by the increased
activation of BMP2-mediated p38 mitogen-activated protein
kinase (MAPK) signaling.51 It is not only the Wnt factors,
which have an inhibitory role in chondrogenesis: the forced
expression of the Wnt receptor Fz7 inhibits mesenchymal
condensation at the precartilage aggregate formation event
through suppressed expression of N-cadherin.52
Despite the compelling evidence for the Wnt components
having an inhibitory effect on mesenchymal chondrogenesis,
some Wnt family members do promote chondrogenesis. For
example, studies have shown that Wnt5a and Wnt5b can
promote early chondrogenesis as indicated by an increase
in the number of cartilaginous nodules formed in vitro.45
Similarly, experimental Wnt5a knockout limbs display
Figure 2. Wnt regulation of chondrocyte differentiation. Schematic representation of the role of Wnt in chondrogenic differentiation and hypertrophy.
Mesenchymal precursor cells differentiate into chondrocytes, which then undergo hypertrophy under the regulation of various Wnt factors and
inhibitors. However, not all chondrocytes mature into a hypertrophic phenotype as some retain their chondrogenic phenotype, and these cells constitute
the articular cartilage
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terminal adactyly and the otic capsule, a cartilaginous struc-
ture that surrounds the inner ear, is compromised in its
ability to differentiate into cartilage when extracted from
the Wnt5a null mouse.53,54 However, unlike Wnt7a and
Wnt3a, Wnt5a does not have an obvious effect on cell adhe-
sion as the expression of N-cadherin is normal.47 It has been
suggested that Wnt5a may act through the activation of
the phosphatidyl-inositol/Ca2+ or protein kinase C (PKC)
pathways.45,55 Furthermore, LEF-1, one of the nuclear
transcription factors with which b-catenin forms a complex
and also promotes chondrogenic differentiation.56
The role of the Wnt antagonists in chondrogenesis has
recently been investigated. One such study has shown that
Dkk1 and sFRP1 can promote early chondrogenesis in
human mesenchymal stem cells.57,58 However, this is in
contrast with the examination of the sFRP1 knockout
mouse, which exhibited increased chondrogenesis.59 In light
of this contradictory evidence, there is a timely need for
further investigation into the therapeutic potential of the
Wnt antagonists.
The role of Wnt in chondrocyte hypertrophic maturation
Differentiated chondrocytes either maintain their chondro-
genic phenotype to form articular cartilage, or they undergo
hypertrophic maturation in the process of endochondral
ossification. The formation and longitudinal growth of the
long bones is attributable to the process of endochondral
ossification, which involves the replacement of a hyaline
cartilage template by mineralized bone.60 This cartilage
anlagen is the growth plate, a developmental region located
between the head and shaft of the long bones. The cells of
the growth plate sit in distinct cellular zones of maturation
and proceed through various stages of differentiation while
maintaining their spatially fixed locations.61 Following the
cessation of chondrocyte proliferation, cells undergo hyper-
trophic maturation and display major phenotypic changes.
These cells have an increase in cellular volume of approxi-
mately ten times larger than that of the proliferative
chondrocytes, and a height increase of approximately five-
fold between the proliferative and hypertrophic zones.61–63
This voluminous increase is due to an increase in organelles
such as mitochondria and the endoplasmic reticulum.61,63,64
Associated with this differentiation is the increased expres-
sion of collagen type X, chondrocalcin, osteonectin and
osteopontin, as well as the increased membrane activity of
alkaline phosphatase.65,66 It is also associated with the
decreased expression of collagen type II, and other early
chondrocyte marker genes, indicative of the final maturation
phase. During this terminal differentiation, the hypertrophic
chondrocytes mineralize their surrounding matrix, localized
to the longitudinal septa of the growth plate.67 This
mineralization facilitates the deposition of hydroxyapatite
and allows vascular invasion, a significant phase in the
development of the skeleton, which allows osteoclasts and
differentiating osteoblasts to remodel the new cartilage into
bone tissue. It is well accepted that the terminally differen-
tiated chondrocyte needs to be removed so as to maintain
the steady-state thickness of the growth plate, and it is likely
that this is by apoptosis.68,69 Numerous factors have been
identified as regulators of chondrocyte hypertrophy includ-
ing Indian hedgehog (Ihh), Runx2 and PTHrP.
More recently, the role of Wnt signaling in the hyper-
trophic maturation of chondrocytes has been investigated
(Figure 2). The activation of b-catenin in mature chondro-
cytes increases cell hypertrophy, as does the overexpression
of b-catenin in chick sternal chondrocytes.70–72 Addition-
ally, b-catenin knockout mice display delayed chondrocyte
maturation.73 It has been suggested that the positive effects
of b-catenin may be through the activation of RUNX2 or
Ihh signaling, which, in turn, may induce collagen type X
expression.71,74 It may also act through inhibiting PTHrP
signaling or through IGF-1 signaling.75,76 It is not just
b-catenin/LRP5/6 signaling that is involved in chondrocyte
maturation. It has been shown that this is particularly
dependent upon the Wnt/PKC signaling, initiated by the
LRP1 receptor.77 Several Wnt factors have been identified
as promoters of chondrocyte hypertrophy including Wnt4
and Wnt8.45,78 In contrast, Wnt5a and 5b have both been
shown to inhibit the hypertrophic maturation of chondro-
cytes.79,80 Moreover, the inhibitory effect of Wnt5a is
associated with an increase in NF-kB activation and inhibition
of RUNX2.79 Fz1 and Fz7 have also been shown to delay
chondrocyte maturation as has the misexpression of the Wnt
inhibitor sFRP3.50,78,81 Similarly, sFRP1 knockout mice
show increased chondrocyte maturation with associated
reduced growth plate widths and increased hypertrophic
mineralization, suggesting accelerated endochondral ossi-
fication. This promotion of chondrocyte hypertrophic
maturation is also observed in in vitro studies.59
The Wnt signaling pathway has great potential as a thera-
peutic target for cartilage degradation. b-catenin accelerates
chondrocyte hypertrophy, and this may lead to a loss in
cartilage integrity.70–73 Therefore, blocking b-catenin,
through the use of inhibitors of b-catenin such as TCF-4
(ICAT) or XAV939, could potentially be a therapeutic
strategy.82,83 However, this must come with caution as it
has also been shown that the inhibition of b-catenin causes
chondrocyte apoptosis.84 It is therefore imperative that
levels of b-catenin remain normal for effective cartilage
function and that any new Wnt-related drug will need to
be carefully targeted, as any off-target effects are likely to
be accompanied by significant risk.
The role of Wnt in joint formation and homeostasis
As previously discussed, as opposed to maturing into a
hypertrophic phenotype, some chondrocytes retain their
chondrocyte phenotype and form articular cartilage. The
articular cartilage is a key component of the complex joint,
and it works in synergy with various other tissues within
the joint to ensure fluid movement of the bones and mechan-
ical stability. More specifically, articular cartilage functions
to reduce friction and to withstand the mechanical stress
placed upon the ends of the long bones during joint
movement. For this reason, articular cartilage is structurally
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adapted to fit this need. Like in the growth plate, articular
cartilage is organized in a strict hierarchy, the organization,
and thus, the mechanical efficiency of which increases with
maturity. Articular cartilage is hypocellular, avascular,
aneural and alymphatic. Chondrocytes constitute less than
5% of articular cartilage with their vast ECM comprising
the rest and as such, their viability is critical. The homeo-
static equilibrium of ECM synthesis and degradation is
also crucial in maintaining healthy and fully functioning
articular cartilage.
The Wnt pathway in joint cavitation. The formation of
synovial joints in the appendicular skeleton is dependent
upon the induction of genes involved in prechondrogenic
condensations and the formation of the joint interzone. With
regard to Wnt signaling, Wnt9a was first identified as a
major player in the induction of joint interzone formation
in chick limb studies.46 It has since been shown that targeted
inactivation of Wnt9a in mice results in ectopic cartilage
nodule formation in some synovial joints, known as
synovial chondroid metaplasia in humans.81 Wnt4 has also
been localized to the cells of future joint formation; however
the Wnt4:Wnt9a double mutant mouse displays limited joint
disruption.46,85,86 This therefore suggests that the third Wnt
factor expressed in the joint interzone area, Wnt16, is
compensating for the absence of Wnts 4 and 9a.85 The
expression of these Wnt factors in the presumptive joint
results in a decrease in Sox9 and collagen type II expression,
whereas it upregulates b-catenin protein levels.85 Moreover,
it has been found that the ectopic expression of active
b-catenin in chondrocytes leads to severely compromised
cartilage and joint formation.73,85,87 This therefore suggests
that joint induction is regulated by Wnt4, 9a and 16
controlled b-catenin signaling. Furthermore, a role for Ihh
has been proposed in joint formation as upregulation of its
signaling in mice results in mild joint fusion.88,89
Wnt signaling appears critical for not only the formation
of the joint but also its maintenance as indicated by the
numerous transgenic mouse models which invariably
display postnatal phenoytpes.90 Any dysregulation in the in-
tegrity of the articular cartilage can lead to its degradation,
as is commonly seen in OA and RA. In these prevalent
and debilitating diseases, the integrity of the cartilage
ECM is compromised with proteoglycan loss and disruption
to the collagen fibrils, making it brittle and susceptible to
fibrillation, fissuring and subsequent fragmentation with
associated chondrocyte cell apoptosis. This subsequently
causes the sufferer pain and disability.
The Wnt pathway in RA. RA is an autoimmune disease,
which is pathologically characterized by bone and cartilage
degradation as well as inflammation of the synovium. The
most prominent change seen is the production of a pannus.
For this, the synovial cells and the underlying connective
tissue form a mesh of proliferating tissue, which produces
large concentrations of enzymes, aiding its growth and
destroying the articular cartilage. Activators of this pannus
formation include the inflammatory cytokines tumour
necrosis factor (TNF)-a and interleukin (IL)-1; however,
despite RA sufferers undergoing anti-inflammatory therapy,
this pannus can still be activated. Recently, components of
the Wnt pathway have been implemented in the pathophysi-
ology of RA (Table 1).
Analysis of RA synovial tissue has identified the
increased expression of Wnts 1, 5a, 7b, 10b, 11 and 13
and Fzs 2, 5 and 7. In particular, increases in the expressions
of Wnt5a and Fz5 in RA synovial tissue have been
observed.91 Wnt5a and Fz5 have been shown to activate
the formation of the pannus, potentially through the PKC
signaling cascade and NF-kB activation. Furthermore,
Wnt5a and Fz5 signaling has been shown to increase the
production of the pro-inflammatory cytokines IL-6, IL-15
and receptor activator for NF-kB ligand (RANKL) causing
further joint destruction.92–94 Similarly, synovial cells
transfected with Wnt7b display increased expression of
TNF-a, IL-1 and IL-6, all of which shift cartilage homeosta-
sis towards catabolism in RA.95,96
Wnt1 is known to promote cell adhesion, cell growth and
survival. In RA patients, Wnt1 is overexpressed. The
in vitro transfection of synovial cells with Wnt1 has shown
that this results in an increased expression of fibronectin
and pro-matrix metalloproteinase (MMP) 3. These proteins
are known to promote survival and invasiveness.97 The
Wnt1-inducible secreted protein, WISP3, although not
directly induced by Wnt1, is also proving to be important
in the molecular regulation of RA with a WISP3 gene
polymorphism being associated with juvenile idiopathic
arthritis.98,99 WISP3 mRNA is increased in RA synovium
compared with control counterparts, and this is increased
even more so by pro-inflammatory cytokines in vitro.100 It
is known that WISP3 acts to maintain cartilage integrity
by regulating the expression of type II collagen and
aggrecan, and by repressing such catabolic molecules as
ADAMTS5 and MMP10.101,102 Another Wnt1-inducible
secreted protein, WISP2, has also been reported in RA.103
The role of the Wnt antagonists in RA has also been
investigated with sFRP1–being observed in the synovial
cells of patients with RA.96,104,105 Dkk1 is also present in
RA tissue, and its expression can be upregulated by the
pro-inflammatory cytokine TNF-a, thus suggesting that
inflammation is an inducer of Dkk1 expression.106 This
recent and comprehensive study showed that treatment with
an anti-Dkk1 antibody induced osteophyte formation in RA
joints and protected them from bone erosions through
decreased osteoclast formation and increased OPG expres-
sion.106 This may form the basis of some future therapeutic
strategy for RA. Moreover, another interesting approach
may be to target molecules downstream of b-catenin signal-
ing that are known to be upregulated in RA, such as WISP2
and WISP3, or to target Wnt factors known to be involved
in the major pathologies of RA. Both Wnt5a and Fz5
are known to activate pannus formation, as well as to
increase proinflammatory cytokine expression, making
them attractive therapeutic targets, which may provide
further insights into the specific roles of Wnt in RA and
cartilage homeostasis.
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The Wnt pathway in OA. OA is a degenerative disease
primarily characterized by the progressive destruction of
the articular cartilage. Associated with this are subchondral
bone thickening, osteophyte formation and inflammation
of the synovial membrane causing pain. It is thought that
biochemical changes in MMP and aggrecanase production
mediate the cartilage destruction, with the pro-inflammatory
cytokines also being implicated. Recently, it has been
suggested that abnormal Wnt signaling may contribute to
OA pathogenesis. This stems from multiple studies, which
have sought to examine the genetic component of OA: it is
known that primary OA has an estimated heritability of
40% for the knee, 60% for the hip and 65% for the hand.107
Several Wnt-related factors have been identified to be
associated with OA through these genetic studies, and their
functional role is slowly being established Table 1.
Genetic analysis of polymorphisms associated with OA
has identified a single nucleotide polymorphism in sFRP3
as a target for OA susceptibility.108–111 Generation of the
sFRP3 null mouse showed no developmental changes;
however, upon induction of OA via either inflammatory,
surgical or enzymatic methods, cartilage degradation in the
sFRP3 null mice was greater than their control counterparts.
This was associated with increased Wnt/b-catenin signaling
and with the inhibition of MMP3.112 Other Wnt antagonists
have been identified as having a role in the pathogenesis of
OA. sFRP1, sFRP2 and sFRP4 expression have all been
reported in OA synovium, and like in RA, Dkk1 expression
has been observed.96,113 This Dkk1 expression has been
shown to impair chondrocyte growth while promoting
chondrocyte apoptosis. Furthermore, Dkk1 expression can
be induced by IL-1b.113,114 Dkk2 expression is higher in
OA osteoblasts compared with control counterparts.115
Correction of the Dkk2 expression by siRNA gene silencing
enhanced Wnt signaling and corrected the abnormal
phenotype, as well as increased osteoblast mineralization.
The increased expression of Dkk2 was shown to be induced
by transforming growth factor b (TGF-b) expression.115
SCL is a well-established inhibitor of Wnt signaling and,
therefore, bone formation. Its role in OA is slowly
emerging; despite no changes in SCL serum levels, there
is a decreased number of SCL positive osteocytes in human
OA patients.116,117 This has been further examined using
mouse and sheep OA models. Interestingly, there was an
increase in SCL expression in the articular chondrocytes of
post-meniscectomy sheep specimens in comparison to
sham-operated animals. This was further confirmed in a
mouse DMM model and in human samples. The increased
expression of SCL in these chondrocytes was further
increased in response to IL-a but not to TNF-a. SCL expres-
sion appeared to inhibit Wnt signaling and the expression
of catabolic MMPs. Contradictory to this, incubation of
chondrocytes with recombinant SCL decreased the expres-
sion of aggrecan, collagen type II and TIMPs.118
Polymorphisms in LRP5 and LRP6 have also been
associated with OA, with their expression being greater in
OA tissues.110 Furthermore, the blocking of LRP5 expres-
sion results in a significant decrease in MMP13 mRNA
and protein levels.119 GSK3b promotes the degradation of
b-catenin, and the inhibition of its activity has been shown
to induce OA features in murine metatarsal bones, highlight-
ing the importance of GSK3b in maintaining the chondro-
cyte phenotype.120
Numerous Wnt factors have been identified as being
unregulated in OA tissue including Wnts 2b, 3a, 4, 6, 7a,
7b, 9b, 10a and 16.95,121–124 Moreover, the Fz2, Fz5 and
Fz7 have been identified.91 The role of Wnt3a in OA has
been well investigated as its activity is reduced in OA.
Articular chondrocytes cultured with Wnt3a exhibited rapid
matrix loss and protease expression. Similar results were
seen with overexpression of b-catenin.125 Furthermore,
Wnt3a stimulated chondrocytes exhibit an upregulation of
MMP3 and ADAMTS-4.126 Wnt3a-dependent activity is
reduced in OA, and this can be corrected by the addition
of recombinant R-spondin2. Moreover, in OA osteoblasts,
R-spondin2 expression is decreased, thought to be because
of the elevated levels of TGF-b in these cells.127 Like in
RA, WISP3 is expressed by OA tissue, and this can be
increased by the pro-inflammatory cytokines TNF-a and
IL-1.100 A polymorphism in the WISP1 gene has been
linked to spinal OA, and similarly, its increased expression
in OA tissue has been observed.122,128,129 Furthermore, it
has been shown that the in vivo and in vitro stimula-
tion of articular chondrocytes with WISP1 increased car-
tilage degeneration through the induction of MMPs and
aggrecanase.122
Molecular mechanisms involved in the expression of
proteins relevant to the pathological changes of cartilage
degeneration, subchondral bone thickening and osteophyte
formation in OA may form potential therapeutic strategies.
b-catenin accelerates chondrocyte hypertrophy, a key aspect
of OA. However, targeting this comes with significant risk,
as previously discussed, and therefore, it seems the develop-
ment of drugs, which selectively inhibit the Wnt pathway,
may prove useful as therapeutic targets. In OA, the blockade
of Dkk1 by a neutralizing antibody led to attenuation
Table 1. Aberrant Wnt expression in joint disease. Detailed is the aberrant expression of Wnt and Wnt associated factors in both RA (rheumatoid arthritis)
and OA (osteoarthritis). Literature detailing the role of the individual factors is cited
Wnt Frizzled Antagonists Other
RA Wnt1,97 Wnt5a,92–94 Wnt7,95,96
and Wnt10b, Wnt11, Wnt1396
Fz2,91 Fz5,91–94 Fz791 sFRP1-5,104,105 Dkk1106 WISP2,103 WISP3101,102
OA Wnt3a,95,121–126 and Wnt2b, Wnt4,
Wnt6, Wnt7a, Wnt7b, Wnt9b,
Wnt10a, Wnt1695,121–124
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of chondrocyte apoptosis, whereas recombinant Dkk1 pro-
moted apoptosis, a key component of OA pathogenesis.114
However, before any finite conclusions can be made, a more
detailed analysis of the role of Dkk1 in OA is required. Like
Dkk1, SCL inhibits Wnt signaling by specifically binding
to the LRP5/6 receptors. Antibodies to SCL have great
therapeutic use in the osteoanabolic therapy of osteoporosis
and inflammatory bone loss, as is currently emerging.130–133
As highlighted by Chan and colleagues, it is imperative that
the effects of blocking SCL activity on OA progression are
fully investigated.118
Conversely, (hetero)arylpyrimidines have been identified
as agonists of Wnt, and this warrants their investigation, along
with other Wnt agonists such as R-spondin2, as therapeutic
targets.134 R-spondin2 and Dkk2 display decreased and
increased expression respectively in response to the increased
TGF-b observed in OA. Both these molecules contribute to
the pathological changes observed in OA cartilage and, as
such, warrant the future investigation of neutralizing TGF-b
activity in OA. Certainly the injection of TGF-b into mouse
knees produces OA-like features; however, any therapeutic
strategy involving TGF-b may prove complex because its
varying reported effects on the joint as are extensively
reviewed by Blaney-Davidson et al.135–139 In view of the
complexity of the molecular mechanisms surrounding OA, it
is important that future studies focus upon the specific and
precise roles that Wnt signaling plays in the individual
components and pathologies of the joint.
CONCLUSION
The evidence presented in this review highlights the critical
role of the Wnt signaling pathway in chondrogenesis and car-
tilage development and homeostasis. The precise individual
roles that the Wnt factors play are complex as they can trigger
multiple Wnt pathways. Future directions should focus upon
better understanding the individual roles of the Wnt factors
in cartilage homeostasis, their downstream targets and the
interactions that they may have with other pathways (Table 1).
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The skeleton: no bones about it
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The skeleton is composed of bone and cartilage. These tissues
are made of an exquisite assembly of functionally distinct cell
populations and are required to support the structural,
biochemical and mechanical integrity of the skeleton. The
functions of the skeleton, which include its role in growth,
locomotion, ion homeostasis and the protection of vital
organs, are fundamental to the healthy organism. Develop-
ment, growth and maintenance of the skeleton is under
complex endocrine and genetic control and depends on a
tight integration of cellular events within the skeleton and
within the systems that deliver and accumulate mineral for
hydroxyapatite formation (Karsenty 2003).
With few exceptions, bone formation is dependent on the
development of the cartilage anlagen from mesenchymal
precursors. These cartilage models of the future bones are
replaced by bone through endochondral ossification, a process
also responsible for linear bone growth at the epiphyseal plate
during pre- and post-natal life (Kronenberg 2003). In essence,
the laying down of a cartilage matrix by the chondrocyte, the
primary cell type of cartilage, is a pre-requisite for future bone
modelling and remodelling by the osteoblast and osteoclast.
To fully appreciate the contribution of both cartilage and
bone elements to skeletal physiology (and pathology), it is
essential that we more thoroughly understand the molecular
events responsible for the integration of the various signals
and cues that impinge on, and direct, the activities of cartilage
and bone cells.
To this goal, considerable advances have been made in our
understanding of the regulatory mechanisms responsible
for the formation and maintenance of the skeleton. This has
been achieved through various classical in vitro and in vivo
approaches including the analysis of specific knockout
animals, transgenic mice and animals which bear spontaneous
mutations. This progress in our understanding has been
captured in these three thematic reviews, where the authors,
in addition to providing a general review of endochondral
ossification and bone formation and resorption, have focussed
on some of the recent advances in chondrocyte, osteoblast
and osteoclast biology.
In the first thematic review, Mackie et al. (2011) summarise
the current concepts of growth plate chondrocyte activity
and growth plate function. Chondrocyte proliferation is
essential for bone growth, and the authors highlight recent
advances in the control of chondrocyte proliferation by
Indian hedgehog and bone morphogenetic proteins (BMPs).
Of particular interest is the recently recognised cooperation
between Schnurri proteins -2 and -3 and receptor-Smads in
the regulation of BMP signalling (Jones et al. 2010). In
addition, a role for the transcriptional repressor, TRPS1,
which interacts with the activator form of Gli3, in
chondrocyte cycle progression has been proposed (Wuelling
et al. 2009). It is also worthy of mention that TRPS1 appears
to be able to regulate chondrocyte hypertrophy by directly
inhibiting PTHrP expression and RUNX2 function.
This suggests that TRPS1 has an important function in the
fine-tuning of cell-cycle exit and in the transition between
the proliferative and the hypertrophic chondrocyte states
(Napierala et al. 2008).
Mineralisation of the hypertrophic chondrocyte matrix is
followed by vascular invasion of the growth plate, and the
subsequent deposition of the bone matrix by osteoblasts on
the vertical cartilage remnants remaining after osteoclastic
matrix resorption. The regulation of invading cells is now
considered to be an active process in which the chondrocytes
produce factors that promote and attract the invasion of
endothelial cells, osteoblasts and osteoclasts. In the second
thematic review, new insights into osteoblast biology are
summarised with a particular focus on the role of
phosphatidylinositol 3-kinase (PI3K) signalling and its down-
stream effector, AKT (Guntur & Rosen 2011). Of topical
interest is the ability of insulin/IGF1 signalling to up-regulate
PI3K activity and, via the Forkhead group of transcription
factors (FOXOs), influence osteoblast function and energy
metabolism through altered osteocalcin and OST-PTP
expression (Rached et al. 2010, Kousteni 2011). This is
in addition to the previously recognised effects of PI3K
signalling on the osteoblast-specific transcription factors,
RUNX2, Osterix and ATF4. Interestingly, recent data suggest
that conditional loss of Pten, a phosphatase that inactivates
PI3K signalling, in osteoprogenitors results in increased
proliferation of osteoblast progenitors and stimulation of
fibroblast growth factor signalling (Guntur et al. 2011).
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The last thematic review concentrates on the bone
resorbing osteoclast whose function is synchronised to that
of the osteoblast during bone remodelling to ensure bone
mass homeostasis (Mellis et al. 2011). The focus of this
thematic review is the key signalling pathways involved in
osteoclast formation and function. The coupling of osteoblast
and osteoclast function is accepted to involve the receptor
activator of nuclear factor kappa-b (RANK)/osteoprotegrin
(OPG)/RANK ligand (RANKL) system, and this review
summarises in detail the downstream signalling events that
occur after RANK receptor activation, which result in
osteoclast formation and bone resorption. Other pathways are
also involved in osteoclast formation and one of these involves
the ratio of the two isoforms – liver-enriched inhibitory
protein (LIP) and liver-enriched activator protein (LAP) – of
the transcription factor CCAATenhancer-binding protein b.
The ratio of LIP and LAP, which is modulated by the
mechanistic target of rapamycin signalling pathway, regulates
osteoclastogenesis through MafB (Smink et al. 2009). Once
formed, osteoclast attachment to the bone matrix is essential
for resorption and this is mediated by various signalling
pathways such as those initiated by SRC kinase. SRC
phosphorylation of cortactin and gelsolin is important for
actin polymerisation and podosome turnover whereas
phosphorylation of spleen tyrosine kinase, SYK, promotes
the activation of small GTPases and cytoskeletal reorgan-
isation (Itzstein et al. 2011).
The aim of these thematic reviews is to bring together in
one collection an appreciation of our current understanding
of the key factors, e.g. endocrine, genetic and signalling
molecules, that regulate skeletal function via interactions
with cells of both cartilage and bone. Each individual cell
type (including the osteocyte, the terminally differentiated
osteoblast) does not live in isolation or in a vacuum and
there is much crosstalk and communication between them
and also with their collagenous-rich extracellular matrix.
Together, these cellular activities and matrix interactions
result in the formation of a complex organ that is indis-
pensable for life.
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